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Abstract 
In biology-oriented synthesis (BIOS), the areas in chemical space represented by bioactive 
natural products (NPs) serve as the starting points for the synthesis of compound collections, 
which can be defined by privileged scaffolds and diverse substitutions. To explore chemical 
space inspired by but beyond NPs, the rapid synthesis of compound collections based on 
privileged scaffolds is crucial. Given the prevalence of stereocenters in NPs, the development 
of corresponding enantioselective methodologies is highly valuable. 
 
Figure 1. Overview of projects described in this thesis. 
To accomplish this goal, Chapter 2 in this thesis demonstrates the development of new chiral 
cyclopentadienyl ligands and catalysts for enantioselective C−H activation to evolve chemistry 
tools for the synthesis of privileged scaffolds enriched in NPs (Fig. 1). Enantioselective 
activation of C‒H bonds is among the most important and efficient transformations in organic 
synthesis, but remains considerably undeveloped due to the inert nature of C−H bonds and the 
lack of efficient catalysis systems. Although metal catalysis facilitated by chiral 
cyclopentadienyl (Cp) ligands has emerged as a highly efficient and attractive approach, the 
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limitations of present Cp ligands on either applicability or structural variability significantly 
hampered their comprehensive application. To exploit such an approach to serve for BIOS, the 
second chapter describes the development of a highly tunable library of chiral cyclopentadienyl 
(Cp) ligands and its Rh(I) complexes as precursors of Rh(III) catalysts. As proofs of concept, 
three different C−H activation transformations have been realized in highly enantioselective 
manner, including one unprecedented transformation affording axially chiral compounds. 
Besides evolving chemistry tools for enantioselective C‒H activation, the other major aspect 
of this thesis depicts the flexible application of current well-established catalysis systems for 
the synthesis of compound collections based on privileged scaffolds enriched in NPs (Fig. 1). 
The catalysis systems involved in this thesis consist of chiral Lewis acids catalysis and Rh(II) 
catalysis, as well as nucleophilic catalysis by using chiral amine and phosphine catalysts. 
Facilitated by chiral Lewis acid catalysis, Chapter 3 describes the synthesis of pyrrolizidines 
in highly enantioselective fashion by using 1,3-dipolar cycloaddition (1,3-DC) of azomethine 
ylides as a key step. In Chapter 4, to establish efficient methods to access seven-membered 
carbocycles (cycloheptanoids) in an enantioselective manner, three catalysis systems are 
exploited involving Rh(II) catalysis, Rh(II)/Lewis aicid catalysis and amine catalysis. In this 
part, either chiral dirhodium(II) catalysts or chiral Lewis acids are employed to steer the 
enantioselective 1,3-DC of highly reactive carbonyl ylides or azomethine ylide generated from 
diazoketones. As alternatives for the synthesis of enantioriched cycloheptanoids, (5+2) 
cycloadditions of pyryliums and a stepwise strategy by using amine catalysis are also depicted. 
Furthermore, Chapter 5 describes the synthesis of highly functionalized pyrroloisoquinolines 
by means of phosphine-catalyzed dearomatizing (3+2) annulations of isoquinolinium 
methylides. Notably, most of the compounds shown in these three chapters were subjected to 
different cell-based assays, among which activities in the low micromolar range were 
discovered such as inhibition of Hedgehog signaling pathway.  
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Zusammenfassung 
In der Biologie-orientierten Synthese (BIOS) wird der durch bioaktive Verbindungen, 
insbesondere Naturstoffe (engl. natural products; NPs), repräsentierte Strukturraum als 
Ausgangspunkt für die Synthese von Substanzbibliotheken genutzt. Die Bibliotheken basieren 
auf vielfältig substituierten privilegierten Gerüsten. Mit dem Ziel den von NPs inspirierten 
chemischen Raum sowohl zu nutzen, als auch zu erweitern, ist die effiziente Synthese von 
Substanzbibliotheken ausgehend von privilegierten Gerüstmolekülen von entscheidender 
Bedeutung. 
 
Abbildung 1. Übersicht der in dieser Arbeit beschriebenen Projekte.  
Um dieses Ziel zu erreichen wurde in Kapitel 2 dieser Arbeit die Entwicklung neuer chiraler 
Cyclopentadienylliganden für die katalytische, enantioselektive C‒H Aktivierung als 
Weiterentwicklung bekannter chemischer Werkzeuge für die Synthese privilegierter 
Grundgerüste, die mit großer Häufigkeit in NPs zu finden sind, demonstriert (Abbildung 1). 
Die enantioselektive Funktionalisierung von C‒H Bindungen ist eine der bedeutendsten und 
effizientesten Transformationen in der organischen Synthese, welche jedoch bedingt durch die 
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inerte Natur von C‒H Bindungen und die bislang noch langsame Entwicklung effizienter 
Katalysesysteme bisher unterentwickelt blieb. Auch wenn sich die Metalkatalyse, vermittelt 
durch chirale Cyclopentadienylliganden (Cp), als hoch effizienter und attraktiven Ansatz 
etabliert hat, sind Cp Liganden in ihrer Variabilität stark limitiert, was eine umfassende 
Anwendbarkeit einschränkt. Zur Etablierung dieses Ansatzes als Grundlage für BIOS 
beschreibt das zweite Kapitel die Entwicklung einer Bibliothek von präzise steuerbaren 
chiralen Cyclopentadienylliganden und deren Rh(I)-Komplexen als Vorläufer für Rh(III)-
Katalysatoren. Als konzeptioneller Beweis wurden drei verschiedene C‒H 
Funktionalisierungen mit hoher Enantioselektivität realisiert, einschließlich einer neuen 
Transformation, welche axial chriale Verbindungen lieferte. 
Neben der Weiterentwicklung chemischer Werkzeuge für die enantioselektive C‒H 
Aktivierung lag das Hauptaugenmerk dieser Arbeit auf der flexiblen Anwendung von 
modernen, bereits etablierten Katalysesystemen zur Darstellung von Substanzbibliotheken 
basierend auf privilegierten Grundgerüsten (Abbildung 1). Die in dieser Arbeit eingesetzten 
Katalysesysteme umfassen sowohl chirale Lewis-Säure- und Rh(II)-Katalysatoren, als auch 
chirale Amin- und Phosphankatalysatoren. Vermittelt durch chirale Lewis-Säure-Katalyse, 
beschreibt Kapitel 3 die Synthese von Pyrrolizidinen durch 1,3-dipolare Cycloaddition (1,3-
DC) mit hoher Enantioselektivität. Kapitel 4 beschreibt die Etablierung einer effizienten 
Methode, welche den Zugang zu siebengliedrigen Carbocyclen (Cycloheptanoide) in 
enantioselektiver Weise eröffnet. Anwendung finden drei Katalysesysteme basierend auf 
Rh(II)-, Rh(II)/Lewis-Säure- und Amin-Katalyse. In diesem Teil wurden entweder chirale 
Dirhodium(II)-Katalysatoren oder chirale Lewis-Säuren, zur Steuerung der enantioselektiven 
1,3-DC von hochreaktiven Carbonylyliden oder Azomethinyliden erzeugt aus Diazoketonen 
eingesetzt. Als Alternative zur Synthese von enantiomerenangereicherten Cycloheptanoiden, 
wurden die (5+2) Cycloaddition von Pyrylium und eine  sequentielle Strategie, durch den 
Einsatz von Amin-Katalysatoren untersucht. Zusätzlich beschreibt Kapitel 5 die Synthese von 
hochfunktionalisierten Pyrroloisochinolinen durch phosphinkatalysierte dearomatisierende 
(3+2) Annulierung von Isochinolinmethyliden. Die Mehrheit der Verbindungen, welche in den 
Kapiteln 3-5 angeführt sind, wurde mit verschiedenen zellbasierten Assays untersucht. 
Biologische Aktivität wurde im niedrigen mikromolekularen Bereich identifiziert, wobei die 
Inhibition des Hedgehog Signalweges beobachtet wurde. 
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 Introduction 
As reliable and rich starting points, bioactive natural products (NPs) have been inspiring drug 
discovery in the history of medicinal chemistry, and also empowering the exploration of 
complex biological networks by using bioactive small molecules in chemical biology 
research.1-3 Through interactions with multiple proteins in both biosynthesis and displaying 
bioactivities, NPs represent diverse areas in chemical space explored and selected in evolution 
by nature.4-7 Due to limited material and time, NPs selected by evolution might only represent 
a fraction of chemical space binding to corresponding proteins, therefore the extension of 
chemical space represented by NPs by organic synthesis is indispensable. However, it is 
estimated that the number of drug-like small molecules exceeds 1060.8 Hence, it is unfeasible 
to explore all these possibilities by organic synthesis. Taken together, it is necessary to develop 
a practical navigation to efficiently identify biologically relevant areas from the nearly infinite 
chemical space defined by small molecules.   
The chemical space of NPs can be defined by conserved NP scaffolds together with diverse 
substituents for complementary differentiation.5 In this regard, the common scaffolds of NPs 
featured with conservatism can be recognized as ‘privileged’, with which NPs exhibit diverse 
bioactivity tuned with the decoration of substituents. Accordingly, the privileged scaffolds of 
NPs in the Dictionary of Natural Product (DNP) were classified hierarchically, resulting in the 
Structural Classification of Natural Products (SCONP) (Fig. 2).5 In analogue to small 
molecules, the binding sites of proteins can be correspondingly characterized by highly 
conserved fold types and variable side chains. In this scenario, Protein Structure Similarity 
Clustering (PSSC) was proposed based on the structural similarity of protein binding sites.5 
The basic reasoning of PSSC relies on the hypothesis that the protein with the conserved 
scaffold or subfold of its binding site should be bound by specific compounds sharing common 
scaffolds. Based on these two complementary approaches, biology-oriented synthesis (BIOS) 
was termed and provides a guideline for the design and synthesis of focused compound 
collections.  
In light of BIOS, two criteria are supposed to be critical for the synthesis of specific compound 
collections, including the rapid access of privileged scaffolds with biological relevance and the 
adequate variability for substitutions. In addition, compared with those compounds obtained 
by combinatorial chemistry based on the major consideration of chemical accessibility, NPs 
distinguish themselves by not only the increased molecular complexity but also the prevalence 
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of stereocenters. Hence, to meet all these requirements, the development of efficient 
methodologies to access complex privileged scaffolds with sufficient substitution patterns, 
especially in an enantioselective manner, would be invaluable and highly desirable. 
 
Figure 2. Graphic representation of the Structural Classification of Natural Product (SCONP). Reprinted from 
ref9, copyright (2005) National Academy of Sciences. 
 Objectives 
Over the last decade, a wide range of privileged scaffolds enriched in NPs has been constructed 
rapidly through C−H activation enabled by cyclopentadienyl (Cp) metal complexes, especially 
by Rh(III) analogues.10-12 Surprisingly, it was not until 2012 that the use of corresponding chiral 
Cp ligands emerged as a general approach to steer such asymmetric transformations.13,14 
However, the present chiral Cp ligands suffer from either limited applicability or constricted 
structural variability.15 To evolve such chemistry tool to serve for BIOS, the discovery of novel 
Cp ligands would be highly valuable and desirable. Inspired by the pioneering work by Dr. 
Marco Potowski, it was envisioned that (6+3) cycloadducts featured with easy accessibility and 
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flexible structural variability could be explored as suitable chiral Cp ligands.16,17 In this regard, 
Chapter 2 in this thesis will depict the endeavor to design and synthesize a new type of chiral 
Cp ligands and Rh(I) complexes, as well as their applications into the construction of versatile 
NPs scaffolds.  
To build N-heterocycles, 1,3-dipolar cycloaddition reactions (1,3-DC) of azomethine ylides are 
among one of the most efficient methods. In continuation to the effort in our lab to construct 
compound libraries by harnessing the power of 1,3-DC, further extension of previously 
established compound libraries based on pyrrolizidines is one of the goals in this thesis.18 This 
work will be presented in chapter 3.  
According to BIOS, the privileged scaffolds in bioactive NPs can be regarded as the starting 
point for the synthesis of compound collections to identify promising hits.5 Owing to the 
continuous interest in Englerin A in our group, the construction of seven-membered 
carbocycles embodied in Englerin A is another target in this thesis.19 Chapter 4 will 
demonstrate versatile approaches in detail to this end. 
As another potential method to build N-heterocycles, the phosphine-catalyzed annulation 
reactions of azomethine ylides and allenes have not been investigated.20,21 Based on this 
consideration, chapter 5 will show the synthesis of nitrogen-contained pyrroloisoquinolines 
through phosphine-catalyzed annulation reactions of isoquinolinium methylides and allenes. 
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2.1 Introduction 
2.1.1 Chiral Cyclopentadienyl Ligands in Asymmetric Catalysis 
Catalytic asymmetric synthesis is one of the most active fields in organic chemistry which 
significantly benefits from the development of novel chiral ligands for metal complex catalysis. 
As common design principles of ‘privileged’ ligands, high chemical robustness, adjustability, 
scaffold rigidity, as well as enriched ligand pool facilitated by ease of synthesis have been 
generally recognized by the chemistry community.22 In spite of numerous chiral ligands 
developed in the past decades, only a few ligands such as bisoxazoline ligands and SALEN 
ligands can be regarded as ‘privileged’, with systematic variation on their scaffolds and a wide 
spectrum of applications in various mechanistically different reactions.22,23 In sharp contrast to 
these privileged ligands, chiral cyclopentadienyl (Cp) ligands with noncoordinating 
substituents were only applied very recently in asymmetric catalysis.24-26 However, the achiral 
Cp ligands, especially its pentamethylcyclopentadienyl analog (Cp*), have emerged as a 
dominant class of anionic ancillary ligands with broad application in versatile transition metals 
catalysis.27 In addition, for some reactions catalyzed by Co(I)28, Rh(I)29, Rh(III)10-12, Ir(III)30, 
and Ru(II)31, chirality can only be induced by Cp ligands since all coordinating sites of such 
metal complexes besides Cp ligands are required during catalytic process, which highlights the 
necessity of development of chiral Cp ligands further.  
Since the discovery of ferrocene in 1951,32 it is rather straightforward that enantioselectivity 
of Cp-metal complexes catalyzed transformations can be introduced by means of chiral 
moieties in Cp ligands. In fact, there was a period when chemists showed strong interest in 
development of such ligands around 1980’s, but only a limited number of chiral Cp derivatives 
were synthesized and rarely applied in asymmetric metal catalysis.24,33 Furthermore, only poor 
enantioselectivity was obtained for most of those few applications based on chiral Cp ligands. 
There are only two reports in which chiral Cp ligands delivered considerable enantiocontrol 
before 2012 (Scheme 1). In 1990, Erker reported successful enantiocontrol of Friedel-Crafts 
hydroxyalkylation of 1-naphthol 1 by using a chiral Cp-Zr complex 3, affording product 4 with 
up to 84% ee.25 In this case, the chiral Cp-Zr complex 3 is supposed to activate ethyl pyruvate 
2 as a Lewis acid to deliver chirality in catalytic process. Later on, the first organometallic 
reaction using chiral Cp-Co complex was described by Gutnov and Heller in 200426 and further 
extended in 201034, providing axially chiral compounds 8 via a [2+2+2] reaction of 1,7-
octadiynes 5 and nitriles 6. This strategy could also be applied to the synthesis of phosphorus-
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bearing axially chiral compounds by using propargylic phosphine oxides and acetylene. 
Although these two early successful reports show great potential for the application of chiral 
Cp ligands in asymmetric catalysis, these ligands are severely limited by the variability of 
ligand scaffolds, which restricts systematic catalyst optimization for broad application in other 
transformation.  
 
Scheme 1. Early examples of enantioselective catalysis based on chiral Cp ligands. 
In the last decade, the rapid development of Cp*Rh(III) catalyzed C−H functionalizations 
evoked the tremendous interest in chiral Cp ligands in the chemistry community.10-12 One of 
those transformations facilitated by Cp*Rh(III) is the synthesis of dihydroisoquinolones from 
hydroxamates and alkenes under mild conditions, discovered by Fagnou35 and Glorius36 in 
2011 (Scheme 2). According to the proposed mechanism, the active catalyst CpRh(III) 12 
coordinates to the substrate 9 by N−H bond insertion. The following C−H bond cleavage step 
gives intermediate 13 through a carboxylate assisted concerted-metalation-deprotonation 
(CMD) process. Afterwards the coordination of alkene to Rh(III) provides intermediate 14, 
which is subjected to a subsequent migratory insertion to yield rhodacycle 15. After reductive 
elimination to generate 16, the desired product 11 is delivered upon protonation process.  
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Scheme 2. Two complementary chiral Cp ligands for enantioselective synthesis of dihydroisoquinolones. 
Using this transformation as a model reaction, two complementary strategies to design chiral 
Cp ligands leading to efficient chirality induction were developed by Ward and Rovis as well 
as Cramer in 2012 (Scheme 2).13,14 The corresponding Rh(I) complexes were synthesized due 
to their air-stability and easy handleability, and could be transformed to reactive Rh(III) 
catalysts under the treatment of an oxidant. In the work by Cramer,13 a series of cyclohexyl-
substituted chiral Cp ligands was designed and synthesized in 5-7 steps, affording the desired 
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dihydroisoquinolones with excellent yield and enantioselectivity. In this catalyst system, 
hydroxamates with different substitutions on diverse positions and specific types of electron-
rich alkenes were well tolerated. According to the hypothesis of back/side wall proposed by 
the authors, the methyl group in catalyst 17 acts as side wall which determines the orientation 
of hydroxamate in intermediate 13. Meanwhile, two phenyl groups far away from the Rh as 
back shields force alkene to approach in opposite direction near Cp moiety. Subsequently, 
larger substitution on alkene, such as the phenyl group in styrene, tends to point away from Cp 
moiety due to unfavorable steric interaction. Such diastereoselective coordination of alkene 
forms intermediate 14. In this scenario, the chirality at metal is already able to define the 
stereochemistry in the final product 11 via a enantiodetermining migratory insertion process. 
Complementary to small molecule Cp ligands aforementioned, Ward and Rovis employed their 
protein-based Cp ligands 18 to induce enantioselectivity to the same transformation by chiral 
environment defined by specific streptavidin.14 Relatively fewer examples were demonstrated 
with 30-95% yield and 12-86% ee. Interestingly, the substrate scope of alkenes in this catalyst 
system is restricted to electron-deficient acrylates, which is complementary to Cramer’s work. 
The authors attributed this behavior to more electron-rich and bulky nature of Cp* implanted 
in protein-based ligands.  
 
Scheme 3. Chiral binaphthyl Cp complexes with Rh(I), Sc(III), Ir(III), and Ru(II). 
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However, the abovementioned two ligands could not be applied in more transformations, 
presumably due to limited generality of these catalyst systems and the multi-step preparation 
of ligands. In 2013, Cramer developed a second generation of Cp ligands 19 based on chiral 
BINOL scaffold (Scheme 3).37 The outcome of excellent enantiocontrol by such ligands was 
rationalized by the authors with the same back/side wall hypothesis. In such scenario, the 
binaphthyl moiety characterizes the back wall in analogy to the bi-phenyl group in 17, while R 
as only variable group in 19 plays the role of side wall as counterpart of methyl group in 17. In 
spite of the relatively lengthier synthesis route (4-14 steps) and only one position for late stage 
modification, this binaphthyl family showed great generality for diverse metals and reactions 
with distinct mechanism, as well as enhanced reactivity and enantioselectivity.15,38 Since the 
discovery of such ligands, not only rhodium(I) complexes but also complexes with 
scandium(III)39, iridium(III)40, and ruthenium(II)41 were successfully synthesized and applied 
in corresponding asymmetric catalyses.  
 
Scheme 4. Application of binaphthyl Cp ligands in rhodium(III) catalyzed enantioselective reaction of 
benzamides.  
The ligand 19 was initially proposed in 2013 by an enantioselective C−H allylations of 
N-methoxybenzamides 26 using Rh(I) complex 20a as catalyst,37 whose non-asymmetric 
version was firstly discovered by Ma42 and Glorius (Scheme 4).43 Notably, catalysts 20 based 
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on binaphthyl resulted in significantly enhanced enantiocontrol compared to catalyst 17 which 
was optimal in the dihydroisoquinolone synthesis. Both steric and electronic variations of 
benzamides 26 as well as versatile allenes 27 were compatible in the reactions, affording the 
desired products 28 with up to 91% yield and 98% ee. Inspired by the pioneering work, 
remarkable progress has been achieved in this field, especially in the discovery of more 
transformations by employing binaphthyl CpRh(I) complexes. In 2014, Cramer et al. extended 
their substrate types to disubstituted alkenes based on similar mechanism.44 An asymmetric 
hydroarylation of tethered olefins on benzamides 29 was demonstrated, providing diverse 
dihydrobenzofurans 30 with up to 90% yield and 92% ee by utilizing 20b as catalyst (Scheme 
4). In this case, one quaternary center can be formed through a 5-exo-trig cyclization process. 
Later on, aldehydes 31 also proved to be suitable for this transformation, producing 
hydroxychromanes 32 in up to 98% yield and up to 85% ee (Scheme 4).45 In addition, in both 
cases the binaphthyl Cp ligands proved again to be superior to cyclohexyl-substituted Cp 
ligands in terms of either reactivity or enantioselectivity. 
 
Scheme 5. Enantioselective synthesis of isoindolones axially chiral biaryl compounds. 
In the last few years, ligand 19 has also proved compatible with a few other transformations 
with different mechanism. In 2014, Cramer reported an enantioselective synthesis of 
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isoindolones 35 via carbene insertion, inspired by the methodology developed by Rovis 
(Scheme 5).46 By enhancing the steric discrimination between R2 and ester group, diazo 
compounds 34 with a bulky 2,4-dimethyl-3-pentyl ester and alkyl groups as R2 were able to 
deliver the final product 35 in up to 94% yield and with up to 93% ee. With regard to the 
substrate scope, high enantioselectivity and acceptable reactivity could be realized with 
hydroxamates 33 with diverse substitutions and bulky diazoesters 34 without α-substitutions. 
In the same year, an interesting approach to access axially chiral biaryl compounds was 
demonstrated by You (Scheme 5).47 Regarding to the design principle, the interconversion of 
biaryl substrates 36 at low temperature can be hampered by alkenylation at ortho-position 
through a rhodium-catalyzed asymmetric dehydrogenative Heck reaction assisted by pyridine 
moiety as a directing group, resulting in stable axially chiral compounds 38. After screening of 
catalysts, 20b was proved to be optimal, delivering up to 86% ee and 96% yield. For the 
substrate scope, although this reaction proceeded well with various alkenes 37, reactivity and 
enantioselectivity were especially sensitive to variation on biaryl substrates 36. Hence, the 
substrate scope of bialy substrates was significantly limited. Impressively, this work also 
demonstrated such axially chiral biaryl compounds such as 38a were capable to be applied as 
ligands for a rhodium(I) catalyzed conjugate addition of phenylboronic acid 40 to 
cyclohexanone 39.  
In 2015, the same group developed an enantioselective intermolecular (3+2) annulation 
reactions of 1-aryl-2-naphthols 42 and disubstituted alkynes 43 by the dearomatization strategy 
(Scheme 6).48 The spirocyclic β-naphthalenones 44 bearing a quaternary chiral center were 
able to be obtained through this reaction with up to 98% yield and up to 94% ee. Independently, 
Lam reported the asymmetric synthesis of spiroindenes 46 based on a similar mechanism 
(Scheme 6).49 The desired products were obtained by the reaction of enols 45 and internal 
alkynes 43 with up to 94% yield and up to 97% ee. Later on, another method to access chiral 
spirocyclic compounds based on sultam 49 was reported by Cramer with the annulation 
reactions of N-sulfonyl ketamines 47 and internal alkynes 43 (Scheme 6).50  
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Scheme 6. Enantioselective synthesis of spirocyclic compounds via intermolecular (3+2) annulation reactions of 
alkynes.  
With regard to other metal complexes, there is only single report to date for scandium(III)39, 
iridium(III)40 and ruthenium(II)41, respectively (Scheme 7). This field remains obviously 
underdeveloped but has shown great potential by these three seminal works. In 2014, Hou 
discovered an enantioselective C−H functionalization of pyridines 50 with alkenes 51 by 
employing scandium(III) complex 21a, giving a variety of 2-alkylated pyridines 52 in up to 
98% yield and 96% ee.39 One year later, Cramer succeeded in the synthesis of reactive 
iridium(III)40 and ruthenium(II)41 complexes (23 and 25) derived from ligand 19 by a two-step 
synthesis, and also their application in intramolecular cycloisomerization of enynes 53 and 
hetero Diels−Alder reaction of yne-enones 55 respectively. In the first case, iridium(III) 
complex 23a was proposed to activate the terminal alkyne moiety, leading to nucleophilic 
addition of electron-rich tethered alkenes. The following 1,2-H shift process and release of Ir 
catalyst ultimately delivered the final cyclopropanes 54. For the latter report, ruthenium(II) 
complex 25a was believed to coordinate to substrate by the interaction with carbonyl, alkene 
and alkyne moiety of 55, initiating subsequent enantiodetermining oxidative cyclization, 
isomerization and final reductive elimination to afford pyranes 56 in excellent yields and 
enantioselectivities. 
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Scheme 7. Examples of enantioselective reactions catalyzed by Sc(III), Ir(III) and Ru(II) complexes.  
Very recently, another type of ligands 57 based on 1,1’-spirobiindane was disclosed by You, 
which could be regarded as an extension on binaphthyl ligand 19 (Scheme 8).51 As a proof of 
concept, the corresponding catalyst 58a was able to deliver up to 96% ee in contrast to previous 
82% ee for the same transformation as shown in Scheme 5. Nevertheless, the generality and 
superiority of such ligands needs to be identified by more applications in the future.  
 
Scheme 8. The features of chiral Cp ligands 57 compared with binaphthyl ligands 19. 
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Based on all the abovementioned reports, an overview on current chiral Cp ligands could be 
summarized as shown in Fig. 3. In general, there are two categories of Cp ligands to date, 
including synthetic organic ligands by Cramer and You respectively, as well as protein-based 
ligands by Ward and Rovis. However, both ligands are significantly limited and actually 
complementary to each other. On one hand, simple synthetic organic ligands are facing 
limitation of possible variations in their chemical structure and tedious preparation (up to 14 
steps), despite their dramatically growing and broad application in asymmetric metal catalysis 
in recent years.15 On the other hand, more complex protein-based ligands can be modified and 
optimized rapidly without limit, but only one successful example has been reported until now 
due to unidentified generality and also tedious preparation.14  
 
Figure 3. Overview of current chiral Cp ligands. 
In conclusion, the development of enantioselective chemistry enabled by chiral Cp ligands is 
still in its early stages, while the pioneering work in the last half decade have already 
demonstrated tremendous potential. The potential lies not only in the discovery of new 
transformations and other metal complexes based on present ligands, but also the design of 
new Cp ligands with expedient synthesis and improved structural adjustability based on 
privileged scaffolds for systematic catalyst optimization.  
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2.1.2 Synthesis of Chiral Cyclopentadiene Derivatives by (6+3) Cycloadditions 
 
Scheme 9. Stereodivergent (6+3) cycloadditions steered by varied ligands. 
Recently, the development of catalytic asymmetric 1,3-dipolar cycloadditions has been 
growing rapidly,52 in which (6+3) cycloaddition reactions of azomethine ylides and 
fulvenes16,17,53 have been disclosed as a highly efficient way to access chiral Cp derivatives 
(Scheme 9). This type of transformations was initially discovered by Hong in 2003, in which 
racemic Cp derivatives with piperidines were obtained upon the treatment of base or/and Lewis 
acid.54 In 2012, Antonchick and Waldmann described the first highly enantioselective (6+3) 
cycloaddition of azomethine ylides 60 and fulvenes 59 catalyzed by complex of Cu(I) and (R)-
Fesulphos ligand 61, affording highly endo-selective chiral cyclopentadiene derivatives in 
excellent enantioselectivities and yields.16 Due to the instability of (6+3) cycloadducts, a 
sequential (4+2) cycloaddition with maleimide was performed to give the products 62. Later 
on in 2013, the highly exo-selective (6+3) cycloadditions can also be realized by using (R)-
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Difluorophos 63 as a ligand by the same group17 and the modified TF-BiphamPhosas ligand 65 
by Wang53, delivering tandem (6+3)/(4+2) products 64 and chiral cyclopentadiene derivatives 
66 in high endo-selectivity, respectively.  
 
Figure 4. The features of ligand-controlled (6+3) cycloadditions. 
There are a couple of prominent features for this transformation as shown in Fig. 4: (i) diverse 
Cp derivatives are able to be obtained rapidly within 2 steps in a highly enantioselective 
manner; (ii) there are three highly tunable positions in the Cp scaffold, originating from 
numerous commercially available aldehydes, ketones and amino acid esters, together with one 
secondary amine with the potential for further modification. (iii) the stereochemistry of such 
Cp compounds could be adjusted in terms of enantioselectivity and diastereoselectivity by 
simple alternation of ligands.  
  
Chapter 2. Development of Tunable Cyclopentadienyl ligands 
 
18 
 
2.1.3 Catalytic Enantioselective Synthesis of Axially Chiral Biaryl Compounds  
 
Figure 5. Representative ligands, catalysts, natural products and pharmaceuticals with axially chiral biaryls. 
Axially chiral biaryl compounds have been attracting intensive attention in the chemistry 
community (Fig. 5).55-57 In asymmetric catalysis, these compounds are extensively exploited 
as versatile chiral ligands and catalysts,55,56 especially for BINOL (67) and its derivatives which 
have been recognized as privileged ligands or catalysts coined by Jacobsen.23,50,51 Due to the 
structural rigidity and the accessibility of the chiral pool, the ligands or catalysts based on axial 
chirality have become dominant in a variety of fields in asymmetric catalysis, such as BINOL 
(67), chiral phosphoric acids (68), BINAP (69), and even the aforementioned binaphthyl based 
Cp ligands (19).22 Besides applications in catalysis, axially biaryl moiety are widely present in 
natural products and pharmaceuticals, such as (R)-gossypol (70), (R)-Streptonigrin (71), and 
(R)-Steganone (72).57 Notably, in analogy to center-chiral bioactive compounds, atropisomers 
are also disclosed to have significantly different biological profiles such as (R)-gossypol (70), 
highlighting the demands for developing enantioselective synthesis of optically enriched 
atropisomer for further biological evaluation.  
In spite of the importance for such scaffolds, there are only a few methods available to 
atroposelectively access axially biaryl compounds in a catalytic way, which can be divided into 
five categories. These strategies involve catalytic kinetic/dynamic kinetic resolution of their 
racemic precursors or desymmetrization of prochiral biaryls,58-64 atroposelective construction 
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of another aryl,63,65-67 transition metal catalyzed aryl-aryl cross coupling,68,69 [3,3]-sigmatropic 
rearrangement,70,71 and central-to-axial chirality transfer.72-76 (Scheme 10) 
 
Scheme 10. Current strategies to atroposelective synthesis of axially chiral biaryls in catalysis manner. 
Among them, the first strategy involving kinetic resolution (KR), dynamic kinetic resolution 
(DKR) and desymmetrization is regarded to be the most powerful and straightforward, but the 
corresponding catalytic processes remain surprisingly scarce.58-63 For the strategy of de novo 
construction of aromatic ring, albeit with limited number of successful examples, transition-
metal-catalyzed enantioselective [2+2+2] cycloadditions have been explored as a general 
method to access axially chiral biaryls, involving Ni(I), Rh(I), Ir(I) and Co(I).65 In 2011, 
Tanaka reported a Pd-catalyzed synthesis of enantioenriched 4-aryl-2-quinolinones by 
enantioselective intraomolecular hydroarylation.67 Additionally, the sole example with 
organocatalysis was reported by Sprr in 2014 by using intramolecular Aldol condensation.66 
As another straightforward way, direct aryl-aryl cross couplings indeed provide axially chiral 
biaryls in high enantioselectivity, but specific substitution patterns on coupling partners were 
usually required in such transformations. [3,3]-Sigmatropic rearrangement to realize axial 
chirality has been known for a long time by using chiral auxiliaries. However, catalytic 
enantioselective methodologies were only reported very recently in 2013 by Kürti70 and List77. 
For the last strategy, the concept of central-to-axial chirality transfer was proved by Meyers78 
in 1984, after the initial hypothesis by Berson79 in 1955. Even throughout another 30 years, the 
applications of such concept are still limited, especially for the catalytic version.80  
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Scheme 11. Enantioselective synthesis of biaryldiols by organocatalysis via 1,4-addition. 
Very recently, enlightened by the strategy of central-to-axial chirality transfer, there are a few 
elegant enantioselective catalytic transformations to access axially chiral biaryls by employing 
organocatalysts.72-76 In 2015, Tan reported an organocatalytic arylation of 2-naphthols 74 and 
quinone derivatives 73 to access axially chiral biaryldiols 76 atroposelectively (Scheme 11).72 
Regarding the reaction process, a 1,4-addition was proposed to generate central-chiral 
intermediate 78 catalyzed by phosphoric acid 75, followed by a process of central-to-axial 
chirality transfer to give the final product 76. Later on in 2016, the same transformation 
catalyzed by quinine 77 was also demonstrated by Salvio and Bella (Scheme 11).75  
In 2016, another application in central-to-axial chirality transfer was shown by Sun, Kürti and 
Xu with phosphoric acid 75 catalyzed reactions of hydroxyarenes 80 and iminoquinones 79 
(Scheme 12).74 The proposed mechanism involved central chirality transfer process from chiral 
aminal 81 to de-aromatized intermediate 82 via [3,3]-sigmatropic rearrangement, and another 
process of central-to-axial chirality transfer from de-aromatized intermediate 82 to final 
product 83. A variety of BINOL derivatives 83 could be obtained in such strategy in high yield 
and enantioselectivity. In the same year, Bressy, Bugaut and Rodriguez76 reported a stepwise 
method involving organocatalyzed Michael addition, Hantzsch-type synthesis and oxidation, 
to access axially chiral 4-arylpyridines 88 inspired by the prior works of Meyers78 and Straub81 
Chapter 2. Development of Tunable Cyclopentadienyl ligands 
21 
 
(Scheme 12). In this case, chiral tertiary amine with thiourea 86 played as an efficient catalyst 
for the enantioselective Michael addition to give chiral Hantzsch-type compound 87, assisted 
by the treatment of NH4OAc. Sequentially, a central-to-axial chirality transfer process enabled 
the formation of axially chiral 4-Arylpyridines 88, in which the utilization of MnO2 as oxidant 
proved to be critical for the efficiency of chirality transfer.  
 
Scheme 12. Other examples of enantioselective synthesis of biaryldiols by organocatalysis. 
In sharp contrast, only two examples have been reported as efficient methods to synthesize 
axially chiral biaryls in the field of asymmetric catalysis harnessed by chiral Cp-metal 
complexes. The earlier example is [2+2+2] cycloadditions catalyzed by chiral Co(I) complexes 
guided by strategy B as shown Scheme 1. A recent example demonstrated in Scheme 5 is 
dehydrogenative Heck coupling of prochiral biaryl precursors by chiral Rh(I) complexes, 
which can be ascribed into dynamic kinetic resolution (DKR) of prochiral precursor in strategy 
A. Therefore, there is no example involving central-to-axial chirality transfer in this field to 
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date (Scheme 13). To conclude, even though there have been quite a few successful 
applications of chiral Cp ligands in central chirality as shown in 1.1.1, the realm of axially 
chirality remains fairly unexplored, especially with the strategy central-to-axial chirality 
transfer. 
 
Scheme 13. Current strategies enabled by chiral Cp ligands to access axially chiral biaryls. 
On the other hand, the racemic reactions especially catalyzed by transition metal complexes 
with Cp* usually act as a starting point to discover application of chiral Cp ligands in 
asymmetric catalysis. In the field of biaryls synthesis, Cp*Rh(III) and Cp*Ir(III) have been 
recognized as efficient and attractive catalysts for direct arylation via C−H activation to 
construct versatile aryl-aryl bonds in the last decade.10,11,82 
 
Scheme 14. Current methods to access biaryls by Cp* transition metal complexes. 
In general, there are three different methods to construct biaryls compounds by using 
Cp*Rh(III) and Cp*Ir(III) as catalyst (Scheme 14). As the majority of current methods, aryl-
aryl coupling assisted by directing group has become the most powerful strategy to construct 
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biaryls, but with limited examples to date. Among these examples, dehydrogenative coupling 
(X = H) with two arenes usually requires harsh reaction conditions which is not beneficial for 
the control of enantioselectivity, although it represents the most convenient and atom-efficient 
method in biaryl synthesis.83-90 There are also some examples of oxidative C−H coupling with 
aryl organometallic reagents such as arylboronic acids and arylsilanes (X = SiR3, BR2).
91-93 
Very recently, aryl iodides94 and aryldiazonium salts95 were identified to be suitable partners 
for arylations of arenes and even alkenes with proper directing groups. In these cases, relatively 
milder reaction conditions are required due to the prefunctionalisation of inert C−H bonds. 
However, in most examples, substitutions in ortho position adjacent to aryl-aryl bond are 
usually not tolerated, which are crucial for the stabilization of axial chiral biaryls. Recently, 
two methods (B and C, Scheme 14) were developed by employing 4-hydroxycyclohexa-2,5-
dieneones96 90 and quinone diazides97 93 as arylating reagents, providing an alternative 
strategy to access biaryl compounds in mild conditions. Notably, both cases involve an 
aromatization process, which can be regarded as a mechanistically basis for the aforementioned 
central-to-axial chirality transfer in asymmetric catalysis.  
 
Scheme 15. Two transformations catalyzed by Cp* metal complexes involving aromatization process. 
In 2014, Li reported a C−H arylation reaction through a formal Michael reaction/aromatization 
pathway by employing 4-hydroxycyclohexa-2,5-dieneones 90 as arylating reagents.96 (Scheme 
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15) A large spectrum of arylated phenols and anilines 92 could be obtained in moderate to good 
yield through dehydration of intermediate 91. In 2015, inspired by the previous reports of 
Cp*Rh(III) catalyzed C−H functionalization with diazo partners,98-101 Li and Wang realized a 
milder C−H arylation reaction with quinone diazides 93 catalyzed by Cp*Rh(III) and 
Cp*Ir(III), affording varied arylated phenols 95 (Scheme 15).97 The similar aromatization 
process of intermediate 94 is also involved in the proposed mechanism. Given the interesting 
mechanism and mild reaction conditions, these two transformations provide suitable candidates 
for the application of chiral Cp ligands in the enantioselective synthesis of axially chiral biaryls. 
2.2 Design Principle and Aim of the Project 
 
Figure 6. Overview of the current Cp ligands and the application of chiral (6+3) cycloadducts to be ligands. 
Throughout the history of chiral Cp derivative synthesis for ligand development, the balance 
between convenient accessibility and sufficient structural variability is recognized as a 
long-standing challenge (Fig 6). In the early examples, chiral Cp derivatives derived from the 
chiral pool such as pulegone, camphor and tartrate indeed can be accessed rapidly. However, 
for this very reason they are generally lacking structural variability, which severely constrains 
their potential application as ligands.24 On the other end, the structures of protein-based Cp 
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derivatives can be varied rapidly due to the protein nature, but the access to molecular biology 
techniques is required.14 Between the two extremes, the Cp derivatives developed by Cramer 
can be regarded to a compromise with acceptable structural variability and accessibility, 
leading to considerable progress in this field over the last few years.38,50 However, for a more 
general approach to enantioselective catalysis with chiral Cp ligands, novel ligand types would 
be required which are able to combine the strengths of current approaches. 
In fact, the enantioselective (6+3) cycloadditions mentioned in 1.1.2 provide a possibility to 
solve the long-standing challenge abovementioned by providing an approach for the synthesis 
of chiral Cp derivatives combining the strengths of both accessibility and structural variability. 
In spite of the obvious advantages compared with the current small molecule Cp derivatives, a 
few challenges await to be solved as shown in Fig 6: i) some sensitive functional groups 
embodied in the (6+3) cycloadducts, such as ester, amine, might influence the metal 
complexation or the catalytic process; ii) diastereomers could be generated during the metal 
complexation of the non-C2-symmetric (6+3) cycloadducts due to face-selectivity; iii) 
according to the back/side wall hypothesis proposed by Cramer, no functional group in (6+3) 
cycloadducts can define the back wall, although the side wall can be characterized by the proper 
functional groups R1 and R2.  
In this project, to develop and demonstrate (6+3) cycloadducts as efficient ligands, a library of 
corresponding Rh(I) complexes was planned, considering that chiral Cp-Rh(I) complexes are 
the most robust and widely applied catalysts in diverse enantioselective reactions to date. At 
this stage, the possible issues derived from sensitive groups and the lack of C2-symmetry need 
to be investigated and addressed. Sequentially, the applicability and generality of such chiral 
Rh(I) complexes should be identified first by testing two reported reactions (Scheme 2 and the 
first example in Scheme 4). If these two reported reactions could be steered in an 
enantioselective manner, the subsequent aim of this project would be the discovery of 
unprecedented transformations to demonstrate the flexible applicability of this approach 
further. 
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2.3 Results and Discussions 
2.3.1 Synthesis of Ligands and Corresponding Rh(I) Complexes  
Considering the availability of chiral ligands for (6+3) cycloadditions, two methodologies by 
employing commercially available ligands 61 and 63 were chosen to access endo- and exo-
selective chiral Cp derivatives (Scheme 16). Starting from simple amino acids, aldehydes, 
ketones and cyclopentadiene, these enantioenriched Cp derivatives 66 and 96 can be 
synthesized rapidly with a diverse range of structural variation. As mentioned in 2.1.2, there 
are four highly tunable positions in this Cp scaffold including one secondary amine. For 
modification of the secondary amine, a reductive amination was chosen as a mild and efficient 
way to obtain alkylated Cp derivatives 97 and 98, since these Cp derivatives are not stable in 
transformations with harsher reaction conditions such as alkylation with iodomethane.  
 
Scheme 16.  Rapid synthesis of chiral Cp derivatives via enantioselective (6+3) cycloadditions.  
In addition, to address the possible issue of diastereoselectivity in the metalation process, two 
strategies were envisioned based on the hypothesis that the installation of additional 
substitution on α position of cyclopentadiene moiety might block the metal complexation to 
one face of (6+3) cycloadducts to some extent or completely (Scheme 17). For the first strategy, 
additional R2 substitution can be generated from disubstituted imine 60. However, the 
corresponding disubstituted imines failed to give isolable (6+3) cycloadducts even after 
intensive condition optimization. Gratifyingly, the desired (6+3) cycloadducts from diverse 
disubstituted fulvenes 59 could be accessed smoothly in moderate ee by using commercial 
ligands (R)-Fesulphos through endo-selective (6+3) cycloadditions.  
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Scheme 17. Two strategies to address possible diastereoselectivity of metalation. 
Based on all the aforementioned considerations, two categories of Cp derivatives (66 and 96) 
were prepared by endo- and exo-selective (6+3) cycloadditions under various optimized 
conditions (see 7.2.1). Collectively, 22 Cp derivatives without modification of secondary 
amine were synthesized (Table 1).  
 
Table 1. Synthesis of chiral Cp ligands by asymmetric (6+3) cycloadditons. 
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Ligands Method[a] R1 R2 R3 yield(%) ee(%)[b] 
96a[c] A Me 2-naphthyl Me 73 70 
96b A Et 2-naphthyl Me 57 60 
96c B -(CH2)3- 2-naphthyl Me 89 29 
96d B -(CH2)5- 2-naphthyl Me 90 66 
96e A Me 4-Br-C6H4 Me 83 62 
96f A Me 4-Me-C6H4 Me 77 67 
96g A Me 2-Me-C6H4 Me 78 66 
96h A Me 2-naphthyl Et 83 71 
96i B 2-naphthyl 4-Br-C6H4 Me 57 96 
66a C 4-Br-C6H4 4-Me-C6H4 Et 61 92 
66b C 4-Br-C6H4 4-Br-C6H4 Et 82 96 
66c C 4-Br-C6H4 4-F-C6H4 Et 82 96 
66d C 4-Br-C6H4 2-Me-C6H4 Et 50 72 
66e C 2-naphthyl 4-Br-C6H4 Me 82 96 
66f C 4-Me- C6H4 4-CF3-C6H4 Et 82 97 
66g C 4-Br-C6H4 4-CF3-C6H4 Et 70 96 
66h C 4-Cl-C6H4 4-CF3-C6H4 Et 67 96 
66i C i-Pr 4-CF3-C6H4 Et 31 89 
66j C 2-naphthyl 4-CF3-C6H4 Et 82 98 
66k[d] D 4-Br-C6H4 4-F-C6H4 Me 74 >99 
66l C 4-Br-C6H4 4-F-C6H4 Bn 50 96 
66m C 4-Br-C6H4 4-Me-C6H4 Me 66 95 
[a] Using Method A-D as shown in experimental part. [b] Determined by HPLC analysis. [c] The optical pure 
form of this ligand could be prepared in gram scale by preparative HPLC of its racemate. Conditions: CHIRAPAK 
IC column, iso-propanol / heptane = 15/85, flow rate = 4 mL min-1, t = 6.8 min, 9.8 min. [d] The optical pure form 
of ligand was prepared by the recrystallization of corresponding asymmetric (6+3) cycloadduct with 95% ee.  
Additionally, alkylated Cp derivatives (97 and 98) were also synthesized by reductive 
amination to investigate the possible influence of secondary amine on catalytic process and 
enantioselectivity (Scheme 18). Notably, mixtures of isomers were found for alkylated Cp 
derivatives due to the isomerization of Cp moiety during reductive amination. 
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Scheme 18.  Synthesis of alkylated Cp ligands by reductive amination with aliphatic aldehydes. 
With the enantioriched Cp derivatives in hand, intensive optimization of Rh(I) complexation 
was performed. Four different methods (see 7.2.2) were developed for corresponding Rh(I) 
complexes based on a few considerations. At first, the acidity of proton on Cp moiety 
differentiates dramatically according to substitutions on R1 and R2. Hence, the deprotonation 
process by thallium alkoxides turned out to be quite sensitive to reaction temperature. Another 
consideration is based on the observation of transesterification between sensitive ester group 
of (6+3) cycloadducts and different alkoxides to various degrees. Additionally, Rh(I) 
complexes are rather unstable in the process of purification, especially on silica. The utilization 
of neutral Al2O3 and Ar pressure proved to be beneficial for the reactivity and yield of Rh(I) 
complexes. Notably, a special design of chromatography combining neutral Al2O3 and 
neutralized silica is critical to isolate the individual diastereomer of Rh(I) complexes (see 
7.2.2). After the establishment of robust metalation and purification methods for Cp 
derivatives, a total of 30 chiral Rh(I) complexes were obtained, which can be divided into two 
categories (99 and 100) based on di- or monosubstitution of R1 (Table 2). As expected, most 
catalysts were obtained as mixtures of diastereomers due to the lack of face-selectivity upon 
metalation. The aforementioned strategy to address face-selectivity of metalation of non-C2-
symmetric (6+3) cycloadducts with di-substitution of R1 turned out to be feasible, leading to 
better diastereoselectivity in the formation of Rh(I) complexes upon metalation (99a-h) 
compared with (6+3) cycloadducts with mono-substitution of R1 (100a-n).  
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Table 2. Synthesis of Rh(I) complexes. 
 
catalys
t 
method[a
] 
R1 R2 R3 R4 yield(%) d.r.  ee(%)[b] 
99a E Me 2-naphthyl Me H 71 >95:5 70 
99b E Et 2-naphthyl Me H 71 72:28 60 
99c E -(CH2)3- 2-naphthyl Me H 74 76:24 29 
99d E -(CH2)5- 2-naphthyl Me H 63 90:10 66 
99e E Me 4-Br-C6H4 Me H 54 >95:5 62 
99f E Me 4-Me-C6H4 Me H 62 85:15 67 
99g E Me 2-Me-C6H4 Me H 78 86:14 66 
99h H Me 2-naphthyl Et H 67 84:16 71 
99i E[c] Me 2-naphthyl Me Me 81 >95:5 100 
99j E[c] Me 2-naphthyl Me Et 45 >95:5 100 
99k E[c] Me 2-naphthyl Me i-Bu 82 55:45 100 
100a F 4-Br-C6H4 4-Me-C6H4 Et H 78 60:40 92 
100b F 4-Br-C6H4 4-Br-C6H4 Et H 60 57:43 96 
100c F 4-Br-C6H4 4-F-C6H4 Et H 76 58:42 96 
100d F 4-Br-C6H4 2-Me-C6H4 Et H 66 56:44 72 
100e G 2-naphthyl 4-Br-C6H4 Me H 65 50:50 96 
100f G 2-naphthyl 4-Br-C6H4 Me Me 81 55:45 96 
100g F 4-Me-C6H4 4-CF3-C6H4 Et H 80 62:38 97 
100h F 4-Br-C6H4 4-CF3-C6H4 Et H 79 59:41 96 
100i F 4-Cl-C6H4 4-CF3-C6H4 Et H 59 57:43 96 
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Continuation of Table 2 
100j F i-Pr 4-CF3-C6H4 Et H 65 67:33 89 
100k F 2-naphthyl 4-CF3-C6H4 Et H 83 59:41 98 
100l G[d] 4-Br-C6H4 4-F-C6H4 Me H 79 60:40 >99 
100m G 4-Br-C6H4 4-F-C6H4 Bn H 74 50:50 96 
100n G 4-Br-C6H4 4-Me-C6H4 Me H 82 57:43 95 
100o G 2-naphthyl 4-Br-C6H4 Me H 88 >95:5 96 
[a] Using Method E-H as shown in experimental part. [b] Determined by ee of corresponding ligands through 
HPLC analysis. [c] The optical pure form of ligand was prepared by preparative HPLC on chiral phase. [d] The 
optical pure form of ligand was prepared by recrystallization of corresponding asymmetric (6+3) cycloadduct with 
95% ee.  
Initially, ligands with moderate to excellent enantioselecetivity were synthesized through 
catalytic enantioselective methodologies due to relatively simplified preparation. Since Cp 
ligands are not optically pure, a concept of chirality transfer (CT) was proposed to evaluate the 
efficiency of chirality induction of a specific ligand. Based on its definition, chirality transfer 
(CT) = eeprod/eecat =  eemax. The eemax also represents the ee of product when eecat is 100%.
102  
However, chirality transfer (CT) as an indicator to screen catalysts can only be feasible under 
the assumption of linear relationship between ee of catalyst and ee of products for the target 
reaction. Fortunately, this assumption has been substantially proven by the first model reaction 
involving enantioselective synthesis of isoquinolinones (see 7.2.3.1, Fig. S1). 
2.3.2 Enantioselective Synthesis of Isoquinolinones as a Model Reaction 
To explore the potential of obtained Rh(I) complexes, the C‒H functionalization of 
hydroxamates with alkenes catalyzed by Cp*Rh(III) as shown in Scheme 2 was investigated. 
As menthioned above, Ward and Rovis as well as Cramer developed two complementary 
strategies to design and synthesize chiral Cp ligands by using the same transformation in 2012, 
respectively (Scheme 2).13,14 
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Table 3. Catalysts optimization.[a] 
 
Entry cat[c] ee of cat (%) ee of product (%) CT 
(%)[b] 
t (h) yield (%) 
1 100f[d] 96 60 63 1 67 
2 100o[d] 96 21 22 1 81 
3 99a 100 68 68 1 90 
4 99b 60 38 63 1 67 
5 99c 29 18 62 1 90 
6 99d 66 24 36 1 58 
7 99e 62 43 69 1 76 
8 99f 67 41 61 1 72 
9 99g 66 44 67 1 67 
10 99h[c] 71 46 65 1 52 
11 99i 100 83 83 4 90 
12 99j 100 76 76 18 49 
13 99k[c] 100 78 78 18 54 
[a] General procedure: Rh(I) catalyst (5.00 μmol, 0.05 equiv.), (BzO)2 (75 wt%, 5.00 μmol, 0.05 equiv.), 
hydroxamate 9 (0.10 mmol, 2.00 equiv.) were dissolved into 1 mL DCM. After stirring at r.t. for 10 mins, 
corresponding alkenes 10 (0.20 mmol, 2.00 equiv.) was added and the reaction was stirred for specific time. [b] 
Chirality transfer (CT) = eeprod/eecat = eemax, eemax: the ee of product when eecat is 100%. [c] Unless otherwise noted, 
catalyst was used as single isomer or major isomer. [d] Catalyst was used as mixture of two isomers.  
Preliminary study revealed that sensitive groups of Cp ligands had no detrimental influence on 
the catalytic process, and the desired isoquinolinone 11a could be obtained smoothly in high 
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yield (Table 3). The optimization of catalyst was initiated from R1 substituents originating from 
different ketones or aldehydes (Table 3, entries 1-6). The methyl group proved to be optimal 
for disubstituted R1, with which the corresponding Rh(I) complex 99a gave the desired product 
with 68% CT in 90% yield. Other groups on R1 resulted in either lower reactivity or 
enantioselectivity. Then, an intensive screening of R2 was performed (Table 3, entries 7-9). R2 
was identified to be critical for the enantioselectivity and the 2-naphthyl group turned out to be 
optimal. In addition, the possible effect of R3 was also investigated, and bulkier groups than 
methyl such as benzyl led to lower reactivity but with similar enantioselectivity (Table 3, entry 
10). At this stage, the optimal Cp ligand 96a was obtained in optically pure form by separation 
of enantiomers of racemic 96a by preparative HPLC on chiral phase in gram scale. After 
optimization of R1, R2 and R3, the protecting group on secondary amine was identified to be 
crucial for both enantioselectivity and reactivity. Finally, the ligand with methyl as protective 
group on the nitrogen (catalyst 99i) produced the desired product in 90% yield and with 83% 
ee. Larger groups such as ethyl and isopropyl resulted in the decrease of both reactivity and 
enantioselectivity. (Table 3, entries 11-13) The absolute configuration of catalyst 99i was 
determined by X-ray crystallographic analysis (by Dr. Constantin G. Daniliuc). 
With optimal catalyst (99i) in hand, the optimization of reaction conditions was carried out (see 
7.2.3.1, Table S1). Solvents showed obvious effects on reactivity but no influence on 
enantioselectivity. Moreover, reducing the temperature to -10C promoted the ee to 90%. After 
establishing the optimal reaction conditions, the substrate scope was subsequently explored. 
As outlined in Scheme 19, various styrenes even with various hetero aromatic substitutions 
were tolerated in this reaction, affording desired products 11a-11l in excellent 
enantioselectivity and yield. Cyclic alkenes were suitable for this catalysis sysmtem (11m-
11o). Surprisingly, ortho‒substituted styrenes afforded the desired products 11h and 11i, which 
has not been reported for this transformation in chiral or racemic manner.13,14,35,36 For aryl 
hydroxamates, substrates with varied electronic and steric properties of substitutions were 
compatible with this reaction, affording the desired products 11p-11x. Notably, different 
electronic properties of substitutions on meta position resulted in the reversed regioselectivity 
of products.  
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Scheme 19. Substrate scope for the enantioselective synthesis of isoquinolinones. 
Protoberberines are an important class of naturally occuring tetracyclic isoquinoline alkaloids 
with diverse biological activities, such as Bharatamine (101), Xylopinine (102) and Gusanlung 
(103).103,104 Facilitated by the unique catalytic property of catalyst for ortho-substituted 
styrenes, the synthesis of protoberberines analogs 105a-105d was achieved by a cascade 
reaction with a sequence of C‒H functionalization followed by intramolecular SN2 reaction of 
104 in one-pot manner (Scheme 20).  
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Scheme 20. Synthesis of protoberberines analogs in one-pot manner. 
To support the rationale of regioselectivity and enantioselectivity of this transformation, 
preliminary computational studies were performed by Dr. Christian Merten. In theory, there 
are four possible stereoisomers based on two regioisomers with the phenyl group at 3- and 4- 
positions, of which only the S configuration of the 3-substituted regioisomer 11a was found 
experimentally. The excellent regioselectivity can be rationalized by the calculations as all 
pathways to the 4-substituted regioisomers feature transition state barriers which are 
approximately 2 kcal/mol higher than those leading to the 3-substituted regioisomers. Hence, 
from a kinetic perspective, and in agreement with the experimental findings, the pathways 
leading to the 4-substituted regioisomer can be excluded from the analysis. As for the 
enantioselectivity of 3-substituted regioisomers, previous mechanistic considerations 
suggested a preferred structure of the rhodacycle intermediate in which the Boc protective 
group is located on the sterically less hindered side, and styrene approaches the rhodacycle 
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intermediate with phenyl pointing away from Cp ligand to avoid unfavorable steric 
interaction.13 Accordingly, in the present case, Boc would point towards the 2-naphthyl group 
(substituent R2) bearing side of the ligand (intermediate B, Scheme 21). On the other hand, 
styrene should approach in the same way (pathway II, Scheme 21), while the other orientation 
of styrene would be less favorable (pathway I, Scheme 21). For the calculations, it’s also 
considered that the hydroxamate is in its presumably less favored orientation with respect to 
the Boc group pointing towards the methyl groups (substituents R1, intermediate A, Scheme 
21). In addition, two different orientations of the Boc carbonyl group were taken into account, 
so that in total four conformers of the rhodacycle intermediate were investigated. Besides, two 
opposite ways of styrene to approach the rhodacycle intermediate were also taken into 
consideration. Through analyzing the free energy profiles of all pathways, previous 
stereochemical model proposed by Cramer group was strongly supported. 
 
Scheme 21. Computation study on reaction mechanism for the isoquinolinone derivative synthesis. 
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2.3.3 Enantioselective C−H Allylations of Benzamides as a Model Reaction 
In order to further investigate the generality and the flexible applicability of this Cp ligands 
library, asymmetric C‒H allylation of benzamides was investigated as the second model 
reaction, previously reported by Cramer using chiral binaphthyl-substituted Cp ligands37 as 
shown in Scheme 4. In the seminal work, cyclohexyl-substituted chiral Cp ligands successfully 
applied in the asymmetric synthesis of isoquinolinones could not induce high enantioselectivity 
in this transformation. By analogy, only 24% ee could be obtained by using optimal catalyst 
99i in the asymmetric synthesis of isoquinolinones (Table 4, entry 3). Delightfully, screening 
of ligand library revealed that catalyst 100a derived from a chiral Cp ligand equipped with two 
aryl groups in trans manner is efficient for this enantioselective transformation, delivering up 
to 86% CT without diminishing the reactivity (Table 4, entry 6). Systematic optimization of 
substituents R1 and R2 in ligands revealed that for this specific transformation ortho substituted 
aryl or aliphatic groups led to decreased enantioselectivity (Table 4, entries 9 and 15), whereas 
ligands with para- or meta- substituted aryl groups had no significant influence on 
enantioselectivity. Furthermore, R3 had no significant effect on enantioselectivity, but other 
esters bulkier than methyl ester led to decreased reactivity (Table 4, entries 8, 17 and 18). 
Contrary to optimal catalyst 99i in the isoquinolinone synthesis, N-methylation of secondary 
amine resulted in a sluggish reaction and decreased enantioselectivity (Table 4, entry 11). 
Eventually, catalyst 100l turned out to be optimal. The corresponding ligand of catalyst 100l 
can be readily prepared with > 99% ee on gram scale by recrystallization of chiral (6+3) 
cycloadduct. 
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Table 4. Catalysts optimization.[a] 
 
Entry  cat[c] ee of cat (%) ee of product (%) CT (%)[b] yield (%) 
1 99a[d] 100 21 21 76 
2 99d[d] 66 32 48 66 
3 99i[d] 100 24 63 82 
4 99j[d] 100 <5 <5 76 
5 99k 100 13 13 79 
6 100a 92 79 86 78 
7 100b 96 84 88 85 
8 100c 96 84 88 85 
9 100d 72 59 82 85 
10 100e 96 82 85 79 
11 100f 96 80 83 51 
12 100g 97 85 88 85 
13 100h 96 85 88 82 
14 100i 96 85 88 82 
15 100j 89 64 72 50 
16 100k 98 86 88 82 
17 100l 99 87 88 87 
18 100m 96 85 89 67 
19 100n 95 83 87 82 
20 100o 96 0 0 63 
[a] Catalyst (5.00 μmol, 0.05 equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.) and 26a (0.12 
mmol, 1.20 equiv.) were dissolved into 0.5 mL DCM. The mixture was allowed to be stirred at r.t. for 10 mins. 
After cooling to -20°C, corresponding allenes 27a (0.1 mmol, 1.00 equiv.) was added and the reaction was stirred 
for 18 hours. [b] Chirality transfer (CT) = eeprod/eecat  =  eemax, eemax: the ee of product when eecat is 100%. [c] Unless 
otherwise noted, catalyst was used as mixture of two isomers. [d] Catalyst was used as single isomer or major 
isomer.  
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The subsequent optimization of reaction conditions disclosed that the reactivity could be 
influenced dramatically by solvent, but not for enantioselectivity (see 7.2.4.1, Table S2). A 4:1 
combination of dichloromethane (DCM) and trifluoroethanol (TFE) proved to be optimal, 
giving the desired product in 85% yield and with 90% ee within 18 h at -20C. Since Rh(I) 
complex 100 is a mixture of diastereomers (Table 2), investigation of the possible difference 
between two diastereomers of the Rh(I) complex was carried out under optimized reaction 
conditions, revealing that there was no significant difference between two diastereomers of 
optimal catalyst 100l in terms of stereoselectivity (Scheme 22). This observation was 
confirmed by the same experiment on catalyst 100n. Hence, Rh(I) complex 100l was utilized 
as a mixture of two diastereomers in the further transformations.  
 
Scheme 22. Investigation of difference between two diastereomers of Rh(I) complexes 2l and 2n. 
Evaluation of the substrate scope (Scheme 23) showed that different substitution patterns on 
benzamides were suitable, affording products 28a-28h with good to excellent ee and yield. 
Additionally, this transformation was also compatible with various allenes (28i-28k). Methods 
K-M were employed according to specific benzamides and allenes, either to avoid double 
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allylation of bezamides or to enhance reactivity by means of increasing concentration (see 
7.2.3.3). 
 
Scheme 23. Substrate scope for enantioselective C−H allylations of benzamides. 
2.3.4 Application of Newly Developed Cyclopentadienyl Ligands in Enantioselective 
Synthesis of Axially Chiral Biaryls 
Besides the successful applications in reported reactions, an unprecedented asymmetric 
reaction was developed to further demonstrate the flexible applicability of this Cp ligands 
library. As presented in 2.1.3, asymmetric catalysis to access axially chiral biaryls is still 
relatively underdeveloped compared with central chirality in spite of the importance of chiral 
biaryls in NPs, chiral auxiliaries, ligands and catalysts (Fig. 5). To date, there are only a few 
available strategies to construct axially chiral biaryls in catalytic manner (Scheme 10).  Among 
them, central-to-axial chirality transfer represents an elegant strategy involving destruction of 
a stereogenic element and a simultaneous formation of different stereogenic element. Even 
though it has been proposed for more than 60 years, successful catalytic examples by this 
strategy are still scarce. In the last two years, the strategy of central-to-axial chirality transfer 
has shown tremendous potential to be a highly efficient way for synthesizing such valuable 
compounds in the field of organocatalysis (Scheme 11 and 12). However, there is no successful 
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application of this promising strategy in the transformations steered by chiral Cp ligands 
(Scheme 13). 
Recently two independent groups reported alternative synthesis of biaryls catalyzed by Cp* 
transition metal complexes with 4-hydroxycyclohexa-2,5-dieneones and quinone diazides as 
coupling partners (Scheme 15). These two reports provide the mechanistic basis for possible 
application of central-to-axial chirality transfer strategy enabled by chiral Cp ligands. Between 
them, quinone diazides were chosen as substrates for the possible application in asymmetric 
catalysis, since the corresponding reaction is more efficient and milder.  
  
Scheme 24. Preliminary result and future plan for optimization. 
Preliminary study was carried out with benzamide 26a and diazonaphthoquinone 106a as 
standard substrates. The reason for choosing benzamide 26a is the ortho-methyl group can 
inhibit possible bi-arylated product, simplifying the process of purification and analysis.  There 
are two main considerations for employing diazonaphthoquinone 106a. On one hand, 
diazonaphthoquinone 106a is capable of providing two ortho-substitutions adjacent to aryl-
aryl bond, leading to stabilized axial chirality. In addition, diazonaphthoquinone is one of the 
most reactive quinone diazides. After initial reaction conditions optimization, catalyst 100l 
could afford the desired product 107a with up to 55% ee, albeit with poor yield (Scheme 24). 
Screening of solvents, temperature and even catalysts did not improve enantioselectivity (see 
7.2.5.1, Table S3). Based on the preliminary result, three approaches were proposed to solve 
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the issues of reactivity and enantioselectivity, including the modification on the diazo part and 
benzamide part, and the optimization of reaction conditions (Scheme 24).  
 
Scheme 25. Investigation on the modification of diazo compounds and benzamides. 
With regard to the modification of diazo compound, easily accessible diazo compound 106b 
with additional ester group was employed in this transformation, surprisingly producing the 
desired product in up to 90% yield within 24 hours (Scheme 25). After obtaining the X-ray 
structure of 107b (by Dr. Constantin G. Daniliuc), the presence of strong H-bonding was found 
between ester group and hydroxyl group. When the diazo compound 106a without ester group 
was employed, the reaction stopped to a certain degree, leading to limited conversion. Taken 
together, the possible reason for enhanced reactivity might lie in the elimination of negative 
influence of hydroxyl group in catalytic cycle by the installation of ester group as H-acceptor. 
However, further experiments are needed for elucidating the proposed mechanism. 
Furthermore, there was no desired product from other diazo compounds except 
diazonaphthoquinone substrates such as 106c-e, which proved the initial consideration 
regarding to reactivity of diazo compound. 
On the other hand, the modification on benzamide part was carried out mainly on the 
installation of another substitution on meta position in the presence of ortho-substitution 
(Scheme 26). Delightfully, meta-substitutions turned out to be beneficial for enantioselectivity 
in spite of leading to acceptably decreased reactivity. Benzamide 26d bearing meta-methyl 
afforded the desired product with up to 89% ee, whereas 26c derived from 3-chloro-2-
naphthoic acid gave 65% ee. Subsequent conditions screening for the reaction involving 
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benzamide 26e disclosed that up to 91% ee was obtained by using 1,4-dioxane as solvent (see 
7.2.5.1, Table S4). 
 
Scheme 26. Investigation on the modification of diazo compounds. 
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Scheme 27. Substrate scope investigation. 
With optimized conditions in hand, substrate scope study was performed. In general, this 
reaction is not compatible with highly electron-deficient benzamides such as 26e and 26f. 
Electron-rich benzamide with ortho-methoxyl (26g) also failed to give the desired product. 
Additionally, benzamide 26h without ortho-substitution gives biarylated compound as major 
product (Scheme 27). In conclusion, to obtain biaryls in high enantioselectivity and 
regioselectivity, benzamides should bear ‘blocking group’ on ortho-position except methoxyl 
and electron-donating ‘ee group’ on meta-position simultaneously. Varied non-C2-symmetrical 
biaryl compounds 107 were achieved in excellent enantioselectivity. Besides X-ray 
crystallographic analysis of 107b (by Dr. Constantin G. Daniliuc), the absolute configuration 
of 107d was also confirmed by vibrational circular dichroism (VCD) spectroscopy (by Dr. 
Christian Merten, see 7.2.6.2). 
 
Scheme 28. Proposed mechanism for the unprecedented reaction. 
According to previous reports,99,105 a plausible mechanism was proposed (Scheme 28). The 
reactive Rh(III) complex 12a generated from Rh(I) complex by treatment with dibenzoyl 
peroxide, and reacts with 26a via N−H insertion followed by sequential concerted-metalation-
deprotonation (CMD) process to give intermediate 108. A subsequent nucleophilic attack by 
diazo compound 106b forms rhodium carbene 110 through intermediate 109 with simultaneous 
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release of nitrogen. Rhodium carbene 110 is subject to a 1,2-migratory insertion to give central 
chiral intermediate 111, followed by protodemetalation to recycle Rh(III) catalyst and generate 
key intermediate 113. The intermediate 113 with central chirality gives final product 107b 
through a central-to-axial chirality transfer process. Another possible pathway is the generation 
of Rh-enolate 112 through isomerization of intermediate 111, followed by a protonation 
process to give the product 107b.  
2.4 Summary and Perspective 
The development of chiral Cp ligands had been hampered for a long period due to their inherent 
difficulties in terms of design and synthesis, in spite of the broad application of Cp* in 
transition metal catalysis in the past. Inspired by the dramatic progress in the realm of 
asymmetric (6+3) cycloadditions catalyzed by Lewis acid, a novel approach to chiral Cp ligand 
discovery had been disclosed as depicted in this chapter. The chiral ligands can readily be 
synthesized on gram scale by either recrystallization of enantioenriched (6+3) cycloadducts or 
preparative HPLC on chiral phase of racemic (6+3) cycloadducts. Besides convenient 
accessibility, more importantly both structure and configuration of such Cp derivatives can 
efficiently be adjusted by means of flexible ligand-controlled enantioselective (6+3) 
cycloaddition reactions.  
The generality and applicability of these chiral Cp ligands was substantially proved by 
successful applications of their corresponding Rh(I) complexes in three different reactions. The 
high enantioselectivity achieved in the first two reported transformations revealed that these 
easily accessed Cp ligands could actually rival previously developed ligands. Furthermore, an 
unprecedented C‒H activation reaction was realized to afford valuable axially chiral biaryl 
compounds with excellent enantioselectivity. Notably, through this reaction was the strategy 
of central-to-axial chirality transfer applied into chiral Cp ligands enabled transformation for 
the first time.  
By integrating the advantages of convenient accessibility, rapid structural variability, as well 
as wide applicability demonstrated by three different reactions, this library of Cp ligands unites 
the strengths of previously developed ligand classes reported by Cramer, Ward and Rovis 
together with You. The findings shown in this chapter suggest that this approach should enable 
the discovery of efficient chiral Cp ligands for further enantioselective transformations. 
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3.1 Introduction 
3.1.1 Pyrrolizidine Moiety in Natural Products and Its Synthesis 
Pyrrolizidine alkaloids (PAs) are a large family of natural products, such as platynecine (114), 
loline (115), 9-angeloylplatynecine (116), and USC1025A (117)106 (Fig. 7). A broad spectrum 
of bioactivity has been identified involving insecticidal, anti-bacterial, anti-viral, anti-tumor, 
anti-diabetic and anti-inflammatory properties, along with diverse toxicity.107-109 For example, 
USC1025A (117) was isolated form the fungus Acremonium sp. KY4917 in 2002, exhibiting 
antimicrobial activity and antiproliferative activity against human tumor cell lines.110  
 
Figure 7. Representative natural products based on pyrrolizidine scaffold. 
Due to their biological importance, these bicyclic ring systems have been receiving 
considerable attention. There had been plenty of methods to construct pyrrolizidine moiety 
efficiently in the last few decades, in which intramolecular cyclization based on flexile 
transformations of secondary amine in substituted pyrrolidine core is one of the most 
straightforward strategies (Scheme 29).106,111 Various transformations were developed to 
access pyrrolizidine scaffold by this strategy, involving SN nucleophilic substitution, reductive 
amination, lactamization, Mitsunobu reaction, hydroamination, aza-Michael reaction, 
vinylation, and so on.111 Besides construction of pyrrolizidine scaffold, another major 
challenge originates from the prevalence of stereocenters in PAs. In general, multistep 
synthesis based on chiral pool is usually required to construct such moiety in enantioselective 
manner.111 In the chiral pool, proline usually serves as the major starting material due to its 
accessibility and presence of multiple functional groups especially secondary amine for further 
transformation. However, catalytic asymmetric preparation of pyrrolizidines for the synthesis 
of compound library remains scarce to date.112 
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Scheme 29. Versatile methods based on intramolecular cyclization of secondary amine in pyrrolidine core. 
Furthermore, due to the lack of robust methodology, there is no chiral PAs-inspired compound 
collection to enable systematic investigation in chemical biology and medicinal chemistry. 
According to BIOS, to define the chemical space based on pyrrolizidine scaffold for potential 
target protein, the development of enantioselective methodology to build a large library of 
pyrrolizidines is highly desirable.  
3.1.2 Catalytic Asymmetric 1,3-Dipolar Cycloaddition Reactions of Azomethine Ylides 
The cycloaddition reaction represents one of the most prominent reactions in modern organic 
synthesis owing to its inherent efficiency and atom economy. Especially, 1,3-dipolar 
cycloaddition reaction (1,3-DC) has become one of the most efficient methods to access 
heterocycles, due to its unique feature of one sole step to construct heterocycles with up to four 
stereocenters.52,113-119 Over the last few decades, versatile dipoles have been successfully 
applied into catalytic asymmetric 1,3-DC, including nitrone, azomethine imine, azomethine 
ylide, nitrile oxide, nitrile imine, nitrile ylide, carbonyl ylide, diazo compound, and azide.52 
Among them, the 1,3-DC of azomethine ylide has been intensively explored with a broad range 
of activated dipolarophiles for the synthesis of enantioriched nitrogen-contained 
heterocycles.18,114,118,120  
As the seminal work in this field, Grigg used stoichiometric CoCl2 as Lewis acid together with 
ephedrine derivative as ligand to realize the asymmetric synthesis of pyrrolidine derivatives in 
1991.121 Inspired by this pioneering work, Zhang122 and Jørgensen123 independently reported 
the first catalytic asymmetric 1,3-DC by employing chiral Ag(I) complex and chiral Zn(II) 
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complex as catalyst respectively in 2002. Through extensive investigation over the last decade, 
a great variety of catalytic systems and substrate types had been developed in this field (Scheme 
30).52  
 
Scheme 30. Catalytic enantioselective 1,3-dipolar cycloaddition reaction and its activation modes. 
Regarding to substrate types of dipolarophile, the scope of commonly used α,β-unsaturated 
alkenes with electron-deficient property haven been extended, such as sterically demanding 
and fluorinated alkenes,120 as well as fullerenes124-128 (Scheme 30a). Furthermore, higher order 
1,3-DC were also realized enabled by utilization of specific substrate as dipolarophiles. For 
example, (6+3) cycloadditions were reported by using fulvenes16,17,53 and tropones129,130, and 
the use of stabilized azomethine imines led to realization of (3+3) cycloadditions131. Besides 
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the rapid exploration of dipolarophile, various types of azomethine ylides were also exploited 
to afford versatile functionalized pyrrolizidines, such as cyclic azomethine ylides, Münchnones, 
α-Imino phosphonates and amides, N-(2-pyridylmethyl) imines, α-silylimines, and ylides 
generated by decarboxylation from proline (Scheme 30a).52,120  
With regard to activation modes (Scheme 30b), Lewis acid catalysis has become the most 
efficient way to steer catalytic asymmetric 1,3-DC. Its effectiveness builds on the generation 
of rigid N-metalated azomethine ylides 119 from imines catalyzed by Lewis acid through 
deprotonation, and the origin of enantioselectivity is from chiral ligands coordinating with 
Lewis acid. A variety of catalytic systems has been described in the last decade, consisting of 
varied metals and structurally versatile ligands. Despite the use of Cu and Ag are still the 
mainstream in current literature, Zn, Ni, Ca and Au were also reported to be effective. As the 
origin of enantioselective induction, diverse chiral ligands have been designed and successfully 
applied into substrate-specific reactions. Especially, some of ligands are regarded to be 
‘privileged’22,23 with the feature of delivering excellent enantioselectivity for a wide range of 
substrates, such as Ugi amine derived ferrocenes 118, Fesulphos 61, Segphos 120, and TF-
Biphamphos 121. In addition, the rise and maturity of organocatalysis over the last decade 
provides an alternative approach to the aforementioned metal catalyzed process (Scheme 30c). 
Currently, there are three major activations in organocatalyzed 1,3-DC.52,120 Iminium 
activation (122) is through covalent interaction of chiral amine with α,β-unsaturated aldehyde, 
while thiourea activation (123) usually cooperates with chiral base intramolecularly through 
H-bonding interaction with nitro or other carbonyl group to induce enantioselectivity 
effectively. Chiral Brønsted acid activation (124) can also induce excellent enantioselectivity 
mainly for some specific azomethine ylides derived from 2-aminomalonate. Besides the major 
activation modes mentioned above, chiral N-heterocyclic carbene through azolium 
mechanism132 and chiral guanidine as strong base and H-bonding donor133 also emerged as 
effective approaches to steer 1,3-DC enantioselectively, albeit with scarce examples. In spite 
of the significant limitations compared with effective Lewis acid catalysis, such as the 
relatively narrow substrate scope and the need for high amount of catalyst loading, 
organocatalyzed 1,3-DC still represents one attractive approach due to environmental 
friendliness, easy handling and compatibility with sensitive substrates.  
Considering the power of catalytic enantioselective 1,3-DC to access chiral pyrrolizidine, a few 
methods guided by BIOS have been developed to build compound collections. These 
compound collections provided the basis for further investigation in chemical biology and 
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medicinal chemistry, in which high rates of active hits with various biological activity were 
identified. An early example is the first Lewis acid catalyzed enantioselective synthesis of 3,3’-
pyrrolidinyl spirooxindoles by Waldmann (Scheme 31).134  
 
Scheme 31. Catalytic enantioselective 1,3-dipolar cycloaddition reaction developed in light of BIOS. 
Using Ugi amine derived ferrocene 126 as chiral ligand, varied spirooxindoles 127 could be 
obtained by 1,3-DC of 3-methylene-2-oxindoles 125 and imino esters 60 in up to 98% ee. A 
compound collection with 39 members was subjected to phenotypic screening associated with 
mitotic arrest in BSC-1 cells, inspired by known principle that 3,3’-pyrrolidinyl spirooxindoles 
induce mitotic arrest by interference with p53-MDM2 interaction. Among them, only 
compound 128 with different relative configuration induced significant phenotypic changes. 
Further study in depth revealed that only (−)-128 out of two enantiomers is active and it actually 
interferes microtubule polymerization other than inhibiting p53-MDM2 interaction. In 2013, 
another iridoid-inspired compound collection (130) of 115 compounds was achieved by 1,3-
DC of pyranones 129 through a process of kinetic resolution.135 Several hits were identified to 
be inhibitors in low micromolar range towards Wnt and Hedgehog pathways. In the same year, 
a focused compound collection of 84 tropanes (133) was reported though 1,3-DC of special 
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cyclic imines 131 wih nitroalekenes 132, providing efficient inhibitors for Hedgehog pathway 
in the low mircomolar range.136  
In spite of such efficiency in the synthesis of pyrrolidines, catalytic asymmetric 1,3-DC of 
azomethine ylide is barely applied in constructing pyrrolizidine scaffold (Scheme 32). 
Recently, Reisman described a highly enantioselective synthesis of pyrrolizidine (141) by a 
one-pot tandem reaction involving two folds of 1,3-DC.112 The first step is an enantioselective 
1,3-DC by using an AgOAc/(S)-QUINAP(136) catalytic system. Another subsequent 1,3-DC 
proceeds in a diastereoselective manner with alkene 140 to afford pyrrolizidines 141 with high 
enantioselectivity (up to 96% ee) and yield (up to 92%). Another example is 1,3-DC of 
azomethine ylide 147 generated in situ from proline 144 and isatin 143 through a process of 
condensation followed by decarboxylation.137 The enantioselectivity was induced by the 
interaction between classic 1,3-dicarbonyl moiety (142) and chiral Lewis acid complex 
generated from Salen 145 and Cu(II).   
 
Scheme 32. Current examples to access pyrrolizidine by means of 1,3-DC. 
Chapter 3. Enantioselective Synthesis of Pyrrolizidines 
53 
 
3.2 Design Principle and Aim of the Project 
Due to the biologically importance of pyrrolizidines, a library of such compounds is highly 
desirable for further biological evaluation. As mentioned in 3.1.1, versatile intramolecular 
cyclization of pyrrolidines with proper substitution has been proven to be an effective approach 
to access pyrrolizidines. Another inspiration is that catalytic asymmetric 1,3-DC is a powerful 
method to access chiral pyrrolidines, as stated in 3.1.2. Hence, a strategy was envisioned to 
combine 1,3-DC and a subsequent intramolecular lactamization for the enantioselective 
synthesis of compound collection based on pyrrolizidine scaffold (Scheme 33). To obtain 
properly substituted pyrrolidines 150, azomethine ylides generated from N-alkylidene glutamic 
acid esters 152 were utilized for 1,3-DC. The resulting functionalized pyrrolidinyl propionic 
acid esters 150 could facilitate a sequential intramolecular lactamization to afford 
pyrrolizidines 149.  
 
Scheme 33. Retrosynthetic proposal for the compound collection.  
In this project, the reactivity of diverse dipolarophiles needs to be investigated for 1,3-DC of 
azomethine ylides generated from N-alkylidene glutamic acid esters. In principle, both tricyclic 
and bicyclic pyrrolizidines could be obtained by employing cyclic dipolarophiles and linear 
dipolarophiles respectively. After identifying the suitable dipolarophile, the realization of 
corresponding enantioselective 1,3-DC would be the next aim by means of intensive screening 
catalysis system including metals, ligands and other proper reaction conditions. Once 
establishing robust methodology, a library of pyrrolizidines, together with pyrrolidines as 
intermediates, would be prepared for the follow-up systematic investigation of biological 
activity.  
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3.3 Result and Discussion  
3.3.1 Pioneering Work to Access Tricyclic Pyrrolizidines Enantioselectively 
Dr. Hiroshi Takayama had developed a highly enantioselective 1,3-DC of maleimides 153 as 
dipolarophiles and azomethine ylides 152 generated from N-alkylidene glutamic acid esters 
(Scheme 34). After obtaining optimized reaction conditions for subsequent intramolecular 
lactaminzation, varied tricyclic pyrrolizidines 155 could be obtained from pyrrolidine 
intermediates 154 in excellent diastereo- and enantioselectivity by using (R)-Fesulphos (61) as 
ligand. Additionally, a 63-member compound collection including pyrrolidine intermediates 
and pyrrolizidines in either racemic and chiral form was obtained and subjected to biological 
evaluation. However, preliminary investigation on cell-based assay found no significant 
bioactivity in both Wnt and Hedgehog pathways signaling.  
 
Scheme 34. The enantioselective synthesis of tricyclic pyrrolizidines. 
3.3.2 Synthesis of Compound Collection Based on Other Dipolarophiles  
Since there was no significant bioactivity found in the compound collection based on 1,3-DC 
of maleimides, intensive screening of other dipolarophiles was conducted in order to expand 
this compound library. Instead of cyclic dipolarophiles, a broad range of linear dipolarophiles 
was screened. Maleates turned out to be suitable for this transformation by using AgOAc as 
catalyst, giving pyrrolidines and subsequent pyrrolizidines in satisfactory yields (Scheme 35). 
With optimized conditions in hands, this robust transformation was subsequently applied in the 
rapid synethsis of 87-member compound collection containing pyrrolidine intermediates and 
corresponding pyrrolizidines in racemic form. With regard to substrate scope, versatile 
substituted aryl and even alkenyl groups as R1, as well as varied R1 such as methyl, allyl and 
benzyl were compatible with 1,3-DC and sequential intramolecular lactamization. When R1 is 
aliphatic group, no desired product was found. The relative configuration of 158 was 
substantially identified by NOE experiment and proved to be identical to racemic 155.  
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Scheme 35. Synthesis of compound collection derived from maleate.  
However, the corresponding asymmetric 1,3-DC of azomethine ylide 152a and methyl maleate 
156a under the previously established conditions failed to afford the desired pyrrolidine 157aa 
in considerable yield (Table 5, entry 1). Further optimization of solvent together with higher 
catalyst loading only gave 26% yield, albeit with excellent diastereo- and enantioselectivity 
(Table 5, entries 2 and 3). Higher temperature resulted in decreased enantioselectivity (Table 
5, entry 4). The possible reason might lie in the relatively low reactivity of maleates compared 
with maleimides.  
Table 5. Optimization of reaction conditions. 
 
Entry solvent base (mol%) Temp (C) yield (%) d.r. ee (%) 
1 DCM 20 r.t 9% n.d n.d 
2 THF 20 r.t 7% n.d n.d 
3* Toluene 20 r.t 16% > 20:1 92% 
4* Toluene 100 40 26% > 20:1 71% 
* 10 mol% catalyst and 12 mol% ligand. 
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3.3.3 Preliminary Biological Study 
Although there was no significant bioactivity for tricyclic pyrrolizidines library described in 
the prior work, the compound library derived from maleates resulted in the discovery of novel 
inhibitors of Hedgehog pathway signaling in mouse embryonic mesoderm fibroblast 
C3H10T1/2 cells. As illustrated in Fig. 8, several inhibitors of the Hedgehog pathway signaling 
were identified with IC50 values <10 µM.  
 
Figure 8. Representative inhibitors of Hedgehog pathway signaling. 
Later on, selected 119 compounds out of 150 compounds were subjected to specific assays 
performed by RIKEN in Japan to evaluate anti-proliferative activities against cancer cell lines, 
bacterium, fungi, and malaria. Delightfully, one third of compounds exhibited anti-malarial 
activities at 100 µM, while no significant activity was observed in other activities (Table 6).  
Table 6. Summary for the number of active compounds in each assay system. 
 
Assessment 
mammalian cancer cells gram+ gram- fungi malaria 
HeLa HL-60 TsFT210 tsNRK S.a. E.c. M.o. C.a. P.f. 
- 105 101 58 107 113 119 118 113 56 
+ 13 6 50 12 6 0 1 5 17 
++ 1 3 9 0 0 0 0 1 8 
+++ 0 9 2 0 0 0 0 0 38 
total 119 119 119 119 119 119 119 119 119 
Notation: 100 µM of compound treatment; -; 0-20% inhibition, +; 20-50% inhibition, ++; 50-80% inhibition, +++; 
> 80% inhibition. The following microorganisms were used as test strains in the assay; Staphylococcus aureus 
(S.a.) 209, Escherichia coli (E.c.) HO141, Candida albicans (C.a.) JCM1542, and Magnaporthe oryzae (M.o.) 
kita-1. 
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Among them, four compounds demonstrated relatively selective and potent activities at IC50 
values of 10 µM or lower (Table 7). Notably, compounds 157bj and 157bh also showed 
activity in Hedgehog pathway signaling as inhibitors. Additionally, both pyrrolizidine 157bi 
and corresponding pyrrolidine 158br were identified to be anti-malarial compounds. Further 
biological evaluation is still in progress.  
Table 7. Summary for the number of active compounds in each assay system.  
Concentration (µM) 1 10 100 
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Notation: -; 0-20% inhibition, +; 20-50% inhibition, ++; 50-80% inhibition, +++; > 80% inhibition 
3.4 Summary and Perspective 
In conclusion, an efficient catalytic approach for the synthesis of a PAs-inspired compound 
collection has been developed by using 1,3-DC of azomethine ylides as the key step. Despite 
the enantioselective 1,3-DC of maleimides proved to be robust and highly efficient by prior 
work, the less reactive maleates as dipolarophile failed to afford enantioriched pyrrolidines in 
considerable yields. Nevertheless, facilitated by the racemic catalytic 1,3-DC of maleates 
catalyzed by AgOAc, a 87-member library of pyrrolizidines and pyrrolidines had been obtained 
efficiently. Together with the prior work by Hiroshi Takayama, 150 compounds had been 
synthesized and subjected to biological evaluation. Although there was no significant 
bioactivity observed in tricyclic pyrrolizidines and their pyrrolidine precursors derived from 
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maleimides, extended compound collection derived from maleates indeed provided hits not 
only in the inhibition of Hedgehog pathway signaling but also with anti-malarial activity. 
Interestingly, some compounds exhibited both aforementioned activities.  
In future, more intensive biological evaluation enabled by this PAs-inspired compound 
collection will be taken into consideration. With regard to 1,3-DC of azomethine ylides in 
chemistry, diverse dipolarophiles and dipoles, as well as catalytic systems have been 
extensively explored in the last decade, leading to the rapid maturation of this field. However, 
the applications of 1,3-DC in cascade reactions and the intramolecular 1,3-DC are still limited. 
Furthermore, more endeavor needs to be devoted to the application of 1,3-DC into chemical 
biology and medicinal chemistry.  
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4.1 Introduction 
4.1.1 Cycloheptanoids in Natural Products and Their Synthesis 
The seven-membered carbocycle moiety as a privileged scaffold, that defines the core of 
cycloheptanoids, is widely present in numerous NPs with a broad range of bioacitivity. Some 
representative examples include Ingenol (159), Phorbol (160), Cartorimine (161), Englerin A 
(162), Alstonisine (163) and other macroline-related oxindole alkaloids with a common tropane 
moiety (164-166), as well as Gardneria alkaloids 167 and 168 (Fig. 9). Two important 
variations of cycloheptanoid NPs are 8-oxabicyclo[3.2.1]octane and 8-azabicyclo[3.2.1]octane 
(tropane) scaffolds, embodied in more than 200 NPs respectively.138 
 
Figure 9. Representative cycloheptanoids in natural products. 
Among them, Englerin A (162) has attracted interest from both biology139-143 and chemistry144-
150 communities recently due to its highly selective activity against renal cancer at nanomolar 
level. Recently, further chemical biological investigation in depth by Waldmann disclosed the 
rapid and selective inhibition of renal cancer cells by Englerin A could be ascribed to the 
activation of calcium-permeable nonselective transient receptor potential canonical (TRPC) 
calcium channels.19 Notably, in contrast to highly potency of 162, its enantiomer ent-162 is 
inactive even at up to micromolar level,142 highlighting the importance of stereochemistry in 
BIOS. Another type of interesting cylcoheptanoid NPs is macroline-related oxindole alkaloids 
(163-166), with the features of both spirocyclic oxindole moiety and tropane scaffold. Despite 
Chapter 4. Enantioselective Synthesis of Cycloheptanoids 
61 
 
spirocyclic oxindole alkaloids are usually associated with significant bioactivity,151,152 no 
investigation was reported in detail for oxindole alkaloids 163-166 due to their paucity in nature. 
Interestingly, there are also naturally occurring alkaloids Chitosenine 167 and Voachalotine 
oxindole 168 with similar scaffold to 163-166, but bearing opposite configuration at spirocyclic 
C7 atom. Considerable effort has been devoted to the total synthesis of such spirocyclic 
oxindole alkaloids mainly starting from tryptophan through a mulit-step linear synthesis.153-157  
In spite of the high occurrence in bioactive NPs, synthetic methods for cycloheptanoids are 
much less developed compared with five- and six-membered rings, constraining the rapid 
construction of such compound collection for further investigation in medicinal chemistry and 
chemical biology.158-162 From a synthetic chemistry point of view, the construction of seven-
membered carbocycles is rather challenging due to unfavorable ring-strain and entropic 
reasons. Through the continuous effort in this field, a few strategies have been developed, in 
which cycloaddition represents one of the most efficient strategies compared with stepwise 
cyclization strategy.158  
 
Scheme 36. Cycloadditions to achieve cycloheptanoid. 
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In the cycloaddition strategy, the most straightforward approach is to start from commercially 
available seven-membered carbocycles. One of valuable feedstocks is tropone, which has 
proven to exhibit a wide spectrum of reactivity especially towards high order cycloadditions 
(Scheme 36a). Representative examples comprise (8+3)163-166 and (8+2)167,168 cycloadditions 
involving carbonyl group, as well as (6+4)169-172, (4+2)173,174 and (6+3)129,130,175-177 
cycloadditions without the participation of carbonyl group. Facilitated by the efficiency of this 
strategy and the diverse reactivity of tropone, quite a few elegant synthetic studies towards 
cycloheptanoid NPs have been reported based on the cylcloaddition reactions of 
tropone.170,174,175,178  
In the de novo synthesis of cycloheptanoids, various cycloadditions have also been 
developed.179 Resulting from the dissection principle of odd-numbered ring, the use of 
zwitterionic or diradicaloid intermediates is necessary to access seven-membered 
cycloheptanoids. In theory, there are three pathways involving (6+1), (5+2), (4+3) 
cycloadditions, along with some formal variations involving fragmentation process (Scheme 
36b).179 Among them, (6+1) cycloaddition is the most challenging from a synthetic chemistry 
point of view, and no example has been reported in the last decade.179 In contrary, (5+2)159,160 
and (4+3)161,162 cycloadditions have attracted considerable interest and are broadly applied into 
the synthesis of cycloheptanoids. Belonging to (5+2) cycloadditions, the 1,3-dipolar 
cycloaddition reactions (1,3-DC) of diverse dipoles, such as six-membered cyclic carbonyl 
ylides and azomethine ylides, together with pyryliums, will be discussed in detail in 4.1.2-
4.1.4, with a main focus on their asymmetric version.  
4.1.2 Catalytic Asymmetric 1,3-Dipolar Cycloaddition Reactions of Carbonyl Ylides 
Generated from Diazo Compounds by Rh(II) Catalysis  
Carbonyl ylides are a family of highly instable and reactive 1,3-dipoles, and their 
corresponding 1,3-DC have been broadly applied to synthesize tetrahydrofuran rings and other 
oxygen-contained heterocycles. Due to the high instability, most of carbonyl ylides are usually 
generated in situ as transient species. Conventional methods for the generation of carbonyl 
ylides consist of thermal extrusion of nitrogen from 1,3,4-oxadiazolines (169), thermolysis or 
photolysis of epoxides (170), loss of carbon dioxide from 1,3-dioxolan-4-ones (171), as well 
as transition metal-catalyzed reaction of carbonyl compounds (172) and diazo compounds 
(173).180 Besides, some simple carbonyl ylides are also formed from 1-iodoalkyl trialkyl 
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ethers181,182 (174) 1,3-elimiation of silyl compounds183 (175) or halogenated ether (176) 
(Scheme 37a).181,184,185  
 
Scheme 37. Carbonyl ylide and its application in catalytic enantioselective 1,3-DC. 
However, most of abovementioned methods to generate carbonyl ylides are not suitable for 
asymmetric catalysis due to either the requirement of harsh reaction conditions or the lack of 
versatility of substrate types. In contrast, transition metal-catalyzed reaction of carbonyl 
compounds (172) with diazo compounds (173) has been largely explored in asymmetric 
catalysis, especially with Rh(II) catalysts.180,186-189 The major reason can be attributed to the 
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ease and mildness properties in the generation of carbonyl ylides by such method (Scheme 
37b). This field had grown rapidly to its mature stage over the last two decades, with the 
appreciable contribution from Padwa.180,186-189 Additionally, copper is also used in carbonyl 
ylide generation but with relatively limited application due to its lower efficiency.190  
To date, there are three major methods to induce enantioselectivity in the process of 1,3-DC of 
carbonyl ylides derive from diazo compounds by Rh(II) catalyst (Scheme 37b).52 First, the 
utilization of chiral Rh(II) catalysts is the most straightforward method, but a requisite 
condition is that transition metal with chiral ligand still associates with carbonyl ylide in the 
process of 1,3-DC (intermediate A, Scheme 37b). In the past two decades, various chiral 
dirhodium(II) catalysts had been designed and synthesized to steer the enantioselective 
transformations involving carbonyl ylides (Scheme 37c).191-193 Another complementary 
strategy is to employ chiral Lewis acids in a relay-catalysis manner. Depending on the 
electronic property of substrates, the chiral Lewis acids can activate either dipolarophiles 
(intermediate B) or dipoles (intermediate C) (Scheme 37b).  
As for the enantiocontrol by chiral dirhodium(II) catalysts, Doyle demonstrated such 
asymmetric catalytic transformation involving carbonyl ylide as an unpublished work in 
1997.191 By using Rh2(4S-MEOX)4 (180a) as catalyst, carbonyl ylide generated from aromatic 
aldehyde 183 and diazoacetate 184 reacted with another molecule of 183 to give dioxolane 185 
in rather poor enantioselectivity (Scheme 38b). It should be noted that there is no successful 
example to date that 1,3-DC of linear carbonyl ylide is able to be realized in high 
enantioselectivity by solely using chiral dirhodium(II) catalyst. In the same year, the first 
catalytic 1,3-DC of carbonyl ylides with considerable enantioselectivity was reported by 
Hodgson.194 The substrates 186 was synthesized to enable a cascade reaction involving cyclic 
carbonyl ylide formation and subsequent intramolecular 1,3-DC, affording the chiral 
cycloheptanoids 188. In the following study, intermolecular asymmetric 1,3-DC was also 
developed with cyclic carbonyl ylides (Scheme 38c). As representatively illustrated in Scheme 
38d, various dipolarophiles 190 with different electronic property and even with heteroatom 
were investigated in the reactions of diazo compounds 189 and dipolarophiles 190 catalyzed 
by dirhodium(II) catalysts (Scheme 38a).  
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Scheme 38. Catalytic enantioselective 1,3-DC of carbonyl ylide by chiral dirhodium catalysts. 
Although quite successful by using chiral dirhodium(II) catalysts, the significant limitations on 
substrate types of both dipoles and carbonyl ylides were found due to the high tendency of 
disassociation of chiral Rh(II) from ylide intermediates. Complementarily, Suga developed a 
relay catalysis system combing chiral Lewis acid and achiral dirhodium(II) catalyst (Scheme 
39b). In this strategy, the enatioselectivity of 1,3-DC was introduced by the interaction between 
chiral Lewis acid and dipolarophile after the generation of carbonyl ylide by achiral dirhodium 
catalyst. 
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Scheme 39. Catalytic enantioselective 1,3-DC of carbonyl ylide by chiral Lewis acid. 
In their preliminary report, the employment of chiral Yb(III) Lewis acid 192 afforded the 
cycloadduct 198 in moderate enantioselectivity through 1,3-DC between 
benzyloxylacetaldehyde 197 and benzopyrylium 196 derived from diazo compound 195.195 
The successive studies revealed that i-Pr-Pybox 193a/Sc(III) delivered a high 
enantioselectivity for the same 1,3-DC with much broader substrate scope.196,197 Facilitated by 
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the same structurally rigid intermediate 196, pyruvate 200 and traditional 1,3-dicarbonyl 
compound 3-acryloyl-2-oxazolidinone 202 also proved to be suitable for this transformation 
under specific reaction conditions.196 Later on, further investigations focusing on the extension 
of dipolarophile scope for the abovementioned transformations were also conducted by the 
same group.198 In 2013, another type of structurally rigid carbonyl ylide 205 generated from 
diazo 204 was reported, with which a highly enantioselective 1,3-DC was realized by using a 
complexes of Ph2-Pybox 193c with different metals (Scheme 39b).
199 Additionally, Suga also 
developed catalytic asymmetric 1,3-DC facilitated by the LUMO activation of carbonyl ylide 
by chiral Lewis acid (Scheme 39c).200,201 The choice of different combination of metal such as 
Ni(II), Ho(III), Tm(III), Eu(III), Gd(III), and ligand (194/193c) is critical for the high 
enantioselectivity of this transformation.  
As described above, most of carbonyl ylides applied in asymmetric catalysis are six-membered 
cyclic species, resulting in the synthesis of enantioenriched 8-oxabicyclo[3.2.1]octanes and 
derivatives. This highly efficient method has been applied successfully into a few total 
synthesis of NPs including Englerin A.180,187,188,202 Recently, instead of traditional diazo-based 
carbene strategy, electrophilic activation of alkyne by transition metals followed by 
nucleophilic attack of carbonyl moiety intramolecularly emerged as a more atom-efficient and 
safe alternative to generated cyclic carbonyl ylides.203-210 To date, transition metals such as 
Cu(II), Ag(I), Pd(I), Pt(II), Au(I), and Rh(II) have been demonstrated as efficient electrophilic 
catalysts. However, the successful applications in cycloaddition in asymmetric form are still 
scare.203  
4.1.3 Catalytic Asymmetric Reactions to Access Tropanes and Cyclic Azomethine Ylides 
Generated from Diazo Compounds by Rh(II) Catalysis 
In spite of the high occurrence of tropane moiety in NPs with diverse bioactivity especially on 
neurological and psychiatric diseases, the development of tropane synthesis in enantioselective 
manner still stays limited.138 To date, the main source of chiral tropanes is from chiral pool, 
such as sugar, amino acids, or other commercially available or synthesized chiral building 
blocks. Besides, prochiral substrates are also able to provide chiral tropanes through one single 
step of transformation, which can be facilitated by traditional chiral auxiliaries, chiral reagent, 
and chiral catalysts. Other strategies are also available but much less developed, such as kinetic 
resolution of racemates of tropanes. As the most efficient and economic strategy, the catalytic 
asymmetric methodologies to access enantioriched tropanes are particularly rare. To date, four 
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strategies with a handful of examples have been depicted in literature, including kinetic 
resolution (KR),211 desymmetrization,212,213 formal (4+3) cycloaddition,214,215 and (3+2) 
cycloaddition of cyclic azomethine ylides136 (Scheme 40). 
 
Scheme 40. Current catalytic enantioselective examples for the synthesis of enantioriched tropanes. 
In the strategy of kinetic resolution, only a few examples by enzyme catalysis138 were reported 
before (3+2) cycloadditions of tropane racemates depicted by Antonchick and Waldmann in 
2016 (Strategy A, Scheme 40).211 The tropanes rac-211 synthesized through (5+2) 
cycloadditions of 3-oxidopyridiniums and alkenes can be resolved by means of asymmetric 
(3+2) cycloadditions of azomethine ylides (60). By using Cu(I) and ligand 212, tropanes (+)-
211 and a hybrid compound collection (213) incorporating both tropane and pyrrolidine 
Chapter 4. Enantioselective Synthesis of Cycloheptanoids 
69 
 
fragments were obtained in highly enantioselective manner. With regard to desymmetrization, 
one of representative examples212,213 is a palladium-catalyzed asymmetric allylic alkylation of 
tropinone derivatives 214 by Hou in 2013 (Strategy B, Scheme 40). The use of ligand 216 
proved to be critical for the synthesis of tropane derivatives 217 with moderate to excellent ee. 
In 2007, Davies developed a highly enantioselective formal (4+3) cycloadditions of pyrroles 
219 and vinyldiazoacetate 218 catalyzed by chiral dirhodium catalyst 182h (Strategy C, 
Scheme 40).215 The tropanes 220 were supposed to be generated through a sequential reaction 
of asymmetric cyclopropanation/Cope rearrangement. Notably, the elegant work from 
Antonchick and Waldmann in 2013 demonstrated the asymmetric synthesis of fused tropanes 
133 by (3+2) cycloadditions of cyclic azomethine ylides 131 (Strategy D, Scheme 40).136  
 
Scheme 41. Cyclic azomethine ylides generated by diazo compounds described by Padwa. 
Although Antonchick and Waldmann indeed provided a novel strategy to access tropanes 
enantiomerically, the presence of aromatic functionalities is critical to stabilize the cyclic 
ketoimine 131, therefore only fused tropanes 133 could be obtained. In fact, some aliphatic 
cyclic azomethine ylides such as 222 were already described by Padwa in 1990s by using diazo 
compound with a tethered oxime moiety 221 (Scheme 41). However, this species of 
azomethine ylide intermediates had only been reported in two reports in 1990 and 1994 with 
extremly limited substrate scope, and never applied in enantioselective transformation.216,217 
One of the main reasons can be attributed to the low reactivity of such intermediates. In the 
seminal reports, only highly reactive dipolarophiles such as DMAD under refluxing condition 
is suitable for such transformation. Another reason is the high instability of such intermediates. 
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Padwa also depicted azomthine ylide 225 with higher reactivity and stability could be generated 
from benzo fused diazo compound 224, so that tropane 226 could be achieved in higher yield 
(94%) and milder condition (40°C) compared with the synthesis of tropane 223. In conclusion, 
the methods described by Padwa can provide both aliphatic tropanes and fused counterparts, 
but suffer from limited application due to the low reactivity and the instability properties of 
cyclic azomethine ylide intermediates. Notably, in both case was only E-isomer of oxime able 
to afford the desired tropane product due to its proper direction of nitrogen lone pair for 
azomethine ylide formation.  
4.1.4 Organocatalysis to Access 8-Oxabicyclo[3.2.1]octanes Enantioselectively  
 
Scheme 42. Organocatalysis to access 8-oxabicyclo[3.2.1]octanes. 
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In the last decade, oranocatalysis using small organic molecules as catalysts had thrived to a 
powerful method in organic synthesis. As a general strategy to construct 8-
oxabicyclo[3.2.1]octanes, (5+2) cycloadditions of pyryliums or even pyridiniums has been 
broadly applied in organic synthesis.158-160 Nevertheless, the corresponding catalytic 
asymmetric variant was not reported until 2011 by Jacobson in an intramolecular manner 
(Scheme 42).218 Enabled by dual catalysis integrating amine catalyst 228a and anion-binding 
catalyst 229, the desired product 231 could be obtained in excellent eantioselectivity, albeit 
with rather limited substrate scope. An intermediate 230 was proposed to rationalize the 
outcome of stereochemistry. Later, by employing the same catalysis system, the intermolecular 
version was realized, suffering the same problem of limited substrate cope (Scheme 42).219 In 
contrast to Jacobsen’s work, Vicario demonstrated a highly enantioselective (5+2) 
cycloaddition of aldehydes 236 and benzopyrylium ylides generated from benzopyranones 235 
through enamine activation by secondary amine 237 (Scheme 42).220  
To conclude, similar to the incapability in metal catalysis to access 8-oxabicyclo[3.2.1]octanes 
in catalytic enantioselective manner as described in 4.1.2, although two strategies with regard 
to (5+2) cycloaddition of pyrylium were conceived in organocatalysis, the further application 
and especially the substrate scope of these methods are significantly limited. 
4.2 Design Principle and Aim of the Project 
In light of BIOS, the chemical space defined by NPs not only relies on the privileged scaffolds, 
but also is complementarily characterized with the sufficient substitutions and the stereogenic 
centers. To cover adequate chemical space based on seven-membered carbocycles, the 
exploration of highly enantioselective methodology to build the compound library of 
cycloheptanoids, especially 8-azabicyclo[3.2.1]octane variant (tropane) and 
8-oxabicyclo[3.2.1]octane variant, is highly desirable and valuable. To this end, four different 
approaches have been designed and will be discussed in this chapter. 
For the first approach, the most straightforward way to construct cycloheptanoids is starting 
directly from commercial available seven-membered carbocycles, as discussed in 4.1.1. In this 
regard, tropone was chosen to be the very starting point due to its easy accessibility and 
versatile reactivity. Although a large spectrum of dipoles such as azomethine ylide had been 
tested for reactions of tropone, the reactivity of carbonyl ylide has never been investigated, 
especially in an enantioselective manner. In this thesis, various diazo compounds as precursors 
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of carbonyl ylides will be synthesized to explore the possible reactivity of tropone by using 
chiral dirhodium(II) catalysts. This part of work will be summarized in 4.3.2. 
As for the second approach, 1,3-DC of six-membered cyclic carbonyl ylides with all-carbon 
partners represents one of the most efficient methods to access cyclopentanoid 8-
oxabicyclo[3.2.1]octanes, as shown in 4.1.2. In spite of extensive exploration of this field for 
more than one decade, the catalytic enantioselective 1,3-DC of carbonyl ylides still suffers 
from severe limitation of dipolarophile types (Scheme 38d). On the other hand, as possible 2π-
, 4π-, 6π-, and even three-carbon components in annulation process, versatile reactivity of 
fulvene have been explored for the rapid construction of polycyclic systems.221 In continuation 
of the effort in this thesis on pentafulvene (Chapter 2), the reactivity of pentafulvene towards 
carbonyl ylides will be intensively investigated in an enantioselective manner. This part of 
work will be summarized in 4.3.3. 
The third approach involves 1,3-DC of six-membered cyclic azomethine ylides. In contrast to 
intensive investigation of cyclic carbonyl ylides generated from diazo compounds by Rh(II) 
catalysis, cyclic azomethine ylides generated in the same way were reported only in two 
seminal works by Padwa in 1990s, as described in 4.1.3. The corresponding catalytic 
enantioselective transformation remains unprecedented. Considering their promising 
application in the synthesis of tropanes, it would be highly valuable to perform systematic 
investigation of such azomethine ylide intermediates. To achieve this target, two issues should 
be addressed, including the enhancement of reactivity of such intermediates and the efficiency 
of enantioselectivity induction. To overcome the low reactivity of the aforementioned 
intermediates, it’s assumed that the rational design of diazo precursors is critical. Regarding to 
the enantioselectivity, in analogy to carbonyl ylides, chiral dirhodium catalysts will be tested 
at first. As alternatives, additional asymmetric catalysis systems can also be tested in a relay 
catalysis manner, such as chiral Lewis acid catalysis described in 4.1.2. This part of work will 
be summarized in 4.3.4. 
Inspired by the pioneering works of Jacobsen218 and Chain222, the fourth approach consists of 
two different strategies to build 8-oxabicyclo[3.2.1]octane compound collection, involving 
intermolecular (5+2) cycloaddition of pyrylium salt and stepwise cyclization. This section will 
be summarized in 4.3.5.  
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4.3 Result and Discussion  
4.3.1 Synthesis of a Library of Chiral Dirhodium(II) Catalysts   
 
Figure 10. Library of chiral dirhodium catalysts. 
Except commercially available chiral dirhodium(II) cataylsts (178, 182b, 182c, 182h, 241), 
other types of catalysts were synthesized according to literature (Fig. 10).223 
4.3.2 Investigation on Reactivity of Tropone in 1,3-Dipolar Cycloaddition Reactions of 
Cyclic Carbonyl Ylides 
 
Scheme 43. 1,3-DC of carbonyl moiety of tropone with carbonyl ylide. 
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In collaboration with Dr. Sandip Murarka, the reactivity of tropone with various carbonyl ylides 
was intensively investigated. In literature, the catalytic enantioselective 1,3-DC of carbonyl 
ylides with carbonyl group is rare. Only some specific aldehydes proved to be suitable for such 
transformation as described in three publications191,197,224, and the corresponding ketone is 
unprecedented. Dr. Sandip Murarka discovered that cyclic carbonyl ylides derived from 
diazodiketoesters 243 underwent (3+2) cycloadditions with the  carbonyl group embodied in 
tropone 242, representing the first case involving carbonyl group in ketone (Scheme 43).225 
Under the optimized conditions, catalyst 182b yielded various 5-alkoxylactone derivatives 246 
instead of spirocyclic compound 244 in good to excellent enantioselectivity, with the substrate 
scope from aliphatic to diverse aromatic patterns. Based on the observations, a plausible 
mechanism involving a cascade process was proposed. Spirocyclic compound 244 generated 
from 1,3-DC of carbonyl functionality of tropone is converted into zwitterion 245, which 
sequentially undergoes cyclization and rearrangement to afford the observed product 246.  
Table 8. Screening of reaction conditions for the synthesis of 214a.
[a]
 
 
Entry Temp (C) yield (%) ee (%) 
1 r.t 60 94 
2[b] r.t 92 94 
3 50 50 92 
4[c] r.t. 75 94 
[a] Unless otherwise noted, a flame dried Schlenk tube was charged with catalyst 182b (2.00 μmol, 0.02 equiv.), 
242 (0.10 mmol, 1.00 equiv.) and 0.5 mL C6H5CF3 under the protection of Ar. Then the solution of diazo 
compound 247a (0.15 mmol, 1.50 equiv.) in 0.5 mL C6H5CF3 was added slowly into the reaction mixture. [b] The 
solution of diazo compound 247a in 0.5 mL C6H5CF3 was added over 1 hour by syringe pump. [c] 20 mg 4Å MS 
was added.  
Independently, a (6+3) cycloaddition reaction was discovered by using diazoketone 247a under 
the same reaction conditions, to afford corresponding cycloheptaoid 248a in moderate yield 
and with excellent enantioselectivity. After optimization of reaction conditions (Table 8), the 
use of a syringe pump to add diazo compound 247a over 1 hour was found critical for high 
yield of this transformation, which is also a standard procedure to reduce background reaction 
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resulting from ‘free’ carbonyl ylide without Rh. Additionally, lower temperature and the 
addition of molecular sieves had a negative effect on yield but no significant influence on 
enantioselectivity. The absolute configuration of 248a was unambiguously identified by 
vibrational circular dichroism (VCD) spectroscopy (by Dr. Christian Merten, see 7.4.1.2).  
Table 9. Substrate scope of (6+3) cycloaddition reaction. 
 
Entry Product R yield (%) ee (%) 
1 248a C6H5 78 94 
2 248b 4-n-HexC6H4 55 92 
3 248c 4-i-PrC6H4 56 89 
4 248d 4-FC6H4 30 92 
5 248e 4-BrC6H4 66 87 
6 248f 4-MeOC6H4 n.r. n.r. 
Reaction conditions: a flame dried Schlenk tube was charged with catalyst 182b (2.00 μmol, 0.02 equiv.), 242 
(0.10 mmol, 1.00 equiv.) and 0.5 mL CF3C6H5 under the protection of Ar. Then the solution of diazo compound 
248a (0.20 mmol, 2.00 equiv.) in 0.5 mL C6H5CF3 was added added over 1 hour by syringe pump. n.r.: no reaction. 
With the optimized reaction conditions in hand, the substrate scope for diazo compound 247 
was investigated. For diazo compounds 247,226 substitutions with different electronic and steric 
properties were tolerated on para-position of aromatic group to give cycloheptanoids 248a-
248e in moderate to good yield and with excellent enantioselectivity (Table 9). No desired 
product was found when 4-methoxyl substituted diazo compound 248f was employed probably 
due to the possible competition of C−H insertion process which is well known in Rh(II) 
carbenoid chemistry.226 
4.3.3 Investigation on Reactivity of Pentafulvenes in 1,3-Dipolar Cycloaddition 
Reactions of Cyclic Carbonyl Ylides 
Towards 1,3-dipole, pentafulvene has been reported to be suitable in both (6+3) cycloaddition 
and (3+2) cycloaddition.221 By analogy, there will be two possible pathways in 1,3-DC of 
carbonyl ylide and fulvene, affording 5-8 fused cyclooctanoids and 5-7 fused cycloheptanoids 
respectively (Scheme 44). Notably, both 5-8 fused cyclooctanoids185 and 5-7 fused 
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cycloheptanoids158 are common structural units in a variety of polycyclic NPs. In the sole work 
involving five-membered cyclic carbonyl ylide and fulvene, the process of (3+2) cycloaddition 
was exclusively favored with substrate-controlled regioselectivity.227  
 
Scheme 44. Possible pathway for 1,3-DC of pentafulvene with carbonyl ylide. 
In the preliminary study, chiral dirhodium(II) catalysts (Fig. 8) were tested in the model 
reaction (Table 10). By analyzing NMR spectra of separable 249a, (3+2) cycloadducts of 
fulvene 59a and carbonyl ylide derived from 243 were identified with endo-selectivity (see 
7.4.2). As outlined in Table 10, in a typical procedure, various dirhodium(II) catalysts were 
investigated for the model reaction, but almost 1:1 mixture of separable isomers was observed 
and the highest ee was only 60% (entries 1-11, Table 10). Out of two optimal catalysts, Rh2(S-
NTTL)4 (240) was chosen as model catalyst for further optimization. In light of previous 
experience, the use of syringe pump to add diazo compound slowly is usually beneficial for 
enantioselectivity. However, decreased enantioselectivity was found when adding diazo 
compound by syringe pump over 1 hour (entry 12, Table 10). Surprisingly, reverse 
enantioselectivity and limited conversion were observed by decreasing temperature to -20oC 
(entry 13, Table 10). Further screening on solvents also failed to improve the regio- and 
enantioselectivity (entries 14-20, Table 10). No desired product was found when using THF as 
solvent, probably owing to fast decomposition of carbonyl ylides in polar solvent (entry 17, 
Table 10). Additionally, significant decrease on enantioselectivity was observed by employing 
the diazo compound with phenyl substitution, albeit with better regioselectivity. (entry 21, 
Table 10)  
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Table 10. Condition optimization of (3+2) cycloaddition reaction of pentafulvene and carbonyl ylide.[a] 
 
Entry R cat solvent yiel
d 
(%) 
Ratio 
(A:B) 
ee (%) 
A B 
1 Me Rh2(S-PTA)4 182d CF3C6H5 55 43:57 47 9 
2 Me Rh2(S-PTV)4 182e CF3C6H5 72 47:53 53 11 
3 Me Rh2(S-PTIL)4 182g CF3C6H5 77 47:53 29 -5 
4 Me Rh2(S-PTTL)4 182a CF3C6H5 65 54:46 60 11 
5 Me Rh2(S-TCPTTL)4 182b CF3C6H5 72 47:53 36 52 
6 Me Rh2(S-TFPTTL)4 182c CF3C6H5 84 54:46 20 32 
7 Me Rh2(S-PTAD)4 182h CF3C6H5 77 53:47 37 -3 
8 Me Rh2(S-PTPA)4 182f CF3C6H5 81 53:47 45 14 
9 Me Rh2(S-DOSP)4 178 CF3C6H5 84 51:49 47 33 
10 Me Rh2(R-BTPCP)4 241 CF3C6H5 72 40:60 -5 -13 
11 Me Rh2(S-NTTL)4 240 CF3C6H5 75 48:52 57 32 
12[b] Me Rh2(S-NTTL)4 240 CF3C6H5 75 48:52 45 31 
13[c] Me Rh2(S-NTTL)4 240 CF3C6H5 29 50:50 -32 -37 
14 Me Rh2(S-NTTL)4 240 Hexane 65 44:56 15 -8 
15 Me Rh2(S-NTTL)4 240 Toluene 70 52:48 50 17 
16 Me Rh2(S-NTTL)4 240 DCM 53 45:55 3 -14 
17 Me Rh2(S-NTTL)4 240 THF n.r. - - - 
18 Me Rh2(S-NTTL)4 240 FC6H5 72 53:47 53 21 
19 Me Rh2(S-NTTL)4 240 Ethyl acetate 36 33:67 11: -13 
20 Me Rh2(S-NTTL)4 240 CF3C6H5: 
Hexane (1:1) 
50 43:57 49 23 
21 Ph Rh2(S-NTTL)4 240 CF3C6H5 82 15:85 35 23 
[a] Unless otherwise noted, a flame dried Schlenk tube was charged with catalyst Rh(II) catalyst (2.00 μmol, 0.02 
equiv.), 59a (0.10 mmol, 1.00 equiv.) and 0.5 mL solvent under the protection of Ar. Then the solution of diazo 
compound 243 (0.15 mmol, 1.50 equiv.) in 0.5 mL solvent was added slowly into the reaction mixture. [b] The 
solution of diazo compound 243 in 0.5 mL CF3C6H5 was added over 1 hour by syringe pump. [c] The reaction 
was performed under -20oC. 
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To address the issue of regioselectivity, a disubstituted fulvene 59b was employed, inspired by 
the improvement of regioselectivity in the seminal work by using the same fulvene.227 As 
expected, only one regioisomer was found in the model reaction (Table 11). However, the 
enantioselectivity remained moderate after screening of catalysts. Notably, the addition of 4Å 
MS in this case was able to promote conversion and yield. In conclusion, the optimization on 
reaction conditions and modification of substrate all failed to give cycloheptanoid 249 in 
considerable enantioselectivity.  
Table 11. Condition optimization of (3+2) cycloaddition reaction of pentafulvene and carbonyl ylide.[a] 
 
Entries cat yield (%, for major) ratio ee (%) 
1 Rh2(S-PTTL)4 42 >90:10 15 
2 [b] Rh2(S-PTTL)4 70 >90:10 17 
3[b] Rh2(S-TFPTTL)4 75 >90:10 32 
4[b] Rh2(S-DOSP)4 73 >90:10 48 
5[b] Rh2(S-TCPTTL)4 94 >90:10 57 
[a] Unless otherwise noted, a flame dried Schlenk tube was charged with catalyst Rh(II) catalyst (2.00 μmol, 0.02 
equiv.), 59b (0.10 mmol, 1.00 equiv.) and 0.5 mL CF3C6H5 under the protection of Ar. Then the solution of diazo 
compound 209a (0.15 mmol, 1.50 equiv.) in 0.5 mL CF3C6H5 was added slowly into the reaction mixture. [b] 20 
mg 4Å MS was added. 
4.3.4 Enantioselective Synthesis of Tropanes by 1,3-Dipolar Cycloaddition Reactions of 
Cyclic Azomethine Ylides Derived from Diazo Compounds 
Besides the potential application in tropane synthesis by cyclic azomethine ylides generated 
from diazo compound (as stated in 4.2), another inspiration for this project is the common 
structure unit embodied in spirooxindole alkaloids 163-168 (Scheme 45a). Due to the paucity 
in natural sources of NPs 163-168, it would be highly valuable to develop methodology to 
construct such privileged scaffold rapidly for further chemical biology study. To date, a linear 
synthesis from tryptophan in 6 steps is the major method to synthesize such core,153-155,228 as 
well as one sole diastereoselective methodology229 with less than 20% yield. There is no 
catalytic asymmetric reaction to access such structure unit. In retrosynthesis analysis, 1,3-DC 
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of six-membered cyclic azomethine ylide and 3-methylene-2-oxindole could be one feasible 
strategy (Scheme 45a). Hence, as one of the most reactive dipolarophiles, 3-methylene-2-
oxindole with cyano group 251 was chosen as standard dipolarophile. For the precursors of 
corresponding azomethine ylide intermediates, diazoketoesters with a tailed oxime 
functionality 250 and 253 were synthesized according to Padwa’s pioneering work (Scheme 
45b).216,217 However, by using Rh(II) catalyst 240, no desired product was found in both cases.  
 
Scheme 45. Preliminary results of 1,3-DC of 3-methylene-2-oxindole with cyclic azomethine ylide. 
Through rational analysis and design, two different strategies were conceived to address the 
issue of inadequate reactivity (Scheme 46). Starting from intermediates 255 and 256, the 
reactivity of intermediate might be enhanced by the removal of ester group from intermediate 
256, due to the raising HOMO level and reduced steric hindrance. However, the precursor 257 
for intermediate 258 could not be synthesized. On the other hand, intermediate 259 without 
ester group compared with 255 might also possess higher reactivity due to the same reasons. 
Delightfully, the precursor 260 could be synthesized. In its subsequent 1,3-DC with 251, the 
desired product 261 could be isolated in 63% yield in a single diastereomer form, albeit with 
no enantioselectivity by using chiral Rh(II) catalysts. In this reaction, the diazo compound 260 
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can be fully consumed immediately after the addition of chiral Rh(II) catalysts, but the reaction 
needs 4h to reach full conversion. Based on this observation, the failure on enantioinduction 
by chiral Rh(II) catalysts was ascribed to the rapid dissociation of Rh(II) from the azomethine 
ylide 259 before being trapped by dipolarophile 251. 
 
Scheme 46. Rational design of azomethine ylide precusors. 
As discussed in asymmetric catalytic reaction of carbonyl ylides (in 4.1.2), chiral Lewis acid 
catalysis usually was introduced as a complementary strategy to chiral Rh(II) catalysis. By 
analogue, chiral Lewis acid catalysis should also be feasible due to the presence of 1,3-
dicarbonyl moiety embedded in 3-methylene-2-oxindole 251. Inspired by the prior works, 
diverse substrates and chiral Lewis acid complexes were tested (Table 12).230-232  
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Table 12. Condition optimization of 1,3-DC of 3-methylene-2-oxindole with cyclic azomethine ylide.. 
 
Entrie
s 
R cat ligand solvent procedure yield 
(%) 
d.r. ee 
(%) 
1 Boc Mg(NTf2)2 262a DCM A 68 >95:5 66 
2 Boc Mg(ClO4)2 262a DCM A 63 3:1 34 
3 Boc Cu(OTf)2 262a DCM A 34 >95:5 5 
4 Boc CuOTf 262a DCM A 58 >95:5 2 
5 Boc Mg(NTf2)2 262a DCM B 68 >95:5 67 
6 Boc Mg(NTf2)2 262a DCM C 78 >95:5 60 
7 Boc Mg(NTf2)2 262a THF B n.r. - - 
8 Boc Mg(NTf2)2 262a Et2O B 24 >95:5 31 
9 Boc Mg(NTf2)2 262a C6H5CF3 B 44 >95:5 59 
10 Boc Mg(NTf2)2 262a CHCl3 B 49 >95:5 58 
11 Boc Mg(NTf2)2 262b DCM B 53 >95:5 12 
12 Boc Mg(NTf2)2 262c DCM B 53 >95:5 0 
13 Boc Mg(NTf2)2 262d DCM B 58 >95:5 0 
14 Boc Mg(NTf2)2 262e DCM B 53 >95:5 8 
15 Boc Mg(NTf2)2 262f DCM B 28 >95:5 -53 
16 Boc Mg(NTf2)2 262g DCM B 49 >95:5 63 
17 Boc Mg(NTf2)2 262h-j DCM A n.r. - - 
18 Boc Sc(OTf)3 262i DCM A n.r. - - 
19 Boc Yb(OTf)3 262i DCM A n.r. - - 
20 Piv Mg(NTf2)2 262a DCM B n.r. - - 
21 Cbz Mg(NTf2)2 262a DCM B 73 >95:5 33 
22 Ac Mg(NTf2)2 262a DCM B 40 >95:5 40 
Reaction conditions: Procedure A, under the protection of Ar, chiral ligand (0.22 equiv., 0.011 mmol) and 
corresponding Lewis acid (0.2 equiv., 0.01 mmol) in 0.5 mL of solvent were stirred vigorously in a flame dried 
Schlenk tube at room temperature for 30 min. Then the 3-methylene-2-oxindole 251 (1 equiv., 0.05 mmol), 
Rh2(OAc)4 (0.01 equiv., 0.0005 mmol), and 20 mg 4AMS were added for another 15 min stirring. After that, the 
diazo compound 260 (1.1 equiv., 0.05 mmol) in 0.5 mL of DCM was added in dropwise. The reaction was allowed 
to proceed in 4 h; Procedure B, the same with procedure A, except Mg was heated to 150oC under vacuum for 
30 min; Procedure C, the same with procedure A, except Mg was heated to 150oC under vacuum for 30 min, and 
syringe pump was used to add diazo compound in 1 h, followed by further 3 h stirring.  
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As outlined in Table 12, different Lewis acids were tested by using 262a as ligand, and 
Mg(NTf2)2 proved to be the optimal, affording the desired product 261 in 68% yield and 66% 
ee (entries 1-4). However, poor reproduciblity was found due to highly hydroscopic nature of 
Mg(NTf2)2. Intensive optimization on procedure revealed that a constantly reliable result could 
be obtained by heating Mg(NTf2)2 to 150
oC for 0.5 hour under high vacuum (entry 5). The 
utilization of syringe pump to add diazo compound 260 over 1 hour led to higher yield but 
reduced ee (entry 6). Subsequent solvent screening disclosed that DCM was optimal (entries 
7-10). Furthermore, no improvement on enantioselectivity was achieved by screening of 
ligands (entries 11-17) and classic combinations of Pybox with either Sc(OTf)3 or Yb(OTf)3 
(entries 18 and 19). Besides the condition optimization, protecting groups were also 
investigated, in which Boc was the optimal (entries 20-24). In conclusion, the reaction 
conditions indicated in entry 5 proved to be the optimal, but only moderate ee (67%) was 
obtained.  
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4.3.5 Enantioselective Synthesis of 8-Oxabicyclo[3.2.1]octanes by Amine Catalysis 
To access 8-oxabicyclo[3.2.1]octane compound collection rapidly, two retrosynthesis 
strategies were conceived based on aminecatalysis (Scheme 47). On one hand, inspired by the 
intramolecular (5+2) cycloaddition by Jacobsen in 2011 (Scheme 42),218 the first strategy 
involves an intermolecular (5+2) cycloaddition of pyrylium generated from protected 
pyranones through group elimination. The other strategy is a stepwise chiral-amine-catalyzed 
Michael reaction followed by reductive radical cyclization mediated by SmI2, inspired by the 
total synthesis of Englerin A by Chain.222  
 
Scheme 47. Two strategies to access 8-oxabicyclo[3.2.1]octanes based on aminecatalysis. 
4.3.5.1 Intermolecular (5+2) Cycloaddition by Amine Catalysis 
Initially, extensive screening of substrate was performed in the intermolecular (5+2) 
cycloaddition of pyrylium derived from Boc protected pyranone 263b, by using amine 228b 
as catalyst and TFA as additive (Scheme 48). In contrast to Jacobsen’s work in which no 
enantioselectivity and low yield were observed by using styrene 10a as dipolarophile (Scheme 
48a),218 it was found that the desired (5+2) cycloadduct could be obtained from styrene 10a in 
24 hours with 70% yield and up to 13% ee for the major diastereomer (Scheme 48b). With this 
starting point, the investigation on protection group of pyranones was conducted (Scheme 48c). 
Compared with Boc protected pyranone 263b, acetyl protected pyranone 263c could afford the 
desired (5+2) cycloadduct in similar yield (60%), decreased d.r. (2:1), and higher ee (27%, 
23%) by prolonging reaction time. The substrate 263a with p-thiomethylbenzoyl gave 
decreased yield (40%) and d.r. (3:2), but with higher ee (21%). Considering the efficiency of 
optimization process, Boc protected pyranone 263b was used as the standard substrate.  
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Scheme 48. Preliminary result of the intermolecular (5+2) cycloaddition. 
After the determination of model reaction, intensive investigations on solvent, acid, catalyst, 
and additive were conducted (Table 13). At first, solvent screening disclosed toluene was 
optimal, while polar solvent such as EtOH, 1,4-dioxane failed to give the desired product 
(entries 1-4). In addition, no product was observed by employing acids except TFA (entries 5-
7). Subsequent extensive screening on catalysts revealed primary amine catalyst without 
hydrogen-bonding donor 228g was optimal, giving 40% ee for the major diastereomer, albeit 
with only 30% yield (entry 13). Screening of 265 as additives indicated that hydrogen-bonding 
doners were beneficial for enantioselectivity, but the highest ee was still limited to 67% (entry 
21).   
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Table 13. Condition optimization of (5+2) cycloaddition reaction of styrene and pyrylium.[a] 
 
Entries solvent acid cat additive yield 
(%) 
t (h) d.r. ee (%) 
major minor 
1 Toluene TFA 228b none 70 24 4:1 13 17 
2 CHCl3 TFA 228b none 50 48 2:1 <5 20 
3 1,4-Dioxane TFA 228b none n.r. - - - - 
4 EtOH TFA 228b none n.r. - - - - 
5 Toluene TsOH 228b none mess - - - - 
6 Toluene AcOH 228b none n.r. - - - - 
7 Toluene BzOH 228b none n.r. - - - - 
8 Toluene TFA 228a none 35 48 4:1 23  <5 
9 Toluene TFA 228c none 55 96 3:2 23  50 
10 Toluene TFA 228d none 45 96 6:5 27  49 
11 Toluene TFA 228e none 25 96 7:1 15 20 
12 Toluene TFA 228f none n.r. - - - - 
13 Toluene TFA 228g none 30 24 4:1 40 <5 
14 Toluene TFA 228h none 60 18 3:1 19  21 
15 Toluene TFA 228i none 30 96 4:1 <5 25 
16 Toluene TFA 228j none 30 96 3:1 <5  13 
17 Toluene TFA 228k none 25 18 12:1 <5  35 
18 Toluene TFA 228g 265a 40 32 4:1 46 30 
19[b] Toluene TFA 228g 265a 45 72 2:1 59 57 
20[b] Toluene TFA 228g 265b 40 96 4:1 53 52 
21[b] Toluene TFA 228g 265c 40 32 5:2 67 40 
22[b] Toluene TFA 228g 265d 35 72 4:1 55  43 
[a] Unless otherwise noted, to the solution of 263b (0.10 mmol, 1.00 equiv.), styrene 10a (0.30 mmol, 3.00 equiv.), 
catalyst 228 (0.02 mmol, 0.20 equiv.), additive 265 (0.02 mmol, 0.20 equiv.) in 1.0 mL solvent was added acid 
(0.04 mmol, 0.40 equiv.) slowly. Then the mixture was allowed to be stirred for specific time at 60oC. [b] Acid 
(0.02 mmol, 0.20 equiv.) was used. 
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4.3.5.2 Stepwise Strategy with Asymmetric Amine-catalyzed Michael Reaction 
The asymmetric amine-catalyzed Michael reaction has been well documented in the last 
decade.233-235 By covalent activation of α,β-unsaturated aldehydes through iminium 
mechanism, enantioselectivity can be induced efficiently. Although various Michael donors 
prove to be suitable, no example involving 3-furone has been reported before proposing this 
project.236,237 By employing cinnamaldehyde 266a as Michael acceptor, the optimization of 
reaction conditions was performed (Table 14). Catalyst 268f could afford the desired product 
efficiently with 86:14 d.r. and up to 97% ee, by using toluene as solvent and OFBA as additive 
(entry 6). Subsequent screening on acid and solvent failed to improve either yield or 
stereoselectivity (entries 7-10). The absolute configuration of 269a was assigned according to 
the known literature.237 
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Table 14. Condition optimization of asymmetric amine-catalyzed Michael reaction.[a] 
 
Entries cat acid solvent t (h) yield 
(%) 
d.r. ee (%)[b] 
Isomer A Isomer B 
1 268a - Toluene 48 trace - - - 
2 268b - Toluene 28 92 40:60 <5 <5 
3 268c - Toluene 40 81 58:42 <5 73 
4 268d - Toluene 96 55 76:24 <5 <5 
5 268e OFBA Toluene 32 89 73:27 96 71 
6 268f OFBA Toluene 48 89 86:14 97 90 
7 268f BA Toluene 72 85 85:15 96 89 
8 268f OFBA CHCl3 96 77 78:22 97 95 
9 268f OFBA THF n.r - - - - 
10 268f OFBA CH3CN n.r - - - - 
[a] Unless otherwise noted, 266a (0.15 mmol, 1.50 equiv.), 3-furone 267 (0.10 mmol, 1.00 equiv.), catalyst 268 
(0.02 mmol, 0.20 equiv.), acid (0.02 mmol, 0.20 equiv.) were added into 1.0 mL solvent. Then the mixture was 
allowed to be stirred for specific time at r.t.. [b] ee was determined by chiral HPLC after 269a was reduced to its 
alcohol by NaBH4 in MeOH. OFBA: 2-fluorobenzoic acid; BA: benzoic acid. 
 
Inspired by the SmI2-mediated cyclization strategy in the total synthesis of Englerin A by 
Chain,222 the Michael adduct 269a was tested in the same conditions (Scheme 49a). 
Delightfully, the desired 8-oxabicyclo[3.2.1]octane 270 was obtained in moderate yield, and 
the relative configuration of additional chiral center in 270 was proposed in analogue to Chain’s 
work.222 Although the robust methodology had been established for the enantioselective 
synthesis of 8-oxabicyclo[3.2.1]octanes, a racemic compound library based on 8-
oxabicyclo[3.2.1]octanes was firstly attained for preliminary biological evaluation.  
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Scheme 49. Compound library towards Englerin A.  
Following the same procedure described in Chain’s paper,222 a library of 28 members was 
synthesized towards Englerin A structure, involving two major categories of compounds as 
demonstrated in Scheme 49. However, no bioactivity was observed for cell-based assays of 
Hedgehog pathway signaling, Wnt pathway signaling and autophagy by COMAS. 
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4.4 Summary and Perspective  
In conclusion, diverse catalysis systems were investigated to access the biologically important 
cycloheptanoids, with a focus on 8-azabicyclo[3.2.1]octanes (tropane) and 
8-oxabicyclo[3.2.1]octanes.  
In 4.3.2, the 1,3-DC of cyclic carbonyl ylides and tropone catalyzed by chiral Rh(II) catalysts 
was intensively investigated to provide efficient methods for the synthesis of enantioriched 
cyclopentanoid. By employing diazodiketoesters, (3+2) cycloaddition reactions of carbonyl 
ylides and carbonyl functionality on ketone was realized for the first time. Besides, through the 
variation of diazo substrate, the chemoselectivity of tropone could be switched to a (6+3) 
cycloaddition process to afford a distinct pattern of bridged cyclopentanoids with high 
molecular complexity and enantioselectivity.  
In 4.3.3, 1,3-DC of pentafulvene was also investigated by employing the same type of cyclic 
carbonyl ylides to access enantioriched 5-7 fused cycloheptanoids. First, the utilization of 
mono-substituted fulvene raised the issue of poor regioselectivity, and no significant 
improvement on regio- and enantioselectivity was achieved by optimization of reaction 
conditions. Subsequently, the employment of di-substituted fulvene indeed led to enhanced 
regioselectivity, but further screening of catalysts still failed to give higher enantioselectivity.  
In 4.4.4, a novel synthesis strategy of enantioriched tropanes was preliminarily investigated by 
a relay catalysis combining Rh(II)-catalyzed azomethine ylides generation and chiral Lewis 
acid catalysis. Although only moderate enantioselectivity had been realized for the standard 
reaction, the unique advantage of flexibly synthesizing varied tropane scaffolds indicates the 
tremendous potential of this methodology. Further optimizations on both catalyst and substrate 
are necessary.  
In 4.4.5, two strategies were designed to synthesize 8-oxabicyclo[3.2.1]octanes. In spite of 
considerable effort, the intermolecular (5+2) cycloaddition of pyrylium and styrene failed to 
give satisfactory stereoselectivity and yield. In addition, during this project, a similar reaction 
by using vinyl ether as dipolarophile was reported by Jacobsen in 2014 (Scheme 42). On the 
other hand, through reliable stepwise strategy, a 28-member compound library inspired by 
Englerin A was synthesized. However, no bioactivity was observed to date. 
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5.1 Introduction 
5.1.1 Pyrroloisoquinolines in Natural Products and Their Synthesis 
Pyrroloisoquinoline moiety occurs in a diverse range of bioactive NPs and synthetic 
pharmaceutical compounds. For example, (+)-crispine A (272) possesses cytotoxic activity 
against SKOV3, KB, and HeLa human cancer cell lines;238 (‒)-Trolline (273) exhibits 
antibacterial activity against respiratory bacteria and antiviral activity against influenza virus 
A and B;239 JNJ-7925476 (274) is a novel triple monoamine uptake inhibitor under 
development by Johnson & Johnson as an antidepressant drug candidate;240 The biological 
study of (‒)-Cryptaustoline (275) is limited except paralytic activity; (+)-Erysotramidine (276) 
is one member of natural erythrina alkaloids, and this family of NPs usually exhibits 
hypotensive, sedative, and anticonvulsive properties (Fig. 10).241  
 
Figure 10. Representative naturally occurring pyrroloisoquinolines. 
Owing to the diverse bioactivity of pyrroloisoquinolines, the development of corresponding 
methodology remains highly desirable.2 Diverse strategies have been developed for the 
synthesis of pyrroloisoquinolines. On one hand, as a reliable approach, varied intramolecular 
cyclization strategies have been broadly applied, such as N-acyliminium mediated 
cyclization,242-244 imide carbonyl activation,245 coupling reactions,246 and so on. Another major 
approach is 1,3-dipolar cycloaddition reactions (1,3-DC) of azomethine ylides due to its 
inherent advantages to access pyrrolidine.247-249  
5.1.2 Phosphine-catalyzed Annulations of Allenes 
Although the use of trivalent phosphines as nucleophilic catalysts can be traced back to the 
1960s, it was not until 1995 that their first application in annulations of allenes was reported 
by Lu (Scheme 50).250 In this work, a novel (3+2) annulation of ethyl 2,3-butadienoate 278 
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with electron-deficient alkenes 277 was demonstrated, affording the cyclopentenes 279 and 
280. The observed regioselectivity was proposed to result from the presence of two reactive 
intermediates 281 and 282, with negative charge on α position and γ position respectively. 
Inspired by this seminal work, considerable interest and effort have been devoted into this field. 
Throughout more than two decades, phosphine-catalyzed annulations of allenes have become 
one of the most efficient synthetic strategies for the synthesis of highly functionalized 
carbocycle or heterocycle motif.20,21 Currently, besides the original (3+2) annulation 
discovered by Lu, (4+2) annulation also emerged as the other major reaction pattern, together 
with some rarely reported patterns such as (8+2), (4+3), (3+3) and (3+2+3).246,247 With regard 
to substrate types, more than eight types of allenes with varied substitutions have been 
explored. The substrate scope of electrophiles has also been largely expanded, such as electron-
deficient alkenes, imines, carbonyl moieties, aziridines, azomethine imines, and so on, 
dramatically increasing the molecular complexity and structural variety of the resulting 
annulation products.  
 
Scheme 50. The first phosphine-catalyzed annulation reaction of allene and diverse reactivity of allenes towards 
azomethine imines. 
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Among diverse electrophiles, the investigation of 1,3-dipoles as electrophiles is still scarce due 
to the complicated reactivity resulting from the nature of 1,3-dipole. To date, only two 
examples involving stabilized azomethine imines were reported in racemic from by Kwon 
(Scheme 50).251,252 In 2011, Kwon reported a phosphine-catalyzed (3+2), (3+3), (4+3) and 
(3+2+3) annulation of different allenes 283 and azomethine imines 284.251 The diverse reaction 
pathways could be influenced by substrate pattern and substitution type on phosphine catalyst. 
Later on, the same group demonstrated (3+2) and (3+4) annulations by the employment of 
another type of azomethine imines 289.252 Similarly, substrate types and phosphine catalysts 
have a critical influence on the ratio of isomers 291 and 292.  
5.2 Design Principle and Aim of the Project 
Although the reactivity of azomethine imines in phosphine-catalyzed annulation of allenes has 
been investigated, azomthine ylides remain surprisingly unexplored. Considering the 
prevalence of isoquinoline moieties in bioactive NPs and synthetic pharmaceutical molecules, 
isoquinolinium methylides, a type of stable azomethine ylides, were chosen as standard 
substrates. The aim of this project is to explore the possible reactivity pathways of 
isoquinolinium methylides in the phosphine-catalyzed annulations of allenes. The subsequent 
aim would be the synthesis of compound library based on isoquinoline motif for further 
chemical biology study. Additionally, the asymmetric version of such transformation was also 
taken into consideration.  
5.3 Result and Discussion  
5.3.1 Racemic Phosphine-catalyzed Annulation Reactions of Isoquinolinium Methylides 
The reaction of isoquinolinium methylide 293a and ethyl 2,3-butadienoate 278a was chosen as 
the model reaction. As summarized in Table 15, without treatment of any phosphine catalyst, 
only 295a was isolated in 51% yield after 6 h as the consequence of background reaction. (entry 
1) The addition of PPh3 as catalyst gave a new product together with trace background product 
295a in 6 h. However, the new product was quite instable, probably due to the presence of 
enamine motif. Hence, a sequential reduction by NaBH4 under acidic condition was performed 
in one pot manner, affording another moderately stable product 294a in 57% yield for two steps 
(entry 2). The structure of 294a was subsequently identified by X-ray crystallography analysis 
(by Dr. Constantin G. Daniliuc). Notably, an unusual alkene translocation occurred after (3+2) 
annulation process, resulting in the more thermally stable product 294a. The following 
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screening of tertiary phosphine catalysts revealed that PBu3 proved to be the optimal catalyst 
giving 75% yield in 10 minutes (Table 1, entry 3).  
Table 15. Screening of reaction conditions.[a] 
 
   Yield[b](%) 
Entry PR3 Time 295a 294a 
1[c] - 6 h 51 0 
2 PPh3 6 h 8 57 
3 PBu3 10 min <5 75 
4 MePPh2 10 min <5 62 
5 Me2PPh 10 min <5 68 
6 PCy3 2 h <5 62 
[a]. Unless otherwise noted, reactions were performed with 293a (0.1 mmol, 1 equiv.), 278a (0.15 mmol, 1.5 
equiv.), PR3 (0.02 mmol, 0.2 equiv.) in CH2Cl2 (1 mL) at room temperature. After reactions completed, NaBH4 
(0.3 mmol, 3 equiv.) and acetic acid (1 mmol, 10 equiv.) were added sequentially at 0 ℃. [b]. Isolated yield after 
column chromatography. [c]. Reaction was performed without phosphine catalyst and sequential reduction in one 
pot. 
With the optimized reaction conditions in hand, the substrate scope of this transformation was 
investigated (Scheme 51). When allenoate 278a was used, isoquinolinium methylide with ethyl 
and benzyl esters were also tolerated well in this reaction, providing the desired products 294b 
and 294c. With respect to variation of R1, substitutions with different electronic properties on 
diverse positions of aromatic ring proved to be suitable, furnishing the products 294d-n in 
satisfactory yield. In addition, without sequential reduction, the relative stable products 294o 
and 294p could be obtained from isoquinolinium methylides with either aromatic or aliphatic 
substitutions on 4-position of isoquinoline.  
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Scheme 51. Substrate scope of (3+2) annulation of isoquinolinium methylides and allenoates. 
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In contrast to allenoate, the reactivity of allenones were less explored in phosphine catalysis. 
Inspired by Loh’s work in 2009,253 α-trimethylsilyl substituted aryl allenones were synthesized 
and subjected to the annulations of isoquinolinium methylides. Delightfully, both aromatic and 
hetero aromatic group on allenones could be well tolerated, providing the desired γ-selective 
cycloadducts 294q-t, in which 294c was isolated as a 78:22 mixture of E/Z isomers. 
Furthermore, the products 294u and 294v were also obtained from isoquinolinium methylides 
with either electron drawing group or electron donating group. Interestingly, there was no 
alkene translocation when allenones were employed as dipoles.  
 
Scheme 52. Proposed mechanism for (3+2) annulations of isoquinolinium methylides and allenes.  
A plausible mechanism was proposed based on prior mechanistic studies of nucleophilic 
phosphine catalysis (Scheme 52). The reactive intermediates 295 and 296 can be generated 
from the nucleophilic addition of phosphine to allenes 278. However, only γ-selective 
intermediates 295 can react with the isoquinolinium methylides 293 to form intermediates 297. 
The following intramolecular conjugate addition of 297 give intermediates 298, followed by 
sequential β-elimination to provide the desired products 294q-v, when R is the aromatic group. 
When R is ethoxy, the more thermally stable products 294a-p are generated due to sequential 
isomerizations after the generation of 299. 
 
Figure 10. Representative compounds for inhibiting hedgehog signaling pathway. 
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This compound collection based on pyrroloisoquinolines was subjected to cell-based assays, 
including hedgehog signaling pathway, Wnt signaling pathway and autophage. Delightfully, 
several pyrroloisoquinoline-inspired compounds inhibited the hedgehog signaling pathway in 
the low micromolar range (Fig. 10).  
5.3.2 Attempts to Asymmtric Phosphine-catalyzed Annulation Reactions of 
Isoquinolinium Methylides  
 
Scheme 53. Chiral catalysts screening for the (3+2) annulations of isoquinolinium methylides and allenes. 
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As shown in Scheme 53, different chiral phosphine catalysts were tested in the (3+2) 
annulations of isoquinolinium methylides with two types of allenes. However, when allenoate 
278a was employed, no eantioselectivity was observed in the treatment of different chiral 
phosphine catalysts (Scheme 53a). In addition, only poor enantioselectivity (up to 37%) was 
achieved by catalyst 300e when allenone 278b was applied (Scheme 53b). To conclude, 
preliminary attempts failed to achieve considerable enantioselectivity for the asymmetric 
reactions of isoquinolinium methylides with allenes.  
5.4 Summary and Perspective  
To conclude, the reactivity of isoquinolinium methylides has been exploited in the annulation 
reactions of allenes enabled by nucleophilic phosphine catalysis. With this methodology, the 
valuable pyrroloisoquinolines can be accessed regio- and diastereoselectively under the 
optimized reaction conditions. However, only poor enantioselectivity was observed in the 
attempts to realize asymmetric version of this transformation, after intensive screening of chiral 
phosphine catalysts. The follow-up biological evaluation of such racemic pyrroloisoquinolines 
revealed several inhibitors in the hedgehog signaling pathway in the low micromolar range. 
For the phosphine-catalyzed annulation reactions of allenes and 1,3-dipoles, only few examples 
were reported, although the reactivity of such transformations had been shown to be 
considerable diverse by Kwon (Scheme 50). In the future, one of the directions in this field 
might be the application of other types of 1,3-dipoles into versatile annulation patterns 
chemoselectively. Additionally, the realization of corresponding transformations in a catalytic 
enantioselective manner would also be highly valuable. 
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In this thesis, to harness and evolve chemistry tools for biology-orientated synthesis (BIOS), 
various catalysis systems were explored to access compound collections inspired by bioactive 
natural products (NPs). On one hand, a novel type of cyclopentadienyl ligands for asymmetric 
C−H activation was developed to provide a more efficient chemistry tool for the exploration 
of chemical space defined by small molecules (Chapter 2). On the other hand, diverse 
compounds collections were synthesized expediently by harnessing the power of known 
catalysis systems (Chapter 3-5). Such known catalysis systems include chiral dirhodium(II) 
catalysis, chiral Lewis acids catalysis, chiral amine catalysis, and nucleophilic phosphine 
catalysis. Remarkably, versatile bioactivities were identified by the follow-up biological 
evaluation of such compound collections in different cell-based assays.  
 
Scheme 54. The synthesis of cyclopentadienyl ligands through (6+3) cycloadditions and their Rh(I) complexes. 
Chapter 2 described the development of chiral Cp ligands for asymmetric C−H activation. As 
proofs of concept, three C−H activation reactions were realized in highly enantioseletive 
manner by using the corresponding Rh(I) complexes as catalysts. As shown in Scheme 54, the 
chiral ligands (66, 96) can readily be synthesized on gram scale by either recrystallization of 
the enantioenriched (6+3) cycloadducts or preparative HPLC on chiral phase of the racemic 
(6+3) cycloadducts. Notably, both structure and configuration of such Cp derivatives can be 
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efficiently adjusted by means of flexible ligand-controlled enantioselective (6+3) cycloaddition 
reactions. Facilitated by the rapid synthesis of chiral Cp ligands through this highly efficient 
approach, a 30-member library of corresponding Rh(I) complexes (99, 100) was constructed.  
 
Scheme 55. Three reactions as proofs of concept to demonstrate the generality of newly developed Cp ligands. 
The generality and applicability of these chiral Cp ligands was substantially proved by 
successful applications of their corresponding Rh(I) complexes in three asymmetric C‒H 
activation reactions (Scheme 55). First, two transformations including the asymmetric 
synthesis of isoquinolones and the asymmetric C‒H allylation of benzamides were realized in 
highly enantioselective manner, which were previously steered enantioselectively by two types 
of known Cp ligands (Scheme 55a, b). These successful applications indicate the newly 
developed Cp ligands can actually rival the previously developed Cp ligands. Notably, 
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ortho-substituted styrenes also proved to be suitable in the enantioselective synthesis of 
isoquinolones enabled by the newly developed Cp ligands, which had not been reported for 
this transformation in chiral or racemic manner before. Facilitated by the unique catalytic 
property for ortho‒substituted styrenes, the synthesis of protoberberines analogs 105 was 
achieved by a cascade reaction with a sequence of C‒H functionalization followed by 
intramolecular SN2 reaction in one-pot manner (Scheme 55a). Furthermore, an unprecedented 
C‒H activation reaction was realized to afford valuable axially chiral biaryl compounds 107 
with excellent enantioselectivity (Scheme 55c).  
 
Scheme 56. The synthesis of compound collection based on pyrrolizidine by 1,3-dipolar cycloadditions. 
Chapter 3 described an efficient catalytic strategy for the synthesis of pyrrolizidine alkaloids 
(PAs) inspired compound collection by 1,3-dipolar cycloaddition reaction (1,3-DC) of 
azomethine ylides 152 and maleates 156 (Scheme 56a). By the employment of AgOAc as 
catalyst, a 87-member library of pyrrolizidines (158) and pyrrolidines (157) was obtained 
rapidly. Through subsequent biological evaluation, the bioactivities such as inhibition of 
Hedgehog pathway signaling were disclosed (Scheme 56b). 
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Scheme 57. Different strategies to access cycloheptanoids especially in enantioselective manner. 
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Chapter 4 demonstrated four different strategies to access biologically important 
cycloheptanoids, with a focus on 8-azabicyclo[3.2.1]octanes (tropane) and 
8-oxabicyclo[3.2.1]octanes (Scheme 57). As shown in Scheme 57a, the first strategy involves 
the 1,3-DC of tropone 242 and cyclic carbonyl ylides derived from diazodiketones 247 
catalyzed by chiral Rh(II) catalyst 182b (Scheme 57b). The bridged cyclopentanoids 248 with 
high molecular complexity and enantioselectivity were obtained efficiently. The second 
strategy is 1,3-DC of pentafulvenes and the same type of cyclic carbonyl ylides to afford the 
enantioriched 5-7 fused cycloheptanoids (Scheme 57c). The employment of di-substituted 
fulvene such as 59b proved to be critaical for the diastereoselectivity, but the enantioselectivity 
remained moderate (up to 57% ee) even after the intensive optimization of reaction conditions 
and catalysts. As for the third strategy, a novel synthesis approach to access enantioriched 
tropanes was preliminarily investigated by a relay catalysis combing Rh(II) catalysis for 
generation of azomethine ylides and chiral Lewis acid catalysis (Scheme 57d). After intensive 
optimization of substrates, catalysts and reaction conditions, only moderate enantioselectivity 
(up to 67% ee) had been achieved for the standard reaction of 3-methylene-2-oxindole 251 and 
diazo compound 260 by using Mg(NTf2)2 as Lewis acid and 262a as ligand. At last, the fourth 
strategy consists of two approaches to synthesize 8-oxabicyclo[3.2.1]octanes by amine 
catalysis (Scheme 57e, f). Regarding the first approach, the optimization of intermolecular 
(5+2) cycloaddition of styrene 10a and pyrylium salts generated from pyranone 263b failed to 
give the desired cycloheptanoids 264 with satisfactory stereoselectivity (up to 67% ee) and 
yield (Scheme 57e). On the other hand, the second stepwise approach comprises a amine-
catalyzed Michael addition of 3-furones 267 and α,β-unsaturated aldehydes 266, and a 
subsequent reductive radical cyclization mediated by SmI2 (Scheme 57f). A 28-member 
compound library (270) inspired by Englerin A was synthesized. However, no bioactivity was 
found in the subsequent biological evaluation. 
Chapter 5 depicted the synthesis of pyrroloisoquinolines 294 by a phosphine-catalyzed 
annulation reaction of isoquinolinium methylides 293 and allenes 278 (Scheme 58a). Trialkyl 
phosphine PBu3 proved to be the efficient catalyst for this transformation. Interestingly, 
allenoate 278a and allenones 278b-e gave different products due to alkene translocation. 
Unfortunately, only poor enantioselectivity was achieved for this transformation after 
screening of various chiral phosphine catalysts. Nevertheless, the follow-up biological 
evaluation of the racemic pyrroloisoquinolines revealed several inhibitors of the hedgehog 
signaling pathway (Scheme 58b). 
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Scheme 58. The synthesis of compound collection based on pyrroloisoquinoline through phophine catalysis. 
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7.1 General Methods and Materials  
Unless otherwise noted, all commercially available compounds were used as provided without 
further purifications. Solvents for chromatography were technical grade.  
Analytical thin-layer chromatography (TLC) was performed on Merck silica gel aluminium 
plates with F-254 indicator. Compounds were visualized by irradiation with UV light or 
potassium permanganate staining. Column chromatography was performed using silica gel 
Merck 60 (particle size 0.040-0.063 mm) or aluminum oxide (activated, neutral, Brockmann I, 
Sigma-Aldrich).  
1H-NMR and 13C-NMR were recorded on a Bruker DRX400 (400 MHz), Bruker DRX500 (500 
MHz), INOVA500 (500 MHz) and Bruker DRX700 using CD2Cl2, CDCl3, benzene-d6 or 
methanol-d4 as solvent. Data are reported in the following order: chemical shift (δ) values are 
reported in ppm with the solvent resonance as internal standard (CD2Cl2: δ = 5.32 ppm for 1H, 
δ = 54.00 ppm for 13C; CDCl3: δ = 7.26 ppm for 1H, δ = 77.16 ppm for 13C; benzene-d6: δ = 
7.16 ppm for 1H, δ = 128.06 ppm for 13C; methanol-d4: δ = 4.87 ppm for 1H, δ = 49.00 ppm for 
13C); multiplicities are indicated br s (broadened singlet), s (singlet), d (doublet), t (triplet), q 
(quartet), m (multiplet); coupling constants (J) are given in Hertz (Hz).  
High resolution mass spectra were recorded on a LTQ Orbitrap mass spectrometer coupled to 
an Accela HPLC-System (HPLC column: Hypersyl GOLD, 50 mm x 1 mm, particle size 1.9 
μm, ionization method: electron spray ionization). Fourier transform infrared spectroscopy 
(FT-IR) spectra were obtained with a Bruker Tensor 27 spectrometer (ATR, neat) and were 
reported in terms of frequency of absorption (cm-1). Optical rotations were measured in a 
Schmidt + Haensch Polartronic HH8 polarimeter. 
The enantiomeric excesses were determined by HPLC analysis using a chiral stationary phase 
column (CHIRALCEL IC, CHIRALCEL IA; eluent: (CH2Cl2/EtOH = 100/2) / iso-hexane, i-
PrOH / iso-hexane; 4.6 mm x 250 mm, particle size 5 μm). The chiral HPLC methods were 
calibrated with the corresponding racemic mixtures. The ratio of regioisomers and 
diastereomers was determined by 1H-NMR analysis via integration of characteristic signals of 
methyl esters. Chemical yields refer to isolated substances. Yields and enantiomeric excesses, 
diastereoselectivity and regioselectivity are given in the tables.  
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7.2 Experimental Part for Development of Tunable Cyclopentadienyl 
Ligands 
7.2.1 Synthesis of Ligands 96a-96i and 66a-66m 
Method A for Synthesis of Chiral Cp Ligands 96a, 96b, 96e-h:  
(Rp)-2-(tert-Butylthio)-1-(diphenylphosphino)ferrocene (0.02 mmol, 0.05 equiv.) and tetrakis-
(acetonitrile)copper(I) tetrafluoroborate (0.02 mmol, 0.05 equiv.) were dissolved in 
DCM:MeOH (2mL:10uL) and stirred at ambient temperature for 5 min. To the resulting 
solution α-iminoesters (0.40 mmol, 1 equiv.), CsCO3 (0.40 mmol, 1 equiv.) and fulvenes (0.60 
mmol, 1.5 equiv.) were added. The mixture was allowed to be stirred at ambient temperature 
for specific time until full conversion monitored by TLC. The solvent was removed in vacuo 
and column chromatography on silica gel afforded the pure products. 
Method B for Synthesis of Chiral Cp Ligands 96c, 96d, 96i:  
(Rp)-2-(tert-Butylthio)-1-(diphenylphosphino)ferrocene (0.012 mmol, 0.03 equiv.) and 
tetrakis-(acetonitrile)copper(I) tetrafluoroborate (0.012 mmol, 0.03 equiv.) were dissolved in 2 
mL 1,4-dioxane and stirred at ambient temperature for 5 min. To the resulting solution α-
iminoesters (0.40 mmol, 1 equiv), Et3N (0.40 mmol, 1 equiv) and fulvenes (0.60 mmol, 1.5 
equiv.) were added. The mixture was allowed to be stirred at ambient temperature for 1 h. The 
solvent was removed in vacuo and column chromatography on silica gel afforded the pure 
products. 
Method C for Synthesis of Chiral Cp Ligands 66a-66j, 66l, 66m:  
R-(‒)-5,5'-Bis(diphenylphosphino)-2,2,2',2'-tetrafluoro-4-4'-bi-1,3-benzodioxole (0.02 mmol, 
0.05 equiv.) and tetrakis-(acetonitrile)copper(I) tetrafluoroborate (0.02 mmol, 0.05 equiv.) 
were dissolved in 4 mL THF and stirred at -40°C for 5 min. To the resulting solution α-
iminoesters (0.40 mmol, 1 equiv), Et3N (0.40 mmol, 1 equiv) and fulvenes (0.60 mmol, 1.5 
equiv.)  were added and the mixture was allowed to be stirred at -40°C for specific time until 
full conversion monitored by TLC. The reaction was quenched by saturated NH4Cl solution, 
and solvent was removed in vacuo and column chromatography on silica gel afforded the pure 
products. 
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Method D for Synthesis of Chiral Cp Ligands 66k in gram scale:  
R-(‒)-5,5'-Bis(diphenylphosphino)-2,2,2',2'-tetrafluoro-4-4'-bi-1,3-benzodioxole (0.04 mmol, 
0.01 equiv.) and tetrakis-(acetonitrile)copper(I) tetrafluoroborate (0.04 mmol, 0.01 equiv.) 
were dissolved in 6 mL THF and stirred at -40°C for 5 min. To the resulting solution α-
iminoesters (4 mmol, 1 equiv), Et3N (4 mmol, 1 equiv) and fulvenes (6 mmol, 1.5 equiv.)  were 
added and the mixture was allowed to be stirred at -40°C for specific time until full conversion 
monitored by TLC. The reaction was quenched by saturated NH4Cl solution, and solvent was 
removed in vacuo and column chromatography on silica gel affords the pure product 66k with 
95% ee. The optical pure form of ligand was prepared by recrystallization in 
dichloromethane/petroleum ether from mother liquor.  
Methyl (1S,3R,7aS)-4,4-dimethyl-1-(naphthalen-2-yl)-2,3,4,7a-tetrahydro-1H-cyclopenta 
[c]pyridine-3-carboxylate 
96a: Using Method A, 73% yield; The spectral data are identical to those 
reported;16,17,53 70% ee. The optical pure form of this ligand could be 
prepared in gram scale by chiral preparative HPLC of its racemate. 
Conditions for preparative HPLC: CHIRAPAK IC column, iso-propanol / 
heptane = 15/85, flow rate = 4 mL min-1, t = 6.8 min, 9.8 min. Procedure 
for synthesis of racemic 96a:54 To the solution of 6,6-dimethylfulvene (7.2 
mmol, 1.2 equiv), α-iminoesters (6 mmol, 1 equiv) in toluene (20 mL) was added Ag2O (0.6 
mmol, 0.1 equiv) and Et3N (7.2 mmol, 1.2 equiv) at r.t., the solution was allowed to be stirred 
until full conversion monitored by TLC. The solution was filtered through celite, concentrated 
in vacuo and the crude residue was purified by column chromatography to give racemic 96a 
(1.62 g, 81% yield). 
Methyl (1S,3R,7aS)-4,4-diethyl-1-(naphthalen-2-yl)-2,3,4,7a-tetrahydro-1H-cyclopenta 
[c]pyridine-3-carboxylate 
96b: Using Method A, 57% yield; 1H NMR (400 MHz, CD2Cl2): δ 7.94 – 
7.85 (m, 4H), 7.60 (dd, J = 8.5, 1.7 Hz, 1H), 7.54 – 7.46 (m, 2H), 6.56 – 
6.46 (m, 1H), 6.20 (s, 1H), 6.00 (d, J = 5.3 Hz, 1H), 3.73 (s, 3H), 3.59 (s, 
1H), 3.12 (s, 2H), 2.18 – 2.07 (m, 2H), 1.74 – 1.58 (m, 1H), 1.39 – 1.27 (m, 
1H), 1.11 (t, J = 7.4 Hz, 3H), 0.70 ppm (t, J = 7.4 Hz, 3H); 13C NMR (101 
MHz, CD2Cl2): δ 172.61, 153.08, 141.20, 134.07, 133.93, 133.71, 132.89, 
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128.70, 128.46, 128.18, 126.68, 126.41, 126.33, 126.26, 126.06, 65.65, 65.50, 57.24, 52.02, 
46.08, 29.59, 26.54, 9.08, 8.66 ppm; HRMS: calc. for [M+H]+ C24H28NO2: 362.21200, found: 
362.21271; CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 15/85, flow rate = 
0.5 mL min-1, major enantiomer: tR = 29.7 min; minor enantiomer: tR = 33.8 min, 60% ee. 
Methyl (1'S,3'R,7a'S)-1'-(naphthalen-2-yl)-1',2',3',7a'-tetrahydrospiro[cyclobutane-1,4'-
cyclopenta[c]pyridine]-3'-carboxylate 
96c: Using Method A, 83% yield; 1H NMR (400 MHz, CD2Cl2): δ 7.92 – 
7.85 (m, 4H), 7.56 (dd, 1H), 7.52 – 7.48 (m, 2H), 6.54 – 6.50 (m, 1H), 6.29 
– 6.24 (m, 1H), 6.06 – 6.02 (m, 1H), 3.82 (s, 3H), 3.26 (s, 1H), 3.15 (d, J = 
10.3 Hz, 1H), 3.07 (d, J = 10.3 Hz, 1H), 2.52 – 2.42 (m, 3H), 1.99 – 1.90 
(m, 2H), 1.78 – 1.65 ppm (m, 1H); 13C NMR (101 MHz, CD2Cl2): δ 172.85, 
157.12, 140.98, 134.22, 134.04, 133.68, 133.11, 128.71, 128.46, 128.16, 
126.69, 126.43, 126.23, 126.01, 122.07, 68.62, 66.35, 56.85, 52.40, 45.59, 30.27, 26.61, 15.75 
ppm; HRMS: calc. for [M+H]+ C23H24NO2: 346.18016, found: 346.17989; HPLC conditions: 
CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow rate = 0.5 mL min-1, major 
enantiomer: tR = 29.9 min; minor enantiomer: tR = 43.7 min, 29% ee. 
Methyl (1'S,3'R,7a'S)-1'-(naphthalen-2-yl)-1',2',3',7a'-tetrahydrospiro[cyclohexane-1,4'-
cyclopenta[c]pyridine]-3'-carboxylate 
96d: Using Method A, 90% yield; 1H NMR (400 MHz, CD2Cl2): δ 7.96 – 
7.83 (m, 4H), 7.59 (dd, J = 8.5, 1.7 Hz, 1H), 7.54 – 7.43 (m, 2H), 6.57 – 
6.49 (m, 1H), 6.39 (s, 1H), 6.09 – 6.01 (m, 1H), 3.74 (s, 3H), 3.31 (d, J = 
10.0 Hz, 1H), 3.13 (s, 1H), 2.96 (d, J = 10.0 Hz, 1H), 2.29 – 2.16 (m, 2H), 
2.10 – 2.02 (m, 1H), 1.97 – 1.86 (m, 1H), 1.81 – 1.55 (m, 4H), 1.48 (td, J 
= 13.0, 3.3 Hz, 1H), 1.30 – 1.11 ppm (m, 2H); 13C NMR (101 MHz, 
CD2Cl2): δ 172.17, 154.97, 141.25, 134.50, 134.05, 133.68, 132.93, 128.75, 128.45, 128.17, 
126.70, 126.43, 126.23, 126.16, 126.02, 72.21, 68.39, 56.64, 52.01, 44.22, 33.33, 32.49, 27.57, 
23.20, 23.05 ppm; HRMS: calc. for [M+H]+ C25H28NO2: 374.21146, found: 374.21167; HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 15/85, flow rate = 
0.5 mL min-1, major enantiomer: tR = 26.8 min; minor enantiomer: tR = 37.5 min, 66% ee. 
Methyl (1S,3R,7aS)-1-(4-bromophenyl)-4,4-dimethyl-2,3,4,7a-tetrahydro-1H-cyclopenta 
[c]pyridine-3-carboxylate 
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96e: Using Method A, 83% yield; 1H NMR (400 MHz, CDCl3): δ 7.55 – 
7.46 (m, 2H), 7.39 – 7.30 (m, 2H), 6.53 – 6.39 (m, 1H), 6.15 (d, J = 0.6 Hz, 
1H), 5.96 (dt, J = 5.4, 1.3 Hz, 1H), 3.75 (s, 3H), 3.17 (s, 1H), 3.07 (d, J = 
10.4 Hz, 1H), 2.86 (d, J = 10.4 Hz, 1H), 2.13 (br s, 1H ), 1.43 (s, 3H), 1.22 
ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ 171.76, 157.66, 141.91, 
133.56, 132.87, 131.86, 128.96, 122.42, 121.68, 69.98, 65.48, 56.29, 51.84, 
38.51, 24.36, 24.34 ppm; HRMS: calc. for [M+H]+ C18H21NO2
79Br: 362.07502, found: 
362.07495; calc. for [M+H]+ C18H21NO2
81Br: 364.07297, found: 364.07251; HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 10/90, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 29.0 min; minor enantiomer: tR = 31.7 min, 62% ee. 
Methyl (1S,3R,7aS)-4,4-dimethyl-1-(4-methylphenyl)-2,3,4,7a-tetrahydro-1H-cyclopenta 
[c]pyridine-3-carboxylate 
96f: Using Method A, 77% yield; 1H NMR (400 MHz, CD2Cl2): δ 7.34 (d, 
J = 7.8 Hz, 2H), 7.21 (d, J = 7.8 Hz, 2H), 6.47 – 6.43 (m, 1H), 6.16 – 6.13 
(m, 1H), 5.98 (dt, J = 5.3, 1.4 Hz, 1H), 3.72 (s, 3H), 3.17 – 3.10 (m, 2H), 
2.84 (d, J = 10.3 Hz, 1H), 2.37 (s, 3H), 2.06 (br s, 1H ), 1.43 (s, 3H), 1.22 
ppm (s, 3H); 13C NMR (101 MHz, CD2Cl2): δ 172.28, 158.71, 140.74, 
138.00, 134.38, 132.84, 129.72, 127.49, 122.38, 70.59, 66.34, 56.93, 51.99, 38.92, 24.58, 
24.56, 21.43 ppm; HRMS: calc. for [M+H]+ C19H24NO2: 298.18016, found: 298.17983; HPLC 
conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 31.0 min; minor enantiomer: tR = 26.5 min, 67% ee. 
Methyl (1S,3R,7aS)-4,4-dimethyl-1-(2-methylphenyl)-2,3,4,7a-tetrahydro-1H-cyclopenta 
[c]pyridine-3-carboxylate 
96g: Using Method A, 78% yield; 1H NMR (400 MHz, CDCl3): δ 7.65 (d, 
J = 7.7 Hz, 1H), 7.35 – 7.23 (m, 1H), 7.25 – 7.13 (m, 2H), 6.50 – 6.43 (m, 
1H), 6.16 (s, 1H), 6.03 – 5.92 (m, 1H), 3.74 (s, 3H), 3.24 (d, J = 10.4 Hz, 
1H), 3.17 (s, 1H), 3.12 (d, J = 10.4 Hz, 1H), 2.26 (s, 3H), 2.03 (br s, 1H ), 
1.44 (s, 3H), 1.23 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ 171.88, 
157.80, 140.73, 136.03, 134.04, 132.56, 130.81, 127.53, 126.52, 125.72, 122.13, 69.94, 61.42, 
56.13, 51.76, 38.59, 24.45, 24.36, 19.52 ppm; HRMS: calc. for [M+H]+ C19H24NO2: 
298.18016, found: 298.18012; HPLC conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 
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100/2) / iso-hexane = 10/90, flow rate = 0.5 mL min-1, major enantiomer: tR = 30.6 min; minor 
enantiomer: tR = 26.5 min, 66% ee. 
Ethyl (1S,3R,7aS)-4,4-dimethyl-1-(naphthalen-2-yl)-2,3,4,7a-tetrahydro-1H-cyclopenta 
[c]pyridine-3-carboxylate 
96h: Using Method A, 83% yield; 1H NMR (400 MHz, CD2Cl2): δ 7.93 (s, 
1H), 7.92 – 7.86 (m, 3H), 7.62 (dd, J = 8.5, 1.8 Hz, 1H), 7.55 – 7.46 (m, 
2H), 6.50 – 6.46 (m, 1H), 6.19 (s, 1H), 6.04 – 5.98 (m, 1H), 4.27 – 4.14 (m, 
2H), 3.28 (d, J = 10.3 Hz, 1H), 3.20 (s, 1H), 3.06 (d, J = 10.3 Hz, 1H), 2.26 
(br s, 1H ), 1.48 (s, 3H), 1.33 – 1.26 ppm (m, 6H); 13C NMR (101 MHz, 
CD2Cl2): δ 171.83, 158.80, 141.24, 134.28, 134.06, 133.71, 132.98, 128.72, 
128.47, 128.17, 126.68, 126.42, 126.26, 126.09, 122.48, 70.58, 66.73, 61.24, 56.93, 39.00, 
24.68, 24.59, 14.73 ppm; HRMS: calc. for [M+H]+ C23H26NO2: 348.19581, found: 348.19565; 
e.e. was determined by Diels‒Alder cycloadduct of chiral cyclopentadiene and N-
methylmaleimide, HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 40.2 min; minor enantiomer: tR = 49.3 
min, 71% ee. 
 
Methyl (1S,3R,4S,7aS)-1-(4-bromophenyl)-4-(naphthalen-2-yl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
96i: Using Method B, The spectral data are identical to those reported;16 96% ee. 
Mixture of isomers 
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98a: optical pure 96a (1 equiv., 0.2 mmol) was dissolved in 2 mL DCE. To the resulting 
solution MgSO4 (10 equiv., 2 mmol), HCHO solution 35 wt. % in H2O (8 equiv., 1.6 mmol) 
and NaBH(OAc)3 (3 equiv., 0.6 mmol) were added in sequential way and the mixture was 
allowed to be stirred at ambient temperature for specific time until full conversion monitored 
by TLC. Column chromatography on silica gel affords the pure product directly without 
removal of solvent, 89% yield; three inseparable isomers with 57:43 ratio; For mixture, 1H 
NMR (500 MHz, CD2Cl2): δ 8.01 – 7.66 (m, 7.02H), 7.57 – 7.37 (m, 5.26H), 6.47 (d, J = 5.2 
Hz, 1H), 6.39 (d, J = 5.0 Hz, 0.75H), 6.19 (d, J = 4.8 Hz, 1H), 6.09 (s, 0.75H), 5.79 (d, J = 5.1 
Hz, 0.75H), 5.31 (s, 1H), 4.14 (s, 1H), 3.75 (s, 3H), 3.74 (s, 2.26H), 3.32 (d, J = 10.8 Hz, 
0.75H), 3.22 (s, 1H), 2.77 – 2.64 (m, 1.75 H), 2.47 (d, J = 10.8 Hz, 0.75H), 2.25 – 2.13 (m, 
4H), 1.92 (s, 2.26H), 1.44 (s, 2.26H), 1.38 (s, 3H), 1.29 (s, 2.26H), 1.21 ppm (s, 3H); For 
mixture, 13C NMR (126 MHz, CD2Cl2): δ 172.33, 172.24, 157.60, 145.41, 141.71, 141.35, 
137.80, 134.90, 133.85, 133.70, 133.63, 132.96, 132.84, 130.51, 128.85, 128.29, 128.17, 
128.16, 127.72, 126.75, 126.60, 126.50, 126.30, 126.18, 121.22, 80.56, 75.87, 75.31, 70.85, 
51.82, 51.74, 42.08, 41.76, 41.38, 37.99, 36.03, 25.61, 25.42, 25.34, 24.75 ppm; HRMS: calc. 
for [M+H]+ C23H26NO2: 348.19581, found: 348.19578. 
Mixture of isomers 
98b: optical pure 96a (1 equiv., 0.2 mmol) was dissolved in 2 mL DCE. To the resulting 
solution MgSO4 (10 equiv., 2 mmol), acetaldehyde (8 equiv., 1.6 mmol) and NaBH(OAc)3 (3 
equiv., 0.6 mmol) were added in sequential way and the mixture was allowed to be stirred at 
ambient temperature for specific time until full conversion monitored by TLC. Column 
chromatography on silica gel affords the pure product directly without removal of solvent, 86% 
yield; two inseparable isomers with 71:29 ratio; For mixture, 1H NMR (400 MHz, CD2Cl2): δ 
7.95 – 7.75 (m, 5.6H), 7.56 – 7.42 (m, 4.2H), 6.50 – 6.45 (m, 0.40H), 6.41 – 6.37 (m, 1H), 6.21 
– 6.17 (m, 0.40H), 6.07 (s, 1H), 5.82 – 5.75 (m, 1H), 4.74 (s, 0.40H), 3.76 (s, 1.20H), 3.75 (s, 
3H), 3.61 (s, 0.40H), 3.34 – 3.28 (m, 1H), 3.16 (s, 1H), 2.96 (d, 1H), 2.87 – 2.75 (m, 0.80H), 
2.78 – 2.70 (m, 0.40H), 2.66 – 2.58 (m, 2H), 2.27 – 2.16 (m, 0.40H), 1.45 (s, 3H), 1.40 (s, 
1.20H), 1.29 (s, 3H), 1.22 (s, 1.20H), 0.92 (t, J = 7.2 Hz, 1.20H), 0.70 ppm (t, J = 7.1 Hz, 3H); 
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For mixture, 13C NMR (101 MHz, CD2Cl2): δ 172.24, 157.93, 145.23, 142.27, 140.98, 138.42, 
135.09, 134.00, 133.95, 133.76, 133.70, 132.84, 132.80, 130.61, 128.88, 128.82, 128.35, 
128.20, 127.49, 127.26, 126.95, 126.61, 126.49, 126.44, 126.34, 126.16, 120.87, 75.13, 71.15, 
69.65, 64.43, 57.23, 51.75, 51.65, 44.66, 44.47, 42.22, 38.20, 36.26, 25.42, 25.37, 25.27, 24.79, 
7.71, 6.36 ppm; HRMS: calc. for [M+H]+ C24H28NO2: 362.21146, found: 362.21140. 
Mixture of isomers 
98c: optical pure 96a (1 equiv., 0.2 mmol) was dissolved in 2 mL DCE. To the resulting 
solution MgSO4 (10 equiv., 2 mmol), isobutyraldehyde (8 equiv., 1.6 mmol) and NaBH(OAc)3 
(3 equiv., 0.6 mmol) were added in sequential way and the mixture was allowed to be stirred 
at ambient temperature for specific time until full conversion monitored by TLC. Column 
chromatography on silica gel affords the pure product directly without removal of solvent, 56% 
yield; three inseparable isomers with 54:33:13 ratio; the resulting mixture was directly 
subjected to Rhodium complex preparation without resolution of 1H NMR and 13C NMR; 
HRMS: calc. for [M+H]+ C26H32NO2: 390.24276, found: 390.24350. 
Ethyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(4-methylphenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66a: Using Method C, 61% yield; For major isomer, 1H NMR (400 
MHz, CD2Cl2): δ 7.51 (d, J = 8.4 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 
7.25 – 7.20 (m, 4H), 6.46 – 6.40 (m, 1H), 6.08 – 6.02 (m, 1H), 5.72 
(s, 1H), 3.97 – 3.86 (m, 3H), 3.53 (d, J = 10.4 Hz, 1H), 3.17 (d, J 
= 10.4 Hz, 1H), 3.12 – 3.04 (m, 1H), 2.38 (s, 3H), 0.96 ppm (t, J = 7.1 Hz, 3H); 13C NMR (101 
MHz, CD2Cl2): δ 172.13, 151.91, 140.21, 138.66, 138.22, 134.39, 133.19, 131.94, 131.36, 
129.79, 127.49, 125.69, 121.22, 67.46, 66.29, 61.37, 59.54, 50.67, 21.44, 14.20 ppm; HRMS: 
calc. for [M+H]+ C24H25NO2
79Br: 438.10632, found: 438.10571; calc. for [M+H]+ 
C18H21NO2
81Br: 440.10427, found: 440.10338; e.e. was determined by Diels‒Alder 
cycloadduct of chiral cyclopentadiene and N-methylmaleimide, HPLC conditions: 
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CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2)/ iso-hexane = 30/70, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 47.5 min; minor enantiomer: tR = 55.1 min, 92% ee. 
Ethyl (1S,3R,4R,7aS)-1,4-bis(4-bromophenyl)-2,3,4,7a-tetrahydro-1H-cyclopenta[c] 
pyridine-3-carboxylate 
66b: Using Method C, 82% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 7.55 (d, J = 8.4 Hz, 2H), 7.51 (d, J = 8.4 Hz, 2H), 7.38 (d, J = 
8.4 Hz, 2H), 7.22 (d, J = 8.4 Hz, 2H), 6.45 (dt, J = 5.4, 1.6 Hz, 
1H), 6.03 (dd, J = 5.4, 1.1 Hz, 1H), 5.72 (s, 1H), 3.96 – 3.86 (m, 
3H), 3.54 (d, J = 10.4 Hz, 1H), 3.18 (d, J = 10.4 Hz, 1H), 3.04 
(dd, J = 10.4, 1.1 Hz, 1H), 0.96 ppm (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CD2Cl2): δ 
171.98, 151.61, 142.29, 138.48, 133.91, 133.56, 132.25, 131.96, 131.35, 129.52, 126.00, 
122.05, 121.29, 67.28, 65.90, 61.45, 59.35, 50.48, 14.19 ppm; HRMS: calc. for [M+H]+ 
C23H22NO2
79Br2: 502.00118, found: 502.00072; calc. for [M+H]
+ C23H22NO2
79Br81Br: 
503.99913, found: 503.99807; calc. for [M+H]+ C23H22NO2
81Br2: 505.99709, found: 
505.99588; e.e. was determined by Diels‒Alder cycloadduct of chiral cyclopentadiene and N-
methylmaleimide, HPLC conditions: CHIRAPAK IA column, (CH2Cl2/EtOH = 100/2)/ iso-
hexane = 25/75, flow rate = 0.5 mL min-1, major enantiomer: tR = 29.7 min; minor enantiomer: 
tR = 27.5 min, 96% ee. 
Ethyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(4-fluorophenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66c: Using Method B, 82% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 7.53 – 7.44 (m, 4H), 7.24 – 7.20 (m, 2H), 7.15 – 7.08 (m, 2H), 
6.44 (d, J = 5.2 Hz, 1H), 6.03 (d, J = 4.6 Hz, 1H), 5.72 (s, 1H), 
4.01 – 3.87 (m, 3H), 3.54 (d, J = 10.4 Hz, 1H), 3.20 (d, J = 10.4 
Hz, 1H), 3.06 (d, J = 10.4 Hz, 1H), 1.92 (br s, 1H), 0.96 ppm (t, J 
= 7.1 Hz, 3H); 13C NMR (101 MHz, CD2Cl2): δ 172.05, 162.90 (d, J = 245.1 Hz), 151.73, 
139.15 (d, J = 3.1 Hz), 138.54, 134.05, 133.47, 131.96, 131.36, 129.37 (d, J = 8.1 Hz), 125.92, 
121.28, 115.89 (d, J = 21.4 Hz), 67.35, 65.78, 61.44, 59.54, 50.53, 14.19 ppm; HRMS: calc. 
for [M+H]+ C23H22NO2
79BrF: 442.08125, found: 442.08058; calc. for [M+H]+ 
C23H22NO2
81BrF: 444.07920, found: 444.07826; HPLC conditions: CHIRAPAK IC column, 
iso-propanol / iso-hexane = 5/95, flow rate = 0.5 mL min-1, major enantiomer: tR = 18.7 min; 
minor enantiomer: tR = 15.1 min, 96% ee. 
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Ethyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(2-methylphenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66d: Using Method B, 50% yield; 1H NMR (400 MHz, CD2Cl2): δ 
7.66 (d, J = 7.6 Hz, 1H), 7.52 (d, J = 8.4 Hz, 2H), 7.34 – 7.28 (m, 
1H), 7.27 – 7.21 (m, 4H), 6.45 (d, J = 5.4 Hz, 1H), 6.08 – 5.98 (m, 
1H), 5.80 – 5.72 (m, 1H), 3.97 – 3.84 (m, 3H), 3.53 (d, J = 10.4 Hz, 
1H), 3.42 (d, J = 10.4 Hz, 1H), 3.22 (d, J = 10.4 Hz, 1H), 2.32 (s, 3H), 1.89 (br s, 1H), 0.96 
ppm (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CD2Cl2): δ 172.2, 151.82, 140.91, 138.62, 
136.76, 134.29, 133.34, 131.97, 131.33, 131.21, 128.05, 126.89, 126.12, 125.65, 121.24, 67.33, 
61.82, 61.36, 59.04, 51.07, 19.67, 14.20 ppm; HRMS: calc. for [M+H]+ C24H25NO2
79Br: 
438.10632, found: 438.10549; calc. for [M+H]+ C24H25NO2
81Br: 440.10427, found: 
440.10303; HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 5/95, flow 
rate = 0.5 mL min-1, major enantiomer: tR = 16.3 min; minor enantiomer: tR = 15.1 min, 72% 
ee. 
  
Methyl (1S,3R,4R,7aS)-1-(4-bromophenyl)-4-(naphthalen-2-yl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66e: Using Method C, 82% yield; The spectral data are identical to those reported;17 96% ee. 
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Mixture of isomers 
97: Ligand 66e (1 equiv., 0.2 mmol) was dissolved in 2 mL DCE. To the resulting solution 
MgSO4 (10 equiv., 2 mmol), HCHO solution 35 wt. % in H2O (8 equiv., 1.6 mmol) and 
NaBH(OAc)3 (3 equiv., 0.6 mmol) were added in sequential way and the mixture was allowed 
to be stirred at ambient temperature for specific time until full conversion monitored by TLC. 
Column chromatography on silica gel affords the pure product directly without removal of 
solvent, 41% yield; two inseparable isomers with 78:22 ratio; For mixture, 1H NMR (400 MHz, 
CD2Cl2): δ 7.89 – 7.76 (m, 5.12H), 7.69 – 7.63 (m, 1.28H), 7.56 – 7.43 (m, 5.12H), 7.37 – 7.29 
(m, 2.56H), 7.29 – 7.22 (m, 1.28H), 6.21 – 6.11 (m, 1.28H), 5.94 – 5.90 (m, 0.28H), 5.89 – 
5.84 (m, 1H), 4.44 – 4.33 (m, 1.28H), 4.26 – 4.15 (m, 1.28H), 3.49 – 3.41 (m, 5.12H), 2.79 – 
2.73 (m, 1.28H), 2.16 (s, 3H), 2.15 (s, 0.66H); For mixture, 13C NMR (101 MHz, CD2Cl2): δ 
173.04, 143.09, 141.75, 141.20, 140.94, 139.02, 138.98, 138.91, 137.88, 134.08, 133.33, 
132.63, 132.59, 132.34, 132.18, 132.12, 131.72, 131.23, 130.81, 128.76, 128.70, 128.26, 
128.23, 128.17, 128.16, 127.07, 126.94, 126.70, 126.66, 126.38, 121.77, 121.64, 74.44, 74.20, 
69.62, 68.36, 52.08, 48.30, 47.13, 42.23, 41.13, 41.04 ppm; HRMS: calc. for [M+H]+ 
C27H25NO2
79Br: 474.10632, found: 474.10574; calc. for [M+H]+ C27H25NO2
81Br: 476.10427, 
found: 476.10329; 96% ee. 
Ethyl (1S,3R,4R,7aS)-4-(4-methylphenyl)-1-(4-(trifluoromethyl)phenyl)-2,3,4,7a-
tetrahydro-1H-cyclopenta[c]pyridine-3-carboxylate 
66f: Using Method C, 82% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 7.69 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.2 Hz, 2H), 7.25 – 7.13 
(m, 4H), 6.46 (d, J = 5.3 Hz, 1H), 6.02 (d, J = 5.3 Hz, 1H), 5.77 
(s, 1H), 3.99 – 3.82 (m, 3H), 3.56 (d, J = 10.4 Hz, 1H), 3.28 (d, J 
= 10.4 Hz, 1H), 3.07 (dd, J = 10.4 Hz, 1H), 2.36 (s, 3H), 0.94 ppm 
(t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CD2Cl2): δ 172.24, 152.32, 147.41, 137.35, 135.98, 
133.78, 133.47, 129.53, 129.86 (q, J = 32.3 Hz), 129.36, 128.24, 126.11 (q, J = 3.8 Hz), 125.91, 
124.88 (q, J = 271.7 Hz), 67.67, 66.21, 61.32, 59.34, 50.78, 21.40, 14.16 ppm; HRMS: calc. 
for [M+H]+ C25H25NO2F3: 428.18319, found: 428.18193; e.e. was determined by Diels‒Alder 
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cycloadduct of chiral cyclopentadiene and N-methylmaleimide, HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2)/ iso-hexane = 30/70, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 32.5 min; minor enantiomer: tR = 53.9 min, 97% ee. 
Ethyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(4-(trifluoromethyl)phenyl)-2,3,4,7a-
tetrahydro-1H-cyclopenta[c]pyridine-3-carboxylate 
66g: Using Method C, 70% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 7.69 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.2 Hz, 2H), 7.51 (d, J = 
8.4 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 6.46 (dt, J = 5.4, 1.4 Hz, 
1H), 6.03 (dd, J = 5.4, 0.9 Hz, 1H), 5.75 (s, 1H), 4.05 – 3.84 (m, 
3H), 3.57 (d, J = 10.4 Hz, 1H), 3.28 (d, J = 10.4 Hz, 1H), 3.08 
(dd, J = 10.4, 0.9 Hz, 1H), 0.96 ppm (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CD2Cl2): δ 
171.94, 151.55, 147.23, 138.43, 133.73, 133.70, 131.99, 131.36, 130.42 (d, J = 32.5 Hz), 
128.23, 126.14 (q, J = 3.8 Hz), 126.08, 124.85 (q, J = 270.6 Hz), 121.33, 67.25, 66.09, 61.50, 
59.28, 50.48, 14.19 ppm; e.e. was determined by Diels‒Alder cycloadduct of chiral 
cyclopentadiene and N-methylmaleimide, HRMS: calc. for [M+H]+ C24H22NO2
79BrF3: 
492.07805, found: 492.07758; calc. for [M+H]+ C24H22NO2
81BrF3: 494.07601, found: 
494.07511; HPLC conditions: CHIRAPAK IA column, (CH2Cl2/EtOH = 100/2)/ iso-hexane = 
25/75, flow rate = 0.5 mL min-1, major enantiomer: tR = 29.7 min; minor enantiomer: tR = 27.5 
min, 96% ee. 
Ethyl (1S,3R,4R,7aS)-4-(4-chlorophenyl)-1-(4-(trifluoromethyl)phenyl)-2,3,4,7a-
tetrahydro-1H-cyclopenta[c]pyridine-3-carboxylate 
66h: Using Method C, 67% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 7.69 (d, J = 8.2 Hz, 2H), 7.64 (d, J = 8.2 Hz, 2H), 7.36 (d, J = 
8.5 Hz, 2H), 7.28 (d, J = 8.5 Hz, 2H), 6.51 – 6.44 (m, 1H), 6.03 
(dd, J = 5.4, 1.0 Hz, 1H), 5.74 (s, 1H), 4.02 – 3.86 (m, 3H), 3.57 
(d, J = 10.4 Hz, 1H), 3.28 (d, J = 10.4 Hz, 1H), 3.08 (dd, J = 
10.4, 1.0 Hz, 1H), 0.96 ppm (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, CD2Cl2): δ 171.97, 
151.65, 147.22, 137.92, 133.73, 133.69, 133.25, 130.99, 130.42 (q, J = 32.3 Hz), 129.02, 
128.23, 126.14, 126.13 (q, J = 3.8 Hz), 124.85 (q, J = 270.6 Hz), 67.32, 66.10, 61.49, 59.30, 
50.43, 14.19 ppm; HRMS: calc. for [M+H]+ C24H22NO2ClF3: 448.12857, found: 448.12771; 
e.e. was determined by Diels‒Alder cycloadduct of chiral cyclopentadiene and N-
methylmaleimide, HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
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20/80, flow rate = 0.5 mL min-1, major enantiomer: tR = 24.0 min; minor enantiomer: tR = 37.5 
min, 96% ee. 
Ethyl (1S,3R,4R,7aS)-4-isopropyl-1-(4-(trifluoromethyl)phenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66i: Using Method C, 31% yield; Only for (6+3) cycloadduct, 1H 
NMR (400 MHz, CD2Cl2): δ 7.65 (d, J = 8.1 Hz, 2H), 7.55 (d, J = 
8.1 Hz, 2H), 6.54 – 6.50 (m, 1H), 6.30 – 6.26 (m, 1H), 5.97 – 5.92 
(m, 1H), 4.19 (q, J = 7.1 Hz, 2H), 3.22 (d, J = 10.4 Hz, 1H), 3.02 (d, 
J = 10.4 Hz, 1H), 2.94 (d, J = 10.4 Hz, 1H), 2.73 (d, J = 10.4 Hz, 1H), 2.22 – 2.10 (m, 1H), 
1.29 (t, J = 7.1 Hz, 2H), 1.16 (d, J = 7.1 Hz, 3H), 1.10 ppm (d, J = 7.1 Hz, 3H); 13C NMR (101 
MHz, CD2Cl2): δ 173.62, 149.93, 133.71, 133.02, 130.22 (q, J = 32.2 Hz), 129.20, 128.15, 
126.05 (q, J = 3.8 Hz), 124.88 (d, J = 271.8 Hz), 124.66, 66.35, 64.91, 61.62, 60.68, 49.74, 
28.66, 19.72, 19.51, 14.45 ppm; e.e. was determined by Diels‒Alder cycloadduct of chiral 
cyclopentadiene and N-methylmaleimide, HPLC conditions: CHIRAPAK IC column, 
(CH2Cl2/EtOH = 100/2)/ iso-hexane = 30/70, flow rate = 0.5 mL min
-1, major enantiomer: tR = 
20.1 min; minor enantiomer: tR = 36.6 min, 89% ee. 
Ethyl (1S,3R,4R,7aS)-4-(naphthalen-2-yl)-1-(4-(trifluoromethyl)phenyl)-2,3,4,7a-
tetrahydro-1H-cyclopenta[c]pyridine-3-carboxylate 
66j: Using Method C, 82% yield; 1H NMR (400 MHz, 
CD2Cl2): δ 7.90 – 7.82 (m, 3H), 7.79 (s, 1H), 7.71 (d, J = 8.6 
Hz, 2H), 7.67 (d, J = 8.4 Hz, 2H), 7.53 – 7.46 (m, 3H), 6.47 (dt, 
J = 5.3, 1.6 Hz, 1H), 6.09 – 6.02 (m, 1H), 5.77 (s, 1H), 4.12 (d, 
J = 10.4 Hz, 1H), 3.87 (q, J = 7.1 Hz, 2H), 3.76 (d, J = 10.4 Hz, 1H), 3.36 (d, J = 10.4 Hz, 1H), 
3.14 (dd, J = 10.4, 1.1 Hz, 1H), 2.21 (br s, 1H), 0.81 (t, J = 7.1 Hz, 3H); 13C NMR (101 MHz, 
CD2Cl2): δ 172.18, 152.07, 147.35, 136.86, 134.13, 133.81, 133.56, 133.36, 130.40 (d, J = 32.3 
Hz), 128.30, 128.27, 128.24, 128.15, 127.69, 126.55, 126.29, 126.25, 126.15 (q, J = 3.8 Hz), 
124.85 (q, J = 271.6 Hz), 123.54, 67.36, 66.18, 61.35, 59.40, 51.18, 14.08 ppm; HRMS: calc. 
for [M+H]+ C28H25NO2F3: 464.18319, found: 464.18256; e.e. was determined by Diels‒Alder 
cycloadduct of chiral cyclopentadiene and N-methylmaleimide, HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2)/ iso-hexane = 30/70, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 32.5 min; minor enantiomer: tR = 46.7 min, 98% ee. 
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Methyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(4-fluorophenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66k: Using Method D, 74% yield, the product with >99% ee was 
obtained from mother liquor through recrystallization of 
cycloadduct with 95% ee in petroleum ether and ethyl acetate; 1H 
NMR (400 MHz, CD2Cl2): δ 7.54 – 7.43 (m, 4H), 7.22 (d, J = 8.4 
Hz, 2H), 7.15 – 7.05 (m, 2H), 6.45 (d, J = 5.4 Hz, 1H), 6.04 (d, J 
= 5.4 Hz, 1H), 5.72 (s, 1H), 3.93 (d, J = 10.4 Hz, 1H), 3.59 (d, J = 10.4 Hz, 1H), 3.49 (s, 3H), 
3.21 (d, J = 10.4 Hz, 1H), 3.07 (d, J = 10.4 Hz, 1H), 2.11 ppm (br s, 1H); 13C NMR (101 MHz, 
CD2Cl2): δ 172.40, 162.90 (d, J = 245.2 Hz), 151.63, 139.11 (d, J = 3.1 Hz), 138.51, 134.05, 
133.48, 132.03, 131.25, 129.36 (d, J = 8.1 Hz), 126.06, 121.33, 115.89 (d, J = 21.4 Hz), 67.24, 
65.79, 59.52, 54.54, 54.27, 54.00, 54.00, 53.73, 53.46, 52.37, 50.20 ppm; HRMS: calc. for 
[M+H]+ C24H22NO2
79BrF: 428.06560, found: 428.06474; calc. for [M+H]+ C22H20NO2
81BrF: 
430.06355, found: 430.06210; HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-
hexane = 5/95, flow rate = 0.5 mL min-1, major enantiomer: tR = 16.2 min; minor enantiomer: 
tR = 14.0 min.  
Benzyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(4-fluorophenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66l: Using Method C, 50% yield; 1H NMR (400 MHz, CD2Cl2): δ 
7.53 – 7.41 (m, 4H), 7.33 – 7.24 (m, 3H), 7.17 (d, J = 8.4 Hz, 2H), 
7.11 (t, J = 8.7 Hz, 2H), 6.99 – 6.89 (m, 2H), 6.44 (d, J = 5.3 Hz, 
1H), 6.06 – 6.01 (m, 1H), 5.72 (s, 1H), 4.97 (d, J = 12.2 Hz, 1H), 
4.87 (d, J = 12.2 Hz, 1H), 3.90 (d, J = 10.4 Hz, 1H), 3.67 – 3.56 
(m, 1H), 3.27 – 3.16 (m, 1H), 3.07 (d, J = 10.5 Hz, 1H), 2.11 ppm (s, 1H); 13C NMR (101 MHz, 
CD2Cl2): δ 172.13, 162.90 (d, J = 245.1 Hz), 151.58, 139.08 (d, J = 2.9 Hz), 138.33, 135.83, 
134.10, 133.47, 132.11, 131.32, 129.36 (d, J = 8.1 Hz), 128.97, 128.74, 128.62, 126.03, 121.44, 
115.90 (d, J = 21.4 Hz), 67.36, 67.27, 65.70, 59.47, 50.65 ppm; HRMS: calc. for [M+H]+ 
C28H24NO2
79BrF: 504.09690, found: 504.09655; calc. for [M+H]+ C28H24NO2
81BrF: 
506.09485, found: 506.09415; HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-
hexane = 5/95, flow rate = 0.5 mL min-1, major enantiomer: tR = 21.7 min; minor enantiomer: 
tR = 16.9 min, 96% ee. 
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Methyl (1S,3R,4R,7aS)-4-(4-bromophenyl)-1-(4-methylphenyl)-2,3,4,7a-tetrahydro-1H-
cyclopenta[c]pyridine-3-carboxylate 
66m: Using Method C, 66% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 7.51 (d, J = 8.5 Hz, 2H), 7.36 (d, J = 7.9 Hz, 2H), 7.25 – 7.20 
(m, J = 8.4, 2.4 Hz, 4H), 6.43 (d, J = 5.1 Hz, 1H), 6.04 (d, J = 5.1 
Hz, 1H), 5.71 (s, 1H), 3.91 (d, J = 10.5 Hz, 1H), 3.57 (d, J = 10.5 
Hz, 1H), 3.48 (s, 3H), 3.17 (d, J = 10.5 Hz, 1H), 3.10 (d, J = 10.5 Hz, 1H), 2.38 (s, 3H), 1.98 
ppm (br s, 1H); 13C NMR (101 MHz, CD2Cl2): δ 172.52, 151.80, 140.17, 138.63, 138.25, 
134.40, 133.20, 132.01, 131.25, 129.80, 127.49, 125.85, 121.28, 67.35, 66.30, 59.51, 52.33, 
50.38, 21.44 ppm; HRMS: calc. for [M+H]+ C23H23NO2
79BrF: 424.09067, found: 424.09042; 
calc. for [M+H]+ C23H23NO2
81BrF: 426.08862, found: 426.08805; HPLC conditions: 
CHIRAPAK IA column, iso-propanol / iso-hexane = 5/95, flow rate = 0.5 mL min-1, major 
enantiomer: tR = 22.3 min; minor enantiomer: tR = 25.5 min, 95% ee. 
  
Chapter 7. Experimental Part 
 
122 
 
7.2.2 Synthesis and Analytic Data of Rh(I) Complexes 99a-k and 100a-o 
Method E for Synthesis of Rh(I) Complexes 99a-99g, 99i-99l:  
Under Ar flow, thallium (I) ethoxide (1.2 equiv., 0.36 mmol, 89.8 mg) was added to 1 mL dry 
methanol in 10 mL Schlenk flask. A white precipitate of thallium (I) methoxide formed 
immediately. After stirring for 5 mins, methanol was decanted and the thallium (I) methoxide 
was washed again with 1 mL dry methanol. Then 4 mL dry and degassed benzene was added. 
Under Ar, to the mixture was added a solution of cyclopetadiene (1 equiv., 0.3 mmol) in 1 mL 
benzene. The mixture was stirred for 1 hour at 80oC with protection from light. After cooling 
down, [Rh(C2H4)2Cl]2 (0.6 equiv., 0.18 mmol, 70 mg) was added. After stirring for another 1 
hour, the reaction mixture was directly subjected to column chromatography on neutral 
aluminum oxide (activated, Brockmann I, Sigma-Aldrich) under Ar using EtOAc/hexane as 
the eluent, affording the desired Rh complexes. 
Method F for Synthesis of Rh(I) Complexes 100a-d, 100g-k: 
Under Ar, to a solution of cyclopetadiene (0.3 mmol) in degassed 4 mL benzene at room 
temperature was added a solution of thallium(I) ethanolate (0.18 mmol) in 1 mL benzene. The 
mixture was stirred for 1 hour at room temperature protected from light. [Rh(C2H4)2Cl]2 (0.6 
equiv., 0.18 mmol, 70 mg) was added.  After stirring for another 1 hour, the reaction mixture 
was directly subjected to column chromatography on neutral aluminum oxide (activated, 
Brockmann I, Sigma-Aldrich) under Ar using EtOAc/hexane as the eluent, affording the 
desired Rh complexes. 
Method G for Synthesis of Rh(I) Complexes 100e, 100f, 100l-2o: 
Under Ar flow, thallium (I) ethoxide (1.2 equiv., 0.36 mmol, 89.8 mg) was added to 1 mL dry 
methanol in 10 mL Schlenk flask. A white precipitate of thallium (I) methoxide formed 
immediately. After stirring for 5 mins, methanol was decanted and the thallium (I) methoxide 
was washed again with 1 mL dry methanol. Then 4 mL dry and degassed benzene was added. 
Under Ar, to the mixture was added a solution of cyclopetadiene (1 equiv., 0.3 mmol) in 1 mL 
benzene. The mixture was stirred for 1 hour at room temperature with protection from light. 
[Rh(C2H4)2Cl]2 (0.6 equiv., 0.18 mmol, 70 mg) was added. After stirring for another 1 hour, 
the reaction mixture was directly subjected to column chromatography on neutral aluminum 
oxide (activated, Brockmann I, Sigma-Aldrich) under Ar using EtOAc/hexane as the eluent, 
affording the desired Rh complexes. 
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Method H for Synthesis of Rh(I) Complexes 99h: 
Under Ar, to a solution of cyclopetadiene (0.3 mmol) in degassed 4 mL benzene at room 
temperature was added a solution of thallium(I) ethanolate (0.18 mmol) in 1 mL benzene. The 
mixture was stirred for 1 hour at 80oC protected from light. [Rh(C2H4)2Cl]2 (0.6 equiv., 0.18 
mmol, 70 mg) was added.  After stirring for another 1 hour, the reaction mixture was directly 
subjected to column chromatography on neutral aluminum oxide (activated, Brockmann I, 
Sigma-Aldrich) under Ar using EtOAc/hexane as the eluent, affording the desired Rh complex. 
For separation of diastereomers of 100l, 100n: 
 
The column was prepared as shown in the left, sea sand, 
neutral Al2O3 as purification zone, sea sand, silica gel as 
separation zone and sea sand were added sequentially. 
Column was neutralized by 1% (v/v) of triethylamine in n-
pentane: ethyl acetate (1:1) for 1 hour. Using Ar as pressure 
source, ethyl acetate was used to wash away extra 
trimethylamine, followed by n-pentane. (be sure there is no 
air in column) A precooling solvent to -40C of n-pentane 
and ethyl acetate was used as eluent. The purification 
process should be always under -40C and argon. Rh(I) 
complexes are stable in solid form.  
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(‒)-Bis(η2-ethylene)[η5-(1R,3R)-3-(methoxycarbonyl)-4,4-dimethyl-1-(naphthalen-2-yl)-
1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99a: Using Method E, 71% yield; single isomer; 1H NMR (400 
MHz, C6D6): δ 7.67 (s, 1H), 7.65 – 7.55 (m, 3H), 7.49 (dd, J = 8.5, 
1.6 Hz, 1H), 7.31 – 7.22 (m, 2H), 4.69 – 4.66 (m, 1H), 4.66 – 4.63 
(m, 1H), 4.32 – 4.27 (m, 1H), 4.04 (s, 1H), 3.79 (s, 1H), 3.36 (s, 3H), 
2.88 – 2.75 (m, 2H), 2.73 – 2.57 (m, 2H), 1.76 (s, 3H), 1.52 (s, 3H), 
1.49 – 1.38 (m, 2H), 1.14 – 1.02 ppm (m, 2H); 13C NMR (101 MHz, C6D6): δ 171.85, 141.32, 
133.94, 133.81, 128.80, 128.52, 127.93, 127.21, 126.75, 126.31, 126.16, 117.20 (d, JRh-C = 4.2 
Hz), 102.20 (d, JRh-C = 3.5 Hz), 85.61 (d, JRh-C = 4.4 Hz), 84.48 (d, JRh-C = 3.9 Hz), 82.84 (d, 
JRh-C = 3.9 Hz), 66.61, 57.16, 51.13, 40.70 (d, JRh-C = 13.3 Hz), 36.74 (d, JRh-C = 13.3 Hz), 
36.36, 29.96, 26.70 ppm; FT‐IR: 
~ = 3054, 2985, 1731, 1506, 1433, 1360, 1183, 1128 cm-1; 
HRMS: calc. for [M+H]+ C26H31O2NRh: 492.14043, found: 492.14041;  RTD = -164.4 
(CH2Cl2, c = 1.00). 
(+)-Bis(η2-ethylene)[η5-(1R,3R)-4,4-diethyl-3-(methoxycarbonyl)-1-(naphthalen-2-yl)-
1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99b: Using Method E, 71% yield; two separable isomers with 72:28 
ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 7.96 (s, 0.4 H), 7.68 
– 7.63 (m, 1.8H), 7.62 – 7.57 (m, 3.4H), 7.52 – 7.48 (m, 1.4H), 7.28 
– 7.22 (m, 2.8H), 5.12 (s, 0.4H), 4.83 (s, 1H), 4.78 – 4.74 (m, 0.4H), 
4.64 (d, J = 2.8 Hz, 0.4H), 4.62 – 4.57 (m, 1H), 4.28 (s, 1.4H), 3.92 
– 3.90 (m,1H), 3.84 (d, J = 4.0 Hz, 1H), 3.58 (s, 0.4H), 3.39 (s, 1.2H), 3.36 (s, 3H), 3.00 (t, J 
= 10.0 Hz, 0.8H), 2.78 (t, J = 10.0 Hz, 2H), 2.68 (t, J = 10.0 Hz, 2H), 2.45 – 2.37 (m, 1H), 2.27 
– 2.19 (m, 1.4H), 2.15 – 2.10 (m, 0.4H), 2.07 (s, 1H), 2.01 – 1.91 (m, 2.4H), 1.76 – 1.69 (m, 
1H), 1.70 – 1.65 (m, 0.4H), 1.57 (t, J = 7.4 Hz, 3H), 1.47 – 1.41 (m, 2H), 1.32 (t, J = 7.4 Hz, 
1.2H), 1.13 – 1.06 (m, 2H), 1.04 – 0.97 (m, 3.4H), 0.92 (t, J = 7.4 Hz, 1.2H), 0.78 – 0.71 
ppm(m, 0.8H); 13C NMR (176 MHz, C6D6): δ 172.52, 172.28, 141.17, 138.32, 133.94, 133.79, 
133.68, 133.30, 128.84, 128.58, 128.41, 128.35, 128.31, 128.12, 128.10, 127.99, 127.36, 
126.77, 126.36, 126.32, 126.18, 126.00, 125.88, 125.31, 113.43 (d, JRh-C = 3.7 Hz), 111.46 (d, 
JRh-C = 4.3 Hz), 106.07 (d, JRh-C = 3.6 Hz), 101.68 (d, JRh-C = 3.3 Hz), 86.03 (d, JRh-C = 3.8 Hz), 
85.67 (d, JRh-C = 4.5 Hz), 85.28 (d, JRh-C = 3.9 Hz), 85.21 (d, JRh-C = 4.3 Hz), 84.40 (d, JRh-C = 
3.7 Hz), 81.69 (d, JRh-C = 4.0 Hz), 63.84, 63.82, 60.07, 59.69, 56.98, 51.20, 51.19, 42.69, 41.94, 
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41.27 (d, JRh-C = 13.4 Hz), 39.62 (d, JRh-C = 13.4 Hz), 39.44 (d, JRh-C = 13.3 Hz), 37.18 (d, JRh-
C = 13.0 Hz), 34.65, 31.70, 30.93, 29.66, 20.56, 14.23, 9.93, 9.55, 9.22, 9.21 ppm; FT‐IR: 
~ = 
3054, 2961, 1731, 1601, 1433, 1359, 1183, 1128, 1032 cm-1; HRMS: calc. for [M+H]+ 
C28H35O2NRh: 520.17173, found: 520.17175;  RTD = +32.6 (CHCl3, c = 0.19). 
(‒)-Bis(η2-ethylene){η5-(1'R,3'R)-3'-(methoxycarbonyl)-1'-(naphthalen-2-yl)-2',3'-
dihydro-1'H-spiro[cyclobutane-1,4'-cycloocta[c]pyridin]-yl)}rhodium(I) 
99c: Using Method E, 74% yield; two separable isomers with 
76:24 ratio; For major isomer, 1H NMR (400 MHz, C6D6): δ 
7.67 (s, 1H), 7.65 – 7.55 (m, 3H), 7.44 (dd, J = 8.5, 1.7 Hz, 1H), 
7.31 – 7.21 (m, 2H), 4.85 – 4.79 (m, 1H), 4.76 (t, J = 2.7 Hz, 
1H), 4.74 (d, J = 5.2 Hz, 1H), 4.41 – 4.32 (m, 1H), 3.99 (d, J = 
4.1 Hz, 1H), 3.40 (s, 3H), 2.94 – 2.65 (m, 6H), 2.29 – 2.15 (m, 1H), 2.14 – 2.10 (m, 1H), 1.91 
– 1.79 (m, 1H), 1.79 – 1.68 (m, 1H), 1.36 – 1.22 ppm(m, 4H); 13C NMR (101 MHz, C6D6): δ 
172.51, 141.66, 133.93, 133.77, 128.81, 127.08, 126.57, 126.29, 126.14, 115.47, 115.44, 
104.82 (d, JRh-C = 3.4 Hz), 84.84 (d, JRh-C = 4.5 Hz), 84.19 (d, JRh-C = 4.0 Hz), 82.47 (d, JRh-C 
= 4.1 Hz), 64.34, 57.97, 51.47, 42.17, 40.20 (d, JRh-C = 13.8 Hz), 38.75 (d, JRh-C = 13.6 Hz), 
33.24, 29.46, 15.30 ppm; FT‐IR: 
~ = 3054, 2986, 2947, 1734, 1432, 1347, 1196, 1125 cm-1; 
HRMS: calc. for [M+H]+ C27H31O2NRh: 504.14043, found: 504.14044;  RTD = -33.4 (CH2Cl2, 
c = 0.38). 
(‒)-Bis(η2-ethylene){η5-(1'R,3'R)-3'-(methoxycarbonyl)-1'-(naphthalen-2-yl)-2',3'-
dihydro-1'H-spiro[cyclohexane-1,4'-cycloocta[c]pyridin]-yl)}rhodium(I) 
99d: Using Method E, 63% yield; two separable isomers with 
90:10 ratio; For major isomer, 1H NMR (700 MHz, C6D6): δ 7.66 
(s, 1H), 7.61 – 7.55 (m, 3H), 7.44 (d, J = 8.4 Hz, 1H), 7.27 – 7.22 
(m, 2H), 4.75 (s, 1H), 4.72 – 4.69 (m, 1H), 4.58 (s, 1H), 4.05 (d, 
J = 5.3 Hz, 1H), 3.92 (d, J = 4.3 Hz, 1H), 3.38 (s, 3H), 2.86 (t, J 
= 10.5 Hz, 2H), 2.65 (t, J = 10.5 Hz, 2H), 2.43 – 2.38 (m, 2H), 2.27 (d, J = 13.5 Hz, 1H), 2.05 
(t, J = 4.8 Hz, 1H), 1.89 (td, J = 12.8, 4.4 Hz, 1H), 1.71 – 1.66 (m, 2H), 1.64 – 1.53 (m, 3H), 
1.49 – 1.42 (m, 2H), 1.11 – 1.03 ppm (m, 2H); 13C NMR (176 MHz, C6D6): δ 172.28, 141.38, 
133.93, 133.76, 128.83, 128.34, 127.34, 126.75, 126.33, 126.19, 115.41 (d, JRh-C = 4.3 Hz), 
102.66 (d, JRh-C = 3.3 Hz), 86.50 (d, JRh-C = 3.8 Hz), 85.57 (d, JRh-C = 4.3 Hz), 84.88 (d, JRh-C 
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= 3.7 Hz), 68.17, 57.31, 51.18, 41.13 (d, JRh-C = 13.5 Hz), 39.19, 38.39, 36.18 (d, JRh-C = 13.2 
Hz), 33.13, 26.41, 23.33, 21.86 ppm; FT‐IR: 
~ = 3054, 2987, 2927, 1733, 1506, 1432, 1352, 
1246, 1198, 1165 cm-1; HRMS: calc. for [M+H]+ C29H35O2NRh: 532.17173, found: 532.17175; 
 RTD = -68.9 (CH2Cl2, c = 0.47). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R)-1-(4-bromophenyl)-3-(methoxycarbonyl)-4,4-dimethyl-
1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99e: Using Method E, 54% yield; single isomer; 1H NMR (700 MHz, 
C6D6): δ 7.28 – 7.20 (m, 2H), 6.97 – 6.89 (m, 2H), 4.63 (t, J = 2.7 
Hz, 1H), 4.61 – 4.56 (m, 1H), 4.26 – 4.19 (m, 1H), 3.68 (d, J = 4.2 
Hz, 1H), 3.64 (d, J = 2.5 Hz, 1H), 3.34 (s, 3H), 2.73 (t, J = 10.3 Hz, 
2H), 2.57 (t, J = 10.3 Hz, 2H), 1.69 (s, 3H), 1.47 – 1.37 (m, 5H), 1.10 
– 1.00 ppm (m, 2H); 13C NMR (176 MHz, C6D6): δ 171.74, 142.83, 131.93, 130.15, 121.84, 
116.97 (d, JRh-C = 4.2 Hz), 101.62 (d, JRh-C = 3.4 Hz), 85.64 (d, JRh-C = 4.3 Hz), 84.11 (d, JRh-C 
= 3.9 Hz), 82.83 (d, JRh-C = 3.9 Hz), 66.37, 56.21, 51.15, 40.67 (d, JRh-C = 13.6 Hz), 36.69 (d, 
JRh-C = 13.3 Hz), 36.20, 29.89, 26.57 ppm; FT‐IR: 
~ = 3054, 2986, 1734, 1484, 1433, 1195, 
1010 cm-1; HRMS: calc. for [M+H]+ C22H28O2N
79BrRh: 520.03530, found: 520.03534; calc. 
for [M+H]+ C22H28O2N
81BrRh: 522.03325, found: 522.03333;  RTD = -56.8 (CH2Cl2, c = 0.22). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R)-3-(methoxycarbonyl)-4,4-dimethyl-1-(4-methylphenyl)-
1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99f: Using Method E, 62% yield; two separable isomers with 85:15 
ratio; For major isomer, 1H NMR (700 MHz, C6D6): δ 7.22 (d, J = 
7.7 Hz, 2H), 6.98 (d, J = 7.7 Hz, 2H), 4.76 (s, 1H), 4.67 (s, 1H), 4.27 
(s, 1H), 3.89 (d, J = 4.5 Hz, 1H), 3.73 (d, J = 3.1 Hz, 1H), 3.34 (s, 
3H), 2.78 (t, J = 10.5 Hz, 2H), 2.61 (t, J = 10.3 Hz, 2H), 2.12 (s, 3H), 
1.72 (s, 3H), 1.46 – 1.41 (m, 5H), 1.08 – 1.02 ppm (m, 2H); 13C NMR (176 MHz, C6D6): δ 
171.48, 140.71, 137.02, 129.14, 128.07, 116.69 (d, JRh-C = 4.2 Hz), 102.18 (d, JRh-C = 3.3 Hz), 
85.08 (d, JRh-C = 4.3 Hz), 84.04 (d, JRh-C = 3.9 Hz), 82.36 (d, JRh-C = 3.9 Hz), 66.21, 56.25, 
50.70, 40.30 (d, JRh-C = 13.6 Hz), 36.17 (d, JRh-C = 13.3 Hz), 35.82, 29.56, 26.26, 20.77 ppm; 
FT‐IR: 
~ = 3053, 2986, 2959, 1735, 1512, 1433, 1360, 1195, 1182, 1019 cm-1; HRMS: calc. 
for [M+H]+ C23H31O2NRh: 456.14043, found: 456.14044;  RTD = -37.3 (CH2Cl2, c = 0.45). 
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(‒)-Bis(η2-ethylene)[η5-(1R,3R)-3-(methoxycarbonyl)-4,4-dimethyl-1-(2-methylphenyl)-
1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99g: Using Method E, 78% yield; two separable isomers with 86:14 
ratio; For major isomer, 1H NMR (700 MHz, C6D6): δ 7.08 – 6.94 
(m, 4H), 4.69 (s, 1H), 4.66 (s, 1H), 4.27 (s, 1H), 3.31 (s, 3H), 2.75 
(t, J = 10.4 Hz, 2H), 2.59 (t, J = 10.4 Hz, 2H), 2.27 (s, 3H), 1.68 (s, 
3H), 1.40 (s, 3H), 1.38 – 1.31 (m, 2H), 1.13 – 1.05 ppm (m, 2H); 13C 
NMR (176 MHz, C6D6): δ 13C NMR (176 MHz, C6D6): δ 171.78, 140.80, 134.54, 130.08, 
127.28, 126.53, 117.11, 116.10 (d, JRh-C = 3.4 Hz), 108.72 (d, JRh-C = 3.9 Hz), 85.17 (d, JRh-C = 
4.6 Hz), 83.48 (d, JRh-C = 3.8 Hz), 81.92 (d, JRh-C = 4.0 Hz), 69.75, 56.04, 51.06, 39.01 (d, JRh-
C = 13.5 Hz), 38.66 (d, JRh-C = 13.3 Hz), 35.35, 30.17, 28.31, 19.66 ppm; FT‐IR: 
~ = 3344, 
3055, 2960, 1734, 1433, 1361, 1124, 1018 cm-1; HRMS: calc. for [M+H]+ C23H31O2NRh: 
456.14043, found: 456.14041;  RTD = -69.0 (CH2Cl2, c = 0.30). 
(+)-Bis(η2-ethylene)[η5-(1R,3R)-3-(ethoxycarbonyl)-4,4-dimethyl-1-(naphthalen-2-yl)-
1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99h: Using Method H, 67% yield; two inseparable isomers with 
84:16 ratio; For major isomer, 1H NMR (700 MHz, C6D6): δ 7.69 – 
7.64 (m, 1H), 7.62 – 7.58 (m, 3H), 7.50 (d, J = 8.4 Hz, 1H), 7.27 – 
7.24 (m, 2H), 4.68 – 4.67 (m, 1H), 4.66 – 4.65 (m, 1H), 4.30 (s, 1H), 
4.05 (d, J = 4.1 Hz, 1H), 4.03 – 3.94 (m, 2H), 3.81 (d, J = 2.3 Hz, 
1H), 2.81 (t, J = 10.4 Hz, 2H), 2.64 (t, J = 10.4 Hz, 2H), 1.79 (s, 3H), 1.56 (s, 3H), 1.47 – 1.42 
(m, 2H), 1.11 – 1.04 (m, 2H), 0.97 ppm (t, J = 7.0 Hz, 3H); 13C NMR (176 MHz, C6D6): δ 
171.52, 141.34, 133.92, 133.79, 128.79, 128.35, 128.10, 127.21, 126.76, 126.29, 126.15, 
117.26 (d, JRh-C = 4.5 Hz), 102.26 (d, JRh-C = 3.7 Hz), 85.61 (d, JRh-C = 4.7 Hz), 84.49 (d, JRh-C 
= 4.3 Hz), 82.82 (d, JRh-C = 4.3 Hz), 66.51, 60.63, 57.13, 40.70 (d, JRh-C = 14.5 Hz), 36.67 (d, 
JRh-C = 14.1 Hz), 36.37, 30.11, 26.69, 14.34 ppm; FT‐IR: 
~ = 3340, 3054, 2984, 1729, 1433, 
1338, 1184, 1029 cm-1; HRMS: calc. for [M+H]+ C27H33O2NRh: 506.15608, found: 506.15604; 
 RTD = +87.4 (CH2Cl2, c = 0.50). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R)-3-(methoxycarbonyl)-2,4,4-trimethyl-1-(naphthalen-2-
yl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
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99i: Using Method E, 81% yield; single isomer; 1H NMR (700 MHz, 
C6D6): δ 7.65 – 7.57 (m, 5H), 7.29 – 7.21 (m, 2H), 4.68 (s, 1H), 4.51 
(s, 1H), 4.20 (s, 1H), 3.78 (s, 1H), 3.61 (s, 1H), 3.39 (s, 3H), 2.85 (t, 
J = 10.5 Hz, 2H), 2.64 (t, J = 10.4 Hz, 2H), 2.25 (s, 3H), 1.81 (s, 3H), 
1.51 (s, 3H), 1.48 – 1.43 (m, 2H), 1.14 – 1.03 ppm (m, 2H); 13C NMR 
(176 MHz, C6D6): δ 171.22, 141.44, 133.86, 133.80, 129.17, 128.35, 128.16, 127.59, 126.63, 
126.34, 126.14, 115.66 (d, JRh-C = 4.3 Hz), 101.53 (d, JRh-C = 3.3 Hz), 85.79 (d, JRh-C = 4.3 Hz), 
85.23 (d, JRh-C = 3.7 Hz), 81.39 (d, JRh-C = 3.9 Hz), 75.25, 66.75, 50.81, 41.56 (d, JRh-C = 13.6 
Hz), 41.08, 36.57 (d, JRh-C = 13.3 Hz), 36.05, 28.72, 28.01 ppm; FT‐IR: 
~ = 3054, 2986, 2850, 
2770, 1744, 1461, 1311, 1193, 1044 cm-1; HRMS: calc. for [M+H]+ C27H33O2NRh: 506.15608, 
found: 506.15582;  RTD = -184.2 (CH2Cl2, c = 0.50). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R)-2-ethyl-3-(methoxycarbonyl)-4,4-dimethyl-1-
(naphthalen-2-yl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99j: Using Method E, 45% yield; single isomer; 1H NMR (700 MHz, 
C6D6): δ 7.70 (s, 1H), 7.66 – 7.57 (m, 4H), 7.29 – 7.24 (m, 2H), 4.71 
(t, J = 2.6 Hz, 1H), 4.56 (s, 1H), 4.27 (s, 1H), 4.21 – 4.15 (m, 2H), 
3.39 (s, 3H), 3.06 (dd, J = 15.3, 7.3 Hz, 1H), 2.89 (t, J = 10.5 Hz, 
2H), 2.75 – 2.63 (m, 3H), 1.81 (s, 3H), 1.50 (s, 3H), 1.48 – 1.41 (m, 
2H), 1.13 – 1.06 (m, 2H), 0.92 ppm (t, J = 7.1 Hz, 3H); 13C NMR (176 MHz, C6D6): δ 171.23, 
141.83, 133.89, 133.80, 129.16, 128.35, 127.99, 127.33, 126.77, 126.34, 126.11, 115.50 (d, 
JRh-C = 4.2 Hz), 101.98 (d, JRh-C = 3.2 Hz), 85.73 (d, JRh-C = 4.3 Hz), 85.44 (d, JRh-C = 3.6 Hz), 
81.22 (d, JRh-C = 3.9 Hz), 70.94, 60.31, 50.79, 44.80, 41.38 (d, JRh-C = 13.5 Hz), 36.44 (d, JRh-
C = 13.3 Hz), 36.21, 28.68, 27.64, 7.96 ppm; FT‐IR: 
~ = 3055, 2967, 1743, 1433, 1376, 1135, 
1053 cm-1; HRMS: calc. for [M+H]+ C28H35O2NRh: 520.17173, found: 520.17163;  RTD = -
83.0 (CH2Cl2, c = 1.00). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R)-2-isobutyl-3-(methoxycarbonyl)-4,4-dimethyl-1-
(naphthalen-2-yl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
99k: Using Method E, 82% yield; two inseparable isomers with 55:45 ratio; For mixture, 1H 
NMR (700 MHz, C6D6): δ 7.68 – 7.65 (m, 1.82H), 7.63 – 7.60 (m, 1.82H), 7.59 – 7.51 (m, 
5.45H), 7.26 – 7.17 (m, 3.64H), 5.23 (s, 1H), 4.76 (s, 0.82H), 4.75 (s, 1H), 4.51 (s, 1H), 4.46 
(s, 0.82H), 4.24 (s, 1H), 4.20 (s, 0.82H), 4.16 (s, 0.82H), 4.02 (s, 0.82H), 3.98 (s, 1H), 3.84 (s, 
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1H), 3.37 (s, 2.45H), 3.32 (s, 3H), 2.96 – 2.84 (m, 3.64H), 2.70 – 
2.64 (m, 3.64H), 2.58 (d, J = 7.1 Hz, 1.82H), 1.92 (s, 3H), 1.72 (s, 
3H), 1.51 (s, 3H), 1.49 (s, 2.45H), 1.48 – 1.39 (m, 6.09H), 1.22 (s, 
3H), 1.17 – 1.07 (m, 3.64H), 0.74 (d, J = 6.6 Hz, 2.45H), 0.58 ppm 
(d, J = 6.6 Hz, 2.45H); 13C NMR (176 MHz, C6D6): δ 171.98, 
170.49, 142.27, 141.11, 135.25, 133.74, 133.69, 133.60, 133.52, 131.86, 128.76, 128.35, 
128.31, 128.23, 128.13, 127.99, 127.61, 127.59, 127.56, 126.34, 126.20, 126.14, 126.05, 
116.24 (d, JRh-C = 4.2 Hz), 115.46 (d, JRh-C = 4.2 Hz), 103.18 (d, JRh-C = 3.4 Hz), 101.44 (d, JRh-
C = 3.4 Hz), 85.81 (d, JRh-C = 4.3 Hz), 85.62 (d, JRh-C = 3.7 Hz), 85.38 (d, JRh-C = 3.7 Hz), 85.22 
(d, JRh-C = 4.4 Hz), 81.51 (d, JRh-C = 3.9 Hz), 81.36 (d, JRh-C = 3.9 Hz), 74.59, 73.66, 65.71, 
65.31, 64.01, 50.72, 50.68, 41.76 (d, JRh-C = 13.0 Hz), 41.69 (d, JRh-C = 13.0 Hz), 36.58 (d, JRh-
C = 13.3 Hz), 36.44 (d, JRh-C = 13.3 Hz), 36.40, 36.08, 29.75, 28.41, 27.82, 27.30, 27.11, 21.61, 
21.35, 21.26, 18.37 ppm; FT‐IR: 
~ = 3054, 2959, 1747, 1727, 1433, 1382, 1269, 1193 cm-1; 
HRMS: calc. for [M+H]+ C30H39O2NRh: 548.20303, found: 548.20270;  RTD = -96.9 (CH2Cl2, 
c = 2.00). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(ethoxycarbonyl)-1-(4-
methylphenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100a: Using Method F, 78% yield; two separable isomers 
with 60:40 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
7.74 (d, J = 7.8 Hz, 2H), 7.65 (d, J = 8.1 Hz, 1.33H), 7.42 (d, 
J = 8.1 Hz, 1.33H), 7.23 (d, J = 8.1 Hz, 2H), 7.15 – 7.11 (m, 
3.33H), 6.97 (d, J = 7.8 Hz, 1.33H), 6.79 (d, J = 8.1 Hz, 2H), 
4.96 (s, 0.67H), 4.85 (s, 1H), 4.81 (d, J = 6.7 Hz, 1H), 4.64 (t, J = 2.4 Hz, 1H), 4.58 (t, J = 2.4 
Hz, 0.67H), 4.13 (d, J = 10.4 Hz, 0.67H), 4.07 (dd, J = 10.3, 6.4 Hz, 0.67H), 3.99 (s, 1H), 3.91 
(d, J = 6.7 Hz, 0.67H), 3.77 – 3.66 (m, 4H), 3.60 (dd, J = 10.2, 6.6 Hz, 1H), 3.29 (d, J = 10.3 
Hz, 1H), 2.82 (t, J = 9.7 Hz, 2H), 2.61 – 2.54 (m, 1.33H), 2.54 – 2.47 (m, 2H), 2.47 – 2.41 (m, 
1.33H), 2.27 (t, J = 6.8 Hz, 1H), 2.21 (s, 3H), 2.12 (s, 2H), 2.02 (t, J = 6.7 Hz, 0.67H), 1.37 – 
1.25 (m, 3.33H), 1.18 – 1.11 (m, 2H), 1.04 – 0.97 (m, 1.33H), 0.69 – 0.63 ppm (m, 5H); 13C 
NMR (176 MHz, C6D6) δ 171.49, 171.43, 141.47, 140.41, 139.82, 139.64, 137.60, 137.42, 
132.04, 131.90, 131.25, 131.16, 129.64, 128.98, 128.57, 128.44, 121.14, 110.65 (d, JRh-C = 4.7 
Hz), 109.83 (d, JRh-C = 4.6 Hz), 100.89 (d, JRh-C = 3.3 Hz), 100.09 (d, JRh-C = 3.5 Hz), 86.62 (d, 
JRh-C = 4.0 Hz), 86.57 (d, JRh-C = 4.1 Hz), 86.19 (d, JRh-C = 3.7 Hz), 85.35 (d, JRh-C = 3.7 Hz), 
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85.07 (d, JRh-C = 3.5 Hz), 84.19 (d, JRh-C = 3.6 Hz), 66.10, 63.31, 60.82, 60.66, 59.16, 56.07, 
45.87, 42.12, 41.46 (d, JRh-C = 13.5 Hz), 41.32 (d, JRh-C = 13.6 Hz), 37.56 (d, JRh-C = 12.4 Hz), 
21.27, 21.12, 13.88, 13.83 ppm; FT‐IR: 
~ = 3055, 2987, 2932, 1734, 1486, 1183, 1010 cm-1; 
HRMS: calc. for [M+H]+ C28H29O2N
79BrRh: 596.06660, found: 596.06628; calc. for [M+H]+ 
C28H29O2N
81BrRh: 598.06455, found: 598.06439;  RTD = +11.2 (CH2Cl2, c = 0.42). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-1,4-bis(4-bromophenyl)-3-(ethoxycarbonyl)-1,2,3,4-
tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100b: Using Method F, 60% yield; two separable isomers with 
57:43 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 7.62 
(d, J = 8.2 Hz, 1.50H), 7.49 (d, J = 8.2 Hz, 2H), 7.44 – 7.40 
(m, 3.50H), 7.23 (d, J = 8.2 Hz, 3.50H), 6.84 (d, J = 8.2 Hz, 
1.50H), 6.76 (d, J = 8.2 Hz, 2H), 4.83 (s, 1H), 4.77 (s, 0.75H), 
4.61 – 4.56 (m, 2H), 4.55 (t, J = 2.6 Hz, 0.75H), 4.08 (d, J = 10.3 Hz, 0.75H), 3.99 (dd, J = 
10.3, 5.8 Hz, 0.75H), 3.77 (s, 1H), 3.75 – 3.66 (m, 4.25H), 3.52 (dd, J = 10.3, 6.0 Hz, 1H), 3.19 
(d, J = 10.3 Hz, 1H), 2.74 (t, J = 9.7 Hz, 2H), 2.57 – 2.51 (m, 1.50H), 2.38 (t, J = 9.5 Hz, 2H), 
2.10 (t, J = 6.4 Hz, 1H), 1.88 (t, J = 6.2 Hz, 0.75H), 1.37 – 1.28 (m, 2H), 1.26 – 1.19 (m, 
1.50H), 1.10 – 1.03 (m, 2H), 1.03 – 0.96 (m, 1.50H), 0.70 – 0.63 ppm (m, 5.25H); 13C NMR 
(176 MHz, C6D6): δ 171.28, 171.25, 142.14, 141.59, 141.22, 139.63, 132.06, 131.99, 131.93, 
131.40, 131.28, 131.11, 130.37, 130.16, 128.41, 122.06, 121.91, 121.38, 121.23, 109.77 (d, 
JRh-C = 4.5 Hz), 109.72 (d, JRh-C = 4.7 Hz), 99.98 (d, JRh-C = 3.3 Hz), 99.91 (d, JRh-C = 3.5 Hz), 
86.91 (d, JRh-C = 4.0 Hz), 86.75 (d, JRh-C = 4.1 Hz), 86.30 (d, JRh-C = 3.7 Hz), 85.15 (d, JRh-C = 
3.5 Hz), 85.08 (d, JRh-C = 3.7 Hz), 83.97 (d, JRh-C = 3.6 Hz), 65.80, 63.08, 60.92, 60.77, 58.69, 
55.68, 45.70, 41.96, 41.57 (d, JRh-C = 13.5 Hz), 41.33 (d, JRh-C = 13.0 Hz), 37.70 (d, JRh-C = 
12.7 Hz), 37.51 (d, JRh-C = 12.7 Hz), 13.86, 13.81 ppm; FT‐IR: 
~ = 3054, 2986, 1730, 1485, 
1184, 1010 cm-1; HRMS: calc. for [M+H]+ C27H29O2N
79Br2Rh: 659.96146, found: 659.96204; 
calc. for [M+H]+ C27H29O2N
79Br81BrRh: 661.95996, found: 661.96014; calc. for [M+H]+ 
C27H29O2N
81Br2Rh: 663.95737, found: 663.95734;  RTD = +49.8 (CH2Cl2, c = 1.00). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(ethoxycarbonyl)-1-(4-
fluorophenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
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100c: Using Method F, 76% yield; two separable isomers with 
58:42 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 7.64 (d, 
J = 8.0 Hz, 1.44H), 7.62 – 7.59 (m, 2H), 7.42 (d, J = 8.0 Hz, 
1.44H), 7.24 (d, J = 8.1 Hz, 2H), 6.98 – 6.93 (m, 3.44H), 6.79 
– 6.74 (m, 3.44H), 4.85 (s, 1H), 4.81 (s, 0.72H), 4.65 (d, J = 6.5 
Hz, 1H), 4.61 (s, 1H), 4.56 (s, 0.72H), 4.10 (d, J = 10.3 Hz, 0.72H), 4.01 (dd, J = 10.3, 6.0 Hz, 
0.72H), 3.79 (s, 1H), 3.78 – 3.66 (m, 4.88H), 3.54 (dd, J = 10.3, 6.0 Hz, 1H), 3.21 (d, J = 10.3 
Hz, 1H), 2.76 (t, J = 9.6 Hz, 2H), 2.59 – 2.52 (m, 1.44H), 2.44 – 2.36 (m, 3.44H), 2.13 (t, J = 
6.3 Hz, 1H), 1.91 (t, J = 6.3 Hz, 0.72H), 1.37 – 1.30 (m, 1.44H), 1.28 – 1.21 (m, 2H), 1.12 – 
1.04 (m, 2H), 1.04 – 0.97 (m, 1.44H), 0.70 – 0.62 ppm (m, 5.16H); 13C NMR (176 MHz, C6D6): 
δ 171.31, 171.30, 162.86 (d, J = 245.5 Hz), 162.77 (d, J = 246.0 Hz), 141.26, 139.67, 139.01 
(d, J = 3.1 Hz), 138.49 (d, J = 3.0 Hz), 132.00, 131.92, 131.28, 131.14, 130.23 (d, J = 7.8 Hz), 
130.08 (d, J = 8.0 Hz), 121.37, 121.22, 115.70 (d, J = 21.3 Hz), 115.01 (d, J = 21.2 Hz), 110.34 
(d, JRh-C = 4.5 Hz), 109.80 (d, JRh-C = 4.5 Hz), 100.38 (d, JRh-C = 3.2 Hz), 99.95 (d, JRh-C = 3.5 
Hz), 86.88 (d, JRh-C = 4.0 Hz), 86.70 (d, JRh-C = 4.1 Hz), 86.25 (d, JRh-C = 3.7 Hz), 85.15 (d, JRh-
C = 3.3 Hz), 85.13 (d, JRh-C = 3.5 Hz), 84.02 (d, JRh-C = 3.6 Hz), 65.89, 63.18, 60.90, 60.75, 
58.62, 55.55, 45.75, 41.99, 41.52 (d, JRh-C = 13.2 Hz), 41.31 (d, JRh-C = 13.4 Hz), 37.67 (d, JRh-
C = 12.5 Hz), 37.40 (d, JRh-C = 13.0 Hz), 13.87, 13.82 ppm; FT‐IR: 
~ = 3318, 3055, 2987, 2926, 
1732, 1603, 1508, 1223, 1185, 1156 cm-1; HRMS: calc. for [M+H]+ C27H29O2N
79BrFRh: 
600.04153, found: 600.04169; calc. for [M+H]+ C27H29O2N
81BrFRh: 602.03948, found: 
602.03967;  RTD = +60.3 (CH2Cl2, c = 0.35). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(ethoxycarbonyl)-1-(2-
methylphenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100d: Using Method F, 66% yield; two inseparable isomers 
with 56:44 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
8.45 (d, J = 7.8 Hz, 0.79H), 7.63 (d, J = 7.8 Hz, 2H), 7.41 (d, 
J = 7.8 Hz, 2H), 7.27 (t, J = 7.5 Hz, 1H), 7.24 – 7.20 (m, 
1.58H), 7.16 – 7.14 (m, 1H), 7.08 – 7.00 (m, 3.37H), 7.00 – 
6.96 (m, 1H), 6.78 (d, J = 7.8 Hz, 1.58H), 5.14 (d, J = 7.4 Hz, 0.79H), 4.90 (s, 1H), 4.87 (s, 
0.79H), 4.66 (s, 0.79H), 4.62 (s, 1H), 4.17 – 4.11 (m, 1H), 4.11 – 4.05 (m, 0.79H), 3.81 (s, 
0.79H), 3.78 – 3.62 (m, 6.37H), 3.28 (d, J = 10.3 Hz, 0.79H), 2.85 – 2.74 (m, 1.58H), 2.56 (d, 
J = 9.7 Hz, 2H), 2.50 – 2.38 (m, 3.58H), 2.29 (s, 2.37H), 2.28 (s, 3H), 2.26 (s, 0.79H), 1.94 – 
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1.85 (m, 1H), 1.17 – 1.09 (m, 1.58H), 1.08 – 0.99 (m, 2H), 0.94 – 0.88 (m, 3.58H), 0.68 (t, J = 
7.1 Hz, 2.37H), 0.63 ppm (t, J = 7.1 Hz, 3H); 13C NMR (176 MHz, C6D6): δ 171.53, 171.43, 
141.43, 141.06, 139.58, 135.27, 131.98, 131.93, 131.29, 131.11, 130.01, 128.42, 128.35, 
128.31, 128.12, 127.59, 126.57, 121.36, 121.18, 110.29 (d, JRh-C = 4.7 Hz), 109.95, 100.85, 
100.15 (d, JRh-C = 3.5 Hz), 86.69 (d, JRh-C = 4.0 Hz), 86.56 (d, JRh-C = 3.4 Hz), 86.27 (d, JRh-C 
= 3.7 Hz), 85.27, 84.81 (d, JRh-C = 3.3 Hz), 83.95 (d, JRh-C = 3.7 Hz), 66.39, 63.24, 60.84, 60.65, 
54.92, 45.95, 42.10, 41.68 (d, JRh-C = 13.9 Hz), 41.57 (d, JRh-C = 13.4 Hz), 37.78 (d, JRh-C = 
12.3 Hz), 37.48 (d, JRh-C = 12.7 Hz), 19.39, 13.90, 13.80 ppm; FT‐IR: 
~ = 3055, 2924, 1723, 
1488, 1185, 1010 cm-1; HRMS: calc. for [M+H]+ C28H32O2N
79BrRh: 596.06660, found: 
596.06622; calc. for [M+H]+ C28H32O2N
81BrRh: 598.06455, found: 598.06439;   RTD = +40.5 
(CH2Cl2, c = 0.20). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-1-(4-bromophenyl)-3-(ethoxycarbonyl)-4-
(naphthalen-2-yl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100e: Using Method G, 65% yield; two inseparable isomers 
with 50:50 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
8.31 (s, 1H), 8.19 (d, J = 8.3 Hz, 1H), 7.78 (d, J = 8.2 Hz, 2H), 
7.72 – 7.66 (m, 2H), 7.63 – 7.57 (m, 3H), 7.53 (d, J = 8.2 Hz, 
2H), 7.44 (d, J = 8.2 Hz, 2H), 7.33 – 7.21 (m, 7H), 6.89 (d, J 
= 8.1 Hz, 2H), 4.93 (s, 1H), 4.82 (s, 1H), 4.67 (d, J = 6.9 Hz, 1H), 4.62 (t, J = 2.5 Hz, 1H), 4.55 
(t, J = 2.5 Hz, 1H), 4.41 (d, J = 10.3 Hz, 1H), 4.29 – 4.24 (m, 1H), 3.85 – 3.78 (m, 3H), 3.76 
(s, 1H), 3.55 (d, J = 10.3 Hz, 1H), 3.04 (s, 3H), 3.00 (s, 3H), 2.83 – 2.76 (m, 2H), 2.66 – 2.60 
(m, 2H), 2.51 – 2.39 (m, 4H), 2.12 (t, J = 6.7 Hz, 1H), 1.89 (t, J = 6.5 Hz, 1H), 1.47 – 1.41 (m, 
2H), 1.30 – 1.22 (m, 2H), 1.16 – 1.05 ppm (m, 4H); 13C NMR (176 MHz, C6D6): δ 171.97, 
171.91, 142.27, 141.69, 139.49, 138.01, 134.05, 133.94, 133.57, 133.24, 132.06, 131.38, 
130.42, 130.23, 129.19, 128.80, 128.41, 128.35, 128.30, 127.71, 126.93, 126.51, 126.25, 
126.19, 126.07, 122.03, 121.86, 110.32 (d, JRh-C = 4.5 Hz), 109.76 (d, JRh-C = 4.7 Hz), 100.35 
(d, JRh-C = 3.5 Hz), 99.96 (d, JRh-C = 3.3 Hz), 86.92 (d, JRh-C = 4.0 Hz), 86.71 (d, JRh-C = 4.1 
Hz), 86.67 (d, JRh-C = 3.8 Hz), 85.54 (d, JRh-C = 3.5 Hz), 85.05 (d, JRh-C = 3.7 Hz), 84.01 (d, JRh-
C = 3.6 Hz), 65.93, 63.37, 60.07, 58.74, 55.81, 51.39, 51.32, 46.40, 42.62, 41.57 (d, JRh-C = 13.7 
Hz), 41.36 (d, JRh-C = 13.2 Hz), 37.91 (d, JRh-C = 12.2 Hz), 37.53 (d, JRh-C = 12.8 Hz) ppm; FT‐
IR: 
~ = 3053, 2988, 2951, 1736, 1484, 1402, 1198, 1168 cm-1; HRMS: calc. for [M+H]+ 
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C30H30O2N
79BrRh: 618.05095, found: 618.05048; calc. for [M+H]+ C30H30O2N
81BrRh: 
620.04890, found: 620.04865;  RTD = +59.0 (CH2Cl2, c = 0.21). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-1-(4-bromophenyl)-3-(ethoxycarbonyl)-2-methyl-4-
(naphthalen-2-yl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100f: Using Method G, 81% yield; two inseparable isomers 
with 55:45 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
8.30 (s, 0.82H), 8.24 (d, J = 8.1 Hz, 0.82H), 7.77 (d, J = 8.3 
Hz, 2H), 7.70 – 7.66 (m, J = 7.1 Hz, 1.82H), 7.63 – 7.50 (m, 
4.64 H), 7.44 (d, J = 8.3 Hz, 1.64H), 7.32 – 7.25 (m, 5.46 H), 
7.25 – 7.20 (m, 1.64H), 7.00 (d, J = 8.2 Hz, 2H), 4.97 (s, 0.82H), 4.74 (d, J = 10.2 Hz, 1H), 
4.69 (s, 1H), 4.61 (t, J = 2.6 Hz, 0.82H), 4.53 (t, J = 2.6 Hz, 1H), 4.02 (d, J = 10.2 Hz, 1H), 
3.92 (s, 0.82H), 3.71 – 3.64 (m, 2.64H), 3.40 (d, J = 10.4 Hz, 0.82H), 3.17 (s, 1H), 2.99 (s, 
2.46H), 2.98 (s, 3H), 2.90 (t, J = 9.6 Hz, 1.64H), 2.68 – 2.60 (m, 2H), 2.54 – 2.47 (m, 2H), 2.41 
(t, J = 9.6 Hz, 1.64H), 2.10 (s, 2.46H), 2.09 (s, 3H), 1.49 – 1.42 (m, 2H), 1.24 – 1.18 (m, 1.64H), 
1.17 – 1.05 ppm (m, 3.64H); 13C NMR (176 MHz, C6D6) δ 171.82, 171.69, 170.03, 142.77, 
142.46, 138.09, 136.88, 134.02, 133.89, 133.71, 133.38, 132.13, 131.34, 131.23, 130.44, 
129.52, 128.86, 128.53, 127.79, 127.64, 126.90, 126.55, 126.33, 126.29, 126.21, 121.82, 
121.68, 110.72 (d, JRh-C = 4.6 Hz), 108.79 (d, JRh-C = 4.5 Hz), 99.94 (d, JRh-C = 3.4 Hz), 98.59 
(d, JRh-C = 3.4 Hz), 87.57 (d, JRh-C = 3.9 Hz), 87.07 (d, JRh-C = 4.1 Hz), 85.62 (d, JRh-C = 3.5 
Hz), 85.47 (d, JRh-C = 3.7 Hz), 84.84 (d, JRh-C = 3.6 Hz), 84.56 (d, JRh-C = 3.5 Hz), 75.05, 72.22, 
67.85, 64.57, 51.21, 51.16, 46.08, 43.62, 42.46 (d, JRh-C = 13.3 Hz), 41.40 (d, JRh-C = 13.0 Hz), 
41.17, 41.06, 37.78 (d, JRh-C = 12.6 Hz), 37.53 (d, JRh-C = 12.9 Hz) ppm; FT‐IR: 
~ = 3053, 
2988, 2951, 1741, 1484, 1402, 1198, 1167 cm-1; HRMS: calc. for C31H32O2N
79BrRh: 
632.06660, found: 632.06702; calc. for [M+H]+ C31H32O2N
81BrRh: 634.06455, found: 
634.06494;  RTD = +60.0 (CH2Cl2, c = 0.26). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-3-(ethoxycarbonyl)-4-(4-methylphenyl)-1-(4-
(trifluoromethyl)phenyl)-1,2,3,4-
tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100g: Using Method F, 80% yield; two inseparable isomers 
with 62:38 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
7.82 (d, J = 7.7 Hz, 1.23H), 7.65 (d, J =  8.0 Hz, 2H), 7.49 (d, J = 8.0 Hz, 2H), 7.32 (d, J = 11.4 
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Hz, 1.23H), 7.13 (d, J = 7.7 Hz, 1.23H), 7.07 (d, J = 7.7 Hz, 2H), 7.03 (d, J = 7.7 Hz, 1.23H), 
6.96 (d, J = 7.7 Hz, 2H), 5.01 (s, 1H), 4.71 (s, 0.61H), 4.68 (d, J = 6.8 Hz, 1H), 4.61 (t, J = 2.5 
Hz, 1H), 4.57 (t, J = 2.5 Hz, 0.61H), 4.27 – 4.24 (m, 0.61H), 4.20 – 4.16 (m, 0.61H), 3.89 (s, 
0.61H), 3.85 (d, J = 6.9 Hz, 0.61H), 3.80 – 3.75 (m, 2H), 3.75 – 3.70 (m, 1.22H), 3.70 (s, 1H), 
3.35 (d, J = 10.3 Hz, 1H), 2.75 (t, J = 9.8 Hz, 2H), 2.61 (d, J = 9.6 Hz, 1.22H), 2.51 (d, J = 
10.3 Hz, 1.22H), 2.36 (t, J = 9.9 Hz, 2H), 2.17 (d, J = 7.0 Hz, 1.83H), 2.15 (t, J = 6.8 Hz, 1H), 
2.10 (s, 3H), 1.89 (t, J = 6.7 Hz, 0.61H), 1.45 – 1.38 (m, 1.22H), 1.25 – 1.17 (m, 2H), 1.13 – 
1.00 (m, 3.22H), 0.73 – 0.67 ppm (m, 4.83H); 13C NMR (176 MHz, C6D6): δ 171.65, 171.59, 
147.22, 146.79, 139.15, 137.33, 136.93, 136.79, 130.14, 130.10 (q, J = 32.2 Hz), 130.00 (q, J 
= 32.1 Hz), 129.57, 129.29, 128.95, 128.93, 128.91, 128.41, 128.35, 128.31, 128.12, 127.99, 
125.94, 125.81 (q, J = 3.6 Hz), 125.09 (q, J = 3.7 Hz), 124.40, 110.72 (d, JRh-C = 4.5 Hz), 
109.28 (d, JRh-C = 4.7 Hz), 100.86 (d, JRh-C = 3.5 Hz), 99.68 (d, JRh-C = 3.3 Hz), 86.92 (d, JRh-C 
= 4.0 Hz), 86.68 (d, JRh-C = 3.7 Hz), 86.59 (d, JRh-C = 4.1 Hz), 85.38 (d, JRh-C = 3.5 Hz), 84.88 
(d, JRh-C = 3.8 Hz), 83.86 (d, JRh-C = 3.7 Hz), 66.11, 63.39, 60.84, 60.69, 58.86, 56.01, 46.04, 
42.08, 41.61 (d, JRh-C = 13.6 Hz), 41.36 (d, JRh-C = 13.7 Hz), 37.72 (d, JRh-C = 13.4 Hz), 37.29 
(d, JRh-C = 12.9 Hz), 21.19, 21.05, 13.91, 13.85 ppm; FT‐IR: 
~ = 3054, 2987, 1731, 1513, 1322, 
1163, 1121, 1066 cm-1; HRMS: calc. for [M+H]+ C29H32O2NF3Rh: 586.14347, found: 
586.14386;  RTD = +40.4 (CHCl3, c = 0.48). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(ethoxycarbonyl)-1-(4-
(trifluoromethyl)phenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100h: Using Method F, 79% yield; two inseparable isomers 
with 59:41 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
7.66 – 7.60 (m, 3.39H), 7.50 (d, J = 8.0 Hz, 12H), 7.43 (d, J 
= 8.0 Hz, 1.39H), 7.32 (d, J = 8.0 Hz, 1.39H), 7.24 (d, J = 8.0 
Hz, 2H), 7.02 (d, J = 8.0 Hz, 1.39H), 6.77 (d, J = 8.0 Hz, 2H), 
4.83 (s, 1H), 4.70 (s, 0.69H), 4.62 (d, J = 6.4 Hz, 1H), 4.60 (t, J = 2.4 Hz, 1H), 4.56 – 4.54 (m, 
0.69H), 4.10 (d, J = 10.3 Hz, 0.69H), 4.00 (dd, J = 10.3, 5.6 Hz, 0.69H), 3.78 – 3.70 (m, 3.39H), 
3.69 (s, 1.69H), 3.52 (dd, J = 10.3, 5.9 Hz, 1H), 3.19 (d, J = 10.3 Hz, 1H), 2.72 (t, J = 9.7 Hz, 
2H), 2.57 – 2.52 (m, J = 1.39H), 2.41 – 2.36 (m, 1.39H), 2.31 (t, J = 9.8 Hz, 2H), 2.13 (t, J = 
6.2 Hz, 1H), 1.91 (t, J = 6.0 Hz, 0.69H), 1.37 – 1.30 (m, 1.39H), 1.23 – 1.16 (m, 2H), 1.09 – 
0.97 (m, 2.39H), 0.70 – 0.64 ppm (m, 5.07H); 13C NMR (176 MHz, C6D6): δ 171.24, 171.22, 
147.01, 146.66, 141.15, 139.56, 131.96, 131.95, 131.31, 131.10, 130.20 (d, J = 32.2 Hz), 
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130.11 (d, J = 32.1 Hz), 128.84, 128.41, 128.35, 128.31, 128.20, 128.12, 128.06, 128.06, 
127.99, 127.92, 125.90, 125.83 (q, J = 3.6 Hz), 125.13 (q, J = 3.6 Hz), 124.36, 121.43, 121.29, 
109.78 (d, JRh-C = 4.5 Hz), 109.28 (d, JRh-C = 4.6 Hz), 99.94 (d, JRh-C = 3.5 Hz), 99.60 (d, JRh-C 
= 3.2 Hz), 87.09 (d, JRh-C = 4.0 Hz), 86.85 (d, JRh-C = 4.0 Hz), 86.41 (d, JRh-C = 3.7 Hz), 85.23 
(d, JRh-C = 3.5 Hz), 84.98 (d, JRh-C = 3.7 Hz), 83.91 (d, JRh-C = 3.6 Hz), 65.64, 62.99, 60.98, 
60.84, 58.81, 55.87, 45.65, 41.94, 41.68 (d, JRh-C = 13.2 Hz), 41.36 (d, JRh-C = 12.9 Hz), 37.78 
(d, JRh-C = 12.8 Hz), 37.40 (d, JRh-C = 12.7 Hz), 13.86, 13.81 ppm; FT‐IR: 
~ = 3056, 2988, 
1731, 1487, 1322, 1162, 1121, 1065 cm-1; HRMS: calc. for [M+H]+ C28H29O2N
79BrF3Rh: 
650.03833, found: 650.03931;  RTD = +29.9 (CH2Cl2, c = 0.78). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-chlorophenyl)-3-(ethoxycarbonyl)-1-(4-
(trifluoromethyl)phenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100i: Using Method F, 59% yield; two inseparable isomers 
with 57:43 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
7.68 (d, J = 8.1 Hz, 1.51H), 7.64 (d, J = 7.9 Hz, 2H), 7.50 (d, 
J = 7.9 Hz, 2H), 7.32 (d, J = 7.9 Hz, 1.51H), 7.27 (d, J = 8.1 
Hz, 1.51H), 7.09 (d, J = 8.1 Hz, 2H), 7.03 (d, J = 7.9 Hz, 
1.51H), 6.83 (d, J = 8.1 Hz, 2H), 4.85 (s, 1H), 4.71 (s, 0.75H), 4.63 (d, J = 6.5 Hz, 1H), 4.60 
(s, 1H), 4.55 (s, 0.75H), 4.12 (d, J = 10.3 Hz, 0.75H), 4.01 (dd, J = 10.4, 5.7 Hz, 0.75H), 3.78 
– 3.71 (m, 3.51H), 3.70 (s, 1.75H), 3.53 (dd, J = 10.3, 5.9 Hz, 1H), 3.21 (d, J = 10.3 Hz, 1H), 
2.72 (t, J = 9.7 Hz, 2H), 2.59 – 2.51 (m, 1.51H), 2.40 (d, J = 9.7 Hz, 1.51H), 2.31 (t, J = 9.8 
Hz, 2H), 2.14 (t, J = 6.2 Hz, 1H), 1.91 (t, J = 6.1 Hz, 0.75H), 1.38 – 1.31 (m, 1.51H), 1.25 – 
1.15 (m, 2H), 1.08 – 0.99 (m, 2H), 0.95 – 0.87 (m, 1.51H), 0.70 – 0.63 ppm (m, 5.25H); 13C 
NMR (176 MHz, C6D6): δ 171.26, 171.23, 147.01, 146.67, 140.66, 139.07, 133.31, 133.18, 
131.61, 130.75, 130.20 (d, J = 32.2 Hz), 130.11 (q, J = 32.1 Hz), 128.99, 128.91, 128.84, 
128.41, 128.35, 128.34, 128.31, 128.12, 127.99, 125.90, 125.86, 125.83 (q, J = 3.6 Hz), 125.80, 
125.68, 125.13 (q, JRh-C = 3.6 Hz), 124.36, 109.89 (d, JRh-C = 4.5 Hz), 109.29 (d, JRh-C = 4.6 
Hz), 100.03 (d, JRh-C = 3.5 Hz), 99.63 (d, JRh-C = 3.2 Hz), 87.09 (d, JRh-C = 4.0 Hz), 86.84 (d, 
JRh-C = 4.0 Hz), 86.41 (d, JRh-C = 3.7 Hz), 85.23 (d, JRh-C = 3.5 Hz), 84.98 (d, JRh-C = 3.7 Hz), 
83.91 (d, JRh-C = 3.6 Hz), 65.71, 63.05, 60.98, 60.83, 58.82, 55.88, 45.59, 41.86, 41.68 (d, JRh-
C = 12.8 Hz), 41.36 (d, JRh-C = 12.8 Hz), 37.75 (d, JRh-C = 12.5 Hz), 37.40 (d, JRh-C = 13.1 Hz), 
14.39, 13.87, 13.81 ppm; FT‐IR: 
~ = 3059, 2988, 1732, 1491, 1322, 1162, 1122, 1065 cm-1; 
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HRMS: calc. for [M+H]+ C28H29O2NClF3Rh: 606.08885, found: 606.08893;  RTD = +51.4 
(Toluene, c = 0.29). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-3-(ethoxycarbonyl)-4-isopropyl-1-(4-
(trifluoromethyl)phenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100j: Using Method F, 65% yield; two inseparable isomers with 
67:33 ratio; For mixture, 1H NMR (700 MHz, C6D6) δ 7.50 (d, J 
= 8.0 Hz, 2H), 7.45 (d, J = 8.0 Hz, 2H), 7.27 (d, J = 7.9 Hz, 1H), 
6.90 (d, J = 7.9 Hz, 1H), 5.29 (s, 1H), 4.73 (s, 1H), 4.70 (s, 0.5H), 
4.57 (s, 0.5H), 4.40 (d, J = 8.7 Hz, 1H), 4.37 (s, 0.5H), 4.00 – 
3.94 (m, 3H), 3.69 (t, J = 9.1 Hz, 0.5H), 3.64 (s, 1H), 3.59 (d, J = 8.5 Hz, 0.5H), 3.51 (t, J = 
9.2 Hz, 1H), 3.20 (d, J = 10.0 Hz, 0.5H), 2.78 (t, J = 10.0 Hz, 2H), 2.70 – 2.57 (m, 2H), 2.37 
(d, J = 9.7 Hz, 1H), 2.32 (t, J = 10.0 Hz, 2H), 2.12 – 2.04 (m, 1.5H), 1.92 – 1.84 (m, 1H), 1.55 
(t, J = 8.3 Hz, 0.5H), 1.46 (d, J = 7.0 Hz, 1.5H), 1.39 – 1.26 (m, 2.5H), 1.26 – 1.17 (m, 2H), 
1.11 – 1.02 (m, 3H), 0.97 – 0.92 (m, 4.5H), 0.89 (d, J = 7.0 Hz, 3H), 0.86 ppm (d, J = 7.0 Hz, 
3H); 13C NMR (176 MHz, C6D6): δ 173.05, 172.99, 146.67, 146.10, 129.99 (q, J = 32.2 Hz), 
129.85 (q, J = 32.1 Hz), 128.87, 128.68, 128.41, 128.35, 128.31, 128.12, 127.99, 125.91, 
125.73 (q, J = 3.7 Hz), 124.99 (q, J = 3.7 Hz), 124.37, 111.06 (d, JRh-C = 4.5 Hz), 106.55 (d, 
JRh-C = 4.2 Hz), 100.33 (d, JRh-C = 3.5 Hz), 99.40 (d, JRh-C = 3.6 Hz), 86.09 (d, JRh-C = 4.1 Hz), 
85.82 (d, JRh-C = 4.2 Hz), 85.70 (d, JRh-C = 3.5 Hz), 85.02 (d, JRh-C = 3.9 Hz), 84.69 (d, JRh-C = 
3.9 Hz), 84.44 (d, JRh-C = 3.8 Hz), 61.11, 60.97, 60.55, 59.95, 57.85, 56.14, 43.76, 41.11 (d, 
JRh-C = 13.5 Hz), 40.75 (d, JRh-C = 13.7 Hz), 39.00, 37.50 (d, JRh-C = 13.0 Hz), 37.30 (d, JRh-C = 
13.1 Hz), 31.36, 31.31, 21.30, 19.90, 18.56, 18.49, 14.07, 14.03 ppm; FT‐IR: 
~ = 3057, 2961, 
1734, 1322, 1132, 1122, 1065 cm-1; HRMS: calc. for [M+H]+ C25H32O2NF3Rh: 538.14347, 
found: 538.14319;  RTD = +32.9 (CH2Cl2, c = 0.14). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-3-(ethoxycarbonyl)-4-(naphthalen-2-yl)-1-(4-
(trifluoromethyl)phenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100k: Using Method  F, 83% yield; two inseparable isomers 
with 59:41 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
8.27 (s, 0.69H), 8.23 (d, J = 8.4 Hz, 0.69H), 7.79 (t, J = 7.7 
Hz, 1.69H), 7.71 (d, J = 7.9 Hz, 0.69H), 7.70 – 7.66 (m, 3H), 
7.64 – 7.58 (m, 3H), 7.52 (d, J = 8.0 Hz, 2H), 7.36 – 7.22 
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(m, 5.45H), 7.08 (d, J = 7.9 Hz, 1.38H), 4.94 (s, 1H), 4.76 (s, 0.69H), 4.73 (d, J = 6.8 Hz, 1H), 
4.62 (t, J = 2.6 Hz, 1H), 4.56 (t, J = 2.5 Hz, 0.69H), 4.42 (d, J = 10.3 Hz, 0.69H), 4.28 (dd, J = 
10.3, 6.0 Hz, 0.69H), 3.87 (d, J = 6.7 Hz, 0.69H), 3.83 (dd, J = 10.3, 6.3 Hz, 1H), 3.77 (s, 
0.69H), 3.74 (s, 1H), 3.73 – 3.60 (m, 3.38H), 3.55 (d, J = 10.3 Hz, 1H), 2.79 (t, J = 9.8 Hz, 
2H), 2.69 – 2.61 (m, J = 9.3 Hz, 1.38H), 2.49 – 2.43 (m, 1.38H), 2.40 (t, J = 9.9 Hz, 2H), 2.23 
(t, J = 6.6 Hz, 1H), 1.99 (t, J = 6.4 Hz, 0.69H), 1.49 – 1.41 (m, 1.38H), 1.27 – 1.19 (m, 2H), 
1.16 – 1.11 (m, 1.38H), 1.11 – 1.04 (m, 2H), 0.57 (t, J = 7.1 Hz, 3H), 0.50 ppm (t, J = 7.1 Hz, 
2.07H); 13C NMR (176 MHz, C6D6): δ 171.65, 171.56, 147.19, 146.77, 139.47, 137.98, 134.00, 
133.90, 133.56, 133.22, 130.15 (q, J = 32.2 Hz), 130.04 (q, J = 32.1 Hz), 129.33, 128.95, 
128.91, 128.77, 128.56, 128.41, 128.35, 128.31, 128.30, 128.12, , 127.99, 127.62, 126.93, 
126.55, 126.28, 126.21, 126.08, 125.94, 125.84 (q, J = 3.6 Hz), 125.72, 125.13 (q, J = 3.6 Hz), 
124.40, 110.39 (d, JRh-C = 4.4 Hz), 109.36 (d, JRh-C = 4.6 Hz), 100.48 (d, JRh-C = 3.5 Hz), 99.66 
(d, JRh-C = 3.2 Hz), 87.08 (d, JRh-C = 4.0 Hz), 86.79 (d, JRh-C = 2.9 Hz), 85.57 (d, JRh-C = 3.4 
Hz), 84.99 (d, JRh-C = 3.7 Hz), 83.96 (d, JRh-C = 3.6 Hz), 65.78, 63.27, 60.86, 60.69, 58.85, 
55.97, 46.62, 42.77, 41.67 (d, JRh-C = 13.4 Hz), 41.41 (d, JRh-C = 13.4 Hz), 37.96 (d, JRh-C = 
12.2 Hz), 37.40 (d, JRh-C = 12.9 Hz), 13.81, 13.71 ppm; FT‐IR: 
~ = 3319, 3057, 2990, 1733, 
1324, 1164, 1121, 1067 cm-1; HRMS: calc. for [M+H]+ C32H32O2NF3Rh: 622.14347, found: 
622.14410;  RTD = +77.7 (CH2Cl2, c = 0.60). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(methoxycarbonyl)-1-(4-
fluorophenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100l: Using Method G, 79% yield; two separable isomers with 
60:40 ratio; HRMS: calc. for [M+H]+ C26H27O2N
79BrFRh: 
586.02588, found: 586.02582; calc. for [M+H]+ 
C26H27O2N
81BrFRh: 588.02383, found: 588.02374;  RTD = 
+65.8 (CH2Cl2, c = 0.26). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(methoxycarbonyl)-1-(4-
fluorophenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100l-major: Major isomer, 1H NMR (700 MHz, C6D6): δ 7.60 (dd, J = 8.1, 5.7 Hz, 2H), 7.23 
(d, J = 8.1 Hz, 2H), 6.95 (t, J = 8.1 Hz, 2H), 6.75 (d, J = 8.1 Hz, 2H), 4.84 (s, 1H), 4.61 (d, J = 
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10.3 Hz, 2H), 3.79 (s, 1H), 3.52 (d, J = 10.3 Hz, 1H), 3.20 
(d, J = 10.3 Hz, 1H), 3.08 (s, 3H), 2.75 (t, J = 9.7 Hz, 2H), 
2.40 (t, J = 9.8 Hz, 2H), 2.06 (s, 1H), 1.28 – 1.19 (m, 2H), 
1.12 – 1.02 ppm (m, 2H); 13C NMR (176 MHz, C6D6): δ 
171.61, 162.87 (d, J = 245.6 Hz), 141.18, 138.47 (d, J = 
3.0 Hz), 131.98, 131.05, 130.23 (d, J = 7.8 Hz), 121.30, 115.01 (d, J = 21.2 Hz), 110.31 (d, 
JRh-C = 4.5 Hz), 99.83 (d, JRh-C = 3.5 Hz), 86.89 (d, JRh-C = 4.0 Hz), 86.24 (d, JRh-C = 3.7 Hz), 
84.01 (d, JRh-C = 3.7 Hz), 65.91, 58.63, 51.43, 41.84, 41.53 (d, JRh-C = 13.2 Hz), 37.41 (d, JRh-
C = 13.0 Hz) ppm; FT‐IR: 
~ = 3053, 2988, 2951, 1739, 1507, 1485, 1434, 1198, 1168 cm-1; 
 RTD = +84.1 (CH2Cl2, c = 0.22). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(methoxycarbonyl)-1-(4-
fluorophenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100l-minor: Minor isomer, 1H NMR (700 MHz, C6D6): δ 
7.62 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 8.0 Hz, 2H), 6.96 (dd, 
J = 7.5, 5.9 Hz, 2H), 6.78 – 6.71 (m, 2H), 4.80 (s, 1H), 
4.54 (s, 1H), 4.11 (d, J = 10.3 Hz, 1H), 4.00 (dd, J = 10.3, 
5.8 Hz, 1H), 3.75 (d, J = 6.6 Hz, 1H), 3.68 (s, 1H), 3.07 (s, 
3H), 2.60 – 2.49 (m, 2H), 2.45 – 2.32 (m, 2H), 1.83 (t, J = 6.1 Hz, 1H), 1.36 – 1.28 (m, 2H), 
1.04 – 0.96 ppm (m, 2H); 13C NMR (176 MHz, C6D6) δ 171.59, 162.78 (d, J = 246.0 Hz), 
139.58, 138.96 (d, J = 3.1 Hz), 131.86, 131.38, 130.07 (d, J = 8.0 Hz), 121.46, 115.69 (d, J = 
21.3 Hz), 109.69 (d, JRh-C = 4.5 Hz), 100.31 (d, JRh-C = 3.2 Hz), 86.71 (d, JRh-C = 4.1 Hz), 85.20 
(d, JRh-C = 3.5 Hz), 85.09 (d, JRh-C = 3.7 Hz), 63.17, 55.59, 51.39, 45.50, 41.30 (d, JRh-C = 13.2 
Hz), 37.70 (d, JRh-C = 12.8 Hz) ppm; FT‐IR: 
~ = 3319, 3054, 2987, 1731, 1604, 1509, 1486, 
1435, 1229, 1177 cm-1;  RTD = -30.5 (CH2Cl2, c = 0.22). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-3-((benzyloxy)carbonyl)-4-(4-bromophenyl)-1-(4-
fluorophenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100m: Using Method G, 74% yield; two separable isomers 
with 50:50 ratio; For mixture, 1H NMR (700 MHz, C6D6): δ 
7.59 (dd, J = 8.0, 5.7 Hz, 2H), 7.54 (d, J = 8.0 Hz, 2H), 7.35 
(d, J = 8.0 Hz, 2H), 7.16 (t, J = 4.0 Hz, 1H), 7.12 – 7.00 (m, 
7H), 6.95 (dd, J = 15.6, 7.2 Hz, 4H), 6.81 (d, J = 7.4 Hz, 2H), 
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6.80 – 6.73 (m, 4H), 6.66 (d, J = 8.1 Hz, 2H), 4.87 – 4.82 (m, 2H), 4.82 (s, 1H), 4.80 (s, 1H), 
4.73 (d, J = 7.1 Hz, 1H), 4.71 (d, J = 7.0 Hz, 1H), 4.61 (d, J = 6.7 Hz, 1H), 4.59 (s, 1H), 4.55 
(s, 1H), 4.08 (d, J = 10.4 Hz, 1H), 4.03 (dd, J = 10.4, 5.9 Hz, 1H), 3.78 (s, 1H), 3.73 (d, J = 6.7 
Hz, 1H), 3.65 (s, 1H), 3.55 (dd, J = 10.4, 6.2 Hz, 1H), 3.16 (d, J = 10.4 Hz, 1H), 2.75 (t, J = 
9.6 Hz, 2H), 2.58 – 2.47 (m, 2H), 2.42 – 2.31 (m, 4H), 2.14 – 2.06 (m, 1H), 1.91 (t, J = 6.2 Hz, 
1H), 1.34 – 1.28 (m, 2H), 1.26 – 1.21 (m, 2H), 1.10 – 1.04 (m, 2H), 1.01 – 0.95 ppm (m, 2H); 
13C NMR (176 MHz, C6D6): δ 171.41, 171.36, 162.85 (d, J = 245.5 Hz), 162.77 (d, J = 246.0 
Hz), 140.93, 139.50, 138.95 (d, J = 3.1 Hz), 138.44 (d, J = 3.0 Hz), 135.65, 132.00, 131.95, 
131.39, 131.00, 130.19 (d, J = 7.8 Hz), 130.05 (d, J = 8.0 Hz), 128.68, 128.66, 128.59, 128.56, 
128.55, 128.45, 128.43, 121.44, 121.22, 115.70 (d, J = 21.3 Hz), 115.01 (d, J = 21.2 Hz), 
110.20 (d, JRh-C = 4.5 Hz), 109.77 (d, JRh-C = 4.5 Hz), 100.31 (d, JRh-C = 3.1 Hz),  99.85 (d, JRh-
C = 3.5 Hz), 86.87 (d, JRh-C = 4.0 Hz), 86.71 (d, JRh-C = 4.0 Hz), 86.20 (d, JRh-C = 3.7 Hz), 85.11, 
84.04 (d, JRh-C = 3.6 Hz), 66.81, 66.73, 65.86, 63.15, 58.49, 55.46, 45.84, 42.26, 41.52 (d, JRh-
C = 13.3 Hz), 41.34 (d, JRh-C = 13.2 Hz), 37.65 (d, JRh-C = 12.5 Hz), 37.39 (d, JRh-C = 12.8 Hz) 
ppm; FT‐IR: 
~ = 3321, 3051, 2989, 1734, 1603, 1508, 1223, 1156 cm-1; HRMS: calc. for 
[M+H]+ C32H31O2N
79BrFRh: 662.05718, found: 662.05713; calc. for [M+H]+ 
C32H31O2N
81BrFRh: 664.05513, found: 664.05505;  RTD = +63.8 (CH2Cl2, c = 0.21). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(methoxycarbonyl)-1-(4-
methylphenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100n: Using Method G, 82% yield; two separable isomers 
with 57:43 ratio; HRMS: calc. for [M+H]+ 
C27H30O2N
79BrRh: 582.05095, found: 582.05115; calc. for 
[M+H]+ C27H30O2N
81BrRh: 584.04890, found: 584.04889; 
 RTD = +31.6 (CH2Cl2, c = 0.23). 
(+)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(methoxycarbonyl)-1-(4-
methylphenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100n-major: Major isomer, 1H NMR (700 MHz, C6D6): 
δ 7.73 (d, J = 7.5 Hz, 2H), 7.23 (d, J = 7.9 Hz, 2H), 7.14 
(d, J = 7.5 Hz, 2H), 6.77 (d, J = 7.9 Hz, 2H), 4.84 (s, 
1H), 4.78 (d, J = 6.7 Hz, 1H), 4.63 (s, 1H), 3.98 (s, 1H), 
3.58 (dd, J = 10.2, 6.5 Hz, 1H), 3.28 (d, J = 10.3 Hz, 
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1H), 3.08 (s, 3H), 2.81 (t, J = 9.5 Hz, 2H), 2.49 (t, J = 9.6 Hz, 2H), 2.24 – 2.18 (m, 4H), 1.34 
– 1.27 (m, 2H), 1.18 – 1.12 ppm (m, 2H); 13C NMR (176 MHz, C6D6): δ 171.80, 141.39, 
139.61, 137.45, 131.96, 131.07, 128.97, 128.56, 121.22, 110.62 (d, JRh-C = 4.6 Hz), 99.97 (d, 
JRh-C = 3.5 Hz), 86.63 (d, JRh-C = 4.1 Hz), 86.19 (d, JRh-C = 3.8 Hz), 84.17 (d, JRh-C = 3.7 Hz), 
66.11, 59.18, 51.39, 41.97, 41.47 (d, JRh-C = 13.1 Hz), 37.56 (d, JRh-C = 13.0 Hz), 21.26 ppm; 
FT‐IR: 
~ = 3051, 2989, 1738, 1513, 1403, 1185, 1105 cm-1;  RTD = +143.1 (CH2Cl2, c = 0.16). 
(‒)-Bis(η2-ethylene)[η5-(1R,3R,4R)-4-(4-bromophenyl)-3-(methoxycarbonyl)-1-(4-
methylphenyl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100n-minor: Minor isomer, 1H NMR (700 MHz, C6D6): 
δ 7.64 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 8.1 Hz, 2H), 7.16 
– 7.15 (m, 2H), 6.97 (d, J = 7.7 Hz, 2H), 4.96 (s, 1H), 
4.57 (s, 1H), 4.14 (d, J = 10.4 Hz, 1H), 4.07 (dd, J = 10.3, 
6.3 Hz, 1H), 3.90 (d, J = 6.7 Hz, 1H), 3.70 (s, 1H), 3.07 
(s, 3H), 2.61 – 2.54 (m, 2H), 2.44 (t, J = 9.5 Hz, 2H), 2.12 (s, 3H), 1.96 (t, J = 6.5 Hz, 1H), 
1.39 – 1.27 (m, 2H), 1.05 – 0.98 ppm (m, 2H); 13C NMR (176 MHz, C6D6): δ 171.72, 140.36, 
139.74, 137.64, 131.90, 131.35, 129.64, 128.43, 121.38, 109.74 (d, JRh-C = 4.6 Hz), 100.83 (d, 
JRh-C = 3.3 Hz), 86.59 (d, JRh-C = 4.1 Hz), 85.32 (d, JRh-C = 3.7 Hz), 85.12 (d, JRh-C = 3.6 Hz), 
63.31, 56.13, 51.34, 45.62, 41.31 (d, JRh-C = 13.1 Hz), 37.61 (d, JRh-C = 12.7 Hz), 21.12 ppm; 
FT-IR: 
~ = 3319, 3054, 2987, 1733, 1485, 1433, 1199, 1172 cm-1;  RTD = -18.0 (CH2Cl2, c = 
0.15). 
(+)-Bis(η2-ethylene)[η5-(1S,3S,4R)-1-(4-bromophenyl)-3-(methoxycarbonyl)-4-
(naphthalen-2-yl)-1,2,3,4-tetrahydrocyclopenta[c]pyridinyl]rhodium(I) 
100o: Using Method G, 88% yield; One single isomer; 1H 
NMR (400 MHz, C6D6): δ 7.86 (s, 1H), 7.73 – 7.68 (m, 1H), 
7.65 (d, J = 7.4 Hz, 1H), 7.63 – 7.56 (m, 2H), 7.36 – 7.29 (m, 
2H), 7.29 – 7.20 (m, 2H), 7.15 – 7.12 (m, 2H), 4.88 – 4.79 (m, 
1H), 4.73 (d, J = 3.3 Hz, 1H), 4.43 (d, J = 1.4 Hz, 1H), 4.39 – 
4.28 (m, 2H), 4.21 (s, 1H), 3.14 (s, 3H), 2.82 – 2.63 (m, 4H), 2.27 (s, 1H), 1.51 – 1.35 ppm (m, 
4H); 13C NMR (101 MHz, C6D6): δ 171.15, 142.79, 139.46, 133.76, 133.28, 132.13, 129.90, 
128.58, 128.17, 128.14, 127.95, 126.24, 126.01, 121.95, 106.71 (d, JRh-C = 3.4 Hz), 106.37 (d, 
JRh-C = 3.7 Hz), 85.61 (d, JRh-C = 4.0 Hz), 85.44 (d, JRh-C = 4.5 Hz), 83.75 (d, JRh-C = 4.0 Hz), 
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61.77, 58.05, 51.25, 43.39, 41.44 (d, JRh-C = 13.5 Hz) ppm; FT-IR: 
~ = 3332, 3053, 2951, 1736, 
1484, 1433, 1199, 1182 cm-1; HRMS: calc. for [M+H]+ C30H30O2N
79BrRh: 618.05095, found: 
618.05210; calc. for [M+H]+ C27H30O2N
81BrRh: 620.04890, found: 620.05016;  RTD = +13.0 
(CH2Cl2, c = 0.50). 
7.2.3 Experiment Details and Analytic Data for Asymmetric Synthesis of Isoquinolones  
7.2.3.1 Reaction Conditions Optimization with Catalyst 99i 
Table S1. Reaction Conditions Optimization with Catalyst 99i. 
 
Entry concentration 
(M) 
temperature t (h) solvent yield(%) ee(%) 
1 0.1 r.t. 4 DCM 90 82 
2 1 r.t. 1 DCM 90 83 
3 1 -10°C 12 DCM 93 90 
4 1 -10°C 24 CHCl3 72 89 
5 1 -10°C 24 DCE 72 90 
6 1 -10°C 24 EtOH 85 87 
7 1 -10°C 24 CH3CN 22 84 
8 1 -10°C 24 Tol 58 87 
9 1 -10°C 24 THF 76 88 
10 1 -10°C 24 Acetone 67 87 
11 1 -10°C 24 Et2O 76 88 
General procedure: optical pure catalyst 99i (2.53 mg, 5.00 μmol, 0.05 equiv.), DBPO (75 wt%, 1.62 mg, 5.00 
μmol, 0.05 equiv.), hydroxamate 9a (0.10 mmol, 2.00 equiv.) were dissolved into 100 μL or 1 mL solvent. After 
stirring at r.t. for 10 mins and/or sequentially cooling to -10°C, corresponding alkenes 10a (0.20 mmol, 2.00 
equiv.) was added and the reaction was stirred for specific time.  
Chapter 7. Experimental Part 
 
142 
 
7.2.3.2 Investigation of Linear Relationship 
Figure S1. Investigation of linear relationship between ee of catalyst and ee of products. 
 
 
Different ee of catalysts were prepared by mixing two enantiomers of catalyst in certain ratio. 
The result reveals its linear relationship, which means chirality transfer (CT) we proposed 
could be regarded to be equal to ee of product when catalyst is optical pure. 
General procedure: catalyst 99i with different ee (2.53 mg, 5.00 μmol, 0.05 equiv.), DBPO 
(75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.), hydroxamates 9a (0.10 mmol, 2.00 equiv.) were 
dissolved into 100 μL DCM. After stirring at r.t. for 10 mins and sequentially cooling to -10°C, 
corresponding alkenes 10a (0.20 mmol, 2.00 equiv.) was added and the reaction was stirred for 
12 hours. 
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7.2.3.3 General Methods and Analytic Data for Synthesis of 11a-11x and 100a-d 
Method I for 11a-11x: 
Without protective precaution from air and moisture, catalyst 99i (2.53 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.), hydroxamates 9 (0.10 
mmol, 1 equiv.) were dissolved into100 μL DCM. The mixture was allowed to be stirred at r.t. 
for 10 mins. After cooling to -10°C, corresponding alkene 10 (0.20 mmol, 2.00 equiv.) was 
added and the reaction was stirred for 12-48 hours. The resulting mixture was purified on a 
silica gel to afford desired product 11a-11n, 11p-11x. For 11o, 1 mL DCM was used as solvent. 
Method J for 105a-105d: 
Procedure for C‒H activation reactions step is the same with method I. After completion of C‒
H activation reactions, 2 mL THF was added and the mixture was allowed to cool to 0°C, then 
t-BuOK (2 equiv., 0.20 mmol) was added. The resulting mixture was purified on a silica gel to 
afford desired product 105a-1005d after 10 min stirring.  
(S)-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
11a: Using Method I, 93% yield; 1H NMR (400 MHz, CDCl3): δ 8.12 (dd, 
J = 7.5, 1.5 Hz, 1H), 7.46 (td, J = 7.5, 1.5 Hz, 1H), 7.42 – 7.32 (m, 6H), 
7.18 (d, J = 7.5 Hz, 1H), 6.06 (s, 1H), 4.86 (ddd, J = 10.9, 4.8, 1.1 Hz, 1H), 
3.21 (dd, J = 15.7, 10.9 Hz, 1H), 3.12 ppm (dd, J = 15.6, 4.8 Hz, 1H); 13C 
NMR (101 MHz, CDCl3): δ 166.47, 141.03, 137.71, 132.70, 129.16, 128.57, 128.40, 128.22, 
127.47, 127.45, 126.56, 56.34, 37.59 ppm; FT‐IR: 
~ = 3204, 3065, 2924, 1652, 1461, 1318 
cm-1; HRMS: calc. for [M+H]+ C15H14NO: 224.10699, found: 224.10738;  RTD = -159.4 
(CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-
hexane = 50/50, flow rate = 0.5 mL min-1, major enantiomer: tR = 50.9 min; minor enantiomer: 
tR = 46.5 min, 90% ee. 
(S)-3-(4-methylphenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11b: Using Method I, 89% yield; 1H NMR (400 MHz, CDCl3): δ 8.12 
(dd, J = 7.5, 1.5 Hz, 1H), 7.46 (td, J = 7.5, 1.5 Hz, 1H), 7.37 (t, J = 7.5 
Hz, 1H), 7.32 – 7.24 (m, 2H), 7.22 – 7.15 (m, 3H), 6.09 (s, 1H), 4.82 
(dd, J = 11.1, 4.6 Hz, 1H), 3.24 – 3.04 (m, 2H), 2.36 ppm (s, 3H); 13C 
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NMR (101 MHz, CDCl3): δ 166.49, 138.35, 138.07, 137.82, 132.61, 129.78, 128.47, 128.19, 
127.45, 127.38, 126.46, 56.05, 37.65, 21.24 ppm; FT‐IR: 
~ = 3194, 3077, 2919, 1653, 1460, 
1386, 1319 cm-1; HRMS: calc. for [M+H]+ C16H16NO: 238.12264, found: 238.12298;  RTD = -
133.0 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) 
/ iso-hexane = 50/50, flow rate = 0.5 mL min-1, major enantiomer: tR = 50.3 min; minor 
enantiomer: tR = 43.4 min, 90% ee. 
(S)-3-(4-(tert-butyl)phenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11c: Using Method I, 86% yield; 1H NMR (400 MHz, CDCl3): δ 8.12 
(dd, J = 7.5, 1.4 Hz, 1H), 7.47 (td, J = 7.5, 1.4 Hz, 1H), 7.43 – 7.35 
(m, 3H), 7.35 – 7.31 (m, 2H), 7.19 (d, J = 7.5 Hz, 1H), 6.10 (s, 1H), 
4.84 (dd, J = 11.4, 4.5 Hz, 1H), 3.21 (dd, J = 15.7, 11.4 Hz, 1H), 3.10 
(dd, J = 15.7, 4.5 Hz, 1H), 1.33 ppm (s, 9H); 13C NMR (101 MHz, CDCl3): δ 166.52, 151.68, 
137.91, 137.79, 132.69, 128.35, 128.22, 127.48, 127.41, 126.28, 126.07, 56.04, 37.56, 34.76, 
31.44 ppm; FT‐IR: 
~ = 3189, 3061, 2960, 1657, 1461, 1387, 1318 cm-1; HRMS: calc. for 
[M+H]+ C19H22NO: 280.16959, found: 280.16990;  RTD = -103.9 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, major enantiomer: tR = 37.4 min; minor enantiomer: tR = 33.6 min, 91% ee. 
(S)-3-(4-methoxyphenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11d: Using Method I, 83% yield; 1H NMR (400 MHz, CDCl3): δ 8.11 
(d, J = 7.4 Hz, 1H), 7.49 – 7.43 (m, 1H), 7.37 (t, J = 7.6 Hz, 1H), 7.34 
– 7.28 (m, 2H), 7.18 (d, J = 7.4 Hz, 1H), 6.94 – 6.87 (m, 2H), 6.02 (s, 
1H), 4.80 (dd, J = 11.2, 4.5 Hz, 1H), 3.81 (s, 3H), 3.19 (dd, J = 15.7, 
11.2 Hz, 1H), 3.07 ppm (dd, J = 15.7, 4.5 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 166.42, 
159.75, 137.86, 133.07, 132.60, 128.50, 128.19, 127.78, 127.45, 127.38, 114.47, 55.78, 55.47, 
37.70 ppm; FT‐IR: 
~ = 3187, 3064, 1659, 1510, 1383, 1247 cm-1; HRMS: calc. for [M+H]+ 
C16H16NO2: 254.11756, found: 254.11823;  RTD = -115.5 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 30/70, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 47.6 min; minor enantiomer: tR = 53.8 min, 90% ee. 
(S)-3-(4-fluorophenyl)-3,4-dihydroisoquinolin-1(2H)-one 
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11e: Using Method I, 87% yield; 1H NMR (400 MHz, CDCl3): δ 8.11 
(dd, J = 7.5, 1.5 Hz, 1H), 7.46 (td, J = 7.5, 1.5 Hz, 1H), 7.41 – 7.33 (m, 
3H), 7.18 (d, J = 7.5 Hz, 1H), 7.11 – 7.03 (m, 2H), 6.14 (s, 1H), 4.85 
(dd, J = 10.0, 5.5 Hz, 1H), 3.22 – 3.03 ppm (m,2H); 13C NMR (101 
MHz, CDCl3): δ 166.40, 162.70 (d, J = 247.3 Hz), 137.45, 136.89 (d, J = 3.2 Hz), 132.74, 
128.37, 128.33, 128.25, 127.85 (d, J = 76.5 Hz), 127.52, 116.05 (d, J = 21.6 Hz), 55.64, 37.62 
ppm; FT‐IR: 
~ = 3194, 3066, 1652, 1602, 1508, 1387, 1223 cm-1; HRMS: calc. for [M+H]+ 
C15H13NOF: 242.09757, found: 242.09803;  RTD = -130.5 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, major enantiomer: tR = 54.6 min; minor enantiomer: tR = 61.6 min, 90% ee. 
(S)-3-(3-methylphenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11f: Using Method I, 72% yield; 1H NMR (400 MHz, CDCl3): δ 8.13 
(dd, J = 7.7, 1.1 Hz, 1H), 7.47 (td, J = 7.5, 1.5 Hz, 1H), 7.38 (t, J = 7.5 
Hz, 1H), 7.31 – 7.25 (m, 1H), 7.24 – 7.13 (m, 4H), 5.99 (s, 1H), 4.82 (dd, 
J = 11.4, 4.5 Hz, 1H), 3.20 (dd, J = 15.6, 11.4 Hz, 1H), 3.10 (dd, J = 15.6, 
4.5 Hz, 1H), 2.37 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ 166.42, 141.03, 138.95, 137.82, 
132.64, 129.30, 129.05, 128.48, 128.22, 127.44, 127.42, 127.25, 123.60, 56.36, 37.69, 21.58 
ppm; FT‐IR: 
~ = 3204, 3068, 1660, 1600, 1463, 1384, 1326, 1155 cm-1; HRMS: calc. for 
[M+H]+ C16H16NO: 238.12264, found: 238.12304;  RTD = -127.6 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, major enantiomer: tR = 52.2 min; minor enantiomer: tR = 43.2 min, 87% ee. 
(S)-3-(3-chlorophenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11g: Using Method I, 78% yield; 1H NMR (400 MHz, CDCl3): δ 8.12 
(d, J = 7.5 Hz, 1H), 7.47 (td, J = 7.5, 1.4 Hz, 1H), 7.42 – 7.35 (m, 2H), 
7.34 – 7.26 (m, 3H), 7.18 (d, J = 7.5 Hz, 1H), 6.05 (s, 1H), 4.88 – 4.81 
(m, 1H), 3.23 – 3.12 ppm (m, 2H); 13C NMR (101 MHz, CDCl3): δ 
166.35, 143.15, 137.22, 135.08, 132.85, 130.49, 128.77, 128.30, 127.62, 127.54, 127.50, 
126.88, 124.69, 55.83, 37.42 ppm; FT‐IR: 
~ = 3185, 3059, 1657, 1602, 1463, 1385, 1322 cm-
1; HRMS: calc. for [M+H]+ C15H13NOCl: 258.06802, found: 258.06850;  RTD = -102.7 
(CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-
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hexane = 50/50, flow rate = 0.5 mL min-1, major enantiomer: tR = 70.5 min; minor enantiomer: 
tR = 57.8 min, 87% ee. 
(S)-3-(2-methylphenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11h: Using Method I, 67% yield; 1H NMR (400 MHz, CDCl3): δ 8.14 (dd, 
J = 7.5, 1.3 Hz, 1H), 7.52 – 7.45 (m, 2H), 7.40 (t, J = 7.5 Hz, 1H), 7.28 – 
7.18 (m, 4H), 5.95 (s, 1H), 5.14 (dd, J = 11.3, 4.6 Hz, 1H), 3.17 (dd, J = 
15.5, 11.3 Hz, 1H), 3.08 (dd, J = 15.5, 4.6 Hz, 1H), 2.39 ppm (s, 3H); 13C 
NMR (101 MHz, CDCl3): δ 166.71, 138.90, 137.85, 135.12, 132.70, 131.10, 128.44, 128.27, 
128.23, 127.49, 127.02, 125.81, 119.03, 52.40, 36.21, 19.28 ppm; FT‐IR: 
~ = 3195, 3064, 
2919, 1661, 1603, 1461, 1383, 1334, 1154 cm-1; HRMS: calc. for [M+H]+ C16H16NO: 
238.12264, found: 128.12318;  RTD = -149.0 (CH2Cl2, c = 1.00); HPLC conditions: 
CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow rate = 0.5 mL min-1, major 
enantiomer: tR = 46.6 min; minor enantiomer: tR = 56.4 min, 92% ee. 
(S)-3-(2-chlorophenyl)-3,4-dihydroisoquinolin-1(2H)-one 
11i: Using Method I, 47% yield; 1H NMR (400 MHz, CDCl3): δ 8.14 (dd, 
J = 7.4, 1.2 Hz, 1H), 7.51 – 7.43 (m, 2H), 7.43 – 7.36 (m, 2H), 7.29 – 7.23 
(m, 2H), 7.18 (d, J = 7.4 Hz, 1H), 6.05 (s, 1H), 5.36 (ddd, J = 9.1, 5.1, 2.0 
Hz, 1H), 3.35 (dd, J = 15.7, 5.1 Hz, 1H), 3.13 ppm (dd, J = 15.7, 9.1 Hz, 
1H); 13C NMR (101 MHz, CDCl3): δ 166.59, 138.45, 137.12, 132.83, 132.66, 130.18, 129.41, 
128.34, 128.21, 127.71, 127.64, 127.53, 127.40, 52.28, 34.96 ppm; FT‐IR: 
~ = 3191, 3079, 
2925, 1666, 1604, 1465, 1391, 1337, 1039 cm-1; HRMS: calc. for [M+H]+ C15H13NOCl: 
258.06802, found: 258.06855;  RTD = -123.0 (CH2Cl2, c = 0.50); HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 46.9 min; minor enantiomer: tR = 43.3 min, 81% ee. 
(S)-3-(naphthalen-2-yl)-3,4-dihydroisoquinolin-1(2H)-one 
11j: Using Method I, 84% yield; 1H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 7.7 Hz, 1H), 7.90 
– 7.79 (m, 4H), 7.54 – 7.43 (m, 4H), 7.38 (t, J = 7.5 Hz, 1H), 7.19 (d, J = 7.7 Hz, 1H), 6.33 (s, 
1H), 5.02 (dd, J = 10.6, 4.9 Hz, 1H), 3.29 (dd, J = 15.7, 10.6 Hz, 1H), 3.20 ppm (dd, J = 15.7, 
4.9 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 166.51, 138.37, 137.60, 133.40, 133.29, 132.68, 
129.06, 128.47, 128.22, 128.06, 127.85, 127.48, 127.44, 126.70, 126.49, 125.57, 124.18, 56.30, 
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37.43 ppm; FT‐IR: 
~ = 3195, 3064, 2919, 1661, 1603, 1461, 1383, 
1334, 1154 cm-1; HRMS: calc. for [M+H]+ C19H16NO: 274.12264, 
found: 274.12327;  RTD = -101.7 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, major enantiomer: tR = 75.6 min; minor enantiomer: tR = 57.6 min, 90% ee. 
(S)-3-(benzofuran-2-yl)-3,4-dihydroisoquinolin-1(2H)-one 
11k: Using Method I, 57% yield; 1H NMR (400 MHz, CDCl3): δ 8.11 
(dd, J = 7.7, 1.0 Hz, 1H), 7.51 – 7.41 (m, 3H), 7.37 (t, J = 7.7 Hz, 1H), 
7.30 – 7.17 (m, 3H), 6.62 – 6.59 (m, 1H), 6.54 (s, 1H), 5.06 (td, J = 6.4, 
1.7 Hz, 1H), 3.44 ppm (d, J = 6.4 Hz, 2H); 13C NMR (101 MHz, 
CDCl3): δ 165.92, 156.24, 155.02, 136.78, 132.89, 128.31, 128.18, 127.96, 127.76, 127.60, 
124.66, 123.18, 121.27, 111.34, 103.80, 49.73, 32.96 ppm; FT‐IR: 
~ = 3191, 3085, 2922, 1672, 
1603, 1454, 1387, 1251, 1171 cm-1; HRMS: calc. for [M+H]+ C17H14NO2: 264.10191, found: 
264.10195;  RTD = -6.4 (CH2Cl2, c = 0.50); HPLC conditions: CHIRAPAK IC column, 
(CH2Cl2/EtOH = 100/2) / iso-hexane = 70/30, flow rate = 0.5 mL min
-1, major enantiomer: tR 
= 39.4 min; minor enantiomer: tR = 27.9 min, 86% ee. 
(S)-3-(benzo[b]thiophen-2-yl)-3,4-dihydroisoquinolin-1(2H)-one 
11l: Using Method I, 50% yield; 1H NMR (400 MHz, CDCl3): δ 8.12 
(dd, J = 7.5, 1.0 Hz, 1H), 7.80 – 7.75 (m, 1H), 7.72 – 7.68 (m, 1H), 7.48 
(td, J = 7.5, 1.5 Hz, 1H), 7.42 – 7.29 (m, 3H), 7.27 – 7.24 (m, 1H), 7.22 
(d, J = 7.5 Hz, 1H), 6.52 (s, 1H), 5.25 – 5.16 (m, 1H), 3.44 – 3.27 ppm 
(m, 2H); 13C NMR (101 MHz, CDCl3): δ 165.93, 144.98, 139.39, 139.26, 137.00, 132.91, 
128.32, 128.24, 127.73, 127.66, 124.84, 124.76, 123.79, 122.60, 122.01, 52.21, 37.10 ppm; 
FT‐IR: 
~ = 3247, 1658, 1636, 1462, 1434, 1381, 1311, 1154 cm-1; HRMS: calc. for [M+H]+ 
C17H14NOS: 280.07906, found: 280.07957;  RTD = -14.3 (CH2Cl2, c = 1.00); HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 70/30, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 38.1 min; minor enantiomer: tR = 28.4 min, 85% ee. 
(3aR,9bR)-1,2,3,3a,4,9b-hexahydro-5H-cyclopenta[c]isoquinolin-5-one 
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11m: Using Method I, 69% yield; 1H NMR (400 MHz, CDCl3): δ 8.09 (dd, J = 
7.5, 1.3 Hz, 1H), 7.45 (td, J = 7.5, 1.3 Hz, 1H), 7.33 (td, J = 7.5, 1.3 Hz, 1H), 
7.23 – 7.19 (m, 1H), 5.95 (s, 1H), 4.19 (td, J = 5.4, 1.3 Hz, 1H), 3.11 (td, J = 
9.1, 5.4 Hz, 1H), 2.23 – 1.98 (m, 2H), 1.99 – 1.88 (m, 1H), 1.87 – 1.69 ppm (m, 
3H); 13C NMR (101 MHz, CDCl3): δ 165.52, 141.74, 132.45, 128.32, 127.63, 127.02, 126.57, 
56.16, 43.20, 34.58, 33.58, 23.15 ppm; FT‐IR: 
~ = 3184, 2955, 1659, 1603, 1460, 1402, 1329 
cm-1; HRMS: calc. for [M+H]+ C12H14NO: 188.10669, found: 188.10731;  RTD = -62.7 
(CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
15/85, flow rate = 0.5 mL min-1, major enantiomer: tR = 49.0 min; minor enantiomer: tR = 75.2 
min, 88% ee. 
(4aR,10bR)-1,4a,5,10b-tetrahydrophenanthridin-6(2H)-one 
11n: Using Method I, 80% yield; 1H NMR (400 MHz, CDCl3): δ 8.12 – 8.02 
(m, 1H), 7.53 – 7.44 (m, 1H), 7.35 (td, J = 7.5, 1.1 Hz, 1H), 7.27 – 7.20 (m, 
1H), 6.03 (dt, J = 9.8, 3.7 Hz, 1H), 5.93 (s, 1H), 5.84 – 5.73 (m, 1H), 4.27 (t, J 
= 4.4 Hz, 1H), 2.94 (dt, J = 12.2, 3.8 Hz, 1H), 2.26 – 2.13 (m, 2H), 2.09 – 1.90 
(m, 1H), 1.79 – 1.62 ppm (m, 1H); 13C NMR (101 MHz, CDCl3): δ 165.07, 142.90, 132.65, 
132.50, 128.17, 127.66, 127.35, 127.24, 124.54, 48.13, 37.98, 25.33, 25.17 ppm; FT‐IR: 
~ = 
3177, 3026, 2917, 1661, 1602, 1466, 1401, 1293, 1168 cm-1; HRMS: calc. for [M+H]+ 
C13H14NO: 200.10699, found: 200.10794;  RTD = -53.2 (CH2Cl2, c = 1.00); HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 70/30, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 39.9 min; minor enantiomer: tR = 45.8 min, 84% ee. 
(3aR,9bR)-1,3a,4,9b-tetrahydrofuro[2,3-c]isoquinolin-5(2H)-one 
11o: Using Method I, 85% yield; 1H NMR (400 MHz, CDCl3): δ 8.16 (d, J = 
7.4 Hz, 1H), 7.58 (td, J = 7.4, 1.5 Hz, 1H), 7.53 – 7.45 (m, 2H), 6.62 (s, 1H), 
4.84 (d, J = 4.6 Hz, 1H), 4.36 (d, J = 4.6 Hz, 1H), 4.13 – 3.96 (m, 2H), 2.50 – 
2.38 (m, 1H), 2.22 – 2.12 ppm (m, 1H); 13C NMR (101 MHz, CDCl3): δ 164.67, 
135.50, 132.90, 129.51, 129.14, 128.20, 127.34, 75.33, 66.73, 54.46, 35.17 ppm; FT‐IR: 
~ = 
3194, 3073, 2925, 1657, 1638, 1412, 1334, 1038 cm-1; HRMS: calc. for [M+H]+ C11H12NO2: 
190.08626, found: 190.08693;  RTD = +9.6 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK 
IC column, iso-propanol / iso-hexane = 30/70, flow rate = 0.5 mL min-1, major enantiomer: tR 
= 41.5 min; minor enantiomer: tR = 82.0 min, 91% ee. 
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(S)-6-methyl-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
11p: Using Method I, 84% yield; 1H NMR (400 MHz, CDCl3): δ 8.00 (d, 
J = 7.9 Hz, 1H), 7.41 – 7.31 (m, 6H), 7.18 (d, J = 7.9 Hz, 1H), 6.99 (s, 
1H), 6.07 (s, 1H), 4.84 (dd, J = 10.8, 4.9 Hz, 1H), 3.16 (dd, J = 15.7, 10.8 
Hz, 1H), 3.08 (dd, J = 15.7, 4.9 Hz, 1H), 2.38 ppm (s, 3H); 13C NMR 
(101 MHz, CDCl3): 166.69, 143.38, 141.14, 137.69, 129.13, 128.50, 128.27, 128.09, 126.54, 
125.70, 56.38, 37.56, 21.75 ppm; FT‐IR: 
~ = 3182, 3067, 2920, 1655, 1610, 1454, 1382, 1332, 
1309 cm-1; HRMS: calc. for [M+H]+ C16H16NO: 238.12264, found: 238.12305;  RTD = -117.8 
(CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-
hexane = 50/50, flow rate = 0.5 mL min-1, major enantiomer: tR = 58.8 min; minor enantiomer: 
tR = 54.0 min, 92% ee. 
(S)-6-methoxy-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
11q: Using Method I, 72% yield; 1H NMR (400 MHz, CDCl3): δ 8.07 
(d, J = 8.6 Hz, 1H), 7.42 – 7.30 (m, 5H), 6.88 (dd, J = 8.6, 2.5 Hz, 
1H), 6.66 (d, J = 2.5 Hz, 1H), 5.93 (s, 1H), 4.84 (dd, J = 10.9, 4.8 Hz, 
1H), 3.84 (s, 3H), 3.17 (dd, J = 15.6, 10.9 Hz, 1H), 3.08 ppm (dd, J = 
15.6, 4.8 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 166.50, 163.09, 141.16, 139.85, 130.38, 
129.13, 128.51, 126.55, 121.23, 112.81, 112.61, 56.35, 55.56, 37.92 ppm; FT‐IR: 
~ = 3175, 
3063, 2925, 1650, 1600, 1454, 1384, 1320, 1253, 1085, 1025 cm-1; HRMS: calc. for [M+H]+ 
C16H16NO2: 254.11756, found: 254.11800;  RTD = -108.4 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 70/30, flow rate = 
0.5 mL min-1, major enantiomer: tR = 38.9 min; minor enantiomer: tR = 37.2 min, 91% ee. 
(S)-6-chloro-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
11r: Using Method I, 93% yield; 1H NMR (400 MHz, CDCl3): δ 8.05 
(d, J = 8.3 Hz, 1H), 7.42 – 7.31 (m, 6H), 7.18 (d, J = 1.1 Hz, 1H), 6.16 
(s, 1H), 4.85 (dd, J = 10.4, 5.1 Hz, 1H), 3.18 (dd, J = 15.8, 10.4 Hz, 
1H), 3.11 ppm (dd, J = 15.8, 5.1 Hz, 1H); 13C NMR (101 MHz, CDCl3): 
δ  165.61, 140.57, 139.34, 138.80, 129.83, 129.23, 128.70, 127.83, 127.55, 126.90, 126.50, 
56.10, 37.27 ppm; FT‐IR: 
~ = 3204, 3080, 1652, 1594, 1459, 1422, 1334, 1294 cm-1; HRMS: 
calc. for [M+H]+ C15H13NOCl: 258.06802, found: 258.06842;  RTD = -116.4 (CH2Cl2, c = 
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1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow rate 
= 0.5 mL min-1, major enantiomer: tR = 36.8 min; minor enantiomer: tR = 38.8 min, 93% ee. 
(S)-6-fluoro-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
11s: Using Method I, 87% yield; 1H NMR (400 MHz, CDCl3): δ 8.13 
(dd, J = 8.6, 5.8 Hz, 1H), 7.46 – 7.29 (m, 5H), 7.05 (td, J = 8.7, 2.5 Hz, 
1H), 6.88 (dd, J = 8.7, 2.5 Hz, 1H), 6.08 (s, 1H), 4.86 (dd, J = 10.7, 4.9 
Hz, 1H), 3.20 (dd, J = 15.9, 10.7 Hz, 1H), 3.12 ppm (dd, J = 15.9, 4.9 
Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 165.61, 165.37 (d, J = 253.6 Hz), 140.66, 140.54 (d, 
J = 9.0 Hz), 131.06 (d, J = 9.6 Hz), 129.23, 128.70, 126.52, 124.79 (d, J = 2.8 Hz), 114.72 (d, 
J = 21.8 Hz), 114.36 (d, J = 22.1 Hz), 56.19, 37.57 ppm; FT‐IR: 
~ = 3210, 3067, 1651, 1605, 
1490, 1455, 1380, 1309, 1248 cm-1; HRMS: calc. for [M+H]+ C15H13NOF: 242.09757, found: 
242.09797;  RTD = -130.8 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, 
(CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 0.5 mL min
-1, major enantiomer: tR 
= 44.8 min; minor enantiomer: tR = 42.8 min, 87% ee. 
(S)-6-nitro-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one 
11t: Using Method I, 82% yield; 1H NMR (400 MHz, CDCl3): δ 8.30 
(d, J = 8.5 Hz, 1H), 8.25 – 8.19 (m, 1H), 8.07 (d, J = 1.9 Hz, 1H), 7.47 
– 7.34 (m, 5H), 6.23 (s, 1H), 4.92 (t, J = 7.7 Hz, 1H), 3.30 ppm (d, J = 
7.7 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 164.23, 150.27, 139.98, 
139.18, 133.71, 129.75, 129.40, 129.00, 126.47, 122.71, 122.45, 55.94, 37.31 ppm; FT‐IR: 
~
= 3198, 3062, 1668, 1616, 1520, 1457, 1393, 1346, 1159 cm-1; HRMS: calc. for [M+H]+ 
C15H13N2O3: 269.09207, found: 269.09237;  RTD = -99.5 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IA column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, major enantiomer: tR = 34.0 min; minor enantiomer: tR = 39.8 min, 87% ee. 
(S)-7-methyl-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (major),  
(S)-5-methyl-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (minor). 
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11u: Using Method I, 82% yield; two 
inseparable isomers with r.r. = 67:33, 
determined by NMR; For major product, 1H 
NMR (400 MHz, CDCl3): δ 7.94 (s, 1H), 7.49 
– 7.27 (m, 6H), 7.06 (t, J = 9.4 Hz, 1H), 6.01 (s, 1H), 4.83 (dd, J = 10.8, 5.0 Hz, 1H), 3.19 – 
3.07 (m, 1H), 2.39 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ 166.70, 141.16, 137.23, 
134.72, 133.47, 129.14, 128.57, 128.52, 128.13, 127.39, 126.56, 56.47, 37.25, 21.20 ppm; FT‐
IR: 
~ = 3193, 3059, 2917, 1657, 1613, 1494, 1409, 1333, 1314, 1144 cm-1; HRMS: calc. for 
[M+H]+ C16H16NO: 238.12264,  found: 238.12315;  RTD = -132.4 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, for major regioisomer: major enantiomer: tR = 54.9 min; minor enantiomer: tR = 
52.5 min; For minor regioisomer: major enantiomer: tR = 61.7 min; minor enantiomer: tR = 
58.6 min, 85% ee for major isomer, 82% ee for minor isomer. 
(S)-6,7-dimethoxy-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (major),  
(S)-5,6-dimethoxy-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (minor). 
11v: Using Method I, 42% yield; two 
separable isomers with r.r. = 91:9, 
determined by NMR; For major product, 1H 
NMR (400 MHz, CDCl3): δ 7.62 (s, 1H), 
7.42 – 7.33 (m, 5H), 6.63 (s, 1H), 6.09 (s, 
1H), 4.85 (dd, J = 10.4, 5.0 Hz, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.13 (d, J = 10.4 Hz, 1H), 3.08 
(d, J = 5.0 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 166.72, 152.82, 148.41, 141.08, 131.56, 
129.15, 128.54, 126.55, 120.64, 110.33, 109.79, 56.61, 56.30, 56.22, 37.17 ppm; FT‐IR: 
~ = 
3203, 2939, 1655, 1601, 1510, 1454, 1373, 1332, 1261, 1217, 1070 cm-1; HRMS: calc. for 
[M+H]+ C17H18NO3: 284.12812, found: 284.12850;  RTD = -6.4 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 30/70, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 69.4 min; minor enantiomer: tR = 85.7 min, 85% ee for major 
isomer. 
(S)-7-bromo-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (minor), 
(S)-5-bromo-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (major). 
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11w: Using Method I, 93% yield; two 
separable isomers with r.r. = 16:84, 
determined by NMR; For major product, 1H 
NMR (400 MHz, CDCl3): δ 8.12 (dd, J = 7.7, 
1.2 Hz, 1H), 7.72 (dd, J = 8.0, 1.2 Hz, 1H), 
7.47 – 7.32 (m, 5H), 7.30 – 7.21 (m, 1H), 6.05 (s, 1H), 4.85 (dd, J = 11.5, 4.5 Hz, 1H), 3.42 
(dd, J = 16.3, 4.5 Hz, 1H), 3.12 ppm (dd, J = 16.3, 11.5 Hz, 1H); 13C NMR (101 MHz, CDCl3): 
δ 165.50, 140.64, 137.45, 136.58, 130.45, 129.30, 128.82, 128.54, 127.64, 126.64, 123.18, 
55.65, 37.42 ppm; FT‐IR: 
~ = 3180, 3068, 1667, 1592, 1560, 1452, 1386, 1314, 1105 cm-1; 
HRMS: calcd. for [M+H]+ C15H33
79BrNO: 302.01750, found: 302.01807; calcd. for [M+H]+ 
C15H13
81BrNO: 304.01546, found: 304.01591;  RTD = -93.8 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 10/90, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 54.5 min; minor enantiomer: tR = 56.7 min, 83% ee for major 
isomer. 
(S)-7-fluoro-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (minor), 
(S)-5-fluoro-3-phenyl-3,4-dihydroisoquinolin-1(2H)-one (major). 
11x: Using Method I, 87% yield; two separable 
isomers with r.r. = 9:91, determined by NMR; 
For major product, 1H NMR (400 MHz, 
CDCl3): δ 7.94 (d, J = 7.7 Hz, 1H), 7.46 – 7.28 
(m, 6H), 7.25 – 7.13 (m, 2 6261H), 6.07 (s, 1H), 
4.85 (dd, J = 11.3, 4.5 Hz, 1H), 3.34 (dd, J = 16.2, 4.5 Hz, 1H), 3.04 ppm (dd, J = 16.2, 11.3 
Hz, 1H); 13C NMR (101 MHz, CDCl3): δ 165.61, 165.37 (d, J = 253.6 Hz), 140.64, 130.36, 
129.27, 128.78, 128.27 (d, J = 7.9 Hz), 126.56, 124.76 (d, J = 18.2 Hz), 123.92 (d, J = 3.3 Hz), 
119.38 (d, J = 21.7 Hz), 55.85, 30.02 ppm; FT‐IR: 
~ = 3196, 3070, 1655, 1615, 1579, 1469, 
1380, 1321, 1239, 1062 cm-1; HRMS: calc. for [M+H]+ C15H13NOF: 242.09757, found: 
242.09815;  RTD = -139.8 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, 
(CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 0.5 mL min
-1, major enantiomer: tR 
= 35.5 min; minor enantiomer: tR = 33.9 min, 90% ee for major isomer. 
(S)-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-one 
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105a: Using Method J, 76% yield; 1H NMR (400 MHz, CDCl3): δ 8.15 (dd, J = 7.5, 1.5 Hz, 
1H), 7.47 (td, J = 7.5, 1.5 Hz, 1H), 7.39 (t, J = 7.5 Hz, 1H), 7.30 – 7.20 (m, 5H), 5.03 – 4.90 
(m, 2H), 3.26 (dd, J = 15.7, 3.7 Hz, 1H), 3.08 – 2.96 (m, 3H), 2.93 – 2.82 ppm (m, 1H); 13C 
NMR (101 MHz, CDCl3): δ 164.70, 137.47, 136.08, 135.22, 131.93, 
129.21, 129.13, 128.72, 127.46, 127.01, 126.99, 126.87, 126.08, 55.35, 
38.83, 38.02, 29.87 ppm; FT‐IR: 
~ = 2933, 2886, 1637, 1600, 1579, 1463, 
1402, 1363, 1287, 1149 cm-1; HRMS: calc. for [M+H]+ C17H16NO: 
250.12264, found: 250.12292;  RTD = -440.4 (CH2Cl2, c = 2.00); HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 32.6 min; minor enantiomer: tR = 31.6 min, 97% ee. 
(S)-5,6,13,13a-tetrahydro-8H-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-8-one 
105b: Using Method J, 55% yield; 1H NMR (400 MHz, CDCl3): δ 8.13 
(dd, J = 7.5, 1.3 Hz, 1H), 7.46 (td, J = 7.5, 1.5 Hz, 1H), 7.38 (t, J = 7.5 
Hz, 1H), 7.27 – 7.21 (m, 1H), 6.71 (s, 1H), 6.67 (s, 1H), 5.96 (s, 2H), 
4.97 – 4.90 (m, 1H), 4.83 (dd, J = 13.3, 3.6 Hz, 1H), 3.18 (dd, J = 15.7, 
3.6 Hz, 1H), 3.02 – 2.86 (m, 3H), 2.81 – 2.68 ppm (m, 1H); 13C NMR 
(101 MHz, CDCl3): δ 164.68, 146.89, 146.71, 137.37, 131.96, 129.19, 129.00, 128.73, 128.69, 
127.49, 127.02, 108.82, 106.02, 101.25, 55.44, 38.93, 38.27, 29.83 ppm; FT‐IR: 
~ = 2889, 
2865, 1633, 1602, 1577, 1484, 1461, 1413. 1238, 1028 cm-1; HRMS: calc. for [M+H]+ 
C18H16NO3: 294.11247, found: 294.11306;  RTD = -200.2 (CH2Cl2, c = 1.00); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 
0.5 mL min-1, major enantiomer: tR = 47.6 min; minor enantiomer: tR = 41.0 min, 97% ee. 
(S)-2,3-dimethoxy-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-one 
105c: Using Method J, 71% yield; 1H NMR (400 MHz, CDCl3): δ 8.14 
(dd, J = 7.7, 1.4 Hz, 1H), 7.46 (td, J = 7.4, 1.4 Hz, 1H), 7.38 (t, J = 7.4 
Hz, 1H), 7.29 – 7.22 (m, 1H), 6.72 (s, 1H), 6.69 (s, 1H), 5.03 – 4.95 (m, 
1H), 4.86 (dd, J = 13.4, 3.7 Hz, 1H), 3.91 (s, 3H), 3.89 (s, 3H), 3.21 (dd, 
J = 15.7, 3.6 Hz, 1H), 3.02 – 2.90 (m, 3H), 2.81 – 2.72 ppm (m, 1H); 13C 
NMR (101 MHz, CDCl3): δ 164.75, 148.20, 148.15, 137.42, 131.91, 129.24, 128.73, 127.80, 
127.47, 127.46, 126.97, 111.66, 109.06, 56.33, 56.09, 55.14, 38.88, 38.27, 29.36 ppm; FT‐IR: 
~ = 2927, 2858, 1644, 1602, 1580, 1516, 1460, 1399, 1285, 1202, 1112, 1022 cm-1; HRMS: 
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calc. for [M+H]+ C19H20NO3: 310.14377, found: 310.14441;  RTD = -353.6 (CH2Cl2, c = 1.00); 
HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 40/60, flow rate = 0.5 
mL min-1, major enantiomer: tR = 34.6 min; minor enantiomer: tR = 30.5 min, 95% ee. 
(S)-2,3,10,11-tetramethoxy-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-
one (major),  
(S)-2,3,11,12-tetramethoxy-5,6,13,13a-tetrahydro-8H-isoquinolino[3,2-a]isoquinolin-8-
one (minor). 
105d: Using Method J, 46% yield in one 
pot; two inseparable isomers with r.r. = 
88:12, determined by NMR; Major 
product, 1H NMR (400 MHz, CDCl3): δ 
7.65 (s, 1H), 6.72 (s, 1H), 6.71 (s, 1H), 
6.69 (s, 1H), 4.98 (dd, J = 8.0, 2.6 Hz, 
1H), 4.84 (dd, J = 13.7, 3.9 Hz, 1H), 3.95 (s, 3H), 3.94 (s, 3H), 3.91 (s, 3H), 3.90 (s, 3H), 3.14 
(dd, J = 15.6, 3.9 Hz, 1H), 2.97 – 2.90 (m, 3H), 2.81 – 2.73 (m, 1H); 13C NMR (101 MHz, 
CDCl3): δ 164.87, 152.09, 148.42, 148.18, 148.14, 131.12, 127.95, 127.55, 121.86, 111.67, 
110.96, 109.36, 109.01, 56.31, 56.22, 56.10, 55.45, 38.88, 37.86, 29.43 ppm; FT‐IR: 
~ = 2932, 
2837, 1644, 1602, 1514, 1455, 1429, 1256, 1221, 1098 cm-1; HRMS: calc. for [M+H]+ 
C21H24NO5: 370.16490, found: 370.16608;  RTD = -191.4 (CH2Cl2, c = 0.50); HPLC 
conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 70/30, flow rate = 
0.5 mL min-1, major enantiomer: tR = 30.2 min; minor enantiomer: tR = 41.9 min, 91% ee. 
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7.2.4 Experiment Details and Analytic Data for Asymmetric C‒H Allylations of 
Benzamides 
7.2.4.1 Reaction Conditions Optimization with Catalyst 100l 
Table S2. Reaction Conditions Optimization with Catalyst 100l. 
 
Entry solvent temperature(
o
C) t(h
) 
yield(%) ee(%) 
1 0.5 mL DCM -20 18  79 87 
2 0.1 mL DCM -20 18  82 88 
3 0.1 mL DCM -40 18  28 87 
4 0.1 mL MeOH -20 18  44 90 
5 0.1 mL Tol -20 18  19 85 
6 0.1 mL MeOH -20 36  79 90 
7 0.1 mL MeOH -10 18  60 90 
8 0.1 mL EtOH -20 18 79 91 
9 0.1 mL iPrOH -20 18  66 90 
10 0.48 mL DCM/0.02 mL EtOH -20 18  82 87 
11 0.4 mL DCM/0.1 mL EtOH -20 18 63 89 
12 0.25 mL DCM/0.25 mL EtOH -20 18 65 91 
13 0.48 mL DCM/0.02 mL TFE -20 18 85 89 
14 0.48 mL DCM/0.02 mL HFIP -20 18 85 87 
15 0.2 mL TFE -20 18 63 88 
16 0.45 mL DCM/0.05 mL TFE -20 18 57 89 
17 0.4 mL DCM/0.1 mL TFE -20 18 85 90 
18 0.35 DCM/0.15 mL TFE -20 18 63 89 
19 0.3 mL DCM/0.2 mL TFE -20 18 72 89 
20 0.48 mL DCM/0.02 mL EtOH -20 18 82 87 
General method: Catalyst 100l (5.00 μmol, 0.05 equiv.), dibenzoylperoxide (75 wt%, 5.00 μmol, 0.05 equiv.) 
and 26a (0.12 mmol, 1.20 equiv.) were dissolved into solvent. The mixture was allowed to be stirred at r.t. for 10 
mins. After cooling to certain temperature, corresponding allene 27a (0.1 mmol, 1.00 equiv.) was added. 
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7.2.4.2 General Methods and Analytic Data for Synthesis of 28a-28k 
Method K for Synthesis of Compounds 28a-28d, 28i, 28j: 
Without protective precaution from air and moisture, catalyst 100l (2.93 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.) and 26 (0.12 mmol, 1.20 
equiv.) were dissolved into 0.4 mL DCM: 0.1 mL TFE. The mixture was allowed to be stirred 
at r.t. for 10 mins. After cooling to -20°C, corresponding allenes 27 (0.1 mmol, 1.00 equiv.) 
was added and the reaction was stirred for 18 hours. The resulting mixture was subjected on a 
silica gel to afford desired products. 
Method L for Synthesis of Compounds 28e-28h: 
Without protective precaution from air and moisture, catalyst 100l (2.93 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.) and 26 (0.10 mmol, 1.00 
equiv.) were dissolved into 0.4 mL DCM: 0.1 mL TFE. The mixture was allowed to be stirred 
at r.t. for 10 mins. After cooling to -20°C, corresponding allene 27 (0.12 mmol, 1.20 equiv.) 
was added and the reaction was stirred for 18 hours. The resulting mixture was subjected on a 
silica gel to afford desired product 28e-28h. 
Method M for Synthesis of Compounds 28k: 
Without protective precaution from air and moisture, catalyst 100l (2.93 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.) and 7 (0.12 mmol, 1.20 
equiv.) were dissolved into 0.08 mL DCM: 0.02 mL TFE. The mixture was allowed to be 
stirred at r.t. for 10 mins. After cooling to -20°C, corresponding allene (0.10 mmol, 1.00 equiv.) 
was added and the reaction was stirred for 18 hours. The resulting mixture was subjected on a 
silica gel to afford desired product 28k. 
(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxybenzamide 
28a: Using method K, 85% yield; 1H NMR (400 MHz, CDCl3): δ 9.64 (br 
s, 1H), 7.46 – 7.36 (m, 2H), 7.30 (d, J = 7.5 Hz, 1H), 7.21 (td, J = 7.5, 1.1 
Hz, 1H), 5.15 (d, J = 9.3 Hz, 1H), 4.22 – 4.05 (m, 1H), 3.89 (s, 3H), 3.38 – 
3.30 (m, 1H), 3.27 (s, 3H), 3.26 – 3.19 (m, 1H), 2.28 – 1.85 (m, 6H), 1.59 
– 1.40 ppm (m, 6H); 13C NMR (101 MHz, CDCl3): δ 167.83, 142.68, 140.77, 133.29, 130.80, 
128.89, 127.31, 126.18, 125.20, 70.42, 64.45, 58.27, 37.30, 36.72, 35.68, 29.30, 28.66, 27.85, 
26.87 ppm; FT‐IR: 
~ = 3191, 2925, 2852, 1653, 1599, 1445, 1387, 1303, 1114, 1033  cm-1; 
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HRMS: calc. for [M+H]+ C19H28O3N: 318.20637, found: 318.20670;  RTD = +10.6 (CH2Cl2, c 
= 1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow 
rate = 0.5 mL min-1, major enantiomer: tR = 43.1 min; minor enantiomer: tR = 40.0 min, 90% 
ee. 
(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxy-4-(trifluoromethyl) 
benzamide 
28b: Using method K, 91% yield; 1H NMR (400 MHz, CDCl3): δ 9.85 
(br s, 1H), 7.59 – 7.52 (m, 2H), 7.51 – 7.45 (m, 1H), 5.12 (d, J = 9.2 
Hz, 1H), 4.20 (dd, J = 15.7, 9.2 Hz, 1H), 3.91 (s, 3H), 3.38 (dt, J = 
10.1, 5.1 Hz, 1H), 3.28 (s, 3H), 3.20 (td, J = 9.5, 4.2 Hz, 1H), 2.23 – 
2.17  (m, 1H), 2.14 – 1.96 (m, 4H), 1.96 – 1.85 (m, 1H), 1.50 – 1.46 ppm (m, J = 6.0 Hz, 6H); 
13C NMR (101 MHz, CDCl3): δ 166.57, 143.71, 141.93, 136.70, 132.75 (q, J = 32.1 Hz), 
129.71, 124.28 (q, J = 3.4 Hz), 124.21, 123.88 (q, J = 272.6 Hz), 123.09 (q, J = 3.4 Hz), 70.15, 
64.55, 58.28, 37.25, 36.60, 35.81, 29.37, 28.62, 27.82, 26.79 ppm; FT‐IR: 
~ = 3189, 2928, 
1657, 1447, 1328, 1167, 1122, 1077 cm-1; HRMS: calc. for [M+H]+ C20H27O3NF3: 386.19375, 
found: 386.19481;  RTD = +5.8 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, 
iso-propanol / iso-hexane = 15/85, flow rate = 0.5 mL min-1, major enantiomer: tR = 11.4 min; 
minor enantiomer: tR = 12.3 min, 91% ee. 
(R)-4-bromo-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxybenzamide 
28c: Using method K, 78% yield; 1H NMR (400 MHz, CDCl3): δ 9.81 
(br s, 1H), 7.41 (d, J = 1.4 Hz, 1H), 7.38 – 7.29 (m, 2H), 5.09 (d, J = 9.2 
Hz, 1H), 4.24 – 4.05 (m, 1H), 3.88 (s, 3H), 3.43 – 3.32 (m, 1H), 3.28 (s, 
3H), 3.27 – 3.19 (m, 1H), 2.27 – 2.14 (m, 1H), 2.11 – 1.94 (m, 4H), 1.93 
– 1.79 (m, 1H), 1.62 – 1.37 ppm (m, J = 20.6 Hz, 6H); 13C NMR (101 MHz, CDCl3): δ 166.78, 
144.96, 141.64, 132.21, 130.73, 130.51, 129.50, 125.28, 124.40, 70.20, 64.46, 58.31, 37.25, 
36.61, 35.66, 29.35, 28.62, 27.82, 26.81 ppm; FT‐IR: 
~ = 3185, 2925, 2852, 1653, 1584, 1391, 
1115, 1034 cm-1; HRMS: calcd. for [M+H]+ C19H27O3N
79Br: 396.11688, found: 396.11713; 
calcd. for [M+H]+ C19H27O3N
81Br: 398.11484, found: 398.11499;  RTD = -50.8 (CH2Cl2, c = 
2.00); HPLC conditions: CHIRAPAK IA column, iso-propanol / iso-hexane = 10/90, flow rate 
= 0.5 mL min-1, major enantiomer: tR = 29.0 min; minor enantiomer: tR = 18.1 min, 91% ee. 
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(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N,4-dimethoxybenzamide 
28d: Using method K, 86% yield; 1H NMR (400 MHz, CDCl3): δ 7.41 
(d, J = 8.5 Hz, 1H), 6.79 (d, J = 2.5 Hz, 1H), 6.73 (dd, J = 8.5, 2.5 Hz, 
1H), 5.12 (d, J = 9.3 Hz, 1H), 4.25 – 4.13 (m, 1H), 3.87 (s, 3H), 3.80 
(s, 3H), 3.38 – 3.30 (m, 1H), 3.28 (s, 3H), 3.27 – 3.20 (m, 1H), 2.28 – 
1.82 (m, 6H), 1.58 – 1.36 ppm (m, 6H); 13C NMR (101 MHz, CDCl3): δ 167.62, 161.44, 145.02, 
140.90, 130.73, 125.86, 125.11, 113.11, 111.18, 70.42, 64.37, 58.31, 55.38, 37.26, 36.77, 
35.56, 29.32, 28.65, 27.83, 26.85 ppm; FT‐IR: 
~ = 3190, 2925, 2851, 1651, 1601, 1570, 1446, 
1237, 1103, 1027 cm-1; HRMS: calc. for [M+H]+ C20H30O4N: 348.21693, found: 348.21759; 
 RTD = -26.9 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-
hexane = 30/70, flow rate = 0.5 mL min-1, major enantiomer: tR = 26.5 min; minor enantiomer: 
tR = 24.0 min, 91% ee. 
(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxy-5-methylbenzamide (major), 
(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxy-3-methylbenzamide (minor). 
28e: Using method L, 81% yield; r.r. = 88:12; 
1H NMR (400 MHz, CDCl3): δ 9.70 (br s, 1H), 
7.27 – 7.23 (m, 1H), 7.23 – 7.16 (m, 2H), 5.12 
(d, J = 9.3 Hz, 1H), 4.18 – 4.02 (m, 1H), 3.89 
(s, 3H), 3.33 (dt, J = 10.2, 5.3 Hz, 1H), 3.28 
(s, 3H), 3.26 – 3.19 (m, 1H), 2.31 (s, 3H), 2.24 – 1.82 (m, 6H), 1.56 – 1.37 ppm (m, 6H); 13C 
NMR (101 MHz, CDCl3): δ 167.91, 140.44, 139.42, 135.86, 133.13, 131.69, 129.34, 127.18, 
125.45, 70.42, 64.42, 58.25, 37.29, 36.64, 35.26, 29.28, 28.65, 27.85, 26.88, 20.91  ppm; FT‐
IR: 
~ = 3200, 2925, 2852, 1652, 1446, 1114, 1038 cm-1; HRMS: calc. for [M+H]+ C20H30O3N: 
332.22202, found: 332.22293;  RTD = +6.3 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK 
IC column, iso-propanol / iso-hexane = 15/85, flow rate = 0.5 mL min-1, major enantiomer: tR 
= 39.7 min; minor enantiomer: tR = 34.5 min, 87% ee for major isomer. 
(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxy-5-(trifluoromethyl) 
benzamide 
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28f: Using method L, 67% yield; 1H NMR (400 MHz, CDCl3): δ 9.93 
(br s, 1H), 7.71 (s, 1H), 7.63 (dd, J = 8.3, 1.7 Hz, 1H), 7.42 (d, J = 8.3 
Hz, 1H), 5.11 (d, J = 9.2 Hz, 1H), 4.27 – 4.14 (m, 1H), 3.90 (s, 3H), 
3.42 – 3.32 (m, 1H), 3.27 (s, 3H), 3.20 (td, J = 9.6, 4.5 Hz, 1H), 2.25 – 
1.85 (m, 6H), 1.56 – 1.40 ppm (m, 6H); 13C NMR (101 MHz, CDCl3): δ 166.35, 146.81, 141.93, 
133.89, 128.64 (q, J = 33.0 Hz),  128.07, 127.35 (q, J = 3.4 Hz), 126.21 (q, J = 3.4 Hz), 124.16, 
123.85 (q, J = 272.0 Hz), 70.15, 64.49, 58.29, 37.27, 36.57, 35.84, 29.34, 28.59, 27.79, 26.77 
ppm; FT‐IR: 
~ = 3183, 2928, 2853, 1654, 1447, 1336, 1271, 1120 cm-1; HRMS: calc. for 
[M+H]+ C20H27O3NF3: 386.19375, found: 386.19501;  RTD = +10.9 (CH2Cl2, c = 2.00); HPLC 
conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 10/90, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 16.9 min; minor enantiomer: tR = 15.7 min, 88% ee. 
(R)-2-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxy-6-methylbenzamide 
28g: Using method L, 91% yield; 1H NMR (400 MHz, CDCl3): δ 9.22 (br 
s, 1H), 7.29 – 7.22 (m, 1H), 7.11 (d, J = 7.7 Hz, 1H), 7.03 (d, J = 7.7 Hz, 
1H), 5.13 (d, J = 9.6 Hz, 1H), 3.91 (s, 3H), 3.88 – 3.79 (m, 1H), 3.40 – 3.16 
(m, 5H), 2.35 (s, 3H), 2.28 – 2.18 (m, 1H), 2.16 – 1.82 (m, 5H), 1.63 – 1.37 
ppm (m, 6H); 13C NMR (101 MHz, CDCl3): δ 168.18, 142.26, 140.36, 136.33, 133.41, 129.89, 
127.93, 125.12, 124.18, 70.39, 64.33, 58.12, 37.39, 36.78, 36.54, 29.16, 28.66, 27.90, 26.91, 
19.47 ppm; FT‐IR: 
~ = 3174, 2927, 2850, 1642, 1594, 1497, 1463, 1150, 1032 cm-1; HRMS: 
calc. for [M+H]+ C20H30O3N: 332.22202, found: 332.22253;  RTD = +2.6 (CH2Cl2, c = 2.00); 
HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow rate = 0.5 
mL min-1, major enantiomer: tR = 30.2 min; minor enantiomer: tR = 25.5 min, 88% ee. 
(R)-2-chloro-6-(1-cyclohexylidene-4-methoxybutan-2-yl)-N-methoxybenzamide 
28h: Using method L, 71% yield; 1H NMR (400 MHz, CDCl3): δ 9.04 (br 
s, 1H), 7.34 – 7.27 (m, 1H), 7.24 – 7.19 (m, 2H), 5.10 (d, J = 9.4 Hz, 1H), 
3.93 (s, 3H), 3.89 – 3.78 (m, 1H), 3.39 – 3.26 (m, 2H), 3.25 (s, 3H), 2.29 – 
2.17 (m, 1H), 2.15 – 1.97 (m, 3H), 1.95 – 1.82 (m, 2H), 1.59 – 1.39 ppm 
(m, 6H); 13C NMR (101 MHz, CDCl3): δ 165.10, 145.56, 141.39, 132.62, 132.16, 131.03, 
127.23, 125.50, 124.09, 70.35, 64.46, 58.22, 37.41, 37.00, 36.92, 29.21, 28.67, 27.84, 26.86 
ppm; FT‐IR: 
~ = 3176, 2928, 2850, 1649, 1501, 1438, 1116 cm-1; HRMS: calc. for [M+H]+ 
C19H27O3NCl: 352.16740, found: 352.16818;  RTD = +12.2 (CH2Cl2, c = 2.00); HPLC 
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conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 15/85, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 44.4 min; minor enantiomer: tR = 35.7 min, 82% ee.  
(R)-2-(1-cyclohexylidene-4-hydroxybutan-2-yl)-N-methoxybenzamide 
28i: Using method K, 86% yield; 1H NMR (400 MHz, CDCl3): δ 7.46 – 
7.39 (m, 1H), 7.38 – 7.29 (m, 2H), 7.19 (t, J = 7.5 Hz, 1H), 5.24 (d, J = 
9.4 Hz, 1H), 4.27 – 4.18 (m, 1H), 3.89 (s, 3H), 3.52 (dt, J = 11.5, 4.1 Hz, 
1H), 3.24 (td, J = 11.5, 2.9 Hz, 1H), 2.25– 2.20 (m, 1H), 2.12 – 1.86 (m, 
4H), 1.89 – 1.74 (m, 1H), 1.61 – 1.33 ppm (m, 6H); 13C NMR (101 MHz, CDCl3): δ 168.46, 
144.36, 140.32, 132.51, 131.35, 128.23, 127.61, 126.00, 125.59, 64.62, 59.86, 41.06, 37.28, 
35.12, 29.34, 28.63, 27.93, 26.87 ppm; FT‐IR: 
~ = 3154, 2927, 2851, 1639, 1531, 1440, 1315, 
1038 cm-1; HRMS: calc. for [M+H]+ C18H26O3N: 304.19072, found: 304.19122;  RTD = +33.2 
(CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
15/85, flow rate = 0.5 mL min-1, major enantiomer: tR = 61.6 min; minor enantiomer: tR = 57.7 
min, 94% ee. 
(R)-2-(1-hydroxy-5-methylhex-4-en-3-yl)-N-methoxybenzamide 
28j: Using method K, 62% yield; 1H NMR (400 MHz, CDCl3): δ 8.96 (br s, 
1H), 7.47 – 7.41 (m, 1H), 7.37 – 7.31 (m, 2H), 7.24 – 7.18 (m, 1H), 5.31 (d, 
J = 9.3 Hz, 1H), 4.23 – 4.11 (m, 1H), 3.55 (dt, J = 11.4, 4.0 Hz, 1H), 3.27 (t, 
J = 9.8 Hz, 1H), 2.51 (br s, 1H), 1.98 (ddd, J = 14.8, 9.8, 4.4 Hz, 1H), 1.87 – 
1.76 (m, 1H), 1.65 (s, 3H), 1.63 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ 168.51, 144.17, 
132.59, 132.34, 131.42, 128.84, 128.28, 127.63, 126.09, 64.75, 59.88, 40.84, 36.18, 25.95, 
18.29ppm; FT‐IR: 
~ = 3153, 2962, 2925, 2853, 1639, 1540, 1439, 1319, 1034 cm-1; HRMS: 
calc. for [M+H]+ C15H22O3N: 264.15942, found: 264.15942;  RTD = +9.6 (CH2Cl2, c = 1.00); 
HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 30/70, flow rate = 0.5 
mL min-1, major enantiomer: tR = 19.3 min; minor enantiomer: tR = 18.2 min, 94% ee. 
(S)-N-methoxy-2-(3-methyl-1-phenylbut-2-en-1-yl)benzamide 
28k: Using method M, 78% yield; 1H NMR (400 MHz, CDCl3): δ 8.10 (br s, 
1H), 7.43 – 7.35 (m, 1H), 7.32 (t, J = 7.2 Hz, 2H), 7.28 – 7.20 (m, 2H), 7.20 
– 7.11 (m, 3H), 5.60 – 5.52 (m, 1H), 5.47 (d, J = 9.3 Hz, 1H), 3.72 (s, 3H), 
1.79 (s, 3H), 1.72 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ 168.11, 
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144.94, 144.11, 134.13, 132.95, 130.90, 129.39, 128.51, 128.43, 127.79, 126.91, 126.22, 
126.19, 64.60, 45.47, 26.00, 18.40 ppm; FT‐ IR: 
~ = 3179, 2930, 1645, 1492, 1441, 1303, 
1033 cm-1; HRMS: calc. for [M+H]+ C19H22O2N: 296.16451, found: 296.16501;  RTD = -18.0 
(CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
15/85, flow rate = 0.5 mL min-1, major enantiomer: tR = 26.1 min; minor enantiomer: tR = 20.3 
min, 79% ee. 
Chapter 7. Experimental Part 
 
162 
 
7.2.5 Experiment Details and Analytic Data for Asymmetric Synthesis of Axially Chiral 
Biaryl Compounds 
7.2.5.1 Optimization of Reaction Conditions 
Table S3. Optimization of Reaction of of Diazonaphthoquinone 106a and Benzamide 26b.  
 
Entr
y 
Solvent CA
T 
Additives Temp T (h) Yield 
(%) 
ee 
(%) 1 0.5 mL MeOH 100l - r.t. 4 h 29 29 
2 0.5 mL DCM 100l - r.t. 4 h 49 27 
3 0.5 mL CH3CN 100l - r.t. 4 h <10 30 
4 0.5 mL THF 100l - r.t. 4 h 33 55 
5 0.5 mL Dioxane 100l - r.t. 4 h 15 43 
6 0.5 mL Tol 100l - r.t. 4 h <10 48 
7 0.5 mL Acetone 100l - r.t. 4 h 26 40 
8 0.5 mL TFE 100l - r.t. 4 h 59 20 
9 0.4 mL THF/0.1 mL TFE 100l - r.t. 4 h 39 42 
10 0.4 mL THF                     100l 0.05 mmol 
PivOH 
r.t. 4 h 36 53 
11 0.5 mL THF 99i  r.t. 4 h 37 14 
12 0.5 mL THF 100l  0oC 24 h 46 55 
General procedure: without protective precaution from air and moisture, catalyst (5.00 μmol, 0.05 equiv.), 
dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.), diazoquinone 106a (0.12 mmol, 1.20 equiv.) and 
26b (0.10 mmol, 1.00 equiv.) were dissolved into solvent. The mixture was allowed to be stirred at r.t. for 18 
hours. The resulting mixture was directly subjected on a silica gel to afford desired product 107a.  
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Table S4. Optimization of Reaction of Diazonaphthoquinone 106b and Benzamide 26b  
 
Entry concentration temperature t (h) solvent yield(%) ee(%) 
1 0.5 M r.t. 24 THF 53 89 
2 0.2 M 50°C 24 THF 63 89 
3 0.5 M r.t. 24 Dioxane 74 91 
4 0.5 M r.t. 24 MeOH 26 82 
5 0.5 M r.t. 24 TFE 37 75 
6 0.5 M r.t. 24 DCM 47 84 
7 0.5 M r.t. 24 CH3CN 26 73 
8 0.5 M r.t. 24 CF3C6H5 52 85 
General procedure: without protective precaution from air and moisture, catalyst 100l (2.93 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.), diazoquinone 106b (0.12 mmol, 1.20 
equiv.) and 26b (0.10 mmol, 1.00 equiv.) were dissolved into solvent. The resulting mixture was directly subjected 
on a silica gel to afford desired product 107e. 
7.2.5.2 General Methods and Analytic Data for the Synthesis of Diazonaphthoquinones 
106a-j and Axially Chiral Biaryl Compounds 107a-q 
Method N for Synthesis of Diazonaphthoquinones 106a, 106b, 106f-j: 
Diazonaphthoquinones were prepared according to the reported procedure. To a solution of 2-
chloro-1,3-dimethylimidazolinium chloride (228 mg, 1.35 mmol) in MeCN (2 mL), NaN3 (99.4 
mg, 1.5 mmol), and 15-crown-5 ether (0.06 mL, 0.3 mmol) was added at -20°C, and the mixture 
was stirred for 30 min. Specific substituted 2-naphthol (0.90 mmol, 1.00 equiv.) and Et3N (0.25 
mL, 1.8 mmol, 2.00 equiv.) in THF (4 mL) was added to the mixture, which was stirred for 2 
h. The reaction was quenched with H2O, and organic materials were extracted three times with 
CH2Cl2. The combined extracts were washed with H2O and brine, and then, dried over anhyd 
Na2SO4. The solvent was removed in vacuo to afford crude compounds. The crude materials 
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were purified by flash column chromatography to give diazonaphthoquinone 106a, 106b, 106f-
j. 
Method O for Synthesis of Diazonaphthoquinones 106c-e: 
Diazonaphthoquinones were prepared according to the reported procedure. To a stirred solution 
of aminophenols (10.0 mmol, 1.0 equiv) in EtOH (60 mL) was slowly added HCl (8.4 mL, 12 
N, 100 mmol, 10.0 equiv) at 0 ºC. This mixture was stirred at 0 ºC for 10 min, then an ice-cold 
solution of NaNO2 (2.07 g, 30 mmol, 3.0 equiv) in H2O (4 mL) was added dropwise over 10 
min. The resulting mixture was stirred for another 2 h at 0 ºC, then diluted with cold CH2Cl2 
(200 mL) followed by addition 30 g of ice. The mixture was stirred vigorously while a cold 
solution of K2CO3 (9.2 g, 67 mmol, 6.7 equiv) in H2O (10 mL) was added. The organic layers 
were then separated, and the aqueous layer was extracted with CH2Cl2 (100 mL). The combined 
organic layer was washed with brine (100 mL), and dried over Na2SO4. Evaporation in vacuo 
resulted in a black solid. This solid was kept anhydrous at -25ºC and used without further 
purification. 
Benzamides 26 were synthesized by Dr. Rajesh Gontla 
 
1-Diazonaphthalen-2(1H)-one 
106a: Using Method N, 81% yield; 1H NMR (500 MHz, CD2Cl2): δ = 7.66 (d, 
J = 9.8 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.56 – 7.49 (m, 1H), 7.33 – 7.25 (m, 
J = 11.0, 8.4, 4.5 Hz, 2H), 6.60 ppm (d, J = 9.8 Hz, 1H); 13C NMR (101 MHz, 
CD2Cl2): δ = 180.35, 140.69, 130.49, 130.24, 127.87, 126.29, 126.17, 125.13, 120.36 ppm; 
HRMS: calc. for [M+H]+ C10H7ON2: 171.05529, found: 171.05510. 
Methyl 4-diazo-3-oxo-3,4-dihydronaphthalene-2-carboxylate 
106b: Using Method N, 72% yield; 1H NMR (500 MHz, CD2Cl2): δ 8.34 
(s, 1H), 7.75 – 7.68 (m, 1H), 7.66 – 7.56 (m, 1H), 7.35 – 7.26 (m, 2H), 
3.88 ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 175.94, 165.59, 145.41, 
132.37, 132.23, 129.87, 126.80, 125.48, 124.37, 120.05, 52.76 ppm; FT‐IR: 
~ =  2098, 1693, 
1606, 1208, 792 cm-1; HRMS: calc. for [M+H]+ C12H9O3N2: 229.06077, found: 229.06072. 
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Methyl 6-diazo-5-oxocyclohexa-1,3-diene-1-carboxylate 
106c: Using Method O, 71% yield; 1H NMR (500 MHz, CD2Cl2): δ = 7.31 
(dd, J = 9.4, 7.0 Hz, 1H), 7.03 (dd, J = 7.0, 0.7 Hz, 1H), 6.81 (dd, J = 9.4, 0.7 
Hz, 1H), 3.92 ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ = 178.41, 163.74, 
136.61, 129.72, 126.07, 120.04, 53.47  ppm; HRMS: calc. for [M+H]+ C8H7O3N2: 179.04512, 
found: 179.04500. 
6-Diazo-5-methylcyclohexa-2,4-dien-1-one 
106d: Using Method O, 61% yield; 1H NMR (400 MHz, CD2Cl2): δ = 7.27 – 
7.18 (m, 1H), 6.51 (dd, J = 9.3, 0.7 Hz, 1H), 6.25 – 6.15 (m, 1H), 2.33 ppm (s, 
3H); 13C NMR (101 MHz, CD2Cl2): δ = 176.49, 138.25, 134.88, 119.88, 116.47, 
18.61 ppm; HRMS: calc. for [M+H]+ C7H7ON2: 135.05529, found: 135.05501. 
2-Diazo-[1,1'-biphenyl]-3(2H)-one 
106e: Using Method O, 76% yield; 1H NMR (400 MHz, CD2Cl2): δ = 7.56 (dd, 
J = 8.0, 1.5 Hz, 2H), 7.54 – 7.40 (m, 4H), 6.79 (d, J = 9.2 Hz, 1H), 6.57 ppm (d, 
J = 7.0 Hz, 1H); 13C NMR (101 MHz, CD2Cl2): δ = 173.46, 138.18, 137.14, 
135.97, 129.53, 129.35, 127.92, 119.12, 116.96, 97.08 ppm; HRMS: calc. for [M+H]+ 
C12H9ON2: 197.07094, found: 197.07093. 
Benzyl 4-diazo-3-oxo-3,4-dihydronaphthalene-2-carboxylate 
106f: Using Method N, 51% yield; 1H NMR (400 MHz, CD2Cl2): δ 8.36 
(s, 1H), 7.70 (d, J = 7.7 Hz, 1H), 7.65 – 7.58 (m, 1H), 7.49 (d, J = 7.2 Hz, 
2H), 7.43 – 7.37 (m, 2H), 7.38 – 7.27 (m, 3H), 5.35 ppm (s, 2H); 13C NMR 
(101 MHz, CD2Cl2): δ 175.94, 164.92, 145.45, 136.64, 132.41, 132.26, 129.93, 129.10, 128.73, 
128.68, 126.78, 125.48, 124.36, 120.08, 67.43 ppm; FT‐IR: 
~ =  2124, 1724, 1604, 1201, 1138, 
1071, 746 cm-1; HRMS: calc. for [M+H]+ C18H12O3N2: 305.09207, found: 305.09204. 
tert-butyl 4-diazo-3-oxo-3,4-dihydronaphthalene-2-carboxylate 
106g: Using Method N, 59% yield; 1H NMR (400 MHz, CD2Cl2): δ 8.19 
(s, 1H), 7.69 (d, J = 8.2 Hz, 1H), 7.63 – 7.56 (m, 1H), 7.35 – 7.26 (m, 
2H), 1.58 ppm (s, 9H); 13C NMR (101 MHz, CD2Cl2): δ 176.12, 164.21, 
143.79, 131.92, 129.52, 128.76, 125.40, 124.59, 120.09, 82.37, 28.49 ppm; FT‐IR: 
~ = 2086, 
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1716, 1613, 1368, 1144, 744 cm-1; HRMS: calc. for [M+H]+ C15H15O3N2: 271.10772, found: 
271.10794. 
3-Benzoyl-1-diazonaphthalen-2(1H)-one 
106h: Using Method N, 53% yield; 1H NMR (400 MHz, CD2Cl2) δ: 7.91 (s, 
1H), 7.86 (d, J = 7.4 Hz, 2H), 7.70 (d, J = 7.8 Hz, 1H), 7.66 – 7.58 (m, 2H), 
7.51 – 7.45 (m, 2H), 7.41 – 7.30 ppm (m, 2H); 13C NMR (101 MHz, 
CD2Cl2): δ 194.56, 177.47, 141.87, 137.72, 135.91, 133.89, 131.83, 131.71, 130.02, 129.10, 
128.95, 125.56, 124.94, 120.27 ppm; FT‐IR: 
~ = 2088, 1655, 1609, 1214, 732 cm-1; HRMS: 
calc. for [M+H]+ C17H11O2N2: 275.08150, found: 275.08154. 
Methyl 7-bromo-4-diazo-3-oxo-3,4-dihydronaphthalene-2-carboxylate 
106i: Using Method N, 70% yield; 1H NMR (400 MHz, CD2Cl2): δ 
8.24 (s, 1H), 7.85 (d, J = 2.0 Hz, 1H), 7.71 (dd, J = 8.5, 2.0 Hz, 1H), 
7.21 (d, J = 8.5 Hz, 1H), 3.89 ppm (s, 3H); 13C NMR (101 MHz, 
CD2Cl2) δ 175.38, 165.25, 143.74, 135.03, 134.27, 128.59, 128.06, 125.77, 121.58, 118.35, 
52.92 ppm; FT‐IR: 
~ = 2085, 1691, 1611, 1548, 1244, 793 cm-1; HRMS: calc. for [M+H]+ 
C12H8O3N2
79Br: 306.97128, found: 306.97155; calc. for [M+H]+ C12H8O3N2
81Br: 308.96923, 
found: 308.96935. 
Methyl 4-diazo-7-methoxy-3-oxo-3,4-dihydronaphthalene-2-carboxylate 
106j: Using Method N, 76% yield; 1H NMR (400 MHz, CD2Cl2): δ 
8.29 (s, 1H), 7.27 – 7.21 (m, 2H), 7.21 – 7.15 (m, 1H), 3.89 (s, 3H), 
3.86 ppm (s, 3H); 13C NMR (101 MHz, CD2Cl2): δ 175.95, 165.69, 
157.77, 144.76, 127.02, 125.44, 122.45, 121.50, 114.12, 56.18, 52.78 ppm; FT‐IR: 
~ = 1719, 
1599, 1648, 1372, 1253, 1144, 844 cm-1; HRMS: calc. for [M+H]+ C13H11O4N2: 259.07133, 
found: 259.07134. 
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Method P: 
Without protective precaution from air and moisture, catalyst 100l (2.93 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.), diazoquinones 106 
(0.12 mmol, 1.20 equiv.) and 26 (0.10 mmol, 1.00 equiv.) were dissolved into 0.5 mL THF. 
The mixture was allowed to be stirred at r.t. for 18 hours. The resulting mixture was directly 
subjected on a silica gel to afford desired product 107a-107c. 
Method Q: 
Without protective precaution from air and moisture, catalyst 100l (2.93 mg, 5.00 μmol, 0.05 
equiv.), dibenzoylperoxide (75 wt%, 1.62 mg, 5.00 μmol, 0.05 equiv.), diazoquinones 106 
(0.12 mmol, 1.20 equiv.) and 26 (0.10 mmol, 1.00 equiv.) were dissolved into 0.2 mL dioxane. 
The mixture was allowed to be stirred at r.t. for 18 hours. The resulting mixture was directly 
subjected on a silica gel to afford desired product 107d-q. 
 
(R)-2-(2-hydroxynaphthalen-1-yl)-N-methoxy-6-methylbenzamide 
107a: According to Method P, 33% yield; 1H NMR (600 MHz, 
methanol-d4): δ 7.77 – 7.69 (m, 2H), 7.46 – 7.40 (m, 1H), 7.33 – 7.28 (m, 
1H), 7.26 – 7.17 (m, 2H), 7.18 – 7.11 (m, 2H), 7.07 (d, J = 7.5 Hz, 1H), 
2.98 (s, 3H), 2.40 ppm (s, 3H); 13C NMR (600 MHz, methanol-d4): δ 
168.36, 153.02, 137.02, 136.80, 136.00, 135.73, 130.86, 130.53, 130.44, 130.20, 129.78, 
128.65, 127.24, 126.19, 123.91, 120.88, 118.80, 63.53, 19.27 ppm; HRMS: calc. for [M+H]+ 
C19H18O3N: 308.12812, found: 308.12816. 
Methyl (R)-3-hydroxy-4-(2-(methoxycarbamoyl)-3-methylphenyl)-2-naphthoate 
107b: According to Method P, 90% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 11.03 (s, 1H), 8.81 (s, 1H), 8.63 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.51 
– 7.42 (m, 2H), 7.42 – 7.34 (m, 2H), 7.19 (d, J = 8.5 Hz, 1H), 7.06 (d, J 
= 7.5 Hz, 1H), 4.05 (s, 3H), 3.19 (s, 3H), 2.45 ppm (s, 3H); 13C NMR 
(126 MHz, CD2Cl2): δ 171.14, 166.47, 152.83, 137.62, 137.38, 135.36, 133.91, 133.41, 130.46, 
130.28, 130.18, 129.97, 128.86, 127.45, 125.41, 124.90, 122.18, 114.07, 63.88, 53.45, 19.45 
ppm; FT-IR: 
~ = 3148, 2935, 1667, 1505, 1436, 1317, 1217, 1154, 1034 cm-1; HRMS: calc. 
for [M+H]+ C21H20O5N: 366.13360, found: 366.13437;  RTD = +8.9 (CH2Cl2, c = 1.00); HPLC 
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conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 40/60, flow rate = 0.5 mL 
min-1, major enantiomer: tR = 26.9 min; minor enantiomer: tR = 31.8 min; 51% ee. 
Methyl (R)-3'-chloro-2-hydroxy-2'-(methoxycarbamoyl)-[1,1'-binaphthalene]-3-
carboxylate 
107c: According to Method P, 78% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 10.94 (s, 1H), 8.71 (s, 1H), 8.66 (s, 1H), 8.00 (s, 1H), 7.89 – 7.85 (m, 
1H), 7.83 (d, J = 8.3 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.36 – 7.27 (m, 
2H), 7.23 (t, J = 7.6 Hz, 1H), 7.05 (d, J = 8.5 Hz, 1H), 6.94 – 6.81 (m, 
1H), 3.99 (s, 3H), 3.19 ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 
171.07, 163.71, 153.72, 137.59, 134.89, 134.43, 134.41, 132.72, 131.38, 130.68, 130.23, 
129.16, 128.92, 128.74, 128.10, 127.84, 127.57, 126.59, 125.22, 118.20, 114.32, 64.10, 53.57  
ppm; FT‐IR: 
~ = 3674, 3335, 2987, 2901, 1683, 1665, 1446, 1434, 1340, 1296, 1232, 1066 
cm-1; HRMS: calc. for [M+H]+ C24H19O5NCl: 436.09463, found: 436.09447;  RTD = +6.9 
(CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 45.5 min; minor enantiomer: tR = 37.2 
min; 65% ee. 
Methyl (R)-3-hydroxy-4-(2-(methoxycarbamoyl)-3,6-dimethylphenyl)-2-naphthoate 
107d: According to Method Q, 74% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 10.95 (s, 1H), 8.63 (s, 1H), 8.60 (s, 1H), 7.89 (d, J = 8.1 Hz, 1H), 7.49 
– 7.43 (m, 1H), 7.42 – 7.36 (m, 1H), 7.36 – 7.31 (m, 1H), 7.27 (d, J = 7.8 
Hz, 1H), 7.13 – 7.09 (m, 1H), 4.06 (s, 3H), 3.14 (s, 3H), 2.38 (s, 3H), 
1.84 ppm (s, 3H); 13C NMR (101 MHz, CD2Cl2) δ 171.22, 166.83, 152.87, 137.23, 135.80, 
135.34, 134.43, 133.46, 133.03, 131.67, 130.55, 130.44, 130.19, 127.70, 125.01, 124.95, 
121.08, 114.32, 63.86, 53.46, 19.54, 19.10 ppm; FT-IR: 
~ = 3197, 2954, 1675, 1626, 1504, 
1435, 1314, 1270, 1218, 1054 cm-1; HRMS: calc. for [M+H]+ C22H22O5N: 380.14925, found: 
380.14981;  RTD = -29.4 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, iso-
propanol / iso-hexane = 40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 21.8 min; 
minor enantiomer: tR = 29.1 min; 91% ee. 
Methyl (R)-4-(3-bromo-2-(methoxycarbamoyl)-6-methylphenyl)-3-hydroxy-2-
naphthoate 
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107e: According to Method Q, 56% yield; 1H NMR (700 MHz, CD2Cl2) 
δ 10.96 (s, 1H), 8.64 (s, 1H), 8.59 (s, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.62 
(d, J = 8.3 Hz, 1H), 7.51 – 7.46 (m, 1H), 7.43 – 7.38 (m, 1H), 7.33 (d, J 
= 8.3 Hz, 1H), 7.13 (d, J = 8.5 Hz, 1H), 4.05 (s, 3H), 3.21 (s, 3H), 1.86 
ppm (s, 3H); 13C NMR (176 MHz, CD2Cl2) δ 171.11, 164.62, 152.99, 
138.49, 136.82, 136.67, 135.73, 133.97, 133.16, 132.88, 130.67, 130.28, 127.60, 125.13, 
124.69, 119.80, 118.36, 114.31, 63.97, 53.50, 19.56  ppm; FT-IR: 
~ = 3315, 3159, 1687, 1664, 
1436, 1332, 1229, 1078, 1048 cm-1; HRMS: calc. for [M+H]+ C21H19O5N
79Br: 444.04411, 
found: 444.04398; calc. for [M+H]+ C21H19O5N
81Br: 446.04207, found: 446.04184;  RTD = 
+9.6 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane 
= 40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 33.3 min; minor enantiomer: tR = 
42.6 min; 86% ee. 
Methyl (R)-4-(3-iodo-2-(methoxycarbamoyl)-6-methylphenyl)-3-hydroxy-2-naphthoate 
107f: According to Method Q, 67% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 10.98 (s, 1H), 8.69 – 8.57 (m, 2H), 7.90 (d, J = 8.1 Hz, 1H), 7.87 (d, J 
= 8.1 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.44 – 7.36 (m, 1H), 7.18 (d, J = 8.1 
Hz, 1H), 7.12 (d, J = 8.4 Hz, 1H), 4.05 (s, 3H), 3.22 (s, 3H), 1.85 ppm 
(s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 171.08, 166.17, 152.87, 140.48, 
139.38, 139.24, 136.73, 135.25, 133.91, 133.29, 130.63, 130.24, 127.53, 125.09, 124.65, 
120.02, 114.22, 91.05, 63.90, 53.49, 19.57 ppm; FT-IR: 
~ = 3673, 3315, 2987, 1686, 1664, 
1435, 1405, 1309, 1276, 1077  cm-1; HRMS: calc. for [M+H]+ C21H19O5NI: 492.03024, found: 
492.02970;  RTD = +4.7 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, iso-
propanol / iso-hexane = 40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 33.6 min; 
minor enantiomer: tR = 47.8 min; 90% ee. 
Methyl (S)-4-(3-bromo-6-methoxy-2-(methoxycarbamoyl)phenyl)-3-hydroxy-2-
naphthoate 
107g: According to Method Q, 87% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 11.00 (s, 1H), 8.72 (s, 1H), 8.63 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.69 
(d, J = 8.9 Hz, 1H), 7.51 – 7.45 (m, 1H), 7.42 – 7.35 (m, 1H), 7.20 (d, J 
= 8.5 Hz, 1H), 7.03 (d, J = 8.9 Hz, 1H), 4.04 (s, 3H), 3.64 (s, 3H), 3.23 
ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 171.09, 164.03, 157.50, 
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153.30, 137.67, 137.29, 134.11, 133.88, 130.36, 130.13, 127.40, 124.97, 124.89, 117.21, 
114.30, 114.21, 111.52, 63.97, 56.64, 53.46 ppm; FT-IR: 
~ = 3674, 2255, 2987, 1683, 1501, 
1434, 1341, 1312, 1211, 1069, 1038 cm-1; HRMS: calc. for [M+H]+ C21H19O6N
79Br: 
460.03903, found: 460.03877; calc. for [M+H]+ C21H19O6N
81Br: 462.03698, found: 
462.03667;  RTD = -11.7 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, iso-
propanol / iso-hexane = 40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 75.2 min; 
minor enantiomer: tR = 51.6 min; 89% ee. 
Methyl (S)-4-(3-iodo-6-methoxy-2-(methoxycarbamoyl)phenyl)-3-hydroxy-2-naphthoate 
107h: According to Method Q, 93% yield; 1H NMR (500 MHz, 
CD2Cl2): δ 11.00 (s, 1H), 8.72 (s, 1H), 8.62 (s, 1H), 7.93 (d, J = 8.8 Hz, 
1H), 7.88 (d, J = 8.2 Hz, 1H), 7.48 (t, J = 7.5 Hz, 1H), 7.39 (t, J = 7.5 
Hz, 1H), 7.19 (d, J = 8.2 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 4.04 (s, 3H), 
3.63 (s, 3H), 3.25 ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 171.09, 
165.62, 158.35, 153.23, 141.48, 140.64, 137.27, 133.85, 130.35, 130.11, 127.40, 124.96, 
124.90, 124.67, 117.49, 114.71, 114.19, 82.97, 63.94, 56.56, 53.46 ppm; FT-IR: 
~ = 3673, 
3151, 2987, 1668, 1436, 1314, 1213, 1072, 1026 cm-1; HRMS: calc. for [M+H]+ C21H19O6NI: 
508.02516, found: 508.02459;  RTD = -12.8 (CH2Cl2, c = 2.00); HPLC conditions: 
CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 60/40, flow rate = 0.5 mL min
-
1, major enantiomer: tR = 25.9 min; minor enantiomer: tR = 14.6 min; 89% ee. 
Methyl (S)-4-(3-bromo-5,6-dimethoxy-2-(methoxycarbamoyl)phenyl)-3-hydroxy-2-
naphthoate 
107i: According to Method Q, 84% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 11.01 (s, 1H), 8.64 (s, 1H), 8.60 (s, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.54 
– 7.45 (m, J = 7.5 Hz, 1H), 7.44 – 7.36 (m, J = 7.5 Hz, 1H), 7.29 (s, 1H), 
7.23 (d, J = 8.5 Hz, 1H), 4.05 (s, 3H), 3.94 (s, 3H), 3.49 (s, 3H), 3.19 
ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 171.10, 163.95, 155.09, 
153.24, 147.28, 137.30, 133.94, 130.39, 130.17, 130.12, 129.42, 127.40, 125.02, 117.36, 
117.24, 115.75, 114.14, 63.88, 60.97, 56.70, 53.47 ppm; FT-IR: 
~ = 3673, 3236, 2987, 2901, 
1672, 1433, 1317, 1287, 1010, 1073, 1029 cm-1; HRMS: calc. for [M+H]+ C22H21O7N
79Br: 
490.04959, found: 490.04917; calc. for [M+H]+ C22H21O7N
81Br: 492.04754, found: 
492.04710;  RTD = +4.3 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, 
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(CH2Cl2/EtOH = 100/2) / iso-hexane = 60/40, flow rate = 1.0 mL min
-1, major enantiomer: tR 
= 13.3 min; minor enantiomer: tR = 7.9 min; 90% ee. 
Methyl (S)-4-(6-bromo-5-(methoxycarbamoyl)benzo[d][1,3]dioxol-4-yl)-3-hydroxy-2-
naphthoate 
107j: According to Method Q, 89% yield; 1H NMR (400 MHz, CD2Cl2): 
δ 11.08 (s, 1H), 8.65 (s, 2H), 7.92 – 7.86 (m, 1H), 7.59 – 7.49 (m, 1H), 
7.44 – 7.39 (m, 1H), 7.36 (d, J = 8.5 Hz, 1H), 7.21 – 7.14 (m, 1H), 5.99 
– 5.96 (m, 1H), 5.95 (dd, J = 1.1, 0.7 Hz, 1H), 4.05 (s, 3H), 3.27 ppm (s, 
3H); 13C NMR (101 MHz, CD2Cl2): δ 171.01, 164.00, 153.78, 149.87, 146.69, 136.88, 134.57, 
130.79, 130.33, 127.51, 125.24, 124.80, 116.96, 114.70, 114.33, 113.32, 113.01, 103.17, 64.01, 
53.46 ppm; FT-IR: 
~ = 3166, 2923, 1676, 1447, 1312, 1228, 1089 cm-1; HRMS: calc. for 
[M+H]+ C21H17O7N
79Br: 474.01829, found: 474.01795; calc. for [M+H]+ C21H17O7N
81Br: 
476.01624, found: 476.01577;  RTD = +7.0 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK 
IA column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 50/50, flow rate = 0.5 mL min
-1, major 
enantiomer: tR = 15.9 min; minor enantiomer: tR = 12.0 min; 79% ee.  
Methyl (R)-2-hydroxy-3'-iodo-2'-(methoxycarbamoyl)-5',6',7',8'-tetrahydro-[1,1'-
binaphthalene]-3-carboxylate 
107k: According to Method Q, 69% yield; 1H NMR (700 MHz, 
CD2Cl2): δ 10.87 (s, 1H), 8.54 (s, 1H), 8.46 (s, 1H), 7.80 (d, J = 8.2 Hz, 
1H), 7.65 (s, 1H), 7.41 – 7.37 (m, 1H), 7.33 – 7.28 (m, 1H), 7.05 (d, J = 
8.5 Hz, 1H), 3.97 (s, 3H), 3.12 (s, 3H), 2.79 – 2.73 (m, 2H), 2.14 – 2.07 
(m, 1H), 1.90 – 1.82 (m, 1H), 1.67 – 1.59 (m, 2H), 1.56 – 1.48 ppm (m, 2H); 13C NMR (176 
MHz, CD2Cl2): δ 171.14, 166.31, 152.80, 142.31, 140.17, 137.99, 137.79, 136.85, 135.05, 
133.78, 130.62, 130.23, 127.61, 125.09, 124.72, 120.07, 114.28, 90.63, 63.89, 53.49, 30.12, 
27.09, 23.22, 22.85 ppm; FT-IR: 
~ = 3673, 3181, 2987, 2920, 1681, 1655, 1505, 1433, 1319, 
1209, 1055 cm-1; HRMS: calc. for [M+H]+ C24H23O5NI: 532.06154, found: 532.06106;  RTD
= -10.4 (CH2Cl2, c = 0.50); HPLC conditions: CHIRAPAK IC column, (CH2Cl2/EtOH = 100/2) 
/ iso-hexane = 60/40, flow rate = 0.5 mL min-1, major enantiomer: tR = 25.1 min; minor 
enantiomer: tR = 13.8 min. 
Methyl (S)-4-(6-acetoxy-3-iodo-2-(methoxycarbamoyl)phenyl)-3-hydroxy-2-naphthoate 
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107l: According to Method Q, 37% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 11.03 (s, 1H), 8.70 (s, 1H), 8.64 (s, 1H), 8.00 (d, J = 8.6 Hz, 1H), 7.88 
(d, J = 8.2 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 1H), 7.19 
(d, J = 8.2 Hz, 1H), 7.11 (d, J = 8.6 Hz, 1H), 4.05 (s, 3H), 3.26 (s, 3H), 
1.66 ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 170.99, 168.73, 
165.11, 153.37, 150.19, 142.31, 140.57, 136.84, 134.47, 130.52, 130.08, 129.00, 127.33, 
126.63, 125.16, 125.02, 116.02, 114.04, 90.84, 64.03, 53.54, 20.61 ppm; FT-IR: 
~ = 3670, 
3195, 2987, 1765, 1676, 1435, 1314, 1187, 1072 cm-1; HRMS: calc. for [M+H]+ C22H19O7NI: 
536.02007, found: 536.01955;  RTD = +8.2 (CH2Cl2, c = 1.00); HPLC conditions: CHIRAPAK 
IC column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 60/40, flow rate = 0.5 mL min
-1, major 
enantiomer: tR = 20.7 min; minor enantiomer: tR = 12.9 min; 87% ee.  
Benzyl (S)-3-hydroxy-4-(3-iodo-6-methoxy-2-(methoxycarbamoyl)phenyl)-2-naphthoate 
107m: According to Method Q, 81% yield; 1H NMR (500 MHz, 
CD2Cl2): δ 10.99 (s, 1H), 8.69 (s, 1H), 8.66 (s, 1H), 7.93 (d, J = 8.8 Hz, 
1H), 7.87 (d, J = 8.2 Hz, 1H), 7.56 – 7.50 (m, 2H), 7.50 – 7.34 (m, 5H), 
7.19 (d, J = 8.5 Hz, 1H), 6.91 (d, J = 8.8 Hz, 1H), 5.51 (d, J = 12.2 Hz, 
1H), 5.46 (d, J = 12.2 Hz, 1H), 3.63 (s, 3H), 3.23 (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 
170.51, 165.60, 158.36, 153.33, 141.49, 140.66, 137.35, 135.64, 133.91, 130.42, 130.12, 
129.26, 129.23, 129.00, 127.40, 125.00, 124.91, 124.67, 117.56, 114.72, 114.18, 82.98, 68.31, 
63.94, 56.57 ppm; FT-IR: 
~ = 3674, 3324, 2987, 1697, 1661, 1435, 1411, 1305, 1280, 1208, 
1066, 1029 cm-1; HRMS: calc. for [M+H]+ C27H23O6NI: 584.05646, found: 584.05606;  RTD
= -7.5 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane 
= 40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 69.9 min; minor enantiomer: tR = 
49.8 min; 90% ee. 
tert-Butyl (S)-3-hydroxy-4-(3-iodo-6-methoxy-2-(methoxycarbamoyl)phenyl)-2-
naphthoate 
107n: According to Method Q, 91% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 11.34 (s, 1H), 8.72 (s, 1H), 8.54 (s, 1H), 7.93 (d, J = 8.8 Hz, 1H), 7.88 
(d, J = 8.2 Hz, 1H), 7.47 – 7.42 (m, 1H), 7.40 – 7.34 (m, 1H), 7.16 (d, J 
= 8.4 Hz, 1H), 6.90 (d, J = 8.8 Hz, 1H), 3.64 (s, 3H), 3.23 (s, 3H), 1.69 
ppm (s, 9H); 13C NMR (126 MHz, CD2Cl2): δ 170.34, 165.65, 158.39, 
Chapter 7. Experimental Part 
173 
 
153.67, 141.55, 140.60, 137.05, 133.81, 130.09, 130.00, 127.32, 124.86, 124.82, 117.27, 
115.63, 114.69, 84.75, 83.03, 63.86, 56.59, 28.47 ppm; FT-IR: 
~ = 3674, 2975, 1668, 1505, 
1456, 1434, 1331, 1282, 1242, 1148 cm-1; HRMS: calc. for [M+H]+ C24H25O6NI: 550.07211, 
found: 550.07167;  RTD = +5.8 (CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, 
iso-propanol / iso-hexane = 40/60, flow rate = 0.5 mL min-1, major enantiomer: tR = 46.1 min; 
minor enantiomer: tR = 28.4 min; 84% ee. 
(S)-2-(3-Benzoyl-2-hydroxynaphthalen-1-yl)-6-iodo-N,3-dimethoxybenzamide 
107o: According to Method Q, 72% yield; 1H NMR (500 MHz, CD2Cl2): 
δ 11.74 (s, 1H), 8.77 (s, 1H), 8.32 (s, 1H), 7.95 (d, J = 8.8 Hz, 1H), 7.85 
– 7.77 (m, 3H), 7.74 – 7.68 (m, 1H), 7.64 – 7.56 (m, 2H), 7.55 – 7.47 (m, 
1H), 7.43 – 7.36 (m, 1H), 7.21 (d, J = 8.5 Hz, 1H), 6.93 (d, J = 8.8 Hz, 
1H), 3.67 (s, 3H), 3.30 ppm (s, 3H); 13C NMR (126 MHz, CD2Cl2): δ 
202.62, 165.70, 158.39, 154.29, 141.56, 140.72, 138.35, 138.11, 137.39, 133.15, 131.03, 
130.50, 130.16, 129.13, 127.12, 125.12, 124.94, 124.60, 120.78, 118.19, 114.76, 83.04, 63.96, 
56.62, ppm; FT-IR: 
~ = 3670, 2987, 2901, 1683, 1628, 1504, 1456, 1339, 1281, 1099 cm-1; 
HRMS: calc. for [M+H]+ C26H21O5NI: 554.04589, found: 554.04542;  RTD = +2.7 (CH2Cl2, c 
= 1.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 40/60, flow 
rate = 0.5 mL min-1, major enantiomer: tR = 88.5 min; minor enantiomer: tR = 69.9 min; 86% 
ee. 
Methyl (S)-7-bromo-3-hydroxy-4-(3-iodo-6-methoxy-2-(methoxycarbamoyl)phenyl)-2-
naphthoate 
107p: According to Method Q, 72% yield; 1H NMR (500 MHz, 
DMSO-d6): δ 11.06 (s, 1H), 10.45 (s, 1H), 8.61 (s, 1H), 8.35 – 8.25 
(m, 1H), 7.92 (d, J = 8.8 Hz, 1H), 7.54 (dd, J = 8.8, 1.2 Hz, 1H), 7.06 
(d, J = 8.8 Hz, 2H), 4.00 (s, 3H), 3.60 (s, 3H), 2.95 ppm (s, 3H); 13C 
NMR (126 MHz, DMSO): δ 169.90, 163.79, 157.89, 141.92, 139.95, 
135.21, 132.37, 132.03, 131.32, 127.82, 127.66, 124.20, 118.05, 117.17, 115.35, 114.92, 83.72, 
62.36, 56.39, 53.64 ppm; FT-IR: 
~ = 3674, 3370, 2987, 1688, 1458, 1337, 1282, 1190, 1066, 
1034 cm-1; HRMS: calc. for [M+H]+ C21H18O6N
79BrI: 585.93567, found: 585.93542; calc. for 
[M+H]+ C21H18O6N
81BrI: 587.93362, found: 587.93333;  RTD = +3.9 (CH2Cl2, c = 2.00); 
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HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 60/40, flow rate = 0.5 
mL min-1, major enantiomer: tR = 42.0 min; minor enantiomer: tR = 32.6 min; 87% ee. 
Methyl (S)-3-hydroxy-4-(3-iodo-6-methoxy-2-(methoxycarbamoyl)phenyl)-7-methoxy-2-
naphthoate 
107q: According to Method Q, 93% yield; 1H NMR (500 MHz, 
CD2Cl2): δ 10.84 (s, 1H), 8.76 (s, 1H), 8.49 (s, 1H), 7.92 (d, J = 8.8 
Hz, 1H), 7.18 – 7.13 (m, 2H), 7.10 (d, J = 9.1 Hz, 1H), 6.89 (d, J = 
8.8 Hz, 1H), 4.03 (s, 3H), 3.89 (s, 3H), 3.64 (s, 3H), 3.26 ppm (s, 
3H); 13C NMR (126 MHz, CD2Cl2): δ 171.15, 165.66, 158.32, 157.04, 151.76, 141.46, 140.62, 
132.85, 131.99, 128.36, 126.45, 124.77, 123.50, 117.75, 114.69, 114.39, 107.30, 82.97, 63.94, 
56.57, 55.88, 53.40 ppm; FT-IR: 
~ = 3674, 3271, 2988, 1670, 1438, 1389, 1341, 1222, 1073 
cm-1; HRMS: calc. for [M+H]+ C22H21O7NI: 538.03572, found: 538.03524;  RTD = -28.3 
(CH2Cl2, c = 2.00); HPLC conditions: CHIRAPAK IC column, iso-propanol / iso-hexane = 
75/25, flow rate = 0.5 mL min-1, major enantiomer: tR = 48.8 min; minor enantiomer: tR = 31.9 
min; 87% ee. 
 
7.2.6 X-Ray Crystallographic Data and VCD Spectra Data. 
7.2.6.1 X-Ray Crystallographic Data of 99i, 105b and 107b (by C.-G.D) 
X-Ray diffraction: For compound 105b data sets were collected with a Bruker APEX II Kappa 
CCD diffractometer. For compound 99i, 107b were collected with a D8 Venture Dual Source 
100 CMOS diffractometer. Programs used: data collection: APEX2 V2014.5-0 (Bruker AXS 
Inc., 2014); cell refinement: SAINT V8.34A (Bruker AXS Inc., 2013); data reduction: SAINT 
V8.34A (Bruker AXS Inc., 2013); absorption correction, SADABS V2014/2 (Bruker AXS 
Inc., 2014); structure solution SHELXT-2014 (Sheldrick, 2014); structure refinement 
SHELXL-2014 (Sheldrick, 2014) and graphics, XP (Bruker AXS Inc., 2014). R-values are 
given for observed reflections, and wR2 values are given for all reflections.  
Exceptions and special features: For compound 99i two disordered over two positions ethene 
groups were found in the asymmetrical unit. Several restraints (SADI, SAME, ISOR and 
SIMU) were used in order to improve refinement stability of the compound. 
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X-ray crystal structure analysis of 99i (CDCC 1450765): A yellow needle-like specimen of 
C27H32NO2Rh, approximate dimensions 0.059 mm x 0.097 mm x 0.253 mm, was used for the 
X-ray crystallographic analysis. The X-ray intensity data were measured. The total exposure 
time was 4.11 hours. The frames were integrated with the Bruker SAINT software package 
using a narrow-frame algorithm. The integration of the data using a monoclinic unit cell yielded 
a total of 17185 reflections to a maximum θ angle of 27.10° (0.78 Å resolution), of which 5380 
were independent (average redundancy 3.194, completeness = 99.9%, Rint = 4.39%, Rsig = 
4.59%) and 4875 (90.61%) were greater than 2σ(F2). The final cell constants of a = 8.8642(3) 
Å, b = 12.6939(5) Å, c = 10.9689(5) Å, β = 98.9220(10)°, volume = 1219.30(8) Å3, are based 
upon the refinement of the XYZ-centroids of 9677 reflections above 20 σ(I) with 4.942° < 2θ 
< 54.96°. Data were corrected for absorption effects using the multi-scan method (SADABS). 
The ratio of minimum to maximum apparent transmission was 0.910. The calculated minimum 
and maximum transmission coefficients (based on crystal size) are 0.8380 and 0.9590. The 
structure was solved and refined using the Bruker SHELXTL Software Package, using the 
space group P21, with Z = 2 for the formula unit, C27H32NO2Rh. The final anisotropic full-
matrix least-squares refinement on F2 with 321 variables converged at R1 = 2.84%, for the 
observed data and wR2 = 5.29% for all data. The goodness-of-fit was 1.084. The largest peak 
in the final difference electron density synthesis was 0.378 e-/Å3 and the largest hole was -
0.577 e-/Å3 with an RMS deviation of 0.072 e-/Å3. On the basis of the final model, the 
calculated density was 1.377 g/cm3 and F(000), 524 e-. 
X-ray crystal structure analysis of 105b (CDCC 1450766): A colorless prism-like specimen 
of C18H15NO3, approximate dimensions 0.171 mm x 0.226 mm x 0.299 mm, was used for the 
X-ray crystallographic analysis. The X-ray intensity data were measured. A total of 815 frames 
were collected. The total exposure time was 14.29 hours. The frames were integrated with the 
Bruker SAINT software package using a wide-frame algorithm. The integration of the data 
using an orthorhombic unit cell yielded a total of 6857 reflections to a maximum θ angle of 
68.03° (0.83 Å resolution), of which 2339 were independent (average redundancy 2.932, 
completeness = 96.5%, Rint = 2.47%, Rsig = 2.49%) and 2279 (97.43%) were greater than 
2σ(F2). The final cell constants of a = 7.30910(10) Å, b = 9.2636(2) Å, c = 19.9469(4) Å, 
volume = 1350.58(4) Å3, are based upon the refinement of the XYZ-centroids of 5456 
reflections above 20 σ(I) with 8.866° < 2θ < 136.0°. Data were corrected for absorption effects 
using the multi-scan method (SADABS). The ratio of minimum to maximum apparent 
transmission was 0.900. The calculated minimum and maximum transmission coefficients 
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(based on crystal size) are 0.7950 and 0.8750. The structure was solved and refined using the 
Bruker SHELXTL Software Package, using the space group P212121, with Z = 4 for the formula 
unit, C18H15NO3. The final anisotropic full-matrix least-squares refinement on F
2 with 199 
variables converged at R1 = 2.66%, for the observed data and wR2 = 6.69% for all data. The 
goodness-of-fit was 1.081. The largest peak in the final difference electron density synthesis 
was 0.128 e-/Å3 and the largest hole was -0.185 e-/Å3 with an RMS deviation of 0.041 e-/Å3. 
On the basis of the final model, the calculated density was 1.442 g/cm3 and F(000), 616 e-. 
X-ray crystal structure analysis of 107b: A colorless prism-like specimen of C21H19NO5, 
approximate dimensions 0.156 mm x 0.338 mm x 0.378 mm, was used for the X-ray 
crystallographic analysis. The X-ray intensity data were measured. A total of 2367 frames were 
collected. The total exposure time was 19.18 hours. The frames were integrated with the Bruker 
SAINT software package using a wide-frame algorithm. The integration of the data using a 
monoclinic unit cell yielded a total of 36215 reflections to a maximum θ angle of 68.44° (0.83 
Å resolution), of which 6754 were independent (average redundancy 5.362, completeness = 
99.5%, Rint = 3.27%, Rsig = 2.29%) and 6592 (97.60%) were greater than 2σ(F2). The final cell 
constants of a = 11.3781(3) Å, b = 7.7075(2) Å, c = 21.5908(6) Å, β = 102.5900(10)°, volume 
= 1847.91(9) Å3, are based upon the refinement of the XYZ-centroids of 9843 reflections above 
20 σ(I) with 7.961° < 2θ < 136.8°. Data were corrected for absorption effects using the multi-
scan method (SADABS). The ratio of minimum to maximum apparent transmission was 0.899. 
The calculated minimum and maximum transmission coefficients (based on crystal size) are 
0.7580 and 0.8880. The final anisotropic full-matrix least-squares refinement on F2 with 509 
variables converged at R1 = 2.90%, for the observed data and wR2 = 7.48% for all data. The 
goodness-of-fit was 1.058. The largest peak in the final difference electron density synthesis 
was 0.134 e-/Å3 and the largest hole was -0.224 e-/Å3 with an RMS deviation of 0.042 e-/Å3. 
On the basis of the final model, the calculated density was 1.313 g/cm3 and F(000), 768 e-. 
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Crystal structure of compound 99i. (CDCC 1450765) 
 
 (Thermals ellipsoids are shown with 50% probability.) 
 
Crystal structure of compound 105b. (CDCC 1450766) 
 
 
(Thermals ellipsoids are shown with 50% probability.)  
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Crystal structure of compound 107b.  
 
 
(Thermals ellipsoids are shown with 50% probability.)  
7.2.6.2 VCD Spectra Data of 11m, 107b (by C.M.) 
Determination absolute configuration of 11m: Experimental IR and VCD spectra were 
obtained for a 0.27 M solution of 11m in CDCl3 (50 mg/ml) at 100 µm path length. The spectra 
were recorded on a Bruker Vertex 70v equipped with a PMA 50 module for VCD 
measurements accumulating 26000 scans for the VCD spectrum. The baseline was corrected 
by subtraction of the solvent spectrum.  
In order to analyse experimental IR and VCD spectra, theoretical spectra were simulated for 
11m in both a cis and a trans form. In contrast to the calculations of the reactions pathways, 
the vibrational spectra calculations were performed at the B3LYP/6-311+G(2d,p) level of 
theory using Gaussian 09 Rev. D.01. Solvent effects were accounted for by applying a 
polarizable continuum model (IEFPCM). Brief conformational analysis yielded one conformer 
for the trans and two for the cis isomer, with one of the cis-conformations being significantly 
more favoured (∆EZPC=2.1 kcal/mol).  
Chapter 7. Experimental Part 
179 
 
 
(R,R)-cis isomer 
 
(S,R)-trans isomer 
For these two major isomers, IR and VCD spectra were calculated for each isomer. In order to 
account for line broadening, a Lorentzian band shape of 8 cm-1 half-width at half-height was 
assigned to the calculated dipole and rotational strengths. For a better visual comparison of the 
spectra, the calculated frequencies were scaled by a factor of 0.98.  
 
Numbers indicate band assignments; T and C mark diastereomer-specific VCD bands. 
Figure S2. Comparison of experimental IR and VCD spectra of 11m with calculated spectra of the possible cis- 
and trans-isomer. 
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In Fig. S1, the experimental and theoretical spectra are compared. As the band assignments 
indicate, visual comparison does not allow any unambiguous differentiation between the 
diastereomers from the IR spectra. In the VCD spectra, both stereoisomers feature quite some 
similarities as well. However, there are also differences in the predicted spectra which can be 
used to distinguish the isomers. They are marked with T (from trans) and C (for cis). From 
these diastereomer-specific bands, 11m can clearly be assigned an (R,R)-cis configuration. 
 
Determination absolute configuration of 107d: 
 
Lowest energy conformer 
 
 
Second-lowest conformer  
(∆G298K=0.7 kcal/mol) 
 
The IR and VCD spectra of 107d were measured for a 0.18 M (70mg/ml) solution in 
chloroform-d1. Calculations were carried out as mentioned above for the (aR)-configured 
stereoisomer. The two lowest energy conformations of 107d are shown above and the 
corresponding experimental and theoretical spectra are presented in Fig.S3. The absolute 
configuration of the reaction product is therefore confirmed to be (aR). 
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Figure S3. Comparison of the experimental IR and VCD spectra of 107d (0.18 M, 100 µm, CDCl3) with the 
calculated spectra of the (aR)-stereoisomer. Numbers indicate band assignments. 
 
7.3 Experimental Part for Enantioselective Synthesis of Pyrrolizidines 
7.3.1 Experimental Detail and Analytic Data for Synthesis of Pyrrolidines 157aa-bm  
General Method: To CH2Cl2 (1 mL) were sequentially added imine (0.30 mmol, 1.50 equiv.), 
maleate (0.20 mmol, 1.00 equiv.), AgOAc (0.02 mmol, 10 mmol%) and Et3N (0.20 mmol, 1.00 
equiv.). The mixture was stirred for 24 h. The crude mixture was directly purified by silica gel 
flash without removal of solvent to give desired product. 
Rel-(2S,3R,4S,5R)-trimethyl 5-(4-fluorophenyl)-2-(3-methoxy-3-oxopropyl)pyrrolidine-
2,3,4-tricarboxylate 
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157aa: 89% yield; 1H NMR (400 MHz, CDCl3): δ = 7.31 – 7.17 (m, 
2H), 6.94 (t, J = 8.7 Hz, 2H), 4.41 (d, J = 6.2 Hz, 1H), 3.72 (s, 3H), 
3.67 (s, 3H), 3.38 (t, J = 6.7 Hz, 1H), 3.26 (d, J = 7.0 Hz, 1H), 3.24 
(s, 3H), 2.59 – 2.46 (m, 1H), 2.43 – 2.32 (m, 1H), 2.21 (ddd, J = 
15.6, 9.9, 5.4 Hz, 1H), 2.06 ppm (ddd, J = 13.5, 10.0, 5.3 Hz, 1H); 13C NMR (126 MHz, CDCl3) 
δ = 173.66, 173.09, 171.08, 170.95, 163.36, 161.40, 133.17, 128.66, 128.60, 115.49, 115.32, 
71.70, 63.40, 57.38, 53.04, 52.92, 52.30, 51.82, 51.51, 35.35, 30.07 ppm; HRMS: calc. for 
[M+H]+ C20H25FNO8: 426.15587, found 426.15552. 
Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-phenylpyrrolidine-2,3,4-
tricarboxylate 
157ab: 75% yield; 1H NMR (400 MHz, CDCl3): δ = 7.17 (d, J = 8.1 
Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 4.43 (d, J = 6.0 Hz, 1H), 3.76 (s, 3H), 
3.72 (s, 3H), 3.62 (s, 3H), 3.39 (t, J = 6.5 Hz, 1H), 3.31 – 3.29 (m, 4H), 
2.65 – 2.54 (m, 1H), 2.49 – 2.38 (m, 1H), 2.29 (s, 3H), 2.27 –  2.22 (m, 
1H), 2.16 – 2.05 ppm (m, 1H); HRMS: calc. for [M+H]+ C20H26NO8: 408.16529, found 
408.16479. 
Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-(p-tolyl)pyrrolidine-2,3,4-
tricarboxylate 
157ac: 47% yield; 1H NMR (400 MHz, CDCl3): δ = 7.17 (d, J = 8.1 
Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 4.43 (d, J = 6.0 Hz, 1H), 3.76 (s, 
3H), 3.72 (s, 3H), 3.62 (s, 3H), 3.39 (t, J = 6.5 Hz, 1H), 3.31-3.29 (m, 
4H), 2.65 – 2.54 (m, 1H), 2.49 – 2.38 (m, 1H), 2.29 (s, 3H), 2.24 (dd, 
J = 15.8, 5.3 Hz, 1H), 2.16 – 2.05 ppm (m, 1H); HRMS: calc. for [M+H]+ C21H28NO8: 
422.18094, found 422.18020. 
Rel-(2S,3R,4S,5R)-trimethyl 5-(4-bromophenyl)-2-(3-methoxy-3-oxopropyl)pyrrolidine-
2,3,4-tricarboxylate 
157ad: 85% yield; 1H NMR (400 MHz, CDCl3): δ = 7.42 (d, J = 
8.4 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 4.42 (s, 1H), 3.75 (s, 3H), 
3.71 (s, 3H), 3.62 (s, 3H), 3.57 – 3.56 (m, 1H), 3.43 (t, J = 6.6 Hz, 
1H), 3.32 – 3.30 (d, J = 6.2 Hz, 4H), 2.65 – 2.50 (m, 1H), 2.42 (dd, 
J = 7.4, 5.9 Hz, 1H), 2.31 – 2.18 (m, 1H), 2.11 ppm (dd, J = 11.5, 3.6 Hz, 1H); 13C NMR (101 
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MHz, CDCl3) δ = 173.63, 173.02, 170.99, 170.86, 136.48, 131.57, 128.57, 121.75, 71.59, 
63.36, 57.48, 52.92, 52.79, 52.31, 51.82, 51.56, 35.38, 30.06 ppm; HRMS: calc. for [M+H]+ 
C20H25O8N
79Br: 486.07581, found 486.07506; calc. for [M+H]+ C20H25O8N
81Br: 488.07376, 
found 488.07268. 
Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-(4-(trifluoromethyl)phenyl) 
pyrrolidine-2,3,4-tricarboxylate 
157ae: 89% yield; 1H NMR (400 MHz, CDCl3): δ = 7.56 (d, J = 
8.2 Hz, 2H), 7.45 (d, J = 8.2 Hz, 2H), 4.52 (d, J = 6.1 Hz, 1H), 3.76 
(s, 3H), 3.71 (s, 3H), 3.70 – 3.64 (m, 1H), 3.63 (s, 3H), 3.50 (t, J = 
6.6 Hz, 1H), 3.34 (d, J = 7.0 Hz, 1H), 3.27 (s, 3H), 2.62 – 2.50 (m, 
1H), 2.49 – 2.36 (m, 1H), 2.34 – 2.19 (m, 1H), 2.17 – 2.04 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-(4-
methoxyphenyl)pyrrolidine-2,3,4-tricarboxylate 
157af: 82% yield; 1H NMR (400 MHz, CDCl3) δ = 7.22 (d, J = 
8.7 Hz, 2H), 6.83 (d, J = 8.7 Hz, 2H), 4.43 (d, J = 6.2 Hz, 1H), 
3.77 (s, 6H), 3.72 (s, 3H), 3.68 (dd, J = 12.2, 7.5 Hz, 1H), 3.63 (s, 
3H), 3.39 (t, J = 6.6 Hz, 1H), 3.32 – 3.28 (m, 4H), 2.65 – 2.54 (m, 
1H), 2.48 – 2.36 (m, 1H), 2.31 – 2.21 (m, 1H), 2.16 – 2.05 ppm (m, 1H).  
Rel-(2S,3R,4S,5R)-trimethyl 5-(4-(allyloxy)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157ag: 61% yield; 1H NMR (400 MHz, CDCl3): δ = 7.22 (d, J = 
8.7 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 6.15 – 5.93 (m, 1H), 5.38 
(dd, J = 17.3, 1.5 Hz, 1H), 5.26 (dd, J = 10.5, 1.3 Hz, 1H), 4.54 – 
4.46 (m, 2H), 4.43 (d, J = 6.2 Hz, 1H), 3.77 (s, 3H), 3.72 (s, 3H), 
3.68 (dd, J = 12.3, 7.5 Hz, 1H), 3.63 (s, 3H), 3.39 (t, J = 6.6 Hz, 1H), 3.31 – 3.29 (m, 4H), 2.59 
(ddd, J = 15.5, 10.0, 5.2 Hz, 1H), 2.43 (ddd, J = 13.4, 10.0, 5.3 Hz, 1H), 2.26 (ddd, J = 15.7, 
10.2, 5.3 Hz, 1H), 2.11 ppm (ddd, J = 13.4, 10.2, 5.2 Hz, 1H); 13C NMR (101 MHz, CDCl3) δ 
= 173.72, 173.28, 171.34, 171.06, 158.19, 133.22, 129.39, 127.99, 117.83, 114.66, 71.52, 
68.83, 63.62, 57.32, 53.09, 52.88, 52.27, 51.82, 51.49, 35.51, 30.07 ppm; ESI-HRMS: calcd. 
for C21H27NO9+H: 464.19151, found 464.19143. 
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Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-(4-nitrophenyl)pyrrolidine-
2,3,4-tricarboxylate 
157ah: 41% yield; 1H NMR (400 MHz, CDCl3): δ = 8.18 (d, J = 
8.8 Hz, 2H), 7.53 (d, J = 8.6 Hz, 2H), 4.57 (s, 1H), 3.77 (s, 3H), 
3.73 (s, 3H), 3.69 – 3.66 (m, 1H), 3.64 (s, 3H), 3.55 (t, J = 6.7 Hz, 
1H), 3.37 (d, J = 7.1 Hz, 1H), 3.31 (s, 3H), 2.63 – 2.52 (m, 1H), 
2.46 (ddd, J = 14.6, 8.7, 4.1 Hz, 2H), 2.33 – 2.21 (m, 1H), 2.13 ppm (ddd, J = 13.6, 9.6, 5.5 
Hz, 1H). 
Rel-(2S,3R,4S,5R)-trimethyl 5-(furan-2-yl)-2-(3-methoxy-3-oxopropyl)pyrrolidine-2,3,4-
tricarboxylate 
157ai: 76% yield; 1H NMR (400 MHz, CDCl3): δ = 7.32 (dd, J = 1.7, 
0.7 Hz, 1H), 6.29 (dd, J = 3.2, 1.8 Hz, 1H), 6.27 (d, J = 3.3 Hz, 1H), 
4.46 (d, J = 6.1 Hz, 1H), 3.75 (s, 3H), 3.71 (s, 3H), 3.67 – 3.60 (m, 4H), 
3.47 (s, 3H), 3.36 (t, J = 6.5 Hz, 1H), 3.24 (d, J = 6.8 Hz, 1H), 2.64 – 
2.50 (m, 1H), 2.41 (ddd, J = 13.4, 10.1, 5.4 Hz, 1H), 2.23 (ddd, J = 15.8, 10.2, 5.4 Hz, 1H), 
2.05 ppm (ddd, J = 13.4, 10.2, 5.2 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ = 173.63, 172.95, 
171.19, 170.63, 150.86, 142.19, 110.51, 107.35, 71.12, 58.25, 56.99, 52.91, 52.27, 51.80, 
51.57, 35.57, 29.99 ppm. 
Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-(thiophen-3-yl)pyrrolidine-
2,3,4-tricarboxylate 
157aj: 75% yield; 1H NMR (400 MHz, CDCl3): δ = 7.22 – 7.18 (m, 
1H), 7.16 (d, J = 2.6 Hz, 1H), 6.96 (dd, J = 5.0, 1.2 Hz, 1H), 4.46 (d, J 
= 6.0 Hz, 1H), 3.70 (s, 3H), 3.67 (s, 3H), 3.58 (s, 3H), 3.53-3.48 (m, 
1H), 3.35 (t, J = 6.5 Hz, 1H), 3.31 (s, 3H), 3.23 (d, J = 6.9 Hz, 1H), 2.60 
– 2.48 (m, 1H), 2.36 (ddd, J = 13.4, 9.9, 5.4 Hz, 1H), 2.20 (ddd, J = 15.7, 10.1, 5.4 Hz, 1H), 
2.04 ppm (ddd, J = 13.4, 10.2, 5.2 Hz, 1H). 
Rel-(2S,3R,4S,5R)-trimethyl 2-(3-methoxy-3-oxopropyl)-5-
(naphthalen-2-yl)pyrrolidine-2,3,4-tricarboxylate 
157ak: 83% yield; 1H NMR (400 MHz, CDCl3): δ = 7.85 – 7.76 (m, 
4H), 7.50 – 7.38 (m, 3H), 4.63 (d, J = 5.9 Hz, 1H), 3.80 (s, 3H), 3.74 
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(s, 3H), 3.72 – 3.67 (m, 1H), 3.64 (s, 3H), 3.56 – 3.51 (m, 1H), 3.38 (d, J = 6.9 Hz, 1H), 3.21 
(s, 3H), 2.66 (ddd, J = 15.4, 9.9, 5.2 Hz, 1H), 2.50 (ddd, J = 13.4, 9.9, 5.3 Hz, 1H), 2.36 – 2.27 
(m, 1H), 2.22 – 2.13 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-phenylpyrrolidine-
2,3,4-tricarboxylate 
157al: 71% yield; 1H NMR (500 MHz, CDCl3): δ = 7.29 – 7.12 (m, 
5H), 5.87 (dq, J = 10.6, 5.9 Hz, 1H), 5.37 (dq, J = 10.7, 5.8 Hz, 1H), 
5.27 (d, J = 17.2 Hz, 1H), 5.18 (d, J = 10.4 Hz, 1H), 4.96 – 4.85 (m, 
2H), 4.54 (d, J = 5.8 Hz, 2H), 4.44 (d, J = 6.0 Hz, 1H), 4.13 (dd, J = 
13.0, 5.4 Hz, 1H), 4.06 – 3.96 (m, 1H), 3.69 (s, 3H), 3.64 – 3.59 (m, 1H), 3.56 (s, 3H), 3.44 (t, 
J = 6.7 Hz, 1H), 3.29 (d, J = 7.1 Hz, 1H), 2.53 (ddd, J = 15.4, 9.6, 5.4 Hz, 1H), 2.43 – 2.30 (m, 
1H), 2.22 (ddd, J = 15.7, 9.8, 5.5 Hz, 1H), 2.14 – 2.01 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(o-tolyl)pyrrolidine-
2,3,4-tricarboxylate 
157am: 80% yield; 1H NMR (500 MHz, CDCl3): δ = 7.42 – 7.31 (m, 
1H), 7.20 – 7.03 (m, 3H), 5.93 (ddt, J = 16.4, 10.5, 5.9 Hz, 1H), 5.44 – 
5.29 (m, 2H), 5.24 (dd, J = 10.4, 1.2 Hz, 1H), 4.98 – 4.87 (m, 2H), 4.70 
(d, J = 6.4 Hz, 1H), 4.66 – 4.53 (m, 2H), 4.19 – 4.05 (m, 1H), 3.99 – 
3.90 (m, 1H), 3.78 (s, 3H), 3.75 – 3.65 (m, 1H), 3.62 (s, 3H), 3.56 (t, J = 6.9 Hz, 1H), 3.38 (d, 
J = 7.2 Hz, 1H), 2.63 – 2.53 (m, 1H), 2.46 (ddd, J = 13.6, 9.7, 5.5 Hz, 1H), 2.33 (s, 3H), 2.32 
– 2.26 (m, 1H), 2.16 ppm (ddd, J = 13.6, 9.9, 5.4 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(m-
tolyl)pyrrolidine-2,3,4-tricarboxylate 
157an: 65% yield; 1H NMR (500 MHz, CDCl3): δ = 7.18 (t, J = 7.9 Hz, 
1H), 7.11 (d, J = 6.1 Hz, 2H), 7.05 (d, J = 7.4 Hz, 1H), 5.93 (ddd, J = 
16.4, 10.6, 5.7 Hz, 1H), 5.45 (ddd, J = 16.6, 8.3, 5.3 Hz, 1H), 5.34 (dd, 
J = 17.2, 1.3 Hz, 1H), 5.25 (dd, J = 10.4, 1.0 Hz, 1H), 5.04 – 4.94 (m, 
2H), 4.65 – 4.57 (m, 2H), 4.47 – 4.45 (m, 1H), 4.21 (dd, J = 13.0, 6.1 Hz, 1H), 4.13 (dd, J = 
13.0, 5.8 Hz, 1H), 3.76 (s, 3H), 3.71 – 3.67  (m, 1H), 3.64 (s, 3H), 3.35 (d, J = 7.1 Hz, 1H), 
2.61 (ddd, J = 15.5, 9.7, 5.4 Hz, 1H), 2.44 (ddd, J = 13.9, 9.7, 5.6 Hz, 1H), 2.31 (s, 3H), 2.30 
– 2.24 (m, 1H), 2.14 ppm (ddd, J = 13.9, 9.9, 5.4 Hz, 1H). 
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Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(p-tolyl)pyrrolidine-
2,3,4-tricarboxylate 
157ao: 84% yield; 1H NMR (500 MHz, CDCl3): δ = 7.19 (d, J = 8.1 
Hz, 2H), 7.09 (d, J = 8.0 Hz, 2H), 5.93 (ddt, J = 22.5, 10.5, 5.9 Hz, 
1H), 5.46 (ddt, J = 16.5, 10.6, 6.0 Hz, 1H), 5.34 (dd, J = 17.2, 1.4 
Hz, 1H), 5.30 – 5.19 (m, 1H), 5.05 – 4.92 (m, 2H), 4.61 (dd, J = 5.8, 
1.0 Hz, 2H), 4.47 (d, J = 6.2 Hz, 1H), 4.21 (dd, J = 13.0, 6.1 Hz, 1H), 4.11 (dd, J = 13.0, 5.9 
Hz, 1H), 3.75 (s, 3H), 3.63 (s, 4H), 3.47 (t, J = 6.7 Hz, 1H), 3.34 (d, J = 7.1 Hz, 1H), 2.60 (ddd, 
J = 15.5, 9.7, 5.4 Hz, 1H), 2.43 (ddd, J = 13.7, 9.7, 5.6 Hz, 1H), 2.30 (s, 3H), 2.26 (dd, J = 
10.1, 5.7 Hz, 1H), 2.13 ppm (ddd, J = 13.7, 9.9, 5.5 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(2-fluorophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157ap: 78% yield; 1H NMR (400 MHz, CDCl3): δ = 7.41 (t, J = 7.2 Hz, 
1H), 7.34 – 7.20 (m, 1H), 7.11 (dd, J = 11.0, 4.1 Hz, 1H), 7.02 (dd, J = 
14.1, 4.6 Hz, 1H), 5.93 (ddt, J = 16.3, 10.5, 5.8 Hz, 1H), 5.53 – 5.39 
(m, 1H), 5.34 (dd, J = 17.2, 1.4 Hz, 1H), 5.25 (dd, J = 10.4, 1.2 Hz, 1H), 
5.01 (d, J = 0.8 Hz, 1H), 4.99 – 4.93 (m, 1H), 4.74 – 4.72 (s, 1H), 4.67 – 4.54 (m, 2H), 4.18 
(dd, J = 13.0, 6.1 Hz, 1H), 4.10 (dd, J = 13.0, 5.8 Hz, 1H), 3.79 – 3.77 (s, 3H), 3.70 – 3.54 (m, 
4H), 3.41 (d, J = 7.2 Hz, 1H), 2.60 (ddd, J = 15.2, 9.7, 5.2 Hz, 1H), 2.52 – 2.39 (m, 1H), 2.30 
(ddd, J = 15.3, 9.9, 5.1 Hz, 1H), 2.16 ppm (ddd, J = 13.5, 10.0, 5.2 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(3-fluorophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157aq: 89% yield; 1H NMR (400 MHz, CDCl3): δ = 7.29 – 7.15 (m, 
1H), 7.06 (d, J = 7.8 Hz, 1H), 7.01 (d, J = 10.0 Hz, 1H), 6.88 (td, J = 
8.3, 2.1 Hz, 1H), 5.87 (ddt, J = 16.3, 10.5, 5.9 Hz, 1H), 5.43 (ddt, J = 
16.7, 10.8, 6.0 Hz, 1H), 5.29 (dd, J = 17.2, 1.4 Hz, 1H), 5.20 (dd, J = 
10.4, 1.1 Hz, 1H), 4.98 (d, J = 1.3 Hz, 1H), 4.95 (dd, J = 9.2, 1.2 Hz, 1H), 4.55 (dd, J = 5.8, 
0.9 Hz, 2H), 4.43 (d, J = 4.0 Hz, 1H), 4.17 (dd, J = 12.9, 6.1 Hz, 1H), 4.10 (dd, J = 12.9, 6.0 
Hz, 1H), 3.70 (s, 3H), 3.64 – 3.49 (m, 4H), 3.46 (t, J = 6.7 Hz, 1H), 3.30 (d, J = 7.1 Hz, 1H), 
2.60 – 2.44 (m, 1H), 2.45 – 2.31 (m, 1H), 2.27 – 2.14 (m, 1H), 2.07 (ddd, J = 13.6, 9.7, 5.5 Hz, 
1H). 13C NMR (101 MHz, CDCl3): δ = 173.65, 172.85, 170.08, 169.98, 164.01, 161.56, 140.06, 
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139.99, 131.92, 131.67, 130.03, 129.95, 122.59, 122.56, 118.77, 118.53, 114.81, 114.60, 
114.29, 114.06, 77.48, 77.16, 76.84, 71.60, 66.07, 65.39, 63.40, 57.72, 53.06, 52.82, 51.80, 
35.26, 30.08. 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(4-fluorophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157ar: 84% yield; 1H NMR (400 MHz, CDCl3): δ = 7.30 (dd, J = 
8.5, 5.3 Hz, 2H), 6.97 (t, J = 8.7 Hz, 2H), 5.92 (ddt, J = 16.3, 10.4, 
5.9 Hz, 1H), 5.46 (ddt, J = 16.6, 10.5, 6.0 Hz, 1H), 5.33 (dd, J = 
17.2, 1.4 Hz, 1H), 5.24 (dd, J = 10.4, 1.2 Hz, 1H), 5.07 – 4.93 (m, 
2H), 4.60 (dd, J = 4.7, 1.2 Hz, 2H), 4.48 (d, J = 6.1 Hz, 1H), 4.25 – 4.15 (m, 1H), 4.14 – 4.03 
(m, 1H), 3.74 (s, 3H), 3.62 (s, 3H), 3.56 – 3.54 (m, 1H), 3.49 (t, J = 6.9 Hz, 1H), 3.34 (d, J = 
7.2 Hz, 1H), 2.62 – 2.50 (m, 1H), 2.41 (ddd, J = 13.5, 9.5, 5.5 Hz, 1H), 2.30 – 2.20 (m, 1H), 
2.11 ppm (ddd, J = 13.5, 9.7, 5.5 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ = 173.69, 173.03, 
170.21, 170.20, 163.60, 161.15, 133.19, 133.16, 131.97, 131.71, 128.80, 128.72, 118.80, 
118.51, 115.46, 115.24, 71.70, 66.10, 65.39, 63.34, 57.49, 53.26, 52.85, 51.84, 35.14, 30.05 
ppm; HRMS: calc. for [M+H]+ C24H29FNO8: 478.18717, found 478.18727. 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(4-bromophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157as: 88% yield; 1H NMR (400 MHz, CDCl3): δ = 7.40 (d, J = 
8.5 Hz, 2H), 7.20 (d, J = 8.4 Hz, 2H), 5.91 (ddt, J = 16.3, 10.5, 5.9 
Hz, 1H), 5.45 (ddt, J = 16.6, 10.5, 6.1 Hz, 1H), 5.33 (dd, J = 17.2, 
1.4 Hz, 1H), 5.24 (dd, J = 10.4, 1.1 Hz, 1H), 5.09 – 4.93 (m, 2H), 
4.59 (d, J = 5.9 Hz, 2H), 4.45 (d, J = 5.9 Hz, 1H), 4.20 (dd, J = 12.9, 6.1 Hz, 1H), 4.13 (dd, J 
= 12.9, 6.0 Hz, 1H), 3.73 (s, 3H), 3.61 (s, 3H), 3.57 – 3.55 (m, 1H), 3.49 (t, J = 6.8 Hz, 1H), 
3.34 (d, J = 7.2 Hz, 1H), 2.62 – 2.48 (m, 1H), 2.46 – 2.35 (m, 1H), 2.34 – 2.18 (m, 1H), 2.11 
ppm (ddd, J = 13.6, 9.6, 5.5 Hz, 1H); 13C NMR (101 MHz, CDCl3): δ = 173.61, 172.90, 170.05, 
170.02, 136.47, 131.90, 131.61, 131.51, 128.73, 121.71, 118.76, 118.58, 71.64, 66.05, 65.38, 
63.32, 57.55, 53.06, 52.81, 51.79, 35.11, 30.03 ppm. 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(4-
(trifluoromethyl)phenyl)pyrrolidine-2,3,4-tricarboxylate 
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157at: 83% yield; 1H NMR (500 MHz, CDCl3): δ = 7.55 (d, J = 8.3 
Hz, 2H), 7.46 (d, J = 8.2 Hz, 2H), 5.92 (ddt, J = 16.4, 10.6, 5.9 Hz, 
1H), 5.39 (ddd, J = 17.1, 8.3, 3.8 Hz, 1H), 5.36 – 5.29 (m, 1H), 
5.24 (dd, J = 10.4, 1.0 Hz, 1H), 5.01 – 4.87 (m, 2H), 4.60 (d, J = 
5.9 Hz, 2H), 4.56 (d, J = 5.4 Hz, 1H), 4.14 (qd, J = 12.9, 6.1 Hz, 2H), 3.75 (s, 3H), 3.67 – 3.65 
(m, 1H), 3.61 (d, J = 14.3 Hz, 3H), 3.55 (t, J = 6.8 Hz, 1H), 3.38 (d, J = 7.2 Hz, 1H), 2.62 – 
2.50 (m, 1H), 2.49 – 2.34 (m, 1H), 2.33 – 2.22 (m, 1H), 2.14 ppm (ddd, J = 13.8, 9.4, 5.7 Hz, 
1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(4-
methoxyphenyl)pyrrolidine-2,3,4-tricarboxylate 
157au: 61% yield; 1H NMR (400 MHz, CDCl3): δ = 7.23 (d, J = 
8.7 Hz, 2H), 6.81 (d, J = 8.7 Hz, 2H), 5.93 (ddt, J = 16.3, 10.5, 
5.9 Hz, 1H), 5.47 (ddt, J = 16.7, 10.7, 6.0 Hz, 1H), 5.33 (dd, J = 
17.2, 1.4 Hz, 1H), 5.24 (dd, J = 10.4, 1.2 Hz, 1H), 4.99 (ddd, J = 
11.7, 6.5, 1.2 Hz, 2H), 4.60 (d, J = 5.8 Hz, 2H), 4.47 (d, J = 6.5 Hz, 1H), 4.22 (dd, J = 13.0, 
6.1 Hz, 1H), 4.14 – 3.99 (m, 1H), 3.76 (s, 3H), 3.74 (s, 3H), 3.62 (s, 3H), 3.45 (t, J = 6.8 Hz, 
1H), 3.33 (d, J = 7.1 Hz, 1H), 2.66 – 2.51 (m, 1H), 2.42 (ddd, J = 13.5, 9.7, 5.4 Hz, 1H), 2.26 
(ddd, J = 15.6, 9.9, 5.4 Hz, 1H), 2.19 – 2.03 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(4-(allyloxy)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157av: 82% yield; 1H NMR (400 MHz, CDCl3): δ = 7.22 – 7.13 
(m, 2H), 6.78 (d, J = 8.7 Hz, 2H), 6.03 – 5.92 (m, 1H), 5.92 – 5.81 
(m, 1H), 5.42 (ddt, J = 16.7, 10.7, 6.0 Hz, 1H), 5.30 (td, J = 17.1, 
1.5 Hz, 2H), 5.20 (ddd, J = 10.2, 7.3, 1.3 Hz, 2H), 5.01 – 4.87 (m, 
2H), 4.55 (d, J = 5.8 Hz, 2H), 4.44 (dd, J = 3.9, 1.3 Hz, 2H), 4.41 (d, J = 6.4 Hz, 1H), 4.17 (dd, 
J = 13.0, 6.1 Hz, 1H), 4.05 (dd, J = 13.0, 5.8 Hz, 1H), 3.69 (s, 3H), 3.66 – 3.59 (m, 1H), 3.57 
(s, 3H), 3.40 (t, J = 6.8 Hz, 1H), 3.28 (d, J = 7.1 Hz, 1H), 2.65 – 2.45 (m, 1H), 2.45 – 2.29 (m, 
1H), 2.21 (ddd, J = 15.6, 9.9, 5.4 Hz, 1H), 2.13 – 1.95 ppm (m, 1H); HRMS: calc. for [M+H]+ 
C27H34NO9: 516.22281, found 516.22322. 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(4-(benzyloxy)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
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157aw: 71% yield; 1H NMR (400 MHz, CDCl3): δ = 7.41 – 7.13 
(m, 8H), 6.84 (d, J = 8.7 Hz, 2H), 5.94 – 5.80 (m, 1H), 5.40 (ddd, 
J = 16.9, 8.9, 5.6 Hz, 1H), 5.28 (dd, J = 17.2, 1.4 Hz, 1H), 5.19 
(dd, J = 10.4, 1.1 Hz, 1H), 5.01 – 4.86 (m, 4H), 4.55 (d, J = 5.8 
Hz, 2H), 4.41 (d, J = 6.3 Hz, 1H), 4.16 (dd, J = 13.0, 6.1 Hz, 1H), 4.03 (dd, J = 13.0, 5.9 Hz, 
1H), 3.69 (s, 3H), 3.57 (s, 3H), 3.51 – 3.49 (m, 1H), 3.40 (t, J = 6.8 Hz, 1H), 3.27 (d, J = 7.1 
Hz, 1H), 2.62 – 2.45 (m, 1H), 2.45 – 2.26 (m, 1H), 2.21 (ddd, J = 15.6, 9.9, 5.4 Hz, 1H), 2.06 
ppm (ddd, J = 13.5, 9.9, 5.3 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(4-(dimethylamino)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157ax: 43% yield; 1H NMR (500 MHz, CDCl3): δ = 7.17 (d, J = 
8.6 Hz, 2H), 6.65 (d, J = 8.6 Hz, 2H), 5.99 – 5.89 (m, 1H), 5.55 – 
5.43 (m, 1H), 5.34 (d, J = 17.2 Hz, 1H), 5.24 (d, J = 10.4 Hz, 1H), 
4.99 (dd, J = 9.9, 6.4 Hz, 2H), 4.62 (d, J = 5.8 Hz, 2H), 4.43 (d, J 
= 6.2 Hz, 1H), 4.24 (ddd, J = 13.0, 6.1, 0.9 Hz, 1H), 4.14 (ddd, J = 13.1, 5.8, 1.0 Hz, 1H), 3.75 
(s, 3H), 3.64 (s, 3H), 3.61 – 3.46 (m, 1H), 3.43 (t, J = 6.8 Hz, 1H), 3.32 (d, J = 7.1 Hz, 1H), 
2.90 (s, 6H), 2.62 – 2.57 (m, 1 H), 2.44 – 2.39 (m, 1H), 2.30 – 2.24 (m, 1H), 2.16 – 2.12 ppm 
(m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(3,4-dimethoxyphenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157ay: 44% yield; 1H NMR (400 MHz, CDCl3): δ = 6.92 – 6.83 
(m, 2H), 6.77 (d, J = 8.9 Hz, 1H), 5.99 – 5.84 (m, 1H), 5.53 – 5.39 
(m, 1H), 5.39 – 5.19 (m, 2H), 5.06 – 4.93 (m, 2H), 4.60 (d, J = 5.9 
Hz, 2H), 4.46 (d, J = 6.5 Hz, 1H), 4.22 (dd, J = 13.0, 6.0 Hz, 1H), 
4.16 – 4.04 (m, 1H), 3.83 (d, J = 2.8 Hz, 6H), 3.73 (s, 3H), 3.62 (s, 3H), 3.55 – 3.50  (m, 1H), 
3.50 (t, J = 7.0 Hz, 1H), 3.32 (d, J = 7.3 Hz, 1H), 2.67 – 2.50 (m, 1H), 2.39 (ddd, J = 13.4, 9.5, 
5.5 Hz, 1H), 2.34 – 2.17 (m, 1H), 2.11 ppm (ddd, J = 13.4, 9.8, 5.4 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 5-(furan-2-yl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
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157az: 79% yield; 1H NMR (500 MHz, CDCl3): δ = 7.37 – 7.27 (m, 
1H), 6.35 – 6.21 (m, 2H), 5.92 (ddt, J = 16.3, 10.5, 5.9 Hz, 1H), 5.67 
(ddt, J = 16.4, 10.4, 6.0 Hz, 1H), 5.37 – 5.29 (m, 1H), 5.23 (dd, J = 
10.4, 1.2 Hz, 1H), 5.18 – 5.06 (m, 2H), 4.59 (ddd, J = 5.6, 2.8, 1.3 Hz, 
2H), 4.49 (d, J = 6.3 Hz, 1H), 4.42 – 4.34 (m, 1H), 4.31 (ddt, J = 13.1, 5.9, 1.2 Hz, 1H), 3.73 
(s, 3H), 3.68 – 3.56 (m, 4H), 3.44 (t, J = 6.7 Hz, 1H), 3.27 (d, J = 7.0 Hz, 1H), 2.64 – 2.48 (m, 
1H), 2.39 (ddd, J = 13.6, 9.7, 5.6 Hz, 1H), 2.24 (ddd, J = 15.8, 9.9, 5.6 Hz, 1H), 2.07 ppm (ddd, 
J = 13.7, 9.9, 5.4 Hz, 1H); 13C NMR (126 MHz, CDCl3): δ = 173.59, 172.78, 170.20, 169.78, 
151.06, 142.03, 132.06, 118.65, 118.36, 110.49, 107.44, 71.29, 66.02, 65.57, 58.28, 57.15, 
52.75, 51.98, 51.73, 35.32, 29.98 ppm. 
Rel-(2S,3R,4S,5R)-3,4-diallyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(naphthalen-2-
yl)pyrrolidine-2,3,4-tricarboxylate 
157ba: 86% yield; 1H NMR (500 MHz, CDCl3): δ = 7.83 – 7.72 (m, 
4H), 7.51 – 7.35 (m, 3H), 5.95 (ddt, J = 22.4, 10.5, 5.9 Hz, 1H), 5.30 
(dddd, J = 23.9, 19.7, 15.9, 7.5 Hz, 3H), 4.79 (ddd, J = 13.8, 11.5, 
1.3 Hz, 2H), 4.75 – 4.52 (m, 3H), 4.19 – 4.07 (m, 1H), 4.06 – 3.95 
(m, 1H), 3.94 – 3.81 (m, 1H), 3.78 (s, 3H), 3.64 (s, 3H), 3.61 (t, J = 6.7 Hz, 1H), 3.42 (d, J = 
7.1 Hz, 1H), 2.65 (ddd, J = 15.4, 9.6, 5.5 Hz, 1H), 2.49 (ddd, J = 13.7, 9.6, 5.5 Hz, 1H), 2.39 – 
2.27 (m, 1H), 2.25 – 2.07 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-
phenylpyrrolidine-2,3,4-tricarboxylate 
157bb: 83% yield; 1H NMR (500 MHz, CDCl3): δ = 7.37 – 7.07 (m, 
14H), 6.85 – 6.77 (m, 2H), 5.06 (s, 2H), 4.61 (d, J = 12.2 Hz, 1H), 4.45 
(d, J = 12.1 Hz, 2H), 3.75 – 3.61 (m, 1H), 3.56 (s, 3H), 3.55 (s, 3H), 
3.47 (t, J = 6.7 Hz, 1H), 3.32 (d, J = 7.1 Hz, 1H), 2.57 – 2.45 (m, 1H), 
2.43 – 2.30 (m, 1H), 2.27 – 2.14 (m, 1H), 2.12 – 2.00 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(o-
tolyl)pyrrolidine-2,3,4-tricarboxylate 
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157bc: 72% yield; 1H NMR (400 MHz, CDCl3): δ = 7.39 – 7.18 (m, 6H), 
7.18 – 6.95 (m, 6H), 6.75 (dd, J = 7.4, 1.8 Hz, 2H), 5.04 (t, J = 6.6 Hz, 
2H), 4.63 (d, J = 5.9 Hz, 1H), 4.53 (d, J = 12.1 Hz, 1H), 4.30 (d, J = 12.1 
Hz, 1H), 3.70 – 3.62 (m, 1H), 3.59 (s, 3H), 3.53 (s, 3H), 3.50 (d, J = 6.8 
Hz, 1H), 3.34 (d, J = 7.1 Hz, 1H), 2.60 – 2.45 (m, 1H), 2.44 – 2.35 (m, 1H), 2.26 – 2.16 (m, 
4H), 2.09 ppm (ddd, J = 13.5, 9.7, 5.1 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(m-
tolyl)pyrrolidine-2,3,4-tricarboxylate 
157bd: 70% yield; 1H NMR (400 MHz, CDCl3) δ 7.35 – 7.10 (m, 8H), 
7.10 – 6.93 (m, 4H), 6.79 (dd, J = 7.5, 1.7 Hz, 2H), 5.05 (d, J = 1.3 Hz, 
2H), 4.59 (d, J = 12.2 Hz, 1H), 4.48 (d, J = 12.2 Hz, 1H), 4.39 (s, 1H), 
3.64 – 3.62  (m, 1H), 3.55 (s, 3H), 3.54 (s, 3H), 3.45 (t, J = 6.6 Hz, 1H), 
3.30 (d, J = 7.1 Hz, 1H), 2.57 – 2.45 (m, 1H), 2.45 – 2.29 (m, 1H), 2.28 – 2.10 (m, 4H), 2.10 – 
2.01 ppm (m, 1H). 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(2-fluorophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157be: 82% yield; 1H NMR (500 MHz, CDCl3): δ 7.46 – 7.30 (m, 6H), 
7.32 – 7.18 (m, 4H), 7.09 (t, J = 7.6 Hz, 1H), 7.01 – 6.93 (m, 3H), 5.13 
(s, 2H), 4.75 (d, J = 3.9 Hz, 1H), 4.69 (d, J = 12.2 Hz, 1H), 4.57 (d, J = 
12.2 Hz, 1H), 3.80 (d, J = 6.7 Hz, 1H), 3.72 – 3.66 (m, 4H), 3.65 (s, 
3H), 3.46 (d, J = 7.2 Hz, 1H), 2.61 (ddd, J = 15.3, 9.5, 5.4 Hz, 1H), 2.54 – 2.44 (m, 1H), 2.32 
(ddd, J = 15.5, 9.7, 5.4 Hz, 1H), 2.18 ppm (ddd, J = 13.9, 9.8, 5.4 Hz, 1H). 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(3-fluorophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157bf: 85% yield; 1H NMR (400 MHz, CDCl3): δ 7.35 – 7.14 (m, 8H), 
7.12 (dd, J = 8.0, 6.0 Hz, 1H), 7.00 (dd, J = 15.0, 8.9 Hz, 2H), 6.85 (ddd, 
J = 10.3, 7.5, 1.8 Hz, 3H), 5.05 (s, 2H), 4.63 (d, J = 12.1 Hz, 1H), 4.53 
(d, J = 12.1 Hz, 1H), 4.40 (d, J = 4.9 Hz, 1H), 3.68 – 3.51 (m, 7H), 3.48 
(t, J = 6.7 Hz, 1H), 3.31 (d, J = 7.1 Hz, 1H), 2.55 – 2.42 (m, 1H), 2.42 – 2.27 (m, 1H), 2.27 – 
2.12 (m, 1H), 2.12 – 2.00 ppm (m, 1H); HRMS: calc. for [M+H]+ C32H33FNO8: 578.21847, 
found 578.21735. 
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Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(4-fluorophenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157bg: 87% yield; 1H NMR (400 MHz, CDCl3): δ 7.36 – 7.09 (m, 
10H), 6.92 – 6.78 (m, 4H), 5.05 (d, J = 12.8 Hz, 2H), 4.63 (d, J = 
12.1 Hz, 1H), 4.54 (d, J = 12.1 Hz, 1H), 4.42 (d, J = 5.9 Hz, 1H), 
3.56 (s, 3H), 3.56 (s, 3H), 3.47 (t, J = 6.9 Hz, 1H), 3.31 (d, J = 7.2 
Hz, 1H), 2.58 – 2.43 (m, 1H), 2.43 – 2.27 (m, 1H), 2.27 – 2.14 (m, 1H), 2.14 – 1.96 ppm (m, 
1H); 13C NMR (126 MHz, CDCl3): δ = 173.62, 172.94, 170.37, 170.27, 163.35, 161.39, 135.58, 
135.30, 133.06, 128.80, 128.74, 128.71, 128.59, 128.51, 128.43, 128.26, 115.47, 115.30, 71.82, 
67.33, 66.52, 63.39, 57.62, 53.25, 52.73, 51.81, 35.10, 30.08 ppm; HRMS: calc. for [M+H]+ 
C32H33FNO8: 578.21847, found 578.21911. 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(4-(allyloxy)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157bh: 65% yield; 1H NMR (500 MHz, CDCl3): δ 7.44 – 7.21 
(m, 10H), 6.98 – 6.91 (m, 2H), 6.83 (d, J = 8.7 Hz, 2H), 6.07 
(ddd, J = 11.8, 10.5, 5.2 Hz, 1H), 5.43 (dd, J = 17.3, 1.5 Hz, 1H), 
5.35 – 5.26 (m, 1H), 5.16 (s, 2H), 4.73 (d, J = 12.2 Hz, 1H), 4.61 
(d, J = 12.2 Hz, 1H), 4.55 – 4.44 (m, 3H), 3.66 (s, 3H), 3.65 (s, 3H), 3.53 (t, J = 6.8 Hz, 1H), 
3.40 (d, J = 7.1 Hz, 1H), 2.65 – 2.55 (m, 1H), 2.51 – 2.38 (m, 1H), 2.36 – 2.23 (m, 1H), 2.21 – 
2.12 ppm (m, 1H); 13C NMR (126 MHz, CDCl3): δ 173.67, 173.11, 170.63, 170.35, 158.31, 
135.67, 135.46, 133.34, 129.42, 128.71, 128.68, 128.49, 128.44, 128.35, 128.20, 128.11, 
117.81, 114.72, 71.72, 68.87, 67.25, 66.44, 63.67, 57.53, 53.38, 52.67, 51.78, 35.25, 30.09 
ppm; HRMS: calc. for [M+H]+ C35H38NO9: 616.25411, found 616.25515. 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(4-(benzyloxy)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157bi: 68% yield; 1H NMR (400 MHz, CDCl3): δ 7.39 – 7.02 (m, 
16H), 6.90 – 6.74 (m, 4H), 5.06 (s, 2H), 4.94 (s, 2H), 4.62 (d, J = 
12.2 Hz, 1H), 4.49 (d, J = 12.2 Hz, 1H), 4.42 – 4.38 (m, 1H), 3.55 
(s, 3H), 3.55 (s, 3H), 3.43 (t, J = 6.8 Hz, 1H), 3.29 (d, J = 7.1 Hz, 
1H), 2.59 – 2.43 (m, 1H), 2.43 – 2.28 (m, 1H), 2.19 (ddd, J = 15.5, 9.7, 5.5 Hz, 1H), 2.04 ppm 
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(ddd, J = 26.5, 15.9, 11.1 Hz, 1H); HRMS: calc. for [M+H]+ C39H40NO9: 666.26976, found 
666.26928. 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(4-(dimethylamino)phenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157bj: 42% yield; 1H NMR (400 MHz, CDCl3): δ 7.40 – 7.05 (m, 
11H), 6.83 (dd, J = 7.5, 1.7 Hz, 2H), 6.55 (d, J = 8.8 Hz, 2H), 5.19 
– 5.01 (m, 2H), 4.62 (d, J = 12.2 Hz, 1H), 4.54 (d, J = 12.2 Hz, 1H), 
4.37 (s, 1H), 3.63 – 3.44 (m, 7H), 3.45 – 3.35 (m, 1H), 3.29 (t, J = 
5.7 Hz, 1H), 2.85 (s, 6H), 2.63 – 2.44 (m, 1H), 2.44 – 2.27 (m, 1H), 2.20 (ddd, J = 15.6, 9.8, 
5.5 Hz, 1H), 2.14 – 1.95 ppm (m, 1H); HRMS: calc. for [M+H]+ C34H39N2O8: 603.27009, found 
603.26802. 
Rel-(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 5-(3,4-dimethoxyphenyl)-2-(3-methoxy-3-
oxopropyl)pyrrolidine-2,3,4-tricarboxylate 
157bk: 53% yield; 1H NMR (500 MHz, CDCl3): δ = 7.41 – 7.22 
(m, 11H), 7.22 – 7.06 (m, 7H), 6.89 – 6.73 (m, 8H), 6.66 (d, J = 
8.9 Hz, 2H), 5.14 – 4.98 (m, 4H), 4.63 (d, J = 12.2 Hz, 2H), 4.54 
(d, J = 12.2 Hz, 2H), 4.41 (d, J = 6.7 Hz, 2H), 3.78 (s, 6H), 3.70 
(s, 6H), 3.56 (d, J = 1.5 Hz, 12H), 3.50 (t, J = 7.0 Hz, 3H), 3.31 (d, J = 7.3 Hz, 2H), 2.62 – 2.42 
(m, 2H), 2.34 (ddd, J = 13.7, 9.4, 5.7 Hz, 2H), 2.28 – 2.14 (m, 2H), 2.13 – 1.96 ppm (m, 2H). 
(2S,3R,4S,5R)-3,4-dibenzyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-(thiophen-3-
yl)pyrrolidine-2,3,4-tricarboxylate 
157bl: 82% yield; 1H NMR (400 MHz, CDCl3): δ 7.35 – 7.09 (m, 10H), 
6.94 (dd, J = 5.6, 3.4 Hz, 3H), 5.06 (s, 2H), 4.70 (d, J = 12.1 Hz, 1H), 
4.54 (d, J = 12.1 Hz, 1H), 4.47 (d, J = 5.8 Hz, 1H), 3.56 (d, J = 7.1 Hz, 
3H), 3.54 (s, 3H), 3.43 (t, J = 6.8 Hz, 1H), 3.28 (d, J = 7.1 Hz, 1H), 2.56 
– 2.43 (m, 1H), 2.42 – 2.26 (m, 1H), 2.26 – 2.11 (m, 1H), 2.11 – 1.98 ppm (m, 1H). 
Rel-(2S,3R,4S,5S)-3,4-dibenzyl 2-methyl 2-(3-methoxy-3-oxopropyl)-5-((E)-4-
methoxystyryl)pyrrolidine-2,3,4-tricarboxylate 
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157bm: 53% yield; 1H NMR (400 MHz, CDCl3): δ 7.42 – 7.22 
(m, 5H), 7.22 – 7.09 (m, 5H), 7.04 (d, J = 8.7 Hz, 2H), 6.72 (d, J 
= 8.7 Hz, 2H), 6.39 (d, J = 15.7 Hz, 1H), 5.89 (dd, J = 15.7, 8.3 
Hz, 1H), 5.04 (q, J = 12.2 Hz, 2H), 4.90 (q, J = 12.1 Hz, 2H), 3.96 
(t, J = 7.8 Hz, 1H), 3.76 – 3.62 (m, 4H), 3.56 (s, 3H), 3.51 (s, 3H), 3.41 (t, J = 7.3 Hz, 1H), 
3.20 (d, J = 7.4 Hz, 1H), 2.51 – 2.36 (m, 1H), 2.30 – 2.03 (m, 2H), 2.03 – 1.90 ppm (m, 1H). 
 
7.3.2 Experimental Detail and Analytic Data for Synthesis of Pyrrolizidines 158aa-bv 
General Method: The specific pyrrolidine was disovled into 5 mL solvent of toluene/AcOH 
(4:1). The mixture was allowed to be stirred under reflux until full conversion indicated by 
TLC.  
Rel-(1S,2S,3R,7aS)-trimethyl 3-(4-fluorophenyl)-5-oxohexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158aa: 88% yield; 1H NMR (400 MHz, CDCl3): δ 7.33 (dd, J = 8.5, 5.4 Hz, 
2H), 6.97 (t, J = 8.7 Hz, 2H), 5.20 (d, J = 8.0 Hz, 1H), 3.84 (s, 3H), 3.83 – 
3.79 (m, 1H), 3.77 (s, 3H), 3.22 (d, J = 6.9 Hz, 1H), 3.18 (s, 3H), 3.02 (d, J 
= 3.0 Hz, 1H), 2.66 – 2.56 (m, 1H), 2.54 – 2.40 ppm (m, 2H); 13C NMR (101 
MHz, CDCl3): δ 176.84, 171.91, 170.38, 168.24, 163.51, 161.07, 131.84, 
131.81, 128.34, 128.26, 115.19, 114.98, 74.19, 60.09, 55.70, 53.21, 53.03, 52.51, 51.63, 36.23, 
34.04 ppm; HRMS: calc. for [M+H]+ C19H21FNO7: 394.12966, found 394.12872. 
Rel-(1R,2S,3R,7aS)-trimethyl 5-oxo-3-phenylhexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ab: 80% yield; 1H NMR (400 MHz, CDCl3): δ 7.33 – 7.09 (m, 5H), 5.18 
(d, J = 8.0 Hz, 1H), 3.76 (dd, J = 20.8, 10.9 Hz, 7H), 3.17 (d, J = 6.9 Hz, 
1H), 3.07 (s, 3H), 3.06 – 2.89 (m, 1H), 2.55 (dd, J = 12.1, 8.7 Hz, 1H), 2.45 
ppm (dt, J = 7.8, 6.4 Hz, 2H); 13C NMR (101 MHz, CDCl3): δ 176.86, 
171.97, 170.42, 168.34, 135.98, 128.14, 127.66, 126.46, 74.25, 60.72, 55.67, 53.24, 52.98, 
52.48, 51.52, 36.33, 34.10 ppm; HRMS: calc. for [M+H]+ C19H22NO7: 376.13908, found 
376.13900. 
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Rel-(1S,2S,3R,7aS)-trimethyl 5-oxo-3-(o-tolyl)hexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ac: 94% yield; 1H NMR (400 MHz, CDCl3): δ 7.64 – 7.56 (m, 1H), 7.21 
– 6.98 (m, 3H), 5.29 (d, J = 7.8 Hz, 1H), 4.04 – 3.89 (m, 1H), 3.86 (s, 3H), 
3.78 (s, 3H), 3.25 (d, J = 6.8 Hz, 1H), 3.08 (s, 3H), 3.05 (dd, J = 9.0, 3.0 Hz, 
1H), 2.62 (dd, J = 12.2, 8.7 Hz, 1H), 2.56 – 2.41 (m, 2H), 2.33 ppm (s, 3H). 
Rel-(1S,2S,3R,7aS)-trimethyl 5-oxo-3-(m-tolyl)hexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ad: 80% yield; 1H NMR (400 MHz, CDCl3): δ 7.16 (dd, J = 16.0, 9.0 
Hz, 3H), 7.01 (d, J = 6.5 Hz, 1H), 5.21 (d, J = 8.0 Hz, 1H), 3.85 (s, 3H), 
3.82 (d, J = 7.9 Hz, 1H), 3.78 (s, 3H), 3.21 (d, J = 6.9 Hz, 1H), 3.15 (s, 3H), 
3.04 (dt, J = 18.7, 11.7 Hz, 1H), 2.61 (dd, J = 12.1, 8.7 Hz, 1H), 2.51 (dt, J 
= 8.0, 6.3 Hz, 2H), 2.31 ppm (s, 3H). 
Rel-(1S,2S,3R,7aS)-trimethyl 5-oxo-3-(p-tolyl)hexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ae: 95% yield; 1H NMR (500 MHz, CDCl3): δ 7.15 (d, J = 8.0 Hz, 2H), 
7.02 (d, J = 8.1 Hz, 2H), 5.14 (d, J = 8.0 Hz, 1H), 3.77 (s, 3H), 3.77 – 3.72 
(m, 1H), 3.71 (s, 3H), 3.15 (d, J = 6.9 Hz, 1H), 3.10 (s, 3H), 3.00 – 2.87 (m, 
1H), 2.53 (dd, J = 12.1, 8.8 Hz, 1H), 2.43 (dt, J = 7.9, 6.4 Hz, 2H), 2.21 ppm 
(s, 3H). 
Rel-(1R,2S,3R,7aS)-trimethyl 3-(2-fluorophenyl)-5-oxohexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158af: 82% yield; 1H NMR (400 MHz, CDCl3): δ 7.67 – 7.53 (m, 1H), 7.23 
(td, J = 7.4, 1.6 Hz, 1H), 7.11 (dd, J = 10.9, 4.1 Hz, 1H), 6.99 (dd, J = 14.0, 
4.6 Hz, 1H), 5.42 (d, J = 7.8 Hz, 1H), 4.05 – 3.93 (m, 1H), 3.86 (s, 3H), 
3.80 (s, 3H), 3.28 (d, J = 6.9 Hz, 1H), 3.18 (s, 3H), 3.06 (dd, J = 8.3, 3.1 
Hz, 1H), 2.64 (dd, J = 12.1, 8.6 Hz, 1H), 2.58 – 2.41 ppm (m, 2H); 13C NMR (101 MHz, 
CDCl3): δ 176.74, 171.92, 170.58, 168.23, 160.97, 158.53, 129.51, 129.43, 128.67, 128.63, 
124.22, 124.18, 123.58, 123.45, 114.66, 114.45, 73.98, 55.76, 55.72, 55.43, 52.99, 52.47, 
51.95, 51.62, 36.29, 34.10 ppm. 
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Rel-(1S,2S,3R,7aS)-trimethyl 3-(3-fluorophenyl)-5-oxohexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ag: 83% yield; 1H NMR (400 MHz, CDCl3): δ 7.35 – 7.20 (m, 3H), 7.20 
– 7.07 (m, 4H), 7.01 – 6.81 (m, 2H), 5.23 (d, J = 8.1 Hz, 2H), 3.94 – 3.82 
(m, 8H), 3.79 (s, 6H), 3.25 (d, J = 7.0 Hz, 2H), 3.21 (s, 6H), 3.04 (ddd, J = 
16.1, 11.8, 8.3 Hz, 2H), 2.63 (dd, J = 12.3, 8.8 Hz, 2H), 2.59 – 2.41 ppm 
(m, 4H). 13C NMR (101 MHz, CDCl3): δ 176.83, 171.81, 170.21, 168.17, 
163.88, 161.44, 138.90, 138.83, 129.69, 129.60, 122.19, 122.16, 114.70, 114.48, 113.97, 
113.74, 74.14, 60.08, 60.06, 55.68, 53.01, 52.98, 52.49, 51.61, 36.14, 33.95 ppm. 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(4-bromophenyl)-5-oxohexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ah: 87% yield; 1H NMR (400 MHz, CDCl3): δ 7.35 (d, J = 8.5 Hz, 4H), 
7.25 – 7.09 (m, 5H), 5.11 (d, J = 8.1 Hz, 2H), 3.79 – 3.74 (m, 8H), 3.71 (s, 
6H), 3.17 (d, J = 7.0 Hz, 2H), 3.14 (s, 6H), 2.96 (dt, J = 18.8, 11.6 Hz, 2H), 
2.54 (dd, J = 12.1, 8.7 Hz, 2H), 2.44 ppm (dt, J = 7.9, 6.5 Hz, 4H); 13C NMR 
(101 MHz, CDCl3): δ 176.80, 171.84, 170.32, 168.17, 135.24, 131.28, 
128.31, 121.67, 74.14, 60.08, 55.67, 53.03, 52.95, 52.51, 51.68, 36.13, 33.98 ppm. 
Rel-(1S,2S,3R,7aS)-trimethyl 5-oxo-3-(4-(trifluoromethyl)phenyl)hexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158ai: 87% yield; 1H NMR (400 MHz, CDCl3): δ 7.55 (d, J = 8.3 Hz, 2H), 
7.48 (d, J = 8.2 Hz, 2H), 5.26 (d, J = 8.1 Hz, 1H), 3.91 – 3.85 (m, 1H), 3.83 
(s, 3H), 3.77 (s, 3H), 3.26 (d, J = 7.0 Hz, 1H), 3.14 (s, 3H), 3.10 – 2.94 (m, 
1H), 2.61 (dd, J = 12.3, 8.8 Hz, 1H), 2.51 ppm (qd, J = 8.8, 3.0 Hz, 2H). 13C 
NMR (101 MHz, CDCl3): δ 176.84, 171.77, 170.23, 168.09, 140.35, 129.99, 
129.67, 126.97, 125.50, 125.15, 125.11, 125.07, 122.80, 74.14, 60.15, 55.68, 53.05, 52.98, 
52.52, 51.60, 36.10, 33.92 ppm. 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(4-methoxyphenyl)-5-oxohexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
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158aj: 90% yield; 1H NMR (400 MHz, CDCl3): δ 7.34 – 7.18 (m, 2H), 6.81 
(d, J = 8.8 Hz, 2H), 5.19 (d, J = 8.0 Hz, 1H), 3.84 (s, 3H), 3.82 – 3.78 (m, 
1H), 3.77 (s, 3H), 3.75 (s, 3H), 3.21 (d, J = 6.9 Hz, 1H), 3.18 (s, 3H), 3.02 
(dt, J = 18.5, 11.7 Hz, 1H), 2.59 (dd, J = 12.2, 8.7 Hz, 1H), 2.49 ppm (dt, J 
= 8.2, 6.3 Hz, 2H). 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(4-(allyloxy)phenyl)-5-oxohexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158ak: 94% yield; 1H NMR (400 MHz, CDCl3): δ 7.19 (d, J = 9.7 Hz, 5H), 
6.77 (d, J = 8.8 Hz, 4H), 6.02 – 5.88 (m, 2H), 5.31 (dd, J = 17.3, 1.5 Hz, 
2H), 5.24 – 5.08 (m, 4H), 4.47 – 4.38 (m, 4H), 3.78 (s, 6H), 3.73 (d, J = 7.8 
Hz, 2H), 3.71 (s, 6H), 3.15 (d, J = 6.9 Hz, 2H), 3.11 (s, 6H), 3.04 – 2.89 (m, 
2H), 2.53 (dd, J = 12.1, 8.7 Hz, 2H), 2.43 ppm (dt, J = 7.8, 6.5 Hz, 4H); 13C 
NMR (101 MHz, CDCl3): δ 176.80, 172.01, 170.52, 168.37, 158.03, 133.36, 
128.17, 127.64, 117.70, 114.41, 74.21, 68.82, 60.29, 55.60, 53.28, 52.97, 52.46, 51.59, 36.29, 
34.12 ppm; HRMS: calc. for [M+H]+ C22H26NO8: 432.16529, found 432.16540. 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(4-(benzyloxy)phenyl)-5-oxohexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158al: 88% yield; 1H NMR (500 MHz, CDCl3): δ = 7.42 – 7.09 (m, 7H), 
6.82 (d, J = 8.6 Hz, 2H), 5.12 (d, J = 8.0 Hz, 1H), 4.96 (s, 2H), 3.77 (s, 3H), 
3.72 (d, J = 7.3 Hz, 1H), 3.71 (s, 3H), 3.13 (d, J = 6.9 Hz, 1H), 3.09 (s, 3H), 
2.95 (dt, J = 18.2, 11.1 Hz, 1H), 2.58 – 2.49 (m, 1H), 2.47 – 2.36 (m, 2H). 
13C NMR (126 MHz, CDCl3): δ = 176.79, 171.99, 170.49, 168.35, 158.25, 
137.15, 128.63, 128.35, 127.99, 127.71, 127.54, 114.63, 74.24, 70.02, 60.35, 55.66, 53.33, 
52.95, 52.44, 51.57, 36.31, 34.11. 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(4-nitrophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158am: 64% yield; 1H NMR (500 MHz, CDCl3): δ 8.16 (d, J = 8.7 Hz, 2H), 
7.55 (d, J = 8.6 Hz, 2H), 5.28 (d, J = 8.2 Hz, 1H), 3.98 – 3.85 (m, 1H), 3.84 
(s, 3H), 3.79 (s, 3H), 3.28 (d, J = 7.0 Hz, 1H), 3.20 (s, 3H), 3.12 – 2.95 (m, 
1H), 2.63 (dd, J = 12.3, 8.9 Hz, 1H), 2.54 ppm (qd, J = 9.0, 2.7 Hz, 2H). 
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Rel-(1S,2S,3R,7aS)-trimethyl 3-(3,4-dimethoxyphenyl)-5-oxohexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158an: 73% yield; 1H NMR (400 MHz, CDCl3): δ 7.03 – 6.88 (m, 2H), 6.79 
(d, J = 8.3 Hz, 1H), 5.19 (d, J = 8.0 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.83 
(s, 3H), 3.82 – 3.79 (m, 1H), 3.78 (s, 3H), 3.21 (d, J = 7.9 Hz, 4H), 3.09 – 
2.85 (m, 1H), 2.58 (s, 1H), 2.54 – 2.35 ppm (m, 2H). 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(furan-2-yl)-5-oxohexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ao: 82% yield; 1H NMR (500 MHz, CDCl3): δ = 7.29 (s, 1H), 6.37 (d, J 
= 3.2 Hz, 1H), 6.32 – 6.24 (m, 1H), 5.24 (d, J = 8.2 Hz, 1H), 3.85 (t, J = 7.7 
Hz, 1H), 3.82 (s, 3H), 3.77 (s, 3H), 3.41 (s, 3H), 3.17 (d, J = 7.2 Hz, 1H), 
2.96 (dd, J = 8.8, 3.7 Hz, 1H), 2.57 (dd, J = 12.0, 9.0 Hz, 1H), 2.52 – 2.39 
(m, 2H). 
Rel-(1S,2S,3R,7aS)-trimethyl 5-oxo-3-(thiophen-3-yl)hexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
158ap: 82% yield; 1H NMR (500 MHz, CDCl3): δ 7.28 (dd, J = 1.9, 0.9 Hz, 
1H), 7.19 (dd, J = 4.9, 3.1 Hz, 1H), 6.98 (d, J = 5.0 Hz, 1H), 5.26 (d, J = 8.1 
Hz, 1H), 3.82 (s, 3H), 3.81 – 3.77 (m, 1H), 3.77 (s, 3H), 3.24 (s, 3H), 3.19 
(d, J = 7.0 Hz, 1H), 3.04 – 2.92 (m, 1H), 2.58 (dd, J = 12.2, 8.8 Hz, 1H), 
2.53 – 2.42 ppm (m, 2H). 
Rel-(1S,2S,3R,7aS)-trimethyl 3-(naphthalen-2-yl)-5-oxohexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158aq: 86% yield; 1H NMR (400 MHz, CDCl3): δ 7.86 (s, 1H), 7.81 (dd, J 
= 6.2, 3.0 Hz, 1H), 7.77 (dd, J = 8.8, 3.9 Hz, 2H), 7.47 – 7.36 (m, 3H), 5.41 
(d, J = 8.1 Hz, 1H), 3.94 (dd, J = 7.9, 7.2 Hz, 1H), 3.88 (s, 3H), 3.78 (s, 3H), 
3.27 (d, J = 7.0 Hz, 1H), 3.17 – 3.04 (m, 1H), 3.02 (s, 3H), 2.64 (dd, J = 
12.2, 8.8 Hz, 1H), 2.59 – 2.47 ppm (m, 2H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 5-oxo-3-phenylhexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
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158ar: 93% yield; 1H NMR (400 MHz, CDCl3): δ 7.30 (d, J = 7.4 Hz, 2H), 
7.27 – 7.10 (m, 3H), 5.87 (ddd, J = 11.4, 10.5, 5.3 Hz, 1H), 5.37 – 5.23 (m, 
2H), 5.20 (dd, J = 7.6, 4.2 Hz, 2H), 5.02 – 4.89 (m, 2H), 4.62 (qd, J = 13.2, 
5.8 Hz, 2H), 4.06 (dd, J = 12.9, 6.2 Hz, 1H), 3.82 (ddd, J = 14.9, 12.7, 6.9 
Hz, 2H), 3.77 (s, 3H), 3.21 (d, J = 6.9 Hz, 1H), 3.05 – 2.90 (m, 1H), 2.63 – 
2.50 (m, 1H), 2.50 – 2.38 ppm (m, 2H); 13C NMR (101 MHz, CDCl3): δ 176.77, 171.86, 169.65, 
167.43, 135.96, 131.85, 131.70, 128.16, 127.63, 126.62, 118.66, 118.47, 74.24, 66.10, 65.54, 
60.76, 55.77, 53.22, 52.85, 36.32, 34.06 ppm. 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 5-oxo-3-(o-tolyl)hexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158as: 83% yield; 1H NMR (500 MHz, CDCl3): δ 7.62 (d, J = 7.4 Hz, 1H), 
7.12 (dt, J = 16.4, 7.3 Hz, 2H), 7.03 (d, J = 7.4 Hz, 1H), 6.00 – 5.86 (m, 
1H), 5.39 – 5.21 (m, 4H), 5.04 – 4.93 (m, 2H), 4.67 (ddd, J = 30.0, 13.2, 
5.8 Hz, 2H), 4.05 (dd, J = 12.9, 6.3 Hz, 1H), 3.93 (t, J = 7.3 Hz, 1H), 3.88 
– 3.78 (m, 4H), 3.28 (d, J = 6.8 Hz, 1H), 3.13 – 2.96 (m, 1H), 2.66 – 2.57 
(m, 1H), 2.56 – 2.44 (m, 2H), 2.32 ppm (s, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 5-oxo-3-(m-tolyl)hexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158at: 94% yield; 1H NMR (400 MHz, CDCl3): δ 7.23 – 7.07 (m, 3H), 7.01 
(d, J = 6.6 Hz, 1H), 5.95 (ddd, J = 16.3, 11.0, 5.8 Hz, 1H), 5.43 – 5.17 (m, 
5H), 5.02 (dd, J = 13.6, 2.1 Hz, 1H), 4.71 (dd, J = 13.2, 5.9 Hz, 1H), 4.65 
(dd, J = 13.2, 5.7 Hz, 1H), 4.11 (dd, J = 12.9, 6.2 Hz, 1H), 3.94 (dd, J = 
12.9, 5.9 Hz, 1H), 3.88 – 3.77 (m, 4H), 3.25 (d, J = 6.9 Hz, 1H), 3.13 – 2.94 
(m, 1H), 2.61 (dd, J = 19.5, 11.5 Hz, 1H), 2.57 – 2.43 (m, 2H), 2.30 ppm (s, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 5-oxo-3-(p-tolyl)hexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158au: 91% yield; 1H NMR (500 MHz, CDCl3): δ 7.18 (dd, J = 12.0, 4.3 
Hz, 2H), 7.01 (d, J = 8.1 Hz, 2H), 5.87 (ddt, J = 16.9, 11.4, 5.8 Hz, 1H), 
5.38 – 5.22 (m, 2H), 5.17 (dd, J = 19.6, 9.2 Hz, 2H), 4.99 – 4.88 (m, 2H), 
4.60 (qd, J = 13.2, 5.8 Hz, 2H), 4.06 (dd, J = 12.9, 6.2 Hz, 1H), 3.87 (dd, 
J = 12.9, 5.9 Hz, 1H), 3.79 – 3.71 (m, 4H), 3.18 (d, J = 6.8 Hz, 1H), 3.01 
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– 2.88 (m, 1H), 2.48 (dddd, J = 22.5, 19.7, 13.3, 9.0 Hz, 3H), 2.21 ppm (s, 3H); 13C NMR (126 
MHz, CDCl3): δ 176.70, 171.88, 169.72, 167.45, 137.18, 132.98, 131.93, 131.87, 128.85, 
126.53, 118.62, 118.28, 74.26, 66.07, 65.51, 60.68, 55.82, 53.26, 52.79, 36.34, 34.08, 21.16 
ppm. 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(2-fluorophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158av: 88% yield; 1H NMR (500 MHz, CDCl3): δ 7.60 (dd, J = 7.6, 7.0 Hz, 
1H), 7.19 (dt, J = 7.4, 3.8 Hz, 1H), 7.09 (t, J = 7.6 Hz, 1H), 6.97 – 6.84 (m, 
1H), 5.92 (tdd, J = 11.5, 8.2, 3.2 Hz, 1H), 5.44 – 5.29 (m, 3H), 5.28 – 5.19 
(m, 1H), 5.08 – 4.95 (m, 2H), 4.66 (qd, J = 13.2, 5.8 Hz, 2H), 4.12 (dd, J = 
13.0, 6.1 Hz, 1H), 3.95 (ddd, J = 18.9, 14.5, 6.6 Hz, 2H), 3.81 (d, J = 0.6 
Hz, 3H), 3.29 (d, J = 6.8 Hz, 1H), 3.10 – 2.92 (m, 1H), 2.68 – 2.57 (m, 1H), 2.59 – 2.43 ppm 
(m, 2H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(3-fluorophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158aw: 84% yield; 1H NMR (500 MHz, CDCl3): δ 7.24 – 7.12 (m, 1H), 
7.12 – 6.97 (m, 2H), 6.83 (dd, J = 13.2, 4.9 Hz, 1H), 5.87 (ddt, J = 16.4, 
10.7, 5.8 Hz, 1H), 5.48 – 5.31 (m, 1H), 5.31 – 5.22 (m, 1H), 5.21 – 5.10 (m, 
2H), 5.04 – 4.88 (m, 2H), 4.71 – 4.48 (m, 2H), 4.09 (ddd, J = 12.9, 6.2, 1.1 
Hz, 1H), 3.93 (ddd, J = 12.9, 6.1, 1.1 Hz, 1H), 3.83 – 3.70 (m, 4H), 3.20 (d, 
J = 6.9 Hz, 1H), 3.03 – 2.87 (m, 1H), 2.54 (dd, J = 17.6, 9.6 Hz, 1H), 2.45 ppm (ddd, J = 19.6, 
13.5, 6.6 Hz, 2H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-fluorophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158ax: 83% yield; 1H NMR (500 MHz, CDCl3): δ 7.34 (dd, J = 8.5, 5.4 
Hz, 2H), 6.96 (t, J = 8.7 Hz, 2H), 5.93 (ddt, J = 16.5, 10.7, 5.8 Hz, 1H), 
5.41 (ddt, J = 18.0, 10.1, 6.1 Hz, 1H), 5.34 (dd, J = 17.2, 1.1 Hz, 1H), 5.25 
(dd, J = 10.4, 0.8 Hz, 1H), 5.21 (d, J = 8.1 Hz, 1H), 5.05 (d, J = 0.8 Hz, 
1H), 5.04 – 4.99 (m, 1H), 4.66 (qd, J = 13.2, 5.8 Hz, 2H), 4.14 (dd, J = 12.9, 6.1 Hz, 1H), 3.96 
(dd, J = 12.9, 6.0 Hz, 1H), 3.83 (d, J = 7.3 Hz, 1H), 3.81 (s, 3H), 3.26 (d, J = 6.9 Hz, 1H), 3.08 
– 2.95 (m, 1H), 2.64 – 2.56 (m, 1H), 2.56 – 2.43 ppm (m, 2H); 13C NMR (126 MHz, CDCl3): 
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δ 176.78, 171.83, 169.60, 167.32, 163.40, 161.44, 131.88, 131.85, 131.58, 128.55, 128.49, 
118.77, 118.72, 115.19, 115.02, 74.24, 66.19, 65.67, 60.23, 55.93, 53.28, 52.90, 36.29, 34.02 
ppm; HRMS: calc. for [M+H]+ C23H25FNO7: 446.16096, found 446.16119. 
Rel-(2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-bromophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158ay: 92% yield; 1H NMR (400 MHz, CDCl3): δ 7.34 (d, J = 8.5 Hz, 2H), 
7.27 – 7.14 (m, 2H), 5.99 – 5.75 (m, 1H), 5.41 – 5.24 (m, 2H), 5.20 (dd, J 
= 10.4, 1.2 Hz, 1H), 5.12 (d, J = 8.0 Hz, 1H), 5.06 – 4.92 (m, 2H), 4.70 – 
4.51 (m, 2H), 4.09 (ddd, J = 11.7, 4.2, 1.1 Hz, 1H), 4.01 – 3.89 (m, 1H), 
3.84 – 3.70 (m, 4H), 3.22 (d, J = 6.9 Hz, 1H), 3.02 – 2.83 (m, 1H), 2.64 – 
2.49 (m, 1H), 2.49 – 2.33 ppm (m, 2H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 5-oxo-3-(4-(trifluoromethyl)phenyl)hexahydro-
1H-pyrrolizine-1,2,7a-tricarboxylate 
158az: 91% yield; 1H NMR (500 MHz, CDCl3): δ 7.52 (dd, J = 19.1, 8.3 
Hz, 4H), 5.99 – 5.86 (m, 1H), 5.39 – 5.21 (m, 4H), 4.97 (dd, J = 14.4, 5.4 
Hz, 2H), 4.66 (qd, J = 13.2, 5.8 Hz, 2H), 4.09 (dd, J = 12.8, 6.2 Hz, 1H), 
3.98 (dd, J = 12.8, 6.2 Hz, 1H), 3.91 – 3.83 (m, 1H), 3.81 (s, 3H), 3.29 (d, 
J = 6.9 Hz, 1H), 3.09 – 2.95 (m, 1H), 2.67 – 2.43 ppm (m, 3H); 13C NMR 
(126 MHz, CDCl3): δ = 176.79, 171.70, 169.42, 167.19, 140.35, 131.78, 131.23, 130.30, 
130.04, 129.78, 129.53, 127.43, 127.22, 125.27, 125.22, 125.19, 125.16, 125.13, 123.10, 
118.89, 118.77, 74.18, 66.19, 65.74, 60.30, 55.88, 53.04, 52.88, 36.17, 33.90 ppm. 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-methoxyphenyl)-5-
oxohexahydro-1H-pyrrolizine-1,2,7a-tricarboxylate 
158ba: 82% yield; 1H NMR (500 MHz, CDCl3): δ 7.21 (dd, J = 10.3, 4.6 
Hz, 2H), 6.75 (d, J = 8.6 Hz, 2H), 5.87 (dq, J = 11.2, 5.8 Hz, 1H), 5.42 – 
5.31 (m, 1H), 5.28 (dd, J = 17.2, 0.8 Hz, 1H), 5.19 (d, J = 10.6 Hz, 1H), 
5.13 (d, J = 8.0 Hz, 1H), 5.02 – 4.92 (m, 2H), 4.60 (qd, J = 13.2, 5.8 Hz, 2H), 4.08 (dd, J = 
12.7, 6.1 Hz, 1H), 3.89 (dd, J = 12.9, 5.8 Hz, 1H), 3.76 – 3.73 (m, 4H), 3.69 (s, 3H), 3.17 (d, J 
= 6.8 Hz, 1H), 3.06 – 2.89 (m, 1H), 2.59 – 2.37 ppm (m, 3H). 
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Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-(allyloxy)phenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bb: 69% yield; 1H NMR (300 MHz, CDCl3): δ = 7.26 (d, J = 8.6 Hz, 
2H), 6.81 (d, J = 8.6 Hz, 2H), 6.08 – 5.80 (m, 2H), 5.48 – 5.11 (m, 6H), 
5.11 – 4.92 (m, 2H), 4.78 – 4.52 (m, 2H), 4.47 (d, J = 5.2 Hz, 2H), 4.13 
(dd, J = 12.9, 6.2 Hz, 1H), 3.93 (dd, J = 12.9, 5.9 Hz, 1H), 3.84 – 3.52 (m, 
4H), 3.23 (d, J = 6.8 Hz, 1H), 3.12 – 2.86 (m, 1H), 2.68 – 2.24 ppm (m, 
3H); 13C NMR (101 MHz, CDCl3): δ 176.75, 171.93, 169.77, 167.47, 
158.15, 133.40, 131.88, 131.80, 128.16, 127.82, 118.70, 118.49, 117.69, 114.47, 74.24, 68.86, 
66.12, 65.58, 60.38, 55.78, 53.33, 52.87, 36.33, 34.12 ppm; HRMS: calc. for [M+H]+ 
C26H30NO8: 484.19659, found 484.19709. 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-(benzyloxy)phenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bc: 86% yield; 1H NMR (300 MHz, CDCl3): δ 7.42 – 7.10 (m, 7H), 6.82 
(d, J = 8.6 Hz, 2H), 5.86 (ddd, J = 16.4, 10.9, 5.5 Hz, 1H), 5.46 – 5.06 (m, 
4H), 4.95 (t, J = 8.1 Hz, 4H), 4.73 – 4.41 (m, 2H), 4.07 (dd, J = 12.9, 6.2 
Hz, 1H), 3.86 (dd, J = 12.9, 5.9 Hz, 1H), 3.79 – 3.70 (m, 4H), 3.17 (d, J = 
6.8 Hz, 1H), 3.10 – 2.80 (m, 1H), 2.64 – 2.24 ppm (m, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-nitrophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bd: 27% yield; 1H NMR (400 MHz, CDCl3): δ = 8.15 (d, J = 8.9 Hz, 
2H), 7.57 (d, J = 8.6 Hz, 2H), 5.94 (ddt, J = 16.3, 10.5, 5.9 Hz, 1H), 5.47 – 
5.21 (m, 4H), 5.04 (dd, J = 13.1, 5.7 Hz, 2H), 4.68 (qd, J = 13.2, 5.9 Hz, 
2H), 4.15 (dd, J = 12.8, 6.1 Hz, 1H), 3.96 (ddd, J = 15.1, 10.4, 6.7 Hz, 2H), 
3.83 (s, 3H), 3.31 (d, J = 6.9 Hz, 1H), 3.16 – 2.95 (m, 1H), 2.65 (t, J = 10.6 
Hz, 1H), 2.56 ppm (dt, J = 15.8, 8.9 Hz, 2H); 13C NMR (126 MHz, CDCl3): δ 176.83, 171.64, 
169.34, 167.05, 147.64, 143.81, 131.80, 131.23, 127.93, 123.51, 119.19, 118.99, 74.20, 66.38, 
65.91, 60.17, 56.15, 53.05, 52.99, 36.16, 33.85 ppm. 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(4-(methylamino)phenyl)-5-oxohexahydro-
1H-pyrrolizine-1,2,7a-tricarboxylate 
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158be: 27% yield; 1H NMR (300 MHz, CDCl3): δ = 7.17 (d, J = 8.4 Hz, 
2H), 6.52 (d, J = 8.5 Hz, 2H), 6.02 – 5.86 (m, 1H), 5.53 – 5.14 (m, 4H), 
5.13 – 4.96 (m, 2H), 4.66 (dd, J = 14.5, 7.2 Hz, 2H), 4.17 (dd, J = 12.8, 
6.2 Hz, 1H), 3.98 (dd, J = 12.8, 5.8 Hz, 1H), 3.89 – 3.70 (m, 4H), 3.22 (d, 
J = 6.8 Hz, 1H), 3.07 – 2.95 (m, 1H), 2.78 (s, 2H), 2.77 – 2.28 ppm (m, 
3H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(3,4-dimethoxyphenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bf: 75% yield; 1H NMR (300 MHz, CDCl3): δ = 6.94 (d, J = 6.9 Hz, 
2H), 6.78 (d, J = 8.6 Hz, 1H), 5.92 (dd, J = 11.1, 5.8 Hz, 1H), 5.30 (ddd, J 
= 26.5, 15.2, 7.8 Hz, 4H), 5.03 (d, J = 11.8 Hz, 2H), 4.67 (t, J = 6.1 Hz, 2H), 
4.16 (dd, J = 12.8, 6.0 Hz, 1H), 3.97 (dd, J = 12.9, 6.0 Hz, 1H), 3.85 (s, 3H), 
3.83 (s, 3H), 3.82 (s, 3H), 3.80 – 3.78 (m, 1H), 3.24 (d, J = 6.8 Hz, 1H), 
3.17 – 2.92 (m, 1H), 2.70 – 2.36 ppm (m, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(furan-2-yl)-5-oxohexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158bg: 86% yield; 1H NMR (500 MHz, CDCl3): δ = 7.21 (s, 1H), 6.33 (d, 
J = 3.2 Hz, 1H), 6.21 (dd, J = 3.2, 1.8 Hz, 1H), 5.87 (ddd, J = 22.9, 11.0, 
5.8 Hz, 1H), 5.59 (ddt, J = 16.6, 10.5, 6.0 Hz, 1H), 5.27 (dd, J = 17.2, 1.3 
Hz, 1H), 5.22 – 5.16 (m, 2H), 5.16 – 5.03 (m, 2H), 4.60 (qd, J = 13.2, 5.8 
Hz, 2H), 4.27 (dd, J = 13.0, 6.1 Hz, 1H), 4.15 (dd, J = 13.0, 6.0 Hz, 1H), 
3.82 (t, J = 7.7 Hz, 1H), 3.73 (s, 3H), 3.16 (d, J = 7.2 Hz, 1H), 2.98 – 2.82 (m, 1H), 2.57 – 2.36 
ppm (m, 3H); 13C NMR (126 MHz, CDCl3): δ 176.02, 171.63, 169.50, 167.16, 149.76, 141.93, 
131.87, 131.85, 118.68, 118.57, 110.75, 108.48, 73.84, 66.13, 65.86, 55.70, 54.79, 52.84, 
51.76, 35.54, 33.77 ppm. 
Rel-(1R,2S,3R,7aS)-1,2-diallyl 7a-methyl 3-(naphthalen-2-yl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
Chapter 7. Experimental Part 
 
204 
 
158bh: 74% yield; 1H NMR (500 MHz, CDCl3): δ 7.86 (s, 1H), 7.82 – 7.68 
(m, 3H), 7.52 – 7.35 (m, 3H), 5.95 (ddt, J = 16.6, 10.9, 5.8 Hz, 1H), 5.42 
(d, J = 8.1 Hz, 1H), 5.35 (dd, J = 17.2, 1.0 Hz, 1H), 5.26 (dd, J = 10.4, 0.8 
Hz, 1H), 5.18 – 5.02 (m, 1H), 4.78 (dd, J = 17.2, 1.0 Hz, 1H), 4.73 – 4.56 
(m, 3H), 4.04 – 3.90 (m, 2H), 3.86 (s, 3H), 3.76 (dd, J = 12.8, 6.2 Hz, 1H), 
3.30 (d, J = 6.9 Hz, 1H), 3.16 – 2.99 (m, 1H), 2.71 – 2.60 (m, 1H), 2.59 – 
2.50 ppm (m, 2H). 
Rel-(1R,2S,3S,7aS)-1,2-diallyl 7a-methyl 3-((E)-4-nitrostyryl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bi: 15% yield; 1H NMR (400 MHz, CDCl3): δ 8.15 (d, J = 8.8 Hz, 2H), 
7.47 (d, J = 8.8 Hz, 2H), 6.82 (d, J = 16.0 Hz, 1H), 6.29 (dd, J = 15.9, 6.6 
Hz, 1H), 5.94 (ddd, J = 16.4, 11.1, 5.2 Hz, 1H), 5.77 – 5.65 (m, 1H), 5.36 
(dd, J = 17.2, 1.4 Hz, 1H), 5.28 (dd, J = 10.4, 1.2 Hz, 1H), 5.17 (dd, J = 
17.2, 1.4 Hz, 1H), 5.05 (d, J = 10.3 Hz, 1H), 4.85 (t, J = 7.5 Hz, 1H), 4.68 
(t, J = 6.1 Hz, 2H), 4.48 (dd, J = 9.7, 6.1 Hz, 2H), 3.83 (d, J = 4.4 Hz, 3H), 
3.76 (t, J = 7.9 Hz, 1H), 3.20 (d, J = 7.5 Hz, 1H), 2.97 – 2.86 (m, 1H), 2.74 – 2.44 ppm (m, 
3H). 
Rel-(1R,2S,3S,7aS)-1,2-diallyl 7a-methyl 3-((E)-4-methoxystyryl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bj: 86% yield; 1H NMR (400 MHz, CDCl3): δ = 7.27 – 7.16 (m, 2H), 
6.74 (d, J = 8.7 Hz, 2H), 6.59 (d, J = 15.9 Hz, 1H), 5.97 – 5.80 (m, 2H), 
5.66 (ddd, J = 17.1, 6.0, 4.3 Hz, 1H), 5.28 (dd, J = 17.2, 1.4 Hz, 1H), 5.19 
(dd, J = 10.4, 1.2 Hz, 1H), 5.10 (dd, J = 17.2, 1.4 Hz, 1H), 4.98 (dd, J = 
10.3, 1.1 Hz, 1H), 4.72 (t, J = 7.7 Hz, 1H), 4.69 – 4.53 (m, 2H), 4.42 (dd, J 
= 7.5, 6.3 Hz, 2H), 3.76 (s, 3H), 3.72 (s, 3H), 3.64 (t, J = 7.9 Hz, 1H), 3.08 
(d, J = 7.5 Hz, 1H), 2.84 (dd, J = 8.7, 4.0 Hz, 1H), 2.50 (dd, J = 12.1, 8.8 Hz, 1H), 2.52 – 2.41 
ppm (m, 2H);  13C NMR (101 MHz, CDCl3): δ 175.94, 171.98, 169.85, 167.62, 159.42, 133.26, 
131.91, 129.15, 128.11, 121.63, 119.01, 118.73, 113.81, 74.22, 66.17, 65.85, 58.38, 55.61, 
55.35, 52.93, 52.04, 35.21, 33.83 ppm. 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 5-oxo-3-phenylhexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
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158bk: 81% yield; 1H NMR (300 MHz, CDCl3): δ = 7.48 – 7.17 (m, 10H), 
7.14 (d, J = 9.4 Hz, 3H), 6.86 (dd, J = 6.2, 2.7 Hz, 2H), 5.24 – 5.01 (m, 3H), 
4.55 (d, J = 12.1 Hz, 1H), 4.21 (d, J = 12.1 Hz, 1H), 3.78 (t, J = 7.4 Hz, 1H), 
3.64 (s, 3H), 3.14 (d, J = 6.8 Hz, 1H), 2.94 (dd, J = 11.7, 6.6 Hz, 1H), 2.61 – 
2.22 ppm (m, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 5-oxo-3-(o-tolyl)hexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158bl: 90% yield; 1H NMR (500 MHz, CDCl3): δ 7.60 (d, J = 7.6 Hz, 1H), 
7.33 – 7.23 (m, 5H), 7.21 – 7.14 (m, 3H), 7.10 (t, J = 7.5 Hz, 1H), 7.04 (dd, 
J = 10.5, 4.1 Hz, 1H), 6.92 (d, J = 7.4 Hz, 1H), 6.86 (dd, J = 6.4, 2.9 Hz, 
2H), 5.22 (d, J = 7.8 Hz, 1H), 5.17 (d, J = 12.2 Hz, 1H), 5.10 (d, J = 12.2 
Hz, 1H), 4.51 (d, J = 12.1 Hz, 1H), 4.18 (d, J = 12.1 Hz, 1H), 3.93 – 3.85 
(m, 1H), 3.66 (s, 3H), 3.22 (d, J = 6.8 Hz, 1H), 3.05 – 2.88 (m, 1H), 2.53 (t, J = 10.7 Hz, 1H), 
2.41 (dt, J = 14.2, 10.2 Hz, 2H), 2.19 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ 176.54, 
171.90, 169.70, 167.59, 135.52, 135.17, 134.39, 134.10, 130.13, 128.71, 128.61, 128.55, 
128.53, 128.36, 128.16, 127.80, 127.17, 126.22, 74.19, 67.43, 66.73, 59.21, 55.88, 52.74, 
51.40, 36.59, 34.19, 19.40 ppm. 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 5-oxo-3-(m-tolyl)hexahydro-1H-pyrrolizine-
1,2,7a-tricarboxylate 
158bm: 85% yield; 1H NMR (300 MHz, CDCl3): δ 7.30 (s, 5H), 7.23 – 6.97 
(m, 6H), 6.95 (d, J = 7.1 Hz, 1H), 6.91 – 6.72 (m, 2H), 5.26 – 5.00 (m, 3H), 
4.55 (d, J = 12.1 Hz, 1H), 4.28 (d, J = 12.1 Hz, 1H), 3.78 (t, J = 7.4 Hz, 1H), 
3.67 (s, 3H), 3.17 (d, J = 6.8 Hz, 1H), 2.96 (dd, J = 12.0, 6.2 Hz, 1H), 2.61 – 
2.22 (m, 3H), 2.20 ppm (s, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(2-fluorophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bn: 87% yield; 1H NMR (300 MHz, CDCl3): δ = 7.56 (t, J = 7.2 Hz, 
1H), 7.29 (s, 5H), 7.22 – 7.14 (m, 3H), 7.03 (ddd, J = 23.2, 14.6, 4.5 Hz, 
4H), 6.83 – 6.68 (m, 1H), 5.34 (d, J = 7.8 Hz, 1H), 5.12 (q, J = 12.2 Hz, 
2H), 4.58 (d, J = 12.3 Hz, 1H), 4.29 (d, J = 12.3 Hz, 1H), 3.95 (t, J = 
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7.2 Hz, 1H), 3.66 (s, 3H), 3.23 (d, J = 6.8 Hz, 1H), 3.04 – 2.81 (m, 1H), 2.64 – 2.26 ppm (m, 
3H). 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(3-fluorophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bo: 90% yield; 1H NMR (300 MHz, CDCl3): δ 7.30 (s, 5H), 7.24 – 7.15 
(m, 3H), 7.14 – 6.99 (m, 3H), 6.97 – 6.87 (m, 2H), 6.81 (t, J = 8.3 Hz, 1H), 
5.25 – 5.00 (m, 3H), 4.59 (d, J = 12.1 Hz, 1H), 4.34 (d, J = 12.1 Hz, 1H), 
3.81 (t, J = 7.5 Hz, 1H), 3.67 (s, 3H), 3.15 (d, J = 6.9 Hz, 1H), 3.03 – 2.79 
(m, 1H), 2.61 – 2.22 ppm (m, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(4-fluorophenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bp: 91% yield; 1H NMR (400 MHz, CDCl3): δ = 7.44 – 7.13 (m, 11H), 
6.95 – 6.74 (m, 4H), 5.26 – 5.08 (m, 4H), 4.58 (d, J = 12.1 Hz, 1H), 4.41 (d, 
J = 12.1 Hz, 1H), 3.85 – 3.75 (m, 1H), 3.67 (s, 3H), 3.20 (d, J = 6.8 Hz, 1H), 
2.96 (ddd, J = 20.8, 16.4, 8.4 Hz, 1H), 2.59 – 2.33 ppm (m, 3H); 13C NMR 
(101 MHz, CDCl3): δ 176.82, 171.90, 169.90, 167.47, 163.56, 161.11, 
135.38, 134.99, 131.71, 128.75, 128.70, 128.66, 128.63, 128.50, 128.46, 128.42, 128.37, 
115.31, 115.09, 74.27, 67.52, 66.81, 60.19, 55.99, 53.13, 52.90, 36.27, 34.05 ppm; HRMS: 
calc. for [M+H]+ C31H29FNO7: 546.19226, found 546.19312. 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(4-(allyloxy)phenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bq: 86% yield; 1H NMR (300 MHz, CDCl3): δ 7.29 (s, 5H), 7.25 – 7.04 
(m, 6H), 6.90 (d, J = 3.3 Hz, 2H), 6.73 (d, J = 8.6 Hz, 2H), 5.96 (ddd, J = 
15.9, 10.6, 5.4 Hz, 1H), 5.32 (d, J = 17.2 Hz, 1H), 5.14 (ddd, J = 16.3, 11.3, 
8.0 Hz, 4H), 4.59 (d, J = 12.1 Hz, 1H), 4.37 (dd, J = 21.0, 8.7 Hz, 3H), 3.78 
(t, J = 7.4 Hz, 1H), 3.67 (s, 3H), 3.19 (d, J = 6.7 Hz, 1H), 3.11 – 2.83 (m, 
1H), 2.62 – 2.28 ppm (m, 3H); 13C NMR (101 MHz, CDCl3): δ 176.75, 
171.97, 170.08, 167.58, 158.14, 135.43, 135.15, 133.40, 128.69, 128.59, 128.54, 128.36, 
128.20, 128.14, 127.85, 117.72, 114.49, 74.28, 68.78, 67.40, 66.71, 60.42, 55.83, 53.22, 52.80, 
36.28, 34.11 ppm; HRMS: calc. for [M+H]+ C34H34NO8: 584.22789, found 584.22875. 
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Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(4-(benzyloxy)phenyl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158br: 82% yield; 1H NMR (300 MHz, CDCl3): δ 7.42 – 7.02 (m, 15H), 
6.88 (d, J = 3.4 Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 5.26 – 5.01 (m, 3H), 4.92 
(s, 2H), 4.57 (d, J = 12.1 Hz, 1H), 4.31 (d, J = 12.1 Hz, 1H), 3.75 (t, J = 7.4 
Hz, 1H), 3.65 (s, 3H), 3.14 (d, J = 6.8 Hz, 1H), 2.99 – 2.77 (m, 1H), 2.61 – 
2.17 ppm (m, 3H); HRMS: calc. for [M+H]+ C38H36NO8: 634.24354, found 
634.24337. 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(4-(methylamino)phenyl)-5-oxohexahydro-
1H-pyrrolizine-1,2,7a-tricarboxylate 
158bs: 54% yield; 1H NMR (300 MHz, CDCl3): δ 7.41 – 7.14 (m, 10H), 
6.97 (s, 2H), 6.50 (d, J = 8.5 Hz, 2H), 5.35 – 5.07 (m, 3H), 4.66 (d, J = 12.1 
Hz, 1H), 4.44 (d, J = 12.2 Hz, 1H), 3.99 – 3.70 (m, 4H), 3.23 (d, J = 6.8 Hz, 
1H), 2.99 (dd, J = 23.3, 13.4 Hz, 1H), 2.79 (s, 3H), 2.53 ppm (dt, J = 16.2, 
11.8 Hz, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 3-(3,4-dimethoxyphenyl)-5-oxohexahydro-
1H-pyrrolizine-1,2,7a-tricarboxylate 
158bt: 76% yield; 1H NMR (300 MHz, CDCl3): δ 7.31 (s, 5H), 7.19 (s, 
3H), 7.00 – 6.77 (m, 4H), 6.68 (d, J = 8.2 Hz, 1H), 5.27 – 5.04 (m, 3H), 
4.58 (d, J = 12.0 Hz, 1H), 4.39 (d, J = 12.1 Hz, 1H), 3.94 – 3.76 (m, 4H), 
3.70 (s, 3H), 3.68 (s, 3H), 3.20 (d, J = 6.8 Hz, 1H), 2.95 (d, J = 15.2 Hz, 
1H), 2.49 ppm (dt, J = 17.6, 11.8 Hz, 3H). 
Rel-(1R,2S,3R,7aS)-1,2-dibenzyl 7a-methyl 5-oxo-3-(thiophen-3-yl)hexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bu: 82% yield; 1H NMR (400 MHz, CDCl3): δ 7.43 – 7.24 (m, 9H), 7.18 
(dd, J = 5.0, 3.0 Hz, 1H), 7.07 (dd, J = 6.6, 2.8 Hz, 2H), 7.01 (dd, J = 5.0, 
1.0 Hz, 1H), 5.32 – 5.14 (m, 3H), 4.75 (d, J = 12.1 Hz, 1H), 4.43 (d, J = 12.1 
Hz, 1H), 3.90 – 3.81 (m, 1H), 3.72 (s, 3H), 3.22 (d, J = 6.9 Hz, 1H), 3.08 – 
2.92 (m, 1H), 2.64 – 2.39 ppm (m, 3H); 13C NMR (101 MHz, CDCl3): δ 176.41, 171.92, 170.03, 
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167.46, 137.06, 135.40, 135.14, 128.69, 128.67, 128.59, 128.55, 128.47, 128.29, 126.50, 
125.51, 122.88, 74.11, 67.42, 66.95, 57.06, 55.81, 52.82, 52.65, 35.94, 33.99 ppm. 
Rel-(1R,2S,3S,7aS)-1,2-dibenzyl 7a-methyl 3-((E)-4-methoxystyryl)-5-oxohexahydro-1H-
pyrrolizine-1,2,7a-tricarboxylate 
158bv: 81% yield; 1H NMR (400 MHz, CDCl3): δ 7.38 – 7.24 (m, 5H), 
7.21 – 7.02 (m, 7H), 6.74 (d, J = 8.7 Hz, 2H), 6.58 (d, J = 15.8 Hz, 1H), 
5.88 (dd, J = 15.9, 7.3 Hz, 1H), 5.14 (q, J = 12.2 Hz, 2H), 4.96 (d, J = 12.1 
Hz, 1H), 4.85 (d, J = 12.1 Hz, 1H), 4.71 (t, J = 7.8 Hz, 1H), 3.74 (s, 3H), 
3.72 – 3.61 (m, 4H), 3.09 (d, J = 7.5 Hz, 1H), 2.92 – 2.79 (m, 1H), 2.54 – 
2.15 ppm (m, 3H). 
 
7.3.3 Experimental Detail and Analytic Data for Enantioselective Synthesis of 
Pyrrolizidine 157aa 
 
(2S,3R,4S,5R)-trimethyl 5-(4-fluorophenyl)-2-(3-methoxy-3-oxopropyl)pyrrolidine-2,3,4-
tricarboxylate 
Chiral-157aa: 16% yield; [α]D20 = +25.5 (c = 1.00 in CH2Cl2); 92% ee, determined by HPLC 
analysis [Daicel CHIRALPAK IA, iso-hexane/(DCM/EtOH = 100/2) = 80/20, 0.5 mL/min, λ 
= 235 nm, t (major) = 37.26 min, t (minor) = 23.49 min]; 1H NMR (400 MHz, CDCl3): δ 7.31 
– 7.17 (m, 2H), 6.94 (t, J = 8.7 Hz, 2H), 4.41 (d, J = 6.2 Hz, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 
3.38 (t, J = 6.7 Hz, 1H), 3.26 (d, J = 7.0 Hz, 1H), 3.24 (s, 3H), 2.59 – 2.46 (m, 1H), 2.43 – 2.32 
(m, 1H), 2.21 (ddd, J = 15.6, 9.9, 5.4 Hz, 1H), 2.06 ppm (ddd, J = 13.5, 10.0, 5.3 Hz, 1H); 13C 
NMR (126 MHz, CDCl3) δ = 173.66, 173.09, 171.08, 170.95, 163.36, 161.40, 133.17, 128.66, 
128.60, 115.49, 115.32, 71.70, 63.40, 57.38, 53.04, 52.92, 52.30, 51.82, 51.51, 35.35, 30.07 
ppm; HRMS: calc. for [M+H]+ C20H25FNO8: 426.15587, found 426.15552. 
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(1S,2S,3R,7aS)-trimethyl 3-(4-fluorophenyl)-5-oxohexahydro-1H-pyrrolizine-1,2,7a-
tricarboxylate 
Chiral-158baa: 82% yield; [α]D20 = +93.0 (c = 0.50 in CH2Cl2); 94% ee, determined by HPLC 
analysis [Daicel CHIRALPAK IA, iso-hexane/(DCM/EtOH = 100/2) = 70/30, 0.5 mL/min, λ 
= 254 nm, t (major) = 13.21 min, t (minor) = 32.47 min]; 1H NMR (400 MHz, CDCl3): δ = 
7.33 (dd, J = 8.5, 5.4 Hz, 2H), 6.97 (t, J = 8.7 Hz, 2H), 5.20 (d, J = 8.0 Hz, 1H), 3.84 (s, 3H), 
3.83 – 3.79 (m, 1H), 3.77 (s, 3H), 3.22 (d, J = 6.9 Hz, 1H), 3.18 (s, 3H), 3.02 (d, J = 3.0 Hz, 
1H), 2.66 – 2.56 (m, 1H), 2.54 – 2.40 (m, 2H); 13C NMR (101 MHz, CDCl3): δ = 176.84, 
171.91, 170.38, 168.24, 163.51, 161.07, 131.84, 131.81, 128.34, 128.26, 115.19, 114.98, 74.19, 
60.09, 55.70, 53.21, 53.03, 52.51, 51.63, 36.23, 34.04 ppm; HRMS: calc. for [M+H]+ 
C19H21FNO7: 394.12966, found 394.12872. 
 
7.4 Experimental Part for Enantioselective Synthesis of Cycloheptanoids 
7.4.1 Experimental Detail and Analytic Data for (6+3) Cycloadditions of Tropone 
7.4.1.1 General Method and Analytic Data of 248a-e 
General Method: A flame dried Schlenk tube was charged with Rh2(S-TCPTTL)4 (3.94 mg, 
0.002 mmol, 2mol%), tropone 242 (10 μL, 0.1 mmol, 1 equiv) and 0.5 mL of α,α,α-
trifluorotoluene as solvent. Then a solution of the corresponding diazo compound 247 (2.0 
equiv) in 0.5 mL α,α,α-trifluorotoluene was added via syringe pump (1 h) to the reaction 
mixture and was allowed to stir for an additional hour at room temperature. After completion, 
the reaction reaction mixture was directly loaded on the silica gel column and was purified 
using 20-30% ethyl acetate/petroleum ether mixture as an eluent to afford desired compounds 
248. 
(1S,2S,6S,7R)-6-Phenyl-13-oxatricyclo[5.4.1.12,6]trideca-8,10-diene-3,12-dione 
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248a: 78% yield; 1H NMR (400 MHz, CD2Cl2): δ = 7.51 – 7.38 (m, 4H), 7.36 
– 7.27 (m, 1H), 6.34 – 6.15 (m, 2H), 6.02 (dd, J = 11.2, 8.0 Hz, 1H), 5.85 (dd, 
J = 10.6, 9.1 Hz, 1H), 5.04 (d, J = 11.4 Hz, 1H), 4.04 – 3.91 (m, 1H), 3.73 (dd, 
J = 8.1, 3.8 Hz, 1H), 2.60 – 2.47 (m, 3H), 2.32 – 2.23 ppm (m, 1H); 13C NMR 
(101 MHz, CD2Cl2): δ = 205.04, 202.10, 148.85, 128.86, 127.91, 127.59, 
126.99, 124.96, 124.61, 123.39, 81.32, 81.27, 63.08, 53.00, 33.42, 31.56 ppm; FT-IR: ṽ = 2927, 
1720, 1419, 1447, 1279, 1188, 1078 cm-1; HRMS: calcd. for [M+H]+ C18H17O3
+: 281.11777, 
found: 281.11685; [𝛼]𝐷
𝑅𝑇= +31.2 (c = 0.5 in CH2Cl2); HPLC conditions: CHIRALPAK IC 
column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 30/70, flow rate = 0.5 mL min
-1, minor 
enantiomer: tR = 27.40 min; major enantiomer: tR = 24.93 min; 94% ee. 
(1S,2S,6S,7R)-6-(4-hexylphenyl)-13-oxatricyclo[5.4.1.12,6]trideca-8,10-diene-3,12-dione 
248b: 55% yield; 1H NMR (600 MHz, CD2Cl2): δ 7.37 – 7.31 (m, 2H), 7.24 
– 7.18 (m, 2H), 6.25 (ddt, J = 11.5, 7.5, 0.7 Hz, 1H), 6.22 – 6.18 (m, 1H), 
6.02 – 5.95 (m, 1H), 5.87 – 5.80 (m, 1H), 5.01 (d, J = 11.5 Hz, 1H), 4.00 – 
3.94 (m, 1H), 3.70 (dd, J = 8.0, 3.8 Hz, 1H), 2.60 (t, J = 7.8 Hz, 2H), 2.56 – 
2.46 (m, 3H), 2.29 – 2.22 (m, 1H), 1.66 – 1.56 (m, 2H), 1.38 – 1.27 (m, 6H), 
0.89 ppm (t, J = 7.0 Hz, 3H); 13C NMR (151 MHz, CD2Cl2): δ 205.49, 202.65, 146.48, 142.91, 
129.18, 128.14, 127.38, 125.32, 125.05, 123.64, 81.72, 81.64, 63.54, 53.46, 36.03, 33.81, 
32.29, 32.04, 31.95, 29.59, 23.19, 14.44 ppm; FT-IR: ṽ = 2926, 2855, 1724, 1681, 1512, 1280, 
1181, 1116, 1058, 986 cm-1; HRMS: calc. for [M+H]+ C24H29O3:365.21112, found: 365.21131; 
 [𝛼]𝐷
𝑅𝑇 = +34.5 (c = 0.6 in CH2Cl2); HPLC conditions: CHIRALPAK IC column, 
(CH2Cl2/EtOH = 100/2) / heptane = 20/80, flow rate = 0.5 mL min
-1, major enantiomer: tR = 
35.0 min; minor enantiomer: tR = 46.4 min; 92% ee. 
(1S,2S,6S,7R)-6-(4-Isopropylphenyl)-13-oxatricyclo[5.4.1.12,6]trideca-8,10-diene-3,12- 
dione 
248c: 56% yield; 1H NMR (400 MHz, CD2Cl2): δ = 7.42 – 7.34 (m, 2H), 7.30 
– 7.21 (m, J = 2.0, 1.2 Hz, 2H), 6.33 – 6.15 (m, 2H), 6.05 – 5.96 (m, 1H), 
5.85 (ddd, J = 11.0, 9.1, 0.7 Hz, 1H), 5.02 (d, J = 11.4 Hz, 1H), 4.04 – 3.91 
(m, 1H), 3.71 (dd, J = 8.0, 3.8 Hz, 1H), 2.99 – 2.87 (m, 1H), 2.58 – 2.45 (m, 
3H), 2.32 – 2.23 (m, 1H), 1.27 ppm (d, J = 6.9 Hz, 6H); 13C NMR (101 MHz, 
CD2Cl2): δ = 205.06, 202.24, 148.39, 146.26, 127.77, 127.02, 126.85, 124.96, 124.66, 123.35, 
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81.34, 81.28, 63.15, 53.12, 33.95, 33.44, 31.58, 23.91 ppm; FT-IR: ṽ = 2958, 1721, 1509, 1460, 
1410, 1283, 1188, 1079, 865 cm-1; HRMS: calcd. for [M+H]+ C21H23O3: 323.16472, found: 
323.16421; [𝛼]𝐷
𝑅𝑇= +29.0 (c = 0.5 in CH2Cl2); HPLC conditions: CHIRALPAK IC column, 
(CH2Cl2/EtOH = 100/2) / iso-hexane = 20/80, flow rate = 0.5 mL min
-1, minor enantiomer: tR 
= 52.41 min; major enantiomer: tR = 40.93 min; 89% ee. 
(1S,2S,6S,7R)-6-(4-Fluorophenyl)-13-oxatricyclo[5.4.1.12,6]trideca-8,10-diene-3,12-dione 
248d: 30% yield; 1H NMR (400 MHz, CD2Cl2): δ = 7.41 – 7.31 (m, 2H), 7.07 
– 6.97 (m, 2H), 6.23 – 6.08 (m, 2H), 5.89 (dd, J = 11.3, 8.0 Hz, 1H), 5.76 (dd, 
J = 10.5, 8.8 Hz, 1H), 4.93 (d, J = 11.4 Hz, 1H), 3.94 – 3.84 (m, 1H), 3.58 (dd, 
J = 8.0, 3.8 Hz, 1H), 2.51 – 2.36 (m, 3H), 2.21 – 2.11 (m, 1H); 13C NMR (101 
MHz, CD2Cl2): δ = 204.66, 201.90, 162.09 (d, J = 245.60 Hz, 1C), 144.75 (d, 
J = 3.1 Hz, 1C), 128.03, 127.05, 125.37 (d, J = 8.10 Hz, 1C), 125.00, 124.29, 115.56 (d, J = 
21.57 Hz, 1C), 81.25, 81.03, 63.01, 52.99, 33.33, 31.63 ppm; FT-IR: ṽ = 2926, 1720, 1604, 
1509, 1409, 1281, 1222, 1189, 1161, 1080, 865 cm-1; HRMS: calcd. for [M+H]+ C18H16O3F: 
299.10835, found: 299.10747; [𝛼]𝐷
𝑅𝑇 = +15.1 (c = 0.3 in CH2Cl2); HPLC conditions: 
CHIRALPAK IA column, (CH2Cl2/EtOH = 100/2) / iso-hexane = 20/80, flow rate = 0.5 mL 
min-1, minor enantiomer: tR = 47.42 min; major enantiomer: tR = 51.58 min; 92% ee. 
(1S,2S,6S,7R)-6-(4-Bromophenyl)-13-oxatricyclo[5.4.1.12,6]trideca-8,10-diene-3,12- 
dione 
248e: 66% yield; 1H NMR (400 MHz, CD2Cl2): δ = 7.59 – 7.53 (m, 2H), 7.41 
– 7.28 (m, 2H), 6.34 – 6.17 (m, 2H), 5.99 (dd, J = 11.3, 8.0 Hz, 1H), 5.85 (dd, 
J = 10.7, 9.0 Hz, 1H), 5.03 (d, J = 11.4 Hz, 1H), 4.03 – 3.93 (m, 1H), 3.67 (dd, 
J = 7.9, 3.8 Hz, 1H), 2.60 – 2.45 (m, 3H), 2.30 – 2.17 ppm (m, 1H); 13C NMR 
(101 MHz, CD2Cl2): δ = 204.60, 201.73, 147.86, 131.92, 128.16, 127.03, 
125.41, 125.00, 124.21, 121.42, 81.23, 81.02, 62.76, 52.92, 33.30, 31.42 ppm; FT-IR: ṽ = 2928, 
1721, 1486, 1396, 1283, 1187, 1074, 1008 cm-1; HRMS: calcd. for [M+H]+ C18H16O3
79Br: 
359.02828 and C18H16O3
81Br: 361.02828, found: 359.02771 and 361.02561; [𝛼]𝐷
𝑅𝑇= +18.9 (c 
= 0.7 in CH2Cl2); HPLC conditions: CHIRALPAK IC column, (CH2Cl2/EtOH = 100/2) / iso-
hexane = 25/75, flow rate = 0.5 mL min-1, minor enantiomer: tR = 46.09 min; major enantiomer: 
tR = 42.32 min; 87% ee.  
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7.4.1.2 VCD Spectra Data of 248a (by C.M.) 
Determination of absolute configurations of 248a 
 
General approach 
Experimental IR and VCD spectra were obtained for a solution of 248a in CDCl3 (50mg/ml) 
at 100 µm path length. The spectra were recorded on a Bruker Vertex 70v equipped with a 
PMA 50 module for VCD measurements accumulating 26000 scans for the VCD spectrum. 
The baseline was corrected by subtraction of the solvent spectrum.  
In order to analyse experimental IR and VCD spectra, a thorough conformational analysis 
followed by spectra calculations for all conformers is necessary. For both compounds, this 
analysis has been performed manually by systematically generating the input structures, 
followed by an geometry optimization at the B3LYP/6-311+G(2d,p) level of theory using 
Gaussian 09 Rev. D.01. Solvent effects were accounted for by applying a polarizable 
continuum model (IEFPCM).254 Following the geometry optimization, the IR and VCD spectra 
were calculated for each conformer. In order to account for line broadening, a Lorentzian band 
shape of 8 cm-1 half-width at half-height was assigned to the calculated dipole and rotational 
strengths. For a better visual comparison of the spectra, the calculated frequencies were scaled 
by a factor of 0.98. Finally, the energy differences within the set of conformations of each 
compound were computed based on the zero-point corrected electronic (∆E) as well as Gibbs 
free energy (∆G) and used to generate population-weighted IR and VCD spectra. During the 
calculations of VCD spectra, magnetic shielding constants are computed as well. The computed 
values are references against TMS calculated at the same level of theory. 
Absolute configuration of 248a. 
Compound 248a features two sets of stereocenters. First, there are the bridge-atoms of the 
oxobridge which can either be both (R)- or (S)-configured. Furthermore, the orientation of the 
tropone moiety can be either endo or exo with respect to the oxobridge. The scheme above 
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shows the endo- and exo-form of 248a with (S)-configuration at the oxo bridge atoms which 
have been considered for the calculations. 
For both diastereomers of 248a, the conformational analysis is straightforward. The seven-
membered ring is very rigid due to the C=C bonds, and it can only adopt one planar 
conformation. In both isomers, a ring-flip of the ketone-containing six-membered ring is 
possible, i.e. the α-CH2 can point away or towards the oxobridge. Thus, only two conformations 
were found for each exo and endo-248a. The relative energies of the conformers of exo-248a 
are summarized in Table S6 and the respective lowest-energy structures are shown below. 
     
Figure S4. Lowest energy structures of exo-(S,S)-248a (left) and endo-(S,S)-248a (right). 
Table S5. Relative energies the two conformers of exo-(S,S)-248a. 
 # ∆E1 ∆G1 Pop-∆E2 Pop-∆G2 
ex
o
 
c0 0.00 0.00 74.46 65.57 
c1 0.63 0.38 25.54 34.43 
1 in kcal/mol 
2 population based on ∆E or ∆G in % 
a with respect to EZPC=-921.132232hartree and G=-921.17587 hartree 
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The experimental 1H-NMR chemical shifts of the protons at the two chiral centers suggest the 
preference of the exo-form. Both protons can easily be identified in the 1H-NMR spectrum 
based on the coupling pattern, as shown in Figure S4 below. From the calculated chemical 
shifts of the lowest-energy conformers of endo- and exo-248a, which are given in the figure as 
well, it can be seen that only for the exo-form the resonance frequencies are predicted in the 
correct order. 
 
Figure S5. Section of the 1H-NMR spectrum of 248a showing the two chiral protons of the tropone bridge head, 
and the theoretically derived values for endo- and exo-248a. 
Figure S5 shows a comparison of the experimental IR and VCD spectra with those computed 
for exo-(S,S)-248a. Again, good agreement between the calculated and measured IR spectrum 
is found. Only the band at ~1140 cm-1 of the experimental spectrum is missing in the 
simulation. Clear band assignments can be made based on the calculated IR which 
subsequently allows an assignment of experimental VCD bands to the predicted ones. From 
the visual comparison, the (S,S)-configuration of the bridge heads can clearly be established.  
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Figure S6. Comparison of experimental and simulated IR and VCD spectra. Band assignments are indicated by 
thin lines connecting the experimental and simulated band positions. 
 
7.4.2 Experimental Detail and Analytic Data for 1,3-Dipolar Cycloaddition Reactions 
of Cyclic Carbonyl Ylides and of Pentafulvenes (249a-c) 
 
Rel-tert-butyl (3aR,4S,8S,8aR,E)-8-methyl-3-(naphthalen-2-ylmethylene)-5-oxo-
3a,5,6,7,8,8a-hexahydro-4,8-epoxyazulene-4(3H)-carboxylate and Rel- tert-butyl 
(3aR,4R,8R,8aR,E)-8-methyl-1-(naphthalen-2-ylmethylene)-5-oxo-3a,5,6,7,8,8a-
hexahydro-4,8-epoxyazulene-4(1H)-carboxylate 
249a. For isomer A: 1H-NMR (500 MHz, CDCl3): δ = 7.84 – 7.75 (m, 4H), 7.55 – 7.43 (m, 
3H), 6.75 (s, 1H), 6.47 (dd, J = 5.4, 1.9 Hz, 1H), 5.98 (dd, J = 5.4, 2.3 Hz, 1H), 4.20 (d, J = 6.4 
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Hz, 1H), 3.97 – 3.88 (m, 1H), 2.84 (ddd, J = 16.6, 11.7, 8.2 Hz, 1H), 2.65 – 2.56 (m, 1H), 2.33 
– 2.26 (m, 1H), 2.23 – 2.14 (m, 1H), 1.56 (d, J = 4.7 Hz, 9H), 1.22 ppm (s, J = 4.1 Hz, 3H); 
13C-NMR (126 MHz, CDCl3): δ = 202.34, 165.68, 146.93, 140.88, 135.31, 133.72, 133.31, 
132.41, 128.38, 127.99, 127.77, 127.38, 126.66, 126.25, 125.88, 124.89, 90.15, 83.74, 83.08, 
59.14, 50.07, 39.85, 34.01, 28.32, 22.28 ppm; HRMS: calc. for [M+H]+ C27H29O4: 417.20604, 
found: 417.20597. For isomer B: 1H NMR (500 MHz, CDCl3) : δ = 7.85 – 7.70 (m, 4H), 7.52 
– 7.42 (m, 3H), 6.99 (d, J = 5.5 Hz, 1H), 6.41 (s, 1H), 6.13 (d, J = 5.5 Hz, 1H), 3.83 (d, J = 6.5 
Hz, 1H), 3.48 (d, J = 6.5 Hz, 1H), 2.80 – 2.67 (m, 1H), 2.55 (dd, J = 16.4, 6.6 Hz, 1H), 2.33 
(td, J = 12.6, 6.8 Hz, 1H), 2.10 (dd, J = 13.1, 7.9 Hz, 1H), 1.56 (s, 9H), 1.50 ppm (s, 3H); 13C 
NMR (126 MHz, CDCl3): δ = 202.29, 165.72, 146.00, 137.51, 135.37, 134.57, 133.62, 132.41, 
128.15, 127.99, 127.76, 127.09, 126.65, 126.45, 126.01, 124.24, 90.94, 83.77, 83.07, 56.67, 
53.99, 40.49, 33.79, 28.32, 23.41 ppm; HRMS: calc. for [M+H]+ C27H29O4: 417.20604, found: 
417.205967. 
Rel-tert-butyl (3aR,4R,8R,8aR,E)-1-(naphthalen-2-ylmethylene)-5-oxo-8-phenyl-
3a,5,6,7,8,8a-hexahydro-4,8-epoxyazulene-4(1H)-carboxylate 
249b, for the major product: 1H NMR (500 MHz, CDCl3): δ = 7.73 
(d, J = 7.5 Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.63 (d, J = 8.4 Hz, 1H), 
7.46 – 7.36 (m, 4H), 7.31 (t, J = 7.8 Hz, 2H), 7.24 – 7.17 (m, 2H), 
6.88 (dd, J = 8.5, 1.5 Hz, 1H), 6.73 (dd, J = 5.7, 1.0 Hz, 1H), 6.13 – 
6.07 (m, 1H), 5.55 (s, 1H), 3.96 (d, J = 6.6 Hz, 1H), 3.64 (d, J = 6.6 
Hz, 1H), 2.96 – 2.88 (m, 1H), 2.85 (dd, J = 13.0, 8.0 Hz, 1H), 2.70 (dd, J = 16.0, 6.6 Hz, 1H), 
2.62 – 2.46 (m, 1H), 1.59 ppm (d, J = 3.2 Hz, 9H); 13C NMR (126 MHz, , CDCl3): δ = 201.99, 
165.52, 145.57, 140.26, 135.98, 135.57, 134.76, 133.36, 132.17, 128.01, 127.86, 127.66, 
127.62, 127.58, 126.60, 126.55, 126.18, 126.02, 125.74, 125.65, 90.88, 87.77, 83.11, 57.05, 
55.55, 38.09, 33.64, 28.45, 28.37 ppm; HRMS: calc. for [M+H]+ C32H31O4: 479.22169, found: 
479.22133. 
Rel-tert-butyl (3aR,4R,8R,8aR)-1-cyclohexylidene-8-methyl-5-oxo-3a,5,6,7,8,8a-
hexahydro-4,8-epoxyazulene-4(1H)-carboxylate 
249c, for the major product: 1H NMR (500 MHz, CDCl3): δ = 6.57 (dd, J = 
5.7, 2.0 Hz, 1H), 5.74 (dd, J = 5.7, 2.2 Hz, 1H), 3.73 (d, J = 6.8 Hz, 1H), 
3.44 (d, J = 6.9 Hz, 1H), 2.70 (ddd, J = 16.7, 11.7, 8.2 Hz, 1H), 2.55 – 2.44 
(m, 1H), 2.37 (d, J = 13.0 Hz, 1H), 2.30 – 2.19 (m, 2H), 2.14 (dd, J = 11.9, 
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7.9 Hz, 1H), 2.09 – 1.97 (m, 2H), 1.68 – 1.56 (m, 4H), 1.56 – 1.45 (m, 12H), 1.32 ppm (s, 3H); 
13C NMR (126 MHz, cdcl3) δ 202.81, 165.93, 135.89, 134.83, 134.71, 130.77, 90.59, 84.12, 
82.76, 57.46, 49.60, 39.69, 33.93, 33.31, 31.78, 28.29, 27.98, 27.69, 26.69, 22.58 ppm; HRMS: 
calc. for [M+H]+ C22H31O4: 359.22169, found: 359.22179. 
 
7.4.3 Experimental Detail and Analytic Data for Enantioselective Synthesis of Tropanes 
(261a-c) 
Rel-tert-butyl (1R,5R,6S,7R)-7-cyano-8-methoxy-5-methyl-2,2'-dioxo-8-azaspiro[bicycle 
[3.2.1]octane-6,3'-indoline]-1'-carboxylate 
261a, 1H NMR (500 MHz, CDCl3): δ = 7.85 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 
7.6 Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 7.30 (t, J = 7.6 Hz, 1H), 4.20 (s, 1H), 
3.68 (d, J = 1.4 Hz, 1H), 3.65 (s, 3H), 3.22 – 3.12 (m, 1H), 2.49 – 2.37 (m, 
2H), 2.16 – 2.08 (m, 1H), 1.67 (s, 9H), 0.82 ppm (s, 3H); 13C NMR (126 MHz, 
CDCl3) δ 206.72, 173.75, 148.49, 139.23, 130.12, 127.48, 127.04, 124.90, 116.68, 115.09, 
85.74, 70.00, 69.67, 62.44, 59.32, 36.14, 33.22, 29.20, 28.23, 21.35 ppm; HRMS: calc. for 
[M+H]+ C22H26O5N3: 412.18725, found: 412.18755. 
Rel-Benzyl (1R,5R,6S,7R)-7-cyano-8-methoxy-5-methyl-2,2'-dioxo-8-azaspiro[bicycle 
[3.2.1]octane-6,3'-indoline]-1'-carboxylate 
261b, 1H NMR (400 MHz, CDCl3): δ = 7.93 (d, J = 8.2 Hz, 1H), 7.76 – 7.67 
(m, 1H), 7.52 (d, J = 6.8 Hz, 2H), 7.46 – 7.37 (m, 4H), 7.36 – 7.28 (m, 1H), 
5.51 (d, J = 12.2 Hz, 1H), 5.44 (d, J = 12.2 Hz, 1H), 4.20 (s, 1H), 3.64 (s, 3H), 
3.23 – 3.06 (m, 1H), 2.51 – 2.33 (m, 2H), 2.15 – 2.03 (m, 1H), 0.80 ppm (s, 
3H); 13C NMR (101 MHz, CDCl3): δ = 206.51, 173.56, 150.16, 138.77, 134.56, 130.30, 129.01, 
128.96, 128.62, 127.48, 127.06, 125.29, 116.52, 115.30, 69.97, 69.77, 69.46, 62.47, 59.42, 
36.11, 33.16, 29.20, 21.35 ppm; HRMS: calc. for [M+H]+ C25H24O5N3: 446:17105, found: 
446:17079. 
Rel- (1R,5R,6S,7R)-1'-acetyl-8-methoxy-5-methyl-2,2'-dioxo-8-azaspiro[bicycle 
[3.2.1]octane -6,3'-indoline]-7-carbonitrile 
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261c, 1H NMR (400 MHz, CDCl3): δ = 8.27 (d, J = 8.1 Hz, 1H), 7.70 (dd, J = 
7.6, 0.9 Hz, 1H), 7.44 (td, J = 8.1, 1.3 Hz, 1H), 7.34 (td, J = 7.6, 0.9 Hz, 1H), 
4.22 (s, 1H), 3.65 (s, 3H), 3.19 – 3.03 (m, 1H), 2.71 (s, 3H), 2.53 – 2.38 (m, 
2H), 2.08 – 1.97 (m,1H), 0.81 ppm (s, 3H); 13C NMR (101 MHz, CDCl3): δ = 
206.31, 176.13, 170.16, 144.96, 139.64, 130.31, 127.19, 125.67, 116.62, 116.48, 69.97, 69.80, 
62.52, 36.04, 33.11, 29.85, 29.32, 27.00, 21.39 ppm; HRMS: calc. for [M+H]+ C19H20O4N3: 
354.14483, found: 354.14499. 
 
Crystal data and structure refinement for 261a. (by C.-G.D) 
Identification code                                             DAN7627  
Empirical formula                                              C22 H25 N3 O5  
Formula weight                                                  411.45  
Temperature                                                       223(2) K  
Wavelength                                                        0.71073 Å  
Crystal system, space group                               monoclinic,  P21/n  (No. 14) 
Unit cell dimensions                                           a = 10.0396(2) Å  
                                                                            b =  8.5802(2) Å   β = 92.593(1)°  
                                                                            c = 24.6644(6) Å  
Volume                                                               2122.46(8) Å3  
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Z, Calculated density                                          4,   1.288 Mg/m3  
Absorption coefficient                                        0.092 mm-1  
F(000)                                                                 872  
Crystal size                                                         0.24 x 0.22 x 0.20 mm  
Theta range for data collection                           4.32 to 26.37°  
Limiting indices                                                 -12<=h<=12, -9<=k<=10, -30<=l<=30  
Reflections collected / unique                            14660 / 4306 [R(int) = 0.042]  
Completeness to theta = 26.37                           99.0 %  
Absorption correction                                        Semi-empirical from equivalents  
Max. and min. transmission                               0.9818 and 0.9782  
Refinement method                                           Full-matrix least-squares on F2  
Data / restraints / parameters                            4306 / 0 / 276  
Goodness-of-fit on F2                                       1.060  
Final R indices [I>2σ(I)]                                  R1 = 0.0531, wR2 = 0.1169  
R indices (all data)                                            R1 = 0.0688, wR2 = 0.1267  
Largest diff. peak and hole                               0.342 and -0.201 e.Å-3  
 
7.4.4 Experimental Detail and Analytic Data for Synthesis of Oxabicyclo[3.2.1]octanes 
by Aminecatalysis (269a, 270a-o, and 271a-m) 
General method for the synthesis of 270:  
 
Cinnamaldehyde 266 (0.15 mmol, 1.50 equiv.), 3-furone 267 (0.10 mmol, 1.00 equiv.), catalyst 
rac-268f (0.02 mmol, 0.20 equiv.), OFBA (0.02 mmol, 0.20 equiv.) were added into 1.0 mL 
toluene. Then the mixture was allowed to be stirred for specific time under room temperature. 
Direct purification by the silica gel column afforded the Michael adduct 269.  
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A solution of samarium(II) iodide in THF (0.1 M, 4,00 mL, 400 μmol, 4.00 equiv) was added 
dropwise to a solution of the Michael adduct 269 (100 μmol, 1 equiv) and HMPA (321 μL,1.85 
mmol, 18.5 equiv) in deoxygenated THF (5 mL). The resultant deep purple mixture was stirred 
at 23°C for 3 h, then was cooled to 0 °C and quenched by the addition aqueous hydrochloric 
acid solution (1 N, 5 mL). The layers were separated and the aqueous layer was extracted with 
dichloromethane (3 × 5 mL). The combined organic layers were washed with saturated aqueous 
sodium bicarbonate solution (10 mL), dried over anhydrous sodium sulfate, and the dried 
solution was concentrated. Purification of the residue by the silica gel column gave the 270. 
General method for the synthesis of 271: 
 
Cinnamic acid (18.0 mg, 120 μmol, 2.00 equiv), triethylamine (25.0 μL, 180 μmol, 3.00 equiv), 
2,4,6-trichlorobenzoyl chloride (25.0 μL, 155 μmol, 2.58 equiv) and 4-dimethylaminopyridine 
(1.0 mg, 8.2 μmol, 0.14 equiv) were added sequentially to a solution of 8 (16.0 mg, 60.0 μmol, 
1 equiv) in toluene (2 mL). The resultant mixture was stirred at 23 °C for 2 d, then quenched 
with aqueous hydrochloric acid solution (1 N, 5 mL). The organic layer of reaction reaction 
mixture was directly loaded on the silica gel column. 
Rel-(S)-3-((R)-5-isopropyl-2-methyl-3-oxo-2,3-dihydrofuran-2-yl)-3-phenylpropanal 
rac-269a, for major isomer: 1H NMR (400 MHz, CDCl3): δ 9.61 (s, 1H), 7.24 
– 7.13 (m, 5H), 5.08 (s, 3H), 3.77 – 3.66 (m, 1H), 3.12 – 3.05 (m, 1H), 2.64 
– 2.55 (m, 1H), 1.39 (s, 3H), 1.15 (d, J = 7.0 Hz, 3H), 1.12 ppm (d, J = 7.0 
Hz, 3H); 13C NMR (101 MHz, CDCl3): δ = 206.44, 200.77, 197.39, 137.48, 129.66, 128.50, 
127.89, 101.31, 91.19, 44.46, 43.61, 30.58, 20.52, 19.93, 19.88 ppm; HRMS: calc. for [M+H]+ 
C17H21O3: 273.14852, found: 273.14815. 
Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-5-methyl-4-phenyl-8-oxabicyclo[3.2.1]octan-6-
one 
Chapter 7. Experimental Part 
221 
 
270a, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.33 – 7.24 (m, 
3H), 7.13 – 7.11 (m, 2H), 4.24 (dd, J = 10.4, 5.8 Hz, 1H), 2.90 (dd, J = 
13.8, 4.8 Hz, 1H), 2.71 (d, J = 18.8 Hz, 1H), 2.45 (d, J = 18.8 Hz, 1H), 
2.30 – 2.18 (m, 1H), 2.17 – 2.04 (m, 1H), 1.92 – 1.77 (m, 1H), 1.15 (d, J 
= 7.1 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.04 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 
215.69, 138.76, 128.50, 128.47, 127.56, 83.61, 82.83, 69.15, 50.22, 40.65, 35.64, 32.86, 18.78, 
17.49, 16.84 ppm; HRMS: calc. for [M+H]+ C17H23O3: 275.16417, found: 275.16428. 
Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-5-methyl-4-(4-(trifluoromethyl)phenyl)-8-
oxabicyclo[3.2.1]octan-6-one 
270b, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.56 (d, J 
= 8.2 Hz, 2H), 7.25 (d, J = 8.1 Hz, 2H), 4.26 (dd, J = 10.5, 5.8 Hz, 
1H), 2.97 (dd, J = 13.8, 4.7 Hz, 1H), 2.73 (d, J = 18.9 Hz, 1H), 2.47 
(d, J = 18.9 Hz, 1H), 2.32 – 2.17 (m, 1H), 2.18 – 2.05 (m, 1H), 1.93 
– 1.75 (m, 1H), 1.15 (d, J = 6.9 Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.03 ppm (s, 3H); 13C NMR 
(126 MHz, CDCl3): δ = 215.46, 142.64, 129.81, 128.72, 125.29 (q, J = 3.7 Hz), 83.08, 82.87, 
68.74, 49.88, 40.50, 35.30, 32.67, 18.60, 17.32, 16.66 ppm. 
Rel-(1S,2R,4S,5R)-4-(4-bromophenyl)-2-hydroxy-1-isopropyl-5-methyl-8-oxabicyclo 
[3.2.1]octan-6-one 
270c, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.43 (d, J 
= 8.4 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 4.23 (dd, J = 10.3, 5.8 Hz, 
1H), 2.87 (dd, J = 13.7, 4.7 Hz, 1H), 2.70 (d, J = 18.8 Hz, 1H), 2.45 
(d, J = 18.8 Hz, 1H), 2.27 – 2.16 (m, 1H), 2.17 – 2.01 (m, 1H), 1.86 
– 1.71 (m, 1H), 1.14 (d, J = 7.1 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.02 ppm (s, 3H); 13C NMR 
(126 MHz, CDCl3): δ = 215.67, 137.77, 131.61, 130.17, 121.56, 83.30, 82.93, 68.98, 49.64, 
40.65, 35.54, 32.83, 18.73, 17.48, 16.83 ppm. 
Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-5-methyl-4-(naphthalen-2-yl)-8-oxabicyclo 
[3.2.1]octan-6-one 
270d, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.90 – 7.73 
(m, 3H), 7.60 (s, 1H), 7.52 – 7.41 (m, 2H), 7.25 (d, J = 8.5 Hz, 1H), 
4.29 (dd, J = 10.4, 5.8 Hz, 1H), 3.08 (dd, J = 13.7, 4.7 Hz, 1H), 2.78 
(d, J = 18.7 Hz, 1H), 2.49 (d, J = 18.7 Hz,1H), 2.34 – 2.21 (m, 1H), 
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2.14 (dd, J = 13.8, 6.9 Hz, 1H), 2.03 – 1.88 (m, 1H), 1.17 (d, J = 6.9 Hz, 3H), 1.14 (d, J = 6.9 
Hz, 3H), 1.08 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 215.76, 136.34, 133.42, 132.92, 
128.03, 128.02, 127.68, 127.42, 126.60, 126.20, 125.97, 83.75, 82.91, 69.18, 50.36, 40.71, 
35.80, 32.90, 18.90, 17.52, 16.87 ppm. 
Rel-(1S,2R,4S,5R)-4-(4-fluorophenyl)-2-hydroxy-1-isopropyl-5-methyl-8-oxabicyclo 
[3.2.1]octan-6-one 
270e, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.12 – 7.04 
(m, 2H), 7.02 – 6.92 (m, 2H), 4.22 (dd, J = 10.0, 5.5 Hz, 1H), 2.87 (dd, 
J = 13.8, 4.8 Hz, 1H), 2.68 (d, J = 18.8 Hz, 1H), 2.50 – 2.34 (m, 1H), 
2.25 – 2.14 (m, 1H), 2.13 – 1.98 (m, 1H), 1.85 – 1.70 (m, 1H), 1.12 (d, 
J = 7.1 Hz, 3H), 1.10 (d, J = 6.9 Hz, 3H), 1.00 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 
215.78, 162.29 (d, J = 245.8 Hz), 134.53, 129.95 (d, J = 8.0 Hz), 115.32 (d, J = 21.2 Hz), 83.48, 
82.88, 69.07, 49.42, 40.67, 35.84, 32.85, 18.73, 17.49, 16.84 ppm. 
Rel-(1S,2R,4S,5R)-4-(3-fluorophenyl)-2-hydroxy-1-isopropyl-5-methyl-8-oxabicyclo 
[3.2.1]octan-6-one 
270f, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.28 – 7.23 (m, 1H), 7.00 – 6.94 (m, 
1H), 6.91 (d, J = 7.7 Hz, 1H), 6.88 – 6.81 (m, 1H), 4.23 (dd, J = 10.2, 5.8 Hz, 1H), 2.90 (dd, J 
= 13.8, 4.7 Hz, 1H), 2.71 (d, J = 18.8 Hz, 1H), 2.45 (dd, J = 18.8, 0.7 Hz, 1H), 2.30 – 2.16 (m, 
1H), 2.16 – 2.03 (m, 1H), 1.85 – 1.73 (m, 1H), 1.14 (d, J = 6.9 Hz, 3H), 
1.11 (d, J = 6.9 Hz, 3H), 1.05 ppm  (s, 3H); 13C NMR (126 MHz, 
CDCl3): δ = 215.55, 162.79 (d, J = 245.8 Hz), 141.31 (d, J = 7.0 Hz), 
129.89 (d, J = 8.3 Hz), 124.20 (d, J = 2.8 Hz), 115.50 (d, J = 21.0 Hz), 114.47 (d, J = 21.0 Hz), 
83.34, 82.93, 68.98, 49.92, 49.91, 40.63, 35.63, 32.84, 18.75, 17.47, 16.82 ppm. 
Rel-(1S,2R,4S,5R)-4-(2-fluorophenyl)-2-hydroxy-1-isopropyl-5-methyl-8-oxabicyclo 
[3.2.1]octan-6-one 
270g, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.27 – 7.20 (m, 
1H), 7.16 – 7.07 (m, 2H), 7.07 – 6.99 (m, 1H), 4.27 (dd, J = 10.3, 5.9 Hz, 
1H), 3.43 (dd, J = 13.8, 4.8 Hz, 1H), 2.71 (d, J = 18.8 Hz, 1H), 2.45 (d, J 
= 18.8 Hz, 1H), 2.23 – 2.03 (m, 2H), 1.88 – 1.76 (m, 1H), 1.15 (d, J = 7.1 
Hz, 3H), 1.12 (d, J = 6.9 Hz, 3H), 1.09 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 215.68, 
161.07 (d, J = 241.7 Hz), 128.79 (d, J = 8.6 Hz), 128.56 (d, J = 3.3 Hz), 125.75 (d, J = 14.0 
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Hz), 124.22 (d, J = 3.7 Hz), 115.45 (d, J = 23.5 Hz), 83.67, 82.89, 68.99, 40.62, 34.62, 32.86, 
17.91, 17.87, 17.49, 16.83 ppm. 
Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-5-methyl-4-(p-tolyl)-8-oxabicyclo[3.2.1]octan-
6-one 
270h, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.11 (d, J = 
8.1 Hz, 2H), 7.01 (d, J = 8.1 Hz, 2H), 4.23 (dd, J = 10.2, 5.6 Hz, 1H), 
2.87 (dd, J = 13.8, 4.8 Hz, 1H), 2.76 – 2.64 (m, 1H), 2.44 (d, J = 19.0 
Hz, 1H), 2.33 (s, 3H), 2.27 – 2.16 (m, 1H), 2.16 – 2.04 (m, 1H), 1.92 – 
1.77 (m, J = 13.7, 10.5 Hz, 1H), 1.14 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.03 ppm 
(s, 3H); 13C NMR (126 MHz, CDCl3): δ = 215.80, 137.20, 135.70, 129.14, 128.33, 83.69, 
82.79, 69.15, 49.76, 40.63, 35.63, 32.83, 21.16, 18.76, 17.47, 16.83 ppm. 
Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-5-methyl-4-(m-tolyl)-8-oxabicyclo[3.2.1]octan-
6-one 
270i, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.22 – 7.14 
(m, 1H), 7.08 (d, J = 7.7 Hz, 1H), 6.96 – 6.86 (m, 1H), 4.23 (dd, J = 
10.5, 5.8 Hz, 1H), 2.86 (dd, J = 13.8, 4.8 Hz, 1H), 2.71 (d, J = 18.8 Hz, 
1H), 2.44 (d, J = 18.8 Hz, 1H), 2.38 – 2.28 (m, 2H), 2.27 – 2.15 (m, 
1H), 2.11 (dd, J = 13.9, 7.0 Hz, 1H), 1.90 – 1.77 (m, 1H), 1.14 (d, J = 6.8 Hz, 3H), 1.12 (d, J 
= 6.8 Hz, 3H), 1.04 ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 215.69, 138.71, 137.97, 
129.27, 128.32, 128.30, 125.57, 83.64, 82.80, 69.16, 50.13, 40.63, 35.69, 32.86, 21.61, 18.80, 
17.48, 16.84 ppm. 
Rel-(1S,2R,4S,5R)-4-(benzo[d][1,3]dioxol-5-yl)-2-hydroxy-1-isopropyl-5-methyl-8-
oxabicyclo[3.2.1]octan-6-one 
270j, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 6.73 (d, J = 
7.9 Hz, 1H), 6.66 – 6.54 (m, 2H), 5.95 (s, 2H), 4.21 (dd, J = 10.0, 5.9 
Hz, 1H), 2.82 (dd, J = 13.8, 4.7 Hz, 1H), 2.68 (d, J = 18.8 Hz, 1H), 
2.43 (d, J = 19.2 Hz, 1H), 2.24 – 2.16 (m, 1H), 2.16 – 2.05 (m, 1H), 
1.82 – 1.68 (m, 1H), 1.13 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.05 ppm (s, 3H); 13C 
NMR (126 MHz, CDCl3): δ = 215.83, 147.67, 146.97, 132.63, 121.93, 108.63, 108.18, 101.14, 
83.65, 82.81, 69.12, 49.86, 40.65, 35.95, 32.83, 18.76, 17.47, 16.83 ppm. 
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Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-4-(4-methoxyphenyl)-5-methyl-8-oxabicyclo 
[3.2.1]octan-6-one 
270k, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.04 (d, 
J = 8.6 Hz, 2H), 6.84 (d, J = 8.6 Hz, 2H), 4.23 (dd, J = 10.5, 5.8 
Hz, 1H), 3.80 (s, 3H), 2.85 (dd, J = 13.8, 4.8 Hz, 1H), 2.69 (d, J = 
18.8 Hz, 1H), 2.44 (d, J = 18.8 Hz, 1H), 2.27 – 2.16 (m, 1H), 2.17 
– 2.02 (m, 1H), 1.86 – 1.72 (m, 1H), 1.14 (d, J = 7.0 Hz, 3H), 1.11 (d, J = 6.9 Hz, 3H), 1.03 
ppm (s, 3H); 13C NMR (126 MHz, CDCl3): δ = 215.88, 159.03, 130.87, 129.44, 113.84, 83.77, 
82.78, 69.20, 55.36, 49.33, 40.67, 35.81, 32.86, 18.76, 17.49, 16.85 ppm. 
Rel-(1S,2R,4S,5R)-4-(furan-2-yl)-2-hydroxy-1-isopropyl-5-methyl-8-oxabicyclo[3.2.1] 
octan-6-one 
270l, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.37 – 7.30 (m, 
1H), 6.37 – 6.28 (m, 1H), 6.12 – 6.03 (m, 1H), 4.20 (dd, J = 10.7, 5.9 Hz, 
1H), 3.04 (dd, J = 13.8, 5.0 Hz, 1H), 2.63 (d, J = 18.8 Hz, 1H), 2.40 (d, J 
= 18.8 Hz, 1H), 2.27 (dt, J = 13.6, 5.4 Hz, 1H), 2.09 (dd, J = 13.9, 7.0 
Hz, 1H), 1.75 (td, J = 13.7, 10.8 Hz, 1H), 1.19 (s, 3H), 1.12 (d, J = 7.1 Hz, 3H), 1.10 ppm (d, 
J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 214.40, 152.72, 141.75, 110.41, 106.73, 
83.28, 82.80, 68.61, 43.10, 40.23, 33.51, 32.85, 18.67, 17.47, 16.84 ppm. 
Rel-(1S,2R,4S,5R)-2-hydroxy-1-isopropyl-5-methyl-4-(thiophen-3-yl)-8-oxabicyclo[3.2.1] 
octan-6-one 
270m, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 7.27 – 7.24 (m, 
1H), 7.06 – 6.99 (m, 1H), 6.95 – 6.83 (m, 1H), 4.30 – 4.15 (m, 1H), 3.05 
(dd, J = 13.7, 4.8 Hz, 1H), 2.72 – 2.64 (m, 1H), 2.43 (d, J = 18.9 Hz, 1H), 
2.26 (dt, J = 13.6, 5.3 Hz, 1H), 2.15 – 2.05 (m, 1H), 1.74 (td, J = 13.6, 10.6 
Hz, 1H), 1.13 (d, J = 6.9 Hz, 3H), 1.11 (d, J = 6.9 Hz,3H), 1.09 ppm (s, 3H); 13C NMR (126 
MHz, CDCl3): δ = 215.79, 139.59, 127.57, 125.37, 122.23, 83.54, 82.82, 68.97, 45.43, 40.64, 
36.38, 32.86, 18.82, 17.49, 16.84 ppm. 
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Rel-(1S,2R,4R,5R)-2-hydroxy-1-isopropyl-4,5-dimethyl-8-oxabicyclo[3.2.1]octan-6-one 
270n, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 4.07 (dd, J = 10.7, 
5.9 Hz, 1H), 2.46 (d, J = 18.7 Hz, 1H), 2.30 (d, J = 18.7 Hz,1H), 2.09 – 1.93 
(m, 2H), 1.82 – 1.66 (m, 1H), 1.19 (s, 3H), 1.09 – 1.04 (m, 7H), 0.84 ppm (d, J 
= 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 216.30, 84.22, 82.64, 69.05, 
40.33, 37.92, 37.52, 32.88, 17.97, 17.52, 16.91, 15.15 ppm. 
Rel-ethyl (1R,2R,4R,5S)-4-hydroxy-5-isopropyl-1-methyl-7-oxo-8-oxabicyclo[3.2.1] 
octane-2-carboxylate 
270o, for major isomer: 1H NMR (500 MHz, CDCl3): δ = 4.25 – 4.05 (m, 
3H), 2.69 (dd, J = 13.1, 5.2 Hz, 1H), 2.63 (d, J = 18.9 Hz, 1H), 2.36 (dd, J 
= 18.9, 0.8 Hz, 1H), 2.23 – 2.14 (m, 1H), 2.06 (dd, J = 13.9, 6.9 Hz, 1H), 
1.91 – 1.77 (m, 1H), 1.28 (dd, J = 14.0, 6.9 Hz, 6H), 1.09 (d, J = 7.1 Hz, 
3H), 1.07 ppm (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 212.92, 170.04, 83.11, 
81.41, 67.93, 61.18, 48.83, 39.74, 32.95, 31.04, 18.73, 17.39, 16.74, 14.23 ppm. 
Rel-(1S,2R,4S,5R)-1-isopropyl-5-methyl-4-phenyl-2-(((E)-styryl)oxy)-8-oxabicyclo[3.2.1] 
octan-6-one 
271a, 1H NMR (500 MHz, CDCl3): δ = 7.70 (d, J = 16.0 Hz, 1H), 
7.58 – 7.50 (m, 2H), 7.48 – 7.37 (m, 3H), 7.33 – 7.23 (m, 3H), 
7.18 – 7.10 (m, 2H), 6.43 (d, J = 16.0 Hz, 1H), 5.48 (dd, J = 10.4, 
6.0 Hz, 1H), 3.01 (dd, J = 13.8, 4.7 Hz, 1H), 2.86 (d, J = 18.7 Hz, 
1H), 2.59 (d, J = 18.7 Hz, 1H), 2.49 (dt, J = 13.5, 5.4 Hz, 1H), 2.07 (dt, J = 13.9, 7.0 Hz, 1H), 
1.90 (td, J = 13.7, 10.6 Hz, 1H), 1.13 – 1.06 ppm (m, 9H); 13C NMR (126 MHz, CDCl3): δ = 
215.14, 165.72, 145.79, 138.39, 134.27, 130.72, 129.09, 128.48, 128.31, 127.63, 117.70, 84.05, 
81.91, 70.43, 49.98, 42.16, 33.63, 32.39, 18.85, 17.59, 16.72 ppm; HRMS: calc. for [M+H]+ 
C19H20O4: 405.20604, found: 405.20583. 
Rel-(1S,2R,4S,5R)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-4-(4-(trifluoromethyl) 
phenyl)-8-oxabicyclo[3.2.1]octan-6-one 
271b, 1H NMR (500 MHz, CDCl3): δ = 7.68 (d, J = 16.0 Hz, 
1H), 7.59 – 7.46 (m, 3H), 7.46 – 7.33 (m, 3H), 7.28 – 7.22 
(m, 3H), 6.40 (d, J = 16.0 Hz, 1H), 5.45 (dd, J = 10.3, 5.9 Hz, 
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1H), 3.06 (dd, J = 14.0, 4.7 Hz, 1H), 2.85 (d, J = 18.7 Hz, 1H), 2.59 (d, J = 18.7 Hz, 1H), 2.47 
(dt, J = 13.4, 5.2 Hz, 1H), 2.13 – 2.01 (m, 1H), 1.93 – 1.76 (m, 1H), 1.14 – 0.97 ppm (m, 9H); 
13C NMR (126 MHz, CDCl3): δ = 215.10, 165.63, 146.03, 134.32, 130.82, 129.12, 128.87, 
128.34, 125.47, 118.66, 117.51, 83.78, 82.13, 70.14, 49.80, 42.19, 33.61, 32.03, 18.83, 17.57, 
16.71 ppm. 
Rel-(1S,2R,4S,5R)-4-(4-bromophenyl)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-8-
oxabicyclo[3.2.1]octan-6-one 
271c, 1H NMR (500 MHz, CDCl3): δ = 7.68 (d, J = 16.0 Hz, 
1H), 7.53 (dd, J = 6.7, 2.8 Hz, 2H), 7.44 – 7.36 (m, 4H), 7.00 
(d, J = 8.5 Hz, 2H), 6.40 (d, J = 16.0 Hz, 1H), 5.43 (dd, J = 
10.3, 5.8 Hz, 1H), 2.95 (dd, J = 13.9, 4.7 Hz, 1H), 2.82 (d, J = 
18.6 Hz, 1H), 2.57 (d, J = 18.6 Hz, 1H), 2.51 – 2.39 (m, 1H), 2.10 – 1.99 (m, 1H), 1.81 (td, J 
= 13.7, 10.5 Hz, 1H), 1.14 – 1.00 ppm (m, 9H). 
Rel-(1S,2R,4S,5R)-1-isopropyl-5-methyl-4-(naphthalen-2-yl)-2-(((E)-styryl)oxy)-8-
oxabicyclo[3.2.1]octan-6-one 
271d, 1H NMR (500 MHz, CDCl3): δ = 7.83 – 7.78 (m, 2H), 
7.76 (d, J = 8.6 Hz, 1H), 7.69 (d, J = 16.0 Hz, 1H), 7.62 – 
7.58 (m, 1H), 7.57 – 7.50 (m, 2H), 7.49 – 7.42 (m, 2H), 7.42 
– 7.35 (m, 3H), 7.26 – 7.21 (m, 1H), 6.42 (d, J = 16.0 Hz, 
1H), 5.51 (dd, J = 10.2, 5.9 Hz, 1H), 3.17 (dd, J = 13.8, 4.7 Hz, 1H), 2.90 (d, J = 18.6 Hz, 1H), 
2.61 (d, J = 18.7 Hz, 1H), 2.58 – 2.50 (m, 1H), 2.11 – 2.03 (m, J = 14.4, 7.5 Hz, 1H), 2.05 – 
1.95 (m, 1H), 1.13 – 1.04 ppm (m, 9H); 13C NMR (126 MHz, CDCl3): δ = 215.23, 165.75, 
145.85, 135.95, 134.27, 133.41, 132.94, 130.73, 129.09, 128.32, 128.05, 127.67, 127.46, 
126.53, 126.20, 125.98, 117.69, 84.20, 82.01, 70.45, 50.11, 42.23, 33.66, 32.50, 18.97, 17.62, 
16.75 ppm. 
Rel-(1S,2R,4S,5R)-4-(4-fluorophenyl)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-8-
oxabicyclo[3.2.1]octan-6-one 
271e, 1H NMR (500 MHz, CDCl3): δ = 7.68 (d, J = 16.0 Hz, 
1H), 7.56 – 7.48 (m, 2H), 7.45 – 7.34 (m, 3H), 7.09 (dd, J = 
8.7, 5.4 Hz, 2H), 7.03 – 6.85 (m, 2H), 6.40 (d, J = 16.0 Hz, 
1H), 5.44 (dd, J = 10.3, 5.9 Hz, 1H), 2.98 (dd, J = 13.9, 4.8 Hz, 
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1H), 2.82 (d, J = 18.7 Hz, 1H), 2.57 (d, J = 18.7 Hz, 1H), 2.46 (dt, J = 13.6, 5.4 Hz, 1H), 2.05 
(dt, J = 13.9, 7.0 Hz, 1H), 1.81 (td, J = 13.7, 10.5 Hz, 1H), 1.16 – 0.96 ppm (m, 9H); 13C NMR 
(126 MHz, CDCl3): δ = 215.26, 165.73, 162.32 (d, J = 245.9 Hz), 145.90, 134.18 (d, J = 3.3 
Hz), 130.76, 129.96 (d, J = 8.0 Hz), 129.10, 128.32, 117.61, 115.35 (d, J = 21.2 Hz), 83.94, 
81.98, 70.33, 49.19, 42.19, 33.61, 32.59, 18.80, 17.58, 16.71ppm. 
Rel-(1S,2R,4S,5R)-4-(3-fluorophenyl)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-8-
oxabicyclo[3.2.1]octan-6-one 
271f, 1H NMR (500 MHz, CDCl3): δ = 7.68 (d, J = 16.0 Hz, 
1H), 7.56 – 7.50 (m, 2H), 7.43 – 7.36 (m, 3H), 7.25 – 7.20 (m, 
1H), 6.98 – 6.92 (m, 1H), 6.91 (d, J = 7.8 Hz, 1H), 6.84 (d, J = 
10.1 Hz, 1H), 6.40 (d, J = 16.0 Hz, 1H), 5.44 (dd, J = 10.3, 6.1 
Hz, 1H), 2.99 (dd, J = 13.8, 4.7 Hz, 1H), 2.83 (d, J = 18.7 Hz, 1H), 2.57 (d, J = 18.7 Hz, 1H), 
2.47 (dt, J = 13.5, 5.2 Hz, 1H), 2.08 – 1.98 (m, 1H), 1.82 (td, J = 13.7, 10.6 Hz, 1H), 1.13 – 
1.00 ppm (m, 9H). 
Rel-(1S,2R,4S,5R)-4-(2-fluorophenyl)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-8-
oxabicyclo[3.2.1]octan-6-one 
271g, 1H NMR (500 MHz, CDCl3): δ = 7.68 (d, J = 16.0 Hz, 1H), 
7.58 – 7.49 (m, 2H), 7.45 – 7.36 (m, 3H), 7.24 – 7.17 (m, 1H), 
7.15 – 6.96 (m, 3H), 6.40 (d, J = 16.0 Hz, 1H), 5.46 (dd, J = 10.3, 
6.0 Hz, 1H), 3.51 (dd, J = 13.8, 4.7 Hz, 1H), 2.83 (d, J = 18.7 Hz, 
1H), 2.57 (d, J = 18.6 Hz, 1H), 2.42 (dt, J = 13.3, 5.4 Hz, 1H), 2.14 – 1.98 (m, 1H), 1.92 – 1.79 
(m, J = 10.7 Hz, 1H), 1.14 – 1.01 ppm (m, 9H). 
Rel-(1S,2R,4S,5R)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-4-(p-tolyl)-8-oxabicyclo 
[3.2.1]octan-6-one 
271h, 1H NMR (500 MHz, CDCl3): δ = 7.67 (d, J = 16.0 Hz, 
1H), 7.57 – 7.49 (m, 2H), 7.45 – 7.30 (m, 3H), 7.09 (d, J = 7.8 
Hz, 2H), 7.00 (d, J = 8.0 Hz, 2H), 6.40 (d, J = 16.0 Hz, 1H), 
5.44 (dd, J = 10.2, 6.0 Hz, 1H), 2.95 (dd, J = 13.8, 4.7 Hz, 1H), 
2.82 (d, J = 18.7 Hz, 1H), 2.56 (d, J = 18.7 Hz, 1H), 2.44 (dt, J = 13.5, 5.4 Hz, 1H), 2.31 (s, 
3H), 2.12 – 1.98 (m, 1H), 1.95 – 1.75 (m, 1H), 1.12 – 0.97 ppm (m, 9H). 
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Rel-(1S,2R,4S,5R)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-4-(m-tolyl)-8-oxabicyclo 
[3.2.1]octan-6-one 
271i, 1H NMR (500 MHz, CDCl3): δ = 7.67 (d, J = 16.0 Hz, 
1H), 7.56 – 7.49 (m, 2H), 7.44 – 7.35 (m, 3H), 7.20 – 7.13 (m, 
1H), 7.06 (d, J = 7.3 Hz, 1H), 6.91 (s, 2H), 6.40 (d, J = 16.0 Hz, 
1H), 5.45 (dd, J = 10.3, 5.9 Hz, 1H), 2.95 (dd, J = 13.8, 4.7 Hz, 
1H), 2.83 (d, J = 18.7 Hz, 1H), 2.56 (d, J = 18.7 Hz, 1H), 2.45 (dt, J = 13.5, 5.3 Hz, 1H), 2.33 
(s, 3H), 2.04 (dt, J = 13.9, 7.0 Hz, 1H), 1.87 (td, J = 13.9, 10.6 Hz, 1H), 1.11 – 1.04 ppm (m, 
9H); 13C NMR (126 MHz, CDCl3): δ = 215.13, 165.72, 145.76, 138.34, 137.99, 134.29, 130.71, 
129.23, 129.09, 128.38, 128.33, 128.31, 125.56, 117.74, 110.14, 84.10, 81.88, 70.48, 49.90, 
42.15, 33.64, 32.43, 21.60, 18.88, 17.60, 16.74 ppm.  
Rel-(1S,2R,4S,5R)-4-(furan-2-yl)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-8-oxabicyclo 
[3.2.1]octan-6-one 
271j, 1H NMR (500 MHz, CDCl3): δ = 7.68 (d, J = 16.0 Hz, 1H), 
7.57 – 7.50 (m, 2H), 7.43 – 7.37 (m, 3H), 7.33 – 7.29 (m, 1H), 
6.40 (d, J = 16.0 Hz, 1H), 6.29 (dd, J = 3.2, 1.8 Hz, 1H), 6.06 (d, 
J = 3.2 Hz, 1H), 5.40 (dd, J = 10.6, 6.0 Hz, 1H), 3.12 (dd, J = 13.8, 
5.0 Hz, 1H), 2.76 (d, J = 18.7 Hz, 1H), 2.56 – 2.43 (m, 2H), 2.03 (dt, J = 13.9, 7.0 Hz, 1H), 
1.80 (td, J = 13.7, 10.6 Hz, 1H), 1.21 (s, 3H), 1.06 (d, J = 6.9 Hz, 3H), 1.04 ppm (d, J = 6.9 
Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 213.84, 165.73, 152.25, 145.89, 141.88, 134.26, 
130.76, 129.11, 128.33, 117.64, 110.38, 106.95, 83.69, 81.91, 69.86, 42.89, 41.74, 33.62, 
30.18, 18.74, 17.56, 16.72 ppm. 
Rel-(1S,2R,4S,5R)-1-isopropyl-5-methyl-2-(((E)-styryl)oxy)-4-(thiophen-3-yl)-8-
oxabicyclo[3.2.1]octan-6-one 
271k, 1H NMR (500 MHz, CDCl3): δ = 7.67 (d, J = 16.0 Hz, 1H), 
7.56 – 7.50 (m, 2H), 7.43 – 7.35 (m, 3H), 7.23 (dd, J = 4.9, 3.0 Hz, 
1H), 7.04 (dd, J = 2.7, 1.0 Hz, 1H), 6.88 (dd, J = 5.0, 1.1 Hz, 1H), 
6.40 (d, J = 16.0 Hz, 1H), 5.41 (dd, J = 10.4, 5.9 Hz, 1H), 3.14 
(dd, J = 13.8, 4.8 Hz, 1H), 2.80 (d, J = 18.7 Hz, 1H), 2.56 (d, J = 18.6 Hz, 1H), 2.50 (dt, J = 
13.6, 5.4 Hz, 1H), 2.04 (dt, J = 13.9, 6.9 Hz, 1H), 1.76 (td, J = 13.7, 10.6 Hz, 1H), 1.12 (s, 3H), 
1.07 (d, J = 6.9 Hz, 3H), 1.06 ppm (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 
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215.28, 165.71, 145.82, 139.17, 134.26, 130.73, 129.09, 128.31, 127.48, 125.42, 122.34, 
117.66, 83.97, 81.91, 70.23, 45.21, 42.15, 33.62, 33.13, 18.88, 17.58, 16.72 ppm. 
Rel-(1S,2R,4R,5R)-1-isopropyl-4,5-dimethyl-2-(((E)-styryl)oxy)-8-oxabicyclo[3.2.1] 
octan-6-one 
271l, 1H NMR (500 MHz, CDCl3): δ = 7.66 (d, J = 16.0 Hz, 1H), 7.58 
– 7.46 (m, 2H), 7.43 – 7.33 (m, 3H), 6.38 (d, J = 16.0 Hz, 1H), 5.30 
(dd, J = 10.6, 6.0 Hz, 1H), 2.61 (d, J = 18.6 Hz, 1H), 2.44 (d, J = 18.6 
Hz, 1H), 2.27 (dt, J = 13.5, 5.6 Hz, 1H), 2.07 – 1.89 (m, 1H), 1.91 – 
1.78 (m, 1H), 1.25 (s, 3H), 1.12 (td, J = 13.3, 10.8 Hz, 1H), 1.04 (d, J = 6.9 Hz, 3H), 1.01 (d, 
J = 6.9 Hz, 3H), 0.86 ppm (d, J = 6.9 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ = 215.71, 
165.83, 145.62, 134.31, 130.68, 129.08, 128.30, 117.85, 84.67, 81.73, 70.47, 41.88, 37.73, 
33.96, 33.63, 18.04, 17.61, 16.78, 15.02 ppm. 
Rel-ethyl (1R,2R,4R,5S)-5-isopropyl-1-methyl-7-oxo-4-(((E)-styryl)oxy)-8-oxabicyclo 
[3.2.1]octane-2-carboxylate 
271m, 1H NMR (500 MHz, CDCl3): δ = 7.67 (d, J = 16.0 Hz, 1H), 
7.57 – 7.48 (m, 2H), 7.47 – 7.39 (m, 3H), 6.39 (d, J = 16.0 Hz, 
1H), 5.32 (dd, J = 10.8, 6.1 Hz, 1H), 4.27 – 4.01 (m, 2H), 2.82 – 
2.66 (m, 2H), 2.48 (d, J = 18.8 Hz, 1H), 2.41 (dt, J = 13.8, 5.7 Hz, 
1H), 2.06 – 1.95 (m, 1H), 1.88 (td, J = 13.6, 10.9 Hz, 1H), 1.33 (s, 3H), 1.26 (t, J = 7.1 Hz, 
3H), 1.03 (d, J = 7.0 Hz, 3H), 1.01 ppm (d, J = 7.2 Hz, 3H). 
 
7.5 Experimental Part for Synthesis of Pyrroloisoquinolines 
7.5.1 Experimenal Details and Analytic Data for Synthesis of Isoquinolinium 
Methylides 293a-p 
General Method: 
To the mixture of 2-bromomalonate and acetone 30 mL was added isoquinoline. The mixture 
was stirred for 24 h under r.t., and the resulting precipitate was filtered out and recrystalized in 
i-PrOH and ether to give colorless solid. Then the solid was disolved in water and basified with 
KCO3(aq) and extracted with CHCl3. Recrystalization gives yellow needle. 
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2-(Isoquinolin-2-ium-2-yl)-1,3-dimethoxy-1,3-dioxopropan-2-ide 
293a, 65% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.28 (s, 1H), 8.30 (d, 
J = 6.8 Hz, 1H), 8.15 (d, J = 8.3 Hz, 1H), 8.00 – 8.01 (m, J = 4.5 Hz, 
2H), 7.97 (d, J = 6.9 Hz, 1H), 7.83 (ddd, J = 8.1, 5.3, 2.8 Hz, 1H), 3.73 
ppm (s, 6H); 13C-NMR (126 MHz, CDCl3): δ = 153.49, 141.41, 136.37, 135.64, 130.21, 
129.75, 127.74, 126.85, 123.55, 97.35, 54.93, 50.74 ppm; FT-IR: ṽ = 3067, 2948, 1702, 1589, 
1440, 1368, 1075 cm-1; HRMS: calcd. for [M+H]+ C14H14NO4: 260.09173, found: 260.09195. 
1,3-Diethoxy-2-(isoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
293b, 73% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.28 (s, 1H), 8.31 (d, 
J = 6.9 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 8.00 – 7.88 (m, 2H), 7.94 (d, J 
= 6.9 Hz, 1H), 7.88 – 7.77 (m, 1H), 4.20 (q, J = 7.0 Hz, 4H), 1.29 ppm (t, 
J = 7.0 Hz, 6H); 13C-NMR (126 MHz, CDCl3): δ = 153.26, 141.40, 136.22, 135.46, 130.11, 
129.68, 127.69, 126.81, 123.32, 97.59, 64.64, 59.12, 14.95 ppm; FT-IR: ṽ = 3081, 2976, 1655, 
1605, 1409, 1372, 1330, 1170, 1049 cm-1; HRMS: calcd. for [M+H]+ C16H18NO4: 288.12303, 
found: 288.12299. 
General Method: 
To a solution of the Cu(acac)2 (1 mol %) in 5 mL of CH2Cl2 were added the corresponding 
isoquinolines (1.0 mmol) and iodonium ylides (1.2 mmol). The reaction was stirred at room 
temperature to 40°C. After reaction completion monitored by TLC, the solution was then 
concentrated and purified by chromatography on silica gel to give the corresponding 
isoquinolinium methylides.  
1,3-Bis(benzyloxy)-2-(isoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
293c, 78% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.33 (s, 1H), 8.37 (d, 
J = 6.8 Hz, 1H), 8.13 (d, J = 8.2 Hz, 1H), 8.03 – 7.99 (m, 2H), 7.96 (d, J 
= 6.9 Hz, 1H), 7.83 (dt, J = 8.2, 4.0 Hz, 1H), 7.44 – 7.36 (m, 4H), 7.33 – 
7.23 (m, 6H), 5.28 ppm (s, 4H); 13C-NMR (126 MHz, CDCl3): δ = 153.38, 141.32, 137.98, 
136.29, 135.57, 130.15, 129.73, 128.41, 127.78, 127.69, 127.41, 126.81, 123.43, 64.97 ppm; 
FT-IR: ṽ = 3031, 2949, 1709, 1575, 1384, 1282, 1052 cm-1; HRMS: calcd. for [M+H]+ 
C26H22NO4: 412.15433, found: 412.15440. 
2-(5-Bromoisoquinolin-2-ium-2-yl)-1,3-dimethoxy-1,3-dioxopropan-2-ide 
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293d, 52% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.68 (s, 1H), 8.42 
(d, J = 6.2 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 7.96 (d, J = 7.6 Hz, 2H), 
7.87 – 7.76 (m, 1H), 3.76 ppm (s, 6H); FT-IR: ṽ = 3023, 2943, 1701, 
1590, 1440, 1377, 1359, 1080 cm-1; HRMS: calcd. for [M+H]+ 
C14H13
79BrNO4: 338.00225, found: 338.00255; calcd. for [M+H]
+ C14H13
81BrNO4: 340.00020, 
found: 340.00045; 
2-(7-Bromoisoquinolin-2-ium-2-yl)-1,3-dimethoxy-1,3-dioxopropan-2-ide 
293e, 80% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.23 (s, 1H), 8.47 
– 8.21 (m, 2H), 8.15 – 8.00 (m, 1H), 8.00 – 7.78 (m, 2H), 3.76 ppm 
(s, 6H); FT-IR: ṽ = 3112, 2947, 1701, 1587, 1442, 1374, 1083, 1077 
cm-1; HRMS: calcd. for [M+H]+ C14H13
79BrNO4: 338.00225, found: 338.00268; calcd. for 
[M+H]+ C14H13
81BrNO4: 340.00020, found: 340.00052; 
2-(8-Bromoisoquinolin-2-ium-2-yl)-1,3-dimethoxy-1,3-dioxopropan-2-ide 
293f, 62% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.67 (s, 1H), 8.40 
(d, J = 6.8 Hz, 1H), 8.06 (d, J = 7.5 Hz, 1H), 8.00 – 7.92 (m, 2H), 7.81 
(t, J = 7.9 Hz, 1H), 3.76 ppm (s, 6H); 13C-NMR (126 MHz, CDCl3): δ 
= 165.60, 153.44, 142.27, 137.90, 135.69, 134.21, 127.26, 126.39, 124.30, 123.68, 50.93 ppm; 
FT-IR: ṽ = 3064, 2948, 1626, 1597, 1439, 1337, 1187, 1075 cm-1; HRMS: calcd. for [M+H]+ 
C14H13
79BrNO4: 338.00225, found: 338.00257; calcd. for [M+H]
+ C14H13
81BrNO4: 340.00020, 
found: 340.00050; 
2-(7,8-Dichloroisoquinolin-2-ium-2-yl)-1,3-dimethoxy-1,3-dioxopropan-2-ide 
293g, 51% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.70 (s, 1H), 8.43 
(dd, J = 6.8, 1.0 Hz, 1H), 7.98 (d, J = 8.8 Hz, 1H), 7.95 (d, J = 6.8 
Hz, 1H), 7.85 (d, J = 8.8 Hz, 1H), 3.76 ppm (s, 6H); 13C-NMR (126 
MHz, CDCl3): δ = 165.56, 150.42, 142.40, 136.66, 135.75, 135.30, 131.80, 127.04, 126.22, 
123.35, 50.94 ppm; FT-IR: ṽ = 3039, 2944, 1585, 1436, 1337, 1183, 1111, 1054 cm-1; HRMS: 
calcd. for [M+H]+ C14H12Cl2NO4: 328.01379, found: 328.01438. 
1,3-Dimethoxy-2-(6-methoxyisoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
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293h, 55% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.04 (s, 1H), 
8.16 (d, J = 6.0 Hz, 1H), 8.01 (d, J = 8.7 Hz, 1H), 7.81 (s, 1H), 7.41 
(d, J = 8.7 Hz, 1H), 7.25 – 7.20 (m, 1H), 4.04 (s, 3H), 3.72 ppm (s, 
6H); 13C-NMR (101 MHz, CDCl3): δ = 167.88, 165.48, 152.34, 141.80, 139.40, 131.57, 
123.48, 123.21, 122.09, 104.86, 56.36, 50.68 ppm; FT-IR: ṽ = 2944, 2847, 1588, 1434, 1337, 
1266, 1184, 1091 cm-1; HRMS: calcd. for [M+H]+ C15H16NO5: 290.10230, found: 290.10282. 
1,3-Dimethoxy-2-(7-methoxyisoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
293i, 58% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.13 (s, 1H), 
8.18 (d, J = 6.8 Hz, 1H), 7.97 – 7.78 (m, 2H), 7.61 (d, J = 9.1 Hz, 
1H), 7.33 (s, 1H), 3.97 (s, 3H), 3.72 ppm (s, 6H); 13C-NMR (126 
MHz, CDCl3): δ = 165.82, 160.56, 151.68, 139.68, 132.28, 129.56, 129.19, 128.27, 123.29, 
106.17, 56.09, 50.72 ppm; FT-IR: ṽ = 3084, 2946, 1705, 1587, 1436, 1375, 1263, 1078 cm-1; 
HRMS: calcd. for [M+H]+ C15H16NO5: 290.10230, found: 290.10236. 
1,3-Dimethoxy-2-(8-methoxyisoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
293j, 61% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.53 (s, 1H), 8.21 (d, 
J = 6.9 Hz, 1H), 7.90 – 7.85 (m, 2H), 7.50 (d, J = 8.3 Hz, 1H), 7.06 (d, J 
= 8.0 Hz, 1H), 4.05 (s, 3H), 3.72 ppm (s, 6H); 13C-NMR (126 MHz, 
CDCl3): δ = 165.92, 157.75, 150.07, 141.73, 137.38, 137.14, 122.99, 120.39, 118.28, 107.90, 
56.39, 50.64 ppm; FT-IR: ṽ = 3045, 2938, 1596, 1428, 1344, 1213, 1085 cm-1; HRMS: calcd. 
for [M+H]+ C15H16NO5: 290.10230, found: 290.10268. 
1,3-Dimethoxy-2-(6-methylisoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
293k, 55% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.18 (s, 1H), 
8.23 (d, J = 6.8 Hz, 1H), 8.03 (d, J = 8.1 Hz, 1H), 7.86 (d, J = 6.8 
Hz, 1H), 7.82 – 7.71 (m, 1H), 7.65 (d, J = 8.1 Hz, 1H), 3.73 (s, 6H), 
2.66 ppm (s, 3H); 13C-NMR (101 MHz, CDCl3): δ = 165.96, 153.09, 147.64, 141.46, 136.81, 
132.53, 129.52, 126.12, 125.92, 122.87, 96.87, 50.72, 22.80 ppm; FT-IR: ṽ = 3033, 2943, 1585, 
1334, 1189, 1090 cm-1; HRMS: calcd. for [M+H]+ C15H16NO4: 274.10738, found: 274.10747. 
1,3-Dimethoxy-2-(7-methylisoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
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293l, 58% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.16 (s, 1H), 8.23 
(d, J = 6.7 Hz, 1H), 7.95 – 7.87 (m, 3H), 7.85 – 7.78 (m, 1H), 3.72 
(s, 6H), 2.61 ppm (s, 3H); 13C-NMR (126 MHz, CDCl3): δ = 165.79, 
152.91, 140.91, 140.67, 138.02, 134.77, 130.08, 128.31, 128.05, 126.56, 123.30, 50.68, 21.90 
ppm; FT-IR: ṽ = 3093, 2948, 1702, 1588, 1438, 1372, 1071 cm-1; HRMS: calcd. for [M+H]+ 
C15H16NO4: 274.10738, found: 274.10748. 
1,3-Dimethoxy-2-(8-methylisoquinolin-2-ium-2-yl)-1,3-dioxopropan-2-ide 
293m, 60% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.41 (s, 1H), 8.29 
(d, J = 6.7 Hz, 1H), 7.95 (d, J = 6.7 Hz, 1H), 7.88 – 7.77 (m, 2H), 7.62 
(d, J = 6.7 Hz, 1H), 3.74 (s, 6H), 2.80 ppm (s, 3H); 13C-NMR (126 MHz, 
CDCl3): δ = 165.71, 151.10, 141.11, 138.33, 137.08, 135.59, 130.88, 127.44, 124.97, 123.97, 
50.73, 18.57 ppm; FT-IR: ṽ = 3042, 2940, 1592, 1432, 1346, 1198, 1091 cm-1; HRMS: calcd. 
for [M+H]+ C15H16NO4: 274.10738, found: 274.10751.  
1,3-Dimethoxy-1,3-dioxo-2-(6-phenylisoquinolin-2-ium-2-yl)propan-2-ide 
293n, 67% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.26 (s, 1H), 8.30 
(s, 1H), 8.25 – 8.13 (m, 2H), 8.13 – 8.03 (m, 1H), 8.03 – 7.94 (m, 1H), 
7.83 – 7.68 (m, 2H), 7.65 – 7.44 (m, 3H), 3.76 ppm (s, 6H); 13C-NMR 
(101 MHz, CDCl3): δ = 165.80, 153.06, 152.00, 141.68, 140.83, 138.61, 130.26, 130.01, 
129.76, 129.56, 127.91, 126.75, 124.16, 123.55, 50.81 ppm; FT-IR: ṽ = 3017, 2952, 1574, 
1439, 1350, 1186, 1080 cm-1; HRMS: calcd. for [M+H]+ C20H18BrNO4: 336.12303, found: 
336.12326. 
1,3-Dimethoxy-1,3-dioxo-2-(4-phenylisoquinolin-2-ium-2-yl)propan-2-ide 
293o, 72% yield; 1H-NMR (400 MHz, CDCl3): δ = 9.27 (s, 1H), 8.33 – 
8.16 (m, 2H), 8.04 (d, 1H), 8.00 – 7.93 (m, 1H), 7.90 – 7.78 (m, 1H), 
7.61 – 7.46 (m, 5H), 3.76 ppm (s, 6H); 13C-NMR (101 MHz, CDCl3): δ 
= 167.87, 165.84, 152.15, 140.40, 137.39, 136.96, 135.64, 134.28, 
133.60, 130.07, 129.59, 129.25, 128.06, 125.51, 50.86 ppm; FT-IR: ṽ = 2945, 1611, 1434, 
1364, 1176, 1074 cm-1; HRMS: calcd. for [M+H]+ C20H18BrNO4: 336.12303, found: 336.12375. 
1,3-Dimethoxy-1,3-dioxo-2-(4-propylisoquinolin-2-ium-2-yl)propan-2-ide 
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293p, 72% yield; 1H-NMR (500 MHz, CDCl3): δ = 9.14 (s, 1H), 8.18 – 
8.10 (m, 3H), 8.06 – 7.96 (m, 1H), 7.87 – 7.76 (m, 1H), 3.73 (s, 6H), 3.06 
(t, J = 7.3 Hz, 2H), 1.87 – 1.71 (m, 3H), 1.07 ppm (t, J = 7.3 Hz, 3H).; 
13C-NMR (126 MHz, CDCl3): δ = 151.84, 140.04, 136.26, 135.97, 135.28, 
130.57, 129.72, 127.88, 123.48, 50.71, 32.06, 23.04, 14.05 ppm; FT-IR: ṽ = 2943, 1707, 1624, 
1434, 1367, 1171, 1072 cm-1; HRMS: calcd. for [M+H]+ C17H20NO4: 302.13868, found: 
302.13920. 
7.5.2 Experimenal Details and Analytic Data for Synthesis of Pyrroloisoquinolines 
294a-v 
General Method: Reactions were performed with 293a (0.1 mmol), 278 (0.15 mmol), PBu3 
(0.02 mmol) in CH2Cl2 (1 mL) at room temperature. After reactions completed, NaBH4 (0.3 
mmol) and acetic acid or trifluoroacetic acid (1 mmol) were added sequentially at 0°C, and the 
reaction mixture was stirred for 10 minutes. Then the reaction mixture was quenched by the 
addition of saturated NaHCO3 and extracted with CH2Cl2 (3×5 ml). The combined organic 
phase was dried over with MgSO4 and solvent was removed under reduced pressure. The crude 
residue was purified by silica gel flash chromatography to give the desired product. 
Dimethyl 2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-3,3(10bH)-
dicarboxylate 
294a: 75% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.19 – 7.07 (m, 4H), 
6.51 (d, J = 1.3 Hz, 1H), 5.17 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.78 (s, 
3H), 3.63 (s, 3H), 3.45 – 3.34 (m, 2H), 3.33 (d, J = 1.3 Hz, 2H), 2.95 – 
2.83 (m, 1H), 2.70 (dd, J = 12.2, 8.0 Hz, 1H), 1.26 ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 
MHz, CDCl3): δ = 170.57, 169.31, 169.26, 137.08, 134.77, 133.21, 133.05, 129.01, 126.43, 
126.04, 124.39, 81.51, 65.53, 60.94, 52.64, 52.52, 42.47, 33.98, 28.34, 14.32 ppm; FT-IR: ṽ = 
2953, 2841, 1731, 1452, 1235, 1138, 1029 cm-1; HRMS: calcd. for [M+H]+ C20H24NO6: 
374.15981, found: 374.15949.  
Diethyl 2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-3,3(10bH)-
dicarboxylate 
294b: 95% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.20 – 7.07 (m, 4H), 
6.54 (s, 1H), 5.23 (s, 1H), 4.33 – 4.22 (m, 2H), 4.14 (q, J = 7.1 Hz, 2H), 
4.11 – 4.01 (m, 2H), 3.48 (s, 1H), 3.41 – 3.30 (m, 3H), 2.98 – 2.87 (m, 
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1H), 2.83 – 2.71 (m, J = 15.7 Hz, 1H), 1.31 (t, J = 7.1 Hz, 3H), 1.26 (t, J = 7.1 Hz, 3H), 1.06 
ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.55, 168.59, 136.40, 134.94, 
133.20, 132.47, 128.70, 126.68, 126.20, 124.40, 81.81, 65.60, 61.90, 60.96, 43.10, 33.99, 
28.54, 14.31, 14.25, 13.79 ppm; FT-IR: ṽ = 2981, 2932, 1728, 1447, 1369, 1225, 1147, 1027 
cm-1; HRMS: calcd. for [M+H]+ C22H28NO6: 402.19111, found: 402.19064. 
Dibenzyl 2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-3,3(10bH)-
dicarboxylate 
294c: 84% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.38 – 7.31 (m, 5H), 
7.31 – 7.24 (m, 3H), 7.20 – 7.13 (m, 2H), 7.14 – 7.06 (m, 4H), 6.56 (d, 
J = 1.4 Hz, 1H), 5.28 – 5.24 (m, 1H), 5.21 (s, 1H), 5.19 (d, J = 12.3 Hz, 
1H), 5.11 (d, J = 12.3 Hz, 1H), 5.03 (d, J = 12.3 Hz, 1H), 4.08 (qd, J = 7.1, 3.5 Hz, 2H), 3.39 
(ddd, J = 8.7, 5.3, 3.5 Hz, 2H), 3.34 (d, J = 8.7 Hz, 2H), 2.89 – 2.76 (m, 1H), 2.65 (dt, J = 16.1, 
4.4 Hz, 1H), 1.22 ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.54, 137.17, 
135.49, 135.03, 134.92, 133.01, 132.97, 128.99, 128.66, 128.59, 128.38, 128.34, 128.23, 
128.18, 126.47, 126.03, 124.31, 81.81, 67.47, 67.39, 65.62, 60.88, 42.56, 33.91, 28.44, 14.25 
ppm; FT-IR: ṽ = 2979, 1731, 1454, 1368, 1139, 1026 cm-1; HRMS: calcd. for [M+H]+ 
C32H32NO6: 526.22241, found: 526.22278. 
Dimethyl 7-bromo-2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294d: 51% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.41 (d, J = 7.5 Hz, 
1H), 7.11 – 6.99 (m, 2H), 6.47 (d, J = 1.2 Hz, 1H), 5.13 (s, 1H), 4.14 
(q, J = 7.1 Hz, 2H), 3.82 (dd, J = 7.8, 2.3 Hz, 1H), 3.78 (s, 3H), 3.67 (s, 
3H), 3.55 (ddd, J = 12.8, 6.7, 2.8 Hz, 1H), 3.37 – 3.28 (m, 3H), 2.81 (dd, J = 9.9, 6.9 Hz, 1H), 
2.74 (d, J = 3.4 Hz, 1H), 1.25 ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 
170.50, 169.05, 139.35, 134.34, 133.60, 132.87, 130.57, 127.26, 125.69, 123.62, 81.05, 65.64, 
61.02, 52.86, 52.63, 42.21, 33.93, 29.31, 14.33 ppm; FT-IR: ṽ = 2981, 2953, 1731, 1562, 1437, 
1240, 1143, 1030 cm-1; HRMS: calcd. for [M+H]+ C20H23
79BrNO6: 452.07033, found: 
452.06829; calcd. for [M+H]+ C220H23
81BrNO6: 454.06828, found: 454.06794.  
Dimethyl 9-bromo-2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
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294e: 69% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.28 – 7.24 (m, 
1H), 7.24 – 7.21 (m, 1H), 6.98 (d, J = 8.1 Hz, 1H), 6.46 (d, J = 1.4 Hz, 
1H), 5.13 (s, 1H), 4.15 (q, J = 7.2 Hz, 2H), 3.82 (dd, J = 6.6, 3.0 Hz, 
1H), 3.78 (s, 3H), 3.63 (s, 3H), 3.47 – 3.28 (m, 3H), 2.86 – 2.73 (m, 1H), 2.63 (dt, J = 16.3, 4.3 
Hz, 1H), 1.26 ppm (t, J = 7.2 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.44, 169.12, 
139.17, 133.74, 133.60, 132.49, 130.69, 129.51, 127.50, 119.61, 81.37, 65.13, 61.06, 52.77, 
52.65, 42.14, 33.94, 27.69, 14.33 ppm; FT-IR: ṽ = 2986, 1731, 1568, 1234, 1173, 1029 cm-1; 
HRMS: calcd. for [M+H]+ C20H23
79BrNO6: 452.07033, found: 452.06919; calcd. for [M+H]
+ 
C220H23
81BrNO6: 454.06828, found: 454.06799. 
Dimethyl 10-bromo-2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294f: 62% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.39 (d, J = 7.3 Hz, 
1H), 7.08 – 6.94 (m, 2H), 6.88 (s, 1H), 5.45 (s, 1H), 4.24 – 4.04 (m, 2H), 
3.78 (s, 3H), 3.73 (s, 3H), 3.60 – 3.45 (m, 1H), 3.39 – 3.21 (m, 2H), 3.17 
(ddd, J = 14.7, 11.4, 3.7 Hz, 1H), 2.72 (ddd, J = 16.5, 11.5, 5.4 Hz, 1H), 2.51 (d, J = 16.5 Hz, 
1H), 1.27 ppm (dt, J = 14.3, 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.53, 169.80, 
169.72, 137.82, 134.91, 133.64, 132.29, 131.28, 129.07, 127.67, 122.08, 82.15, 66.65, 60.99, 
52.96, 52.79, 41.67, 33.96, 27.52, 14.33 ppm; FT-IR: ṽ = 2981, 2953, 1731, 1558, 1434, 1226, 
1138, 1027 cm-1; HRMS: calcd. for [M+H]+ C20H23
79BrNO6: 452.07033, found: 452.06934; 
calcd. for [M+H]+ C220H23
81BrNO6: 454.06828, found: 454.06767. 
Dimethyl 9,10-dichloro-2-(2-ethoxy-2-oxoethyl)-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294g: 52% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.27 – 7.24 (m, 
1H), 6.95 (d, J = 8.2 Hz, 1H), 6.79 (d, J = 1.1 Hz, 1H), 5.49 (s, 1H), 
4.16 – 4.09 (m, 2H), 3.78 (s, 3H), 3.73 (s, 3H), 3.56 (ddd, J = 14.2, 5.5, 
2.2 Hz, 1H), 3.34 – 3.24 (m, 2H), 3.21 – 3.12 (m, 1H), 2.70 (ddd, J = 17.0, 11.4, 5.7 Hz, 1H), 
2.53 (d, J = 17.0 Hz, 1H), 1.25 ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 
170.42, 169.62, 169.44, 135.70, 135.64, 132.89, 132.84, 131.05, 130.31, 128.96, 128.12, 81.87, 
65.63, 61.05, 53.02, 52.85, 41.40, 33.95, 27.10, 14.33 ppm; FT-IR: ṽ = 2953, 1731, 1432, 1225, 
1138, 1028 cm-1; HRMS: calcd. for [M+H]+ C20H22Cl2NO6: 442.08187, found: 442.08248. 
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Dimethyl 2-(2-ethoxy-2-oxoethyl)-8-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294h: 59% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.01 (d, J = 8.4 
Hz, 1H), 6.72 (dd, J = 8.4, 2.5 Hz, 1H), 6.65 (d, J = 2.5 Hz, 1H), 
6.48 (s, 1H), 5.13 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.78 (s, 3H), 
3.76 (s, 3H), 3.64 (s, 3H), 3.41 – 3.33 (m, 2H), 3.32 (d, J = 1.2 Hz, 2H), 2.94 – 2.79 (m, 1H), 
2.67 (dd, J = 11.9, 4.2 Hz, 1H), 1.25 ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 
= 170.58, 169.22, 158.15, 136.09, 133.40, 132.80, 129.42, 125.42, 114.01, 112.04, 81.57, 
65.14, 60.95, 55.39, 52.70, 52.56, 42.47, 33.98, 28.62, 14.33 ppm; FT-IR: ṽ = 2930, 2840, 1761, 
1719, 1609, 1434, 1306, 1018 cm-1; HRMS: calcd. for [M+H]+ C21H26NO7: 404.17038, found: 
404.16921.  
Dimethyl 2-(2-ethoxy-2-oxoethyl)-9-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294i: 79% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.01 (d, J = 8.3 
Hz, 1H), 6.70 (dd, J = 8.3, 2.6 Hz, 1H), 6.64 (d, J = 2.6 Hz, 1H), 6.48 
(s, 1H), 5.16 (s, 1H), 4.14 (q, J = 7.1 Hz, 2H), 3.85 – 3.74 (m, 6H), 
3.65 (s, 3H), 3.43 (ddd, J = 12.4, 6.2, 3.6 Hz, 1H), 3.38 – 3.27 (m, 3H), 2.86 – 2.73 (m, 1H), 
2.68 – 2.52 (m, 1H), 1.26 ppm (t, J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.56, 
169.31, 157.90, 137.91, 133.15, 133.05, 129.96, 126.66, 112.21, 109.96, 81.45, 65.67, 60.95, 
55.43, 52.68, 52.53, 42.54, 33.95, 27.28, 14.31 ppm; FT-IR: ṽ = 3004, 2954, 2928, 1726, 1606, 
1500, 1350, 1064 cm-1; HRMS: calcd. for [M+H]+ C21H26NO7: 404.17038, found: 404.16866.  
Dimethyl 2-(2-ethoxy-2-oxoethyl)-10-methoxy-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294j: 84% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.15 – 7.03 (m, J = 
7.9 Hz, 1H), 6.75 – 6.59 (m, 3H), 5.31 (s, 1H), 4.12 (dd, J = 14.1, 7.0 
Hz, 2H), 3.81 (s, 3H), 3.76 (s, 3H), 3.69 (s, 3H), 3.54 (dd, J = 14.1, 5.7 
Hz, 1H), 3.32 – 3.23 (m, 2H), 3.25 – 3.11 (m, 1H), 2.79 – 2.63 (m, 1H), 2.58 – 2.45 (m, 1H), 
1.25 ppm (t, J = 7.0 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.80, 170.04, 156.24, 136.06, 
134.91, 130.95, 126.97, 124.82, 121.88, 107.74, 81.44, 63.48, 60.84, 55.21, 52.77, 52.56, 
41.67, 34.04, 27.32, 14.30 ppm; FT-IR: ṽ = 2953, 2838, 1730, 1581, 1468, 1248, 1088 cm-1; 
HRMS: calcd. for [M+H]+ C21H26NO7: 404.17038, found: 404.16929.  
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Dimethyl 2-(2-ethoxy-2-oxoethyl)-8-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294k: 67% yield; 1H-NMR (400 MHz, CDCl3): δ = 7.02 – 6.94 (m, 
2H), 6.94 – 6.88 (m, 1H), 6.48 (s, 1H), 5.15 (s, 1H), 4.15 (q, J = 7.1 
Hz, 2H), 3.77 (s, 3H), 3.64 (s, 3H), 3.45 – 3.33 (m, 2H), 3.33 – 3.26 
(m, 2H), 2.89 – 2.77 (m, 1H), 2.64 (dt, J = 16.2, 4.2 Hz, 1H), 2.28 (s, 3H), 1.26 ppm (t, J = 7.1 
Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 170.58, 169.26, 135.89, 134.54, 134.06, 133.41, 
132.77, 129.62, 126.81, 124.30, 81.54, 65.40, 60.92, 52.65, 52.51, 42.48, 33.98, 28.21, 21.17, 
14.32 ppm; FT-IR: ṽ = 2981, 2953, 1731, 1550, 1433, 1235, 1140, 1030 cm-1; HRMS: calcd. 
for [M+H]+ C21H26NO6: 388.17546, found: 388.17670.  
Dimethyl 2-(2-ethoxy-2-oxoethyl)-9-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294l: 72% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.03 – 6.85 (m, 3H), 
6.50 (s, 1H), 5.16 (s, 1H), 4.19 – 4.04 (m, 2H), 3.78 (s, 3H), 3.64 (s, 
3H), 3.46 – 3.38 (m, 1H), 3.36 – 3.23 (m, 3H), 2.83 – 2.79 (m, 1H), 
2.65 – 2.60 (m, 1H), 2.30 (s, 3H), 1.26 ppm (td, J = 7.1, 2.7 Hz, 3H); 13C-NMR (126 MHz, 
CDCl3): δ = 170.48, 169.26, 135.40, 133.24, 132.71, 131.37, 128.83, 127.10, 124.94, 122.02, 
81.37, 65.45, 60.82, 52.55, 52.41, 42.38, 33.84, 27.61, 21.13, 14.19 ppm; FT-IR: ṽ = 2953, 
2918, 1731, 1433, 1217, 1150, 1029 cm-1; HRMS: calcd. for [M+H]+ C21H26NO6: 388.17546, 
found: 388.17688.  
Dimethyl 2-(2-ethoxy-2-oxoethyl)-10-methyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294m: 80% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.04 (t, J = 7.4 Hz, 
1H), 6.99 (d, J = 7.4 Hz, 1H), 6.92 (d, J = 7.4 Hz, 1H), 6.50 (s, 1H), 
5.45 (s, 1H), 4.18 – 4.09 (m, 2H), 3.78 (s, 3H), 3.72 (s, 3H), 3.50 (ddd, 
J = 13.6, 5.4, 2.6 Hz, 1H), 3.34 – 3.27 (m, 2H), 3.17 (ddd, J = 13.6, 11.1, 
3.8 Hz, 1H), 2.79 – 2.70 (m, 1H), 2.62 – 2.51 (m, J = 18.3 Hz, 1H), 2.34 (s, 3H), 1.25 ppm (t, 
J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ = 170.63, 169.76, 135.05, 134.47, 134.23, 
133.35, 132.28, 128.75, 127.53, 126.23, 81.90, 65.36, 60.92, 52.85, 52.68, 41.96, 33.88, 28.18, 
20.17, 14.31 ppm; FT-IR: ṽ = 2980, 2953, 1730, 1433, 1224, 1133, 1031 cm-1; HRMS: calcd. 
for [M+H]+ C21H26NO6: 388.17546, found: 388.17725.  
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Dimethyl 2-(2-ethoxy-2-oxoethyl)-8-phenyl-5,6-dihydropyrrolo[2,1-a]isoquinoline-
3,3(10bH)-dicarboxylate 
294n: 76% yield; 1H-NMR (500 MHz, CDCl3): δ = 7.58 – 7.53 (m, 
2H), 7.45 – 7.37 (m, 3H), 7.37 – 7.29 (m, 2H), 7.19 (d, J = 7.9 Hz, 
1H), 6.54 (d, J = 1.4 Hz, 1H), 5.23 (s, 1H), 4.16 (q, J = 7.1 Hz, 2H), 
3.79 (s, 3H), 3.66 (s, 3H), 3.52 – 3.44 (m, 1H), 3.45 – 3.36 (m, 1H), 3.36 – 3.30 (m, 2H), 2.95 
(ddd, J = 15.9, 9.2, 6.8 Hz, 1H), 2.76 (dt, J = 15.9, 3.9 Hz, 1H), 1.27 ppm (t, J = 7.1 Hz, 3H); 
13C-NMR (126 MHz, CDCl3): δ = 170.58, 169.34, 141.14, 139.45, 136.11, 135.11, 133.19, 
133.06, 128.82, 127.83, 127.24, 127.15, 124.94, 124.90, 81.47, 65.44, 60.98, 52.73, 52.57, 
42.41, 33.97, 28.37, 14.33 ppm; FT-IR: ṽ = 2953, 1731, 1433, 1234, 1148, 1029 cm-1; HRMS: 
calcd. for [M+H]+ C26H28NO6: 450.19111, found: 450.19098.  
Dimethyl 2-(2-ethoxy-2-oxoethyl)-6-phenylpyrrolo[2,1-a]isoquinoline-3,3(10bH)-
dicarboxylate 
294o: 60% yield; 1H-NMR (400 MHz, CDCl3): δ = 7.52 – 7.33 (m, 4H), 
7.32 – 7.27 (m, 1H), 7.20 – 7.04 (m, 4H), 6.81 – 6.73 (m, 2H), 5.58 (s, 
1H), 4.19 (q, J = 7.2 Hz, 2H), 3.79 (s, 3H), 3.73 (s, 3H), 3.47 (s, 2H), 
1.29 ppm (t, J = 7.2 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ = 170.42, 
168.39, 167.90, 138.83, 133.30, 132.50, 130.72, 129.83, 129.27, 128.63, 128.59, 127.03, 
126.41, 126.38, 123.02, 122.85, 118.08, 80.41, 65.62, 61.16, 53.24, 53.15, 33.66, 14.34 ppm; 
FT-IR: ṽ = 2954, 1732, 1607, 1443, 1244, 1178, 1029 cm-1; HRMS: calcd. for [M+H]+ 
C26H26NO6: 448.17546, found: 448.17365.  
Dimethyl 2-(2-ethoxy-2-oxoethyl)-6-propylpyrrolo[2,1-a]isoquinoline-3,3(10bH)-
dicarboxylate 
294p: 87% yield; 1H-NMR (500 MHz, CDCl3):
 δ = 7.21 – 7.10 (m, 3H), 
7.00 (d, J = 7.4 Hz, 1H), 6.71 (d, J = 0.5 Hz, 1H), 6.40 (s, 1H), 5.45 (s, 
1H), 4.17 (q, J = 7.1 Hz, 2H), 3.82 (s, 3H), 3.60 (s, 3H), 3.44 – 3.34 (m, 
2H), 2.56 (ddd, J = 13.7, 8.2, 5.4 Hz, 1H), 2.26 – 2.18 (m, 1H), 1.67 – 
1.58 (m, 1H), 1.56 – 1.44 (m, 1H), 1.27 (t, J = 7.1 Hz, 3H), 0.96 ppm (t, J = 7.1 Hz, 3H); 13C-
NMR (126 MHz, CDCl3): δ = 170.43, 168.61, 168.20, 133.25, 132.44, 131.08, 130.42, 127.76, 
126.97, 126.00, 122.76, 121.16, 115.22, 80.79, 65.62, 61.08, 53.01, 52.92, 33.70, 32.18, 22.52, 
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14.33, 14.06 ppm; FT-IR: ṽ = 2956, 1735, 1686, 1441, 1244, 1173, 1129, 1031 cm-1; HRMS: 
calcd. for [M+H]+ C23H28NO6: 414.19111, found: 414.19033. 
Diethyl (E or Z)-2-(2-oxo-2-phenylethylidene)-1,5,6,10b-tetrahydropyrrolo[2,1-a] 
isoquinoline-3,3(2H)-dicarboxylate 
294q: 91% yield; 1H-NMR (400 MHz, CDCl3):
 δ = 8.00 – 7.92 (m, 2H), 
7.61 – 7.53 (m, 1H), 7.51 – 7.44 (m, 2H), 7.45 – 7.39 (m, 1H), 7.21 – 
7.10 (m, 4H), 4.39 – 4.22 (m, 4H), 4.19 (dd, J = 9.6, 6.3 Hz, 1H), 3.96 
(ddd, J = 18.2, 6.2, 1.9 Hz, 1H), 3.59 (dd, J = 11.1, 5.9 Hz, 1H), 3.30 – 
3.18 (m, 1H), 2.98 – 2.79 (m, 3H), 1.35 (t, J = 6.1 Hz, 3H), 1.31 ppm (t, J = 6.1 Hz, 3H); 13C-
NMR (101 MHz, CDCl3): δ = 190.56, 168.03, 167.64, 156.95, 138.73, 137.98, 134.29, 132.98, 
128.92, 128.78, 128.40, 126.65, 126.06, 125.55, 120.33, 79.07, 62.28, 61.95, 60.32, 44.54, 
37.80, 30.19, 14.62, 14.25 ppm; FT-IR: ṽ = 2980, 1727, 1671, 1368, 1228, 1040 cm-1; HRMS: 
calcd. for [M+H]+ C26H28NO5: 434.19620, found: 434.19605. 
Diethyl (E or Z)-2-(2-(furan-2-yl)-2-oxoethylidene)-1,5,6,10b-tetrahydropyrrolo[2,1-
a]isoquinoline-3,3(2H)-dicarboxylate 
294r: 83% yield; 1H-NMR (400 MHz, CDCl3):
 δ = 7.64 – 7.54 (m, 
1H), 7.31 – 7.28 (m, 1H), 7.23 – 7.21 (m, 1H), 7.18 – 7.11 (m, 4H), 
6.60 – 6.48 (m, 1H), 4.42 – 4.21 (m, 4H), 4.23 – 4.12 (m, 1H), 4.03 
(ddd, J = 18.5, 6.3, 1.9 Hz, 1H), 3.57 (dd, J = 11.0, 6.3 Hz, 1H), 3.32 
– 3.16 (m, 1H), 2.97 – 2.76 (m, 3H), 1.35 (t, J = 7.1 Hz, 3H), 1.30 ppm (t, J = 7.1 Hz, 3H); 13C-
NMR (101 MHz, CDCl3): δ = 178.52, 167.87, 167.44, 157.59, 154.24, 146.47, 137.97, 134.27, 
128.91, 126.66, 126.09, 125.57, 119.36, 117.26, 112.58, 79.10, 62.28, 61.94, 60.34, 44.53, 
37.89, 30.17, 14.60, 14.23 ppm; FT-IR: ṽ = 2980, 1727, 1667, 1621, 1466, 1232, 1040 cm-1; 
HRMS: calcd. for [M+H]+ C24H26NO6: 424.17546, found: 424.17525. 
Diethyl (E or Z)-2-(2-(3-bromophenyl)-2-oxoethylidene)-1,5,6,10b-tetrahydropyrrolo 
[2,1-a]isoquinoline-3,3(2H)-dicarboxylate 
294s: 83% yield; Ratio of isomer, 78:22; For major product: 1H-
NMR (400 MHz, CDCl3):
 δ = 8.10 – 8.04 (m, 1H), 7.91 – 7.84 (m, 
1H), 7.68 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.40 – 7.29 (m, 2H), 7.22 
– 7.06 (m, 4H), 4.37 – 4.24 (m, 4H), 4.18 (dd, J = 9.6, 6.3 Hz, 1H), 
3.93 (ddd, J = 18.4, 6.3, 1.8 Hz, 1H), 3.59 (dd, J = 11.1, 6.3 Hz, 1H), 3.30 – 3.15 (m, 1H), 2.96 
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– 2.78 (m, 3H), 1.40 – 1.29 ppm (m, 6H); 13C-NMR (101 MHz, CDCl3): δ = 189.01, 167.91, 
167.49, 158.26, 140.50, 137.87, 135.79, 134.28, 131.44, 130.38, 128.94, 126.89, 126.69, 
126.08, 125.51, 123.12, 119.74, 79.10, 62.37, 62.03, 60.26, 44.51, 37.94, 30.18, 14.63, 14.26 
ppm; FT-IR: ṽ = 2980, 1727, 1673, 1368, 1220, 1038 cm-1; HRMS: calcd. for [M+H]+ 
C26H27
79BrNO5: 512.10671, found: 512.10677; calcd. for [M+H]
+ C22H21
81BrNO6: 514.10467, 
found: 514.10462; For minor isomer, 1H-NMR (400 MHz, CDCl3):
 δ = 8.17 – 8.07 (m, 1H), 
7.91 – 7.87 (m, 1H), 7.68 (ddd, J = 8.0, 2.0, 1.0 Hz, 1H), 7.35 (dd, J = 10.4, 5.4 Hz, 1H), 7.20 
– 7.11 (m, 4H), 7.09 – 7.05 (m, 1H), 4.31 – 4.24 (m, 3H), 4.18 – 4.12 (m, 1H), 4.06 (dd, J = 
10.8, 7.1 Hz, 1H), 3.77 (dd, J = 10.8, 7.1 Hz, 1H), 3.33 (dd, J = 15.6, 5.4 Hz, 1H), 3.25 – 3.14 
(m, 1H), 2.91 – 2.72 (m, 3H), 1.27 (t, J = 7.1 Hz, 3H), 1.09 ppm (t, J = 7.1 Hz, 3H). 
Diethyl (E or Z)-2-(2-(naphthalen-1-yl)-2-oxoethylidene)-1,5,6,10b-tetrahydropyrrolo 
[2,1-a]isoquinoline-3,3(2H)-dicarboxylate 
294t: 79% yield; 1H-NMR (400 MHz, CDCl3):
 δ = 8.52 (d, J = 8.2 
Hz, 1H), 7.99 (d, J = 8.2 Hz, 1H), 7.90 (d, J = 8.2 Hz, 1H), 7.84 (d, 
J = 7.2 Hz, 1H), 7.61 – 7.49 (m, 3H), 7.26 – 7.23 (m, 1H), 7.21 – 
7.10 (m, 4.9 Hz, 4H), 4.38 – 4.22 (m, 5H), 4.00 (dd, J = 18.3, 6.2 
Hz, 1H), 3.62 (dd, J = 11.4, 6.2 Hz, 1H), 3.34 – 3.22 (m, 1H), 3.06 – 2.81 (m, 3H), 1.31 ppm 
(q, J = 7.2 Hz, 6H); 13C-NMR (101 MHz, CDCl3): δ = 13C NMR (101 MHz, cdcl3) δ 194.17, 
167.69, 167.39, 137.67, 134.25, 134.10, 132.65, 128.99, 128.70, 128.16, 127.85, 126.87, 
126.66, 126.24, 125.88, 125.64, 124.80, 124.62, 79.13, 62.49, 62.18, 60.58, 44.74, 37.70, 
30.13, 14,68, 14.28 ppm; FT-IR: ṽ = 2978, 2924, 1727, 1673, 1368, 1230, 1039 cm-1; HRMS: 
calcd. for [M+H]+ C30H30NO5: 484.21185, found: 484.21150. 
Dimethyl (E or Z)-9-bromo-2-(2-oxo-2-phenylethylidene)-1,5,6,10b-tetrahydropyrrolo 
[2,1-a]isoquinoline-3,3(2H)-dicarboxylate 
294u: 64% yield; 1H-NMR (400 MHz, CDCl3):
 δ = 7.98 – 7.93 (m, 
2H), 7.60 – 7.54 (m, 1H), 7.50 – 7.46 (m, 2H), 7.40 (dd, J = 3.1, 1.9 
Hz, 1H), 7.29 – 7.25 (m, 2H), 7.01 (d, J = 8.4 Hz, 1H), 4.15 – 4.06 
(m, 1H), 3.92 (ddd, J = 11.7, 8.0, 2.7 Hz, 1H), 3.87 (s, 3H), 3.82 (s, 
3H), 3.54 (dd, J = 10.8, 6.4 Hz, 1H), 3.14 (dd, J = 14.7, 8.0 Hz, 1H), 2.91 – 2.74 ppm (m, 3H); 
13C-NMR (101 MHz, CDCl3): δ = 190.37, 168.45, 167.92, 155.98, 139.88, 138.53, 133.17, 
133.12, 130.59, 129.78, 128.83, 128.52, 128.45, 120.56, 119.65, 78.99, 59.98, 53.43, 52.66, 
44.25, 37.56, 29.61 ppm; FT-IR: ṽ = 2955, 1755, 1728, 1672, 1443, 1220, 1118, 1033 cm-1; 
Chapter 7. Experimental Part 
 
242 
 
HRMS: calcd. for [M+H]+ C24H23
79BrNO5: 484.07541, found: 484.07507; calcd. for [M+H]
+ 
C24H23
81BrNO5: 486.07337, found: 486.07296.  
Dimethyl (E or Z)-9-methoxy-2-(2-oxo-2-phenylethylidene)-1,5,6,10b-tetrahydropyrrolo 
[2,1-a]isoquinoline-3,3(2H)-dicarboxylatedimethyl 
294v: 78% yield; 1H-NMR (400 MHz, CDCl3):
 δ = 7.99 – 7.92 (m, 
2H), 7.59 – 7.55 (m, 1H), 7.51 – 7.42 (m, 2H), 7.40 (dd, J = 3.2, 1.9 
Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.75 (dd, J = 8.4, 2.6 Hz, 1H), 
6.67 (d, J = 2.4 Hz, 1H), 4.14 (dd, J = 9.7, 6.1 Hz, 1H), 3.94 (ddd, 
J = 8.1, 6.1, 3.0 Hz, 1H), 3.87 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 3.53 (dd, J = 10.7, 6.1 Hz, 
1H), 3.22 – 3.11 (m, 1H), 2.94 – 2.82 (m, 2H), 2.81 – 2.74 ppm (m, 1H); 13C-NMR (101 MHz, 
CDCl3): δ = 190.52, 168.64, 168.02, 158.04, 156.57, 138.67, 138.61, 133.06, 129.88, 128.81, 
128.43, 126.16, 120.46, 113.27, 110.21, 79.22, 60.48, 55.55, 53.38, 52.54, 44.69, 37.64, 29.27 
ppm; FT-IR: ṽ = 2953, 1730, 1672, 1614, 1503, 1443, 1226, 1040 cm-1; HRMS: calcd. for 
[M+H]+ C25H26NO6: 436.17546, found: 436.17547.  
7.5.3 X-Ray Crystallographic Data of 294a (by C.-G.D) 
   
Empirical formula                                    C20 H23 N O6  
Formula weight                                        373.39  
Temperature                                             223(2) K  
Wavelength                                              0.71073 Å  
Crystal system, space group                    monoclinic,  P21/c  (No. 14) 
Unit cell dimensions                                a =  8.7052(2) Å  
                                                                 b =  7.8790(2) Å   β  = 93.841(1)°  
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                                                                 c = 27.3581(9) Å  
Volume                                                   1872.23(9) Å3  
Z, Calculated density                              4,  1.325 Mg/m3  
Absorption coefficient                            0.098 mm-1  
F(000)                                                     792  
Crystal size                                             0.30 x 0.15 x 0.03 mm  
Theta range for data collection               4.48 to 26.37°  
Limiting indices                                    -10<=h<=10, -9<=k<=8, -34<=l<=34  
Reflections collected / unique                16357 / 3784 [R(int) = 0.073]  
Completeness to theta = 26.37               98.8 %  
Absorption correction                            Semi-empirical from equivalents  
Max. and min. transmission                   0.9971 and 0.9712  
Refinement method                                 Full-matrix least-squares on F2  
Data / restraints / parameters                   3784 / 0 / 247  
Goodness-of-fit on F2                             1.060  
Final R indices [I>2σ(I)]                        R1 = 0.0643, wR2 = 0.1242  
R indices (all data)                                 R1 = 0.1122, wR2 = 0.1476  
Largest diff. peak and hole                    0.192 and -0.220 e.Å-3  
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Ac Acyl 
aq aqueous 
Ar Aryl 
BA Benzoic acid 
Boc tert-butoxycarbonyl 
Bn Benzyl 
Binol 1,1’-Bi-2-napthol 
BIOS Biology-oriented synthesis 
Bu Butyl 
Box Bisoxazoline 
Bz Benyoate 
(BzO)2 Benzoyl peroxide 
Calcd Calculated 
cat catalyst  
CDCl3 Deuterated chloroform 
CHCl3 Chloroform 
CMD Concerted metalation deprotonation 
CSA Camphor sulphonic acid 
COMAS Compound management and screening center 
Cp Cyclopentadienyl 
Cp* Pentamethylcyclopentadienyl 
DBPO Benzoyl peroxide 
DBU 1,8-Diazabicycloundec-7-ene 
DCM Dichloromethane 
DG Directing group 
DKR Dynamic kinetic resolution 
DMF Dimethyl formamide 
DMSO Dimethyl sulfoxide 
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DNP Dictionary of natural products 
d.r. Diastereomeric ratio 
ee Enantiomeric excess 
EDG Electron donating group  
Equiv. Equivalent 
ESI Electron spray inonisation 
Et2O Diethylether 
Et Ethyl 
Et3N triethylamine 
EWG Electron withdrawing group  
HMBC Heteronuclear multiple bond correlation 
HPLC High performance liquid chromatography 
HOMO Highest occupied molecular orbital 
HRMS High resolution mass spectroscopy 
i-Bu isobutyl 
IC50 Half maximal inhibitory concentration 
i-Pr isopropyl 
J Coupling constant 
KR Kinetic resolution 
L Ligand 
LA Lewis acid 
M Metal 
Me Methyl 
MeCN Acetonitrile 
MeOH Methanol 
MHz Megahertz 
MOM Methoxymethyl 
Ms Mesyl 
NMR Nuclear manetic resonance 
NOE Nucler Overhauser effect 
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NPs Natural producs 
n.r. No reaction 
OFBA 2-fluorobenzoic acid 
PAs Pyrrolizidine alkaloids  
PG Protecting group 
Ph Phenyl 
Piv Pivaloyl  
PSSC Protein Structure Similarity Clustering 
Py Pyridine  
r.t. Room temperature 
SCONP Structural Classification of Natural Products 
SN Nucleophilic substitution 
T Temperature 
TBDPS tert-butyldiphenylsilyl 
TBS tert-butyl dimethylsilyl 
t-Bu tert-butyl 
TFA Trifluoroacetic acid 
THF Tetrahydrofuran 
TIPS Triisopropylsilyl 
TLC Thin Layer Chromatography 
TM Transition meal 
TMS Trimethylsilyl 
Ts Tosyl 
VCD Vibrational circular dichroism 
Xyl Xylene 
1,3-DC 1,3-dipolar cycloaddition reaction 
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